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ABSTRACT
I. Total Synthesis of the (+)-12,12'-Dideoxyverticillin A
The fungal metabolite (+)-12,12'-dideoxyverticillin A, a cytotoxic alkaloid isolated from a
marine Penicillium sp., belongs to a fascinating family of densely functionalized,
stereochemically complex, and intricate dimeric epidithiodiketopiperazine natural products.
Although the dimeric epidithiodiketopiperazines have been known for nearly four decades, none
has succumbed to total synthesis. We report a concise enantioselective total synthesis of (+)-
12,12'-dideoxyverticillin A via a strategy inspired by our biosynthetic hypothesis for this
alkaloid. Highly stereo- and chemoselective advanced-stage tetrahydroxylation and
tetrathiolation reactions, as well as a mild strategy for the introduction of the
epidithiodiketopiperazine core in the final step, were developed to address this highly sensitive
substructure. Our rapid functionalization of the advanced molecular framework aims to mimic
plausible biosynthetic steps and offers an effective strategy for the chemical synthesis of other
members of this family of alkaloids.
II. General Approach to Epipolythiodiketopiperazine Alkaloids: Total Synthesis of (+)-
Chaetocins A and C and (+)-12,12'-Dideoxychetracin A
A highly stereoselective and systematic strategy for the introduction of polysulfides in the
synthesis of epipolythiodiketopiperazine alkaloids is described. We report the first total
synthesis of dimeric epitri- and epitetrathiodiketopiperazine alkaloids.
III. Concise Total Synthesis and Stereochemical Revision of (+)-Naseseazines A and B:
Regioselective Arylative Dimerization of Diketopiperazine Alkaloids
Concise and enantioselective total syntheses of (+)-naseseazines A and B are described. Our
regioselective and directed dimerization of diketopiperazines provides their critical C3-Csp2
linkages, an assembly with plausible biogenetic relevance. We have revised the absolute
stereochemistry of (+)-naseseazines A and B.
IV. Concise Total Synthesis of (+)-Bionectins A and C
The concise and efficient total synthesis of (+)-bionectins A and C is described. Our approach to
these natural products features a new and scalable method for erythro-p-hydroxytryptophan
7
amino acid synthesis, an intramolecular Friedel-Crafts reaction of a silyl-tethered indole, and a
new mercaptan reagent for epipolythiodiketopiperazine (ETP) synthesis that can be unravelled
under very mild conditions. In evaluating the impact of Cl 2-hydroxylation, we have identified a
unique need for an intramolecular variant of our Friedel-Crafts indolylation chemistry. Several
key discoveries including the first example of permanganate-mediated stereoinvertive
hydroxylation of the a-stereocenters of diketopiperazines as well as the first example of a direct
triketopiperazine synthesis from a parent cyclo-dipeptide are discussed. Finally, the synthesis of
(+)-bionectin A and its unambiguous structural assignment through X-ray analysis provides
motivation for the reevaluation of its original characterization data and assignment.
Thesis Supervisor: Professor Mohammad Movassaghi
Title: Associate Professor of Chemistry
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The fungal metabolite (+)-12,12'-dideoxyverticillin A (1, Fig. 1)' is a member of the
epidithiodiketopiperazine alkaloids, a large family of natural products that has received
significant attention from the scientific community for its rich biological activity and complex
molecular architecture. 24 The dimeric subset of alkaloids to which the title compound belongs
has been known for nearly four decades with the isolation of (+)-chaetocin A (2)6 and (+)-
verticillin A (4).7 Reflective of the daunting challenges posed by molecular structures replete
with sterically congested stereogenic centers, and highly acid-, base-, and redox-sensitive
functional groups, no dimeric epidithiodiketopiperazine alkaloid had yet succumbed to total
synthesis. Herein, we describe a concise strategy for the enantioselective total synthesis of the
dimeric epidithiodiketopiperazine alkaloid (+)-1. Our biosynthetically inspired synthesis features
stereo- and chemoselective advanced stage tetrahydroxylation and tetrathiolation reactions,
providing a generalizable solution to the epidithiodiketopiperazine substructure found in the
broader family of these alkaloids.
Biological Significance
Structure-activity relationship studies have demonstrated the essential nature of the
epipolythiodiketopiperazine functional group for the biological action of these natural
products, 2,3c and a central role has been assigned to the obligatory epidisulfide moiety in each of
the mechanisms of action that have been proposed. One of the modes of toxicity identified in
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(+)-12,12'-dideoxyverticillin A (1)
these studies involves redox cycling,9  a process initiated by reduction of the
epidithiodiketopiperazine moiety by native cellular reductants such as glutathione.10 The
resulting dithiol is rapidly autoxidized back to the precursor epidisulfide, generating reactive
oxygen species (ROS) like superoxide and hydrogen peroxide in the process. There is as yet
much ambiguity in the precise role of ROS's, but these species have been implicated in the
initiation of cell death either directly through oxidative damage or indirectly as secondary
messengers in signaling pathways. Furthermore, the prevalence and generality of this mechanism
have yet to be established as studies on gliotoxin-treated cells, in contrast to preceding studies on
sporidesmin-treated cells, have challenged the role of ROS's in the induction of apoptosis."
Another mode of toxicity for ETPs involves the direct interaction of the
epidithiodiketopiperazine motif with target proteins. Gliotoxin (39) (Scheme 2), for example, has
been shown to form a 1:1 covalent complex with alcohol dehydrogenase through the formation
of mixed disulfides. 8b,1 2 Epidithiodiketopiperazines have also been shown to catalyze disulfide
bond formation between proximal cysteine residues of creatine kinase.13 Disulfide shuffling is
an integral component of the zinc ejection mechanism. Rearrangement of the disulfide bonds in
the CHI domain of transcriptional co-factors and the subsequent sequestration of an essential
zinc ion by ETPs results in disruption of the protein's tertiary structure and loss of function.14
Epidithiodiketopiperazine alkaloids are able to take advantage of a redox-uptake
mechanism to enhance their toxicity effects in highly reducing environments.1 5 Cells often have
active transporters involved in the rapid efflux of epidisulfide-containing secondary metabolites,
but reduction of the disulfide moiety by glutathione or other native cellular reductants prevents
the small molecule from being actively transported across the plasma membrane.
Epidithiodiketopiperazines can accumulate to concentrations several orders of magnitude greater
than the applied concentration through this mechanism, and their cytotoxic effects can be highly
amplified within the cells as a result.
Prior Approaches to the Epidithidiketopiperazine Motif
In the four decades preceding our work, a number of synthetic approaches to the
epidithiodiketopiperazine motif had been developed and applied to total syntheses with varying
degrees of success (Scheme 1). In fact, three general reaction manifolds gradually emerged, and
each method could be classified into one of the following categories: SN 2 displacement of pre-
16
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activated diketopiperazines with anionic thiolating agents, electrophilic sulfuration of
diketopiperazine-derived enolates, and nucleophilic attack of N-acyliminium ions with neutral
thiolating agents.
The first synthesis of an epidithiodiketopiperazine substructure, disclosed by Trown in
1968, implemented the first of these reaction modes.4a In his seminal study, sarcosine anhydride
(7) was brominated with molecular bromine in refluxing 1,2-dichlorobenzene, and the resulting





























dithioester intermediate. Subsequent hydrolysis and oxidation of the resulting dithiol with
Ellman's reagent afforded the target epidithiodiketopiperazine motif. The simplicity of this
method proved highly enabling, leading to its adoption as the opening sequence to several total
syntheses centered on the elaboration of an ETP core.sa-,16 One limitation to this method,
however, was its lack of generality. In addition to the problem of overoxidation faced by
substrates containing amino acid residues other than glycine or sarcosine, the tertiary Ca-
bromides accessed in such instances were not amenable to direct nucleophilic displacement.
A complementary method featuring enolate sulfenylation was subsequently reported by
Hino in 19 7 1 .4b Use of sulfur monochloride as an electrophile enabled the simultaneous and
diastereospecific installation of both sulfur atoms in their correct oxidation state. While direct in
its incorporation of the disulfide bridge, execution of this double sulfuration method necessitated
the use of readily enolizable substrates containing 1,3-dicarbonyl substructures. Its limitations in
substrate scope and marginal efficiency notwithstanding, the conciseness of this transformation
ultimately rendered it indispensable in several total syntheses.4k' 5e Nevertheless, in the following
year, Schmidt was able to take advantage of the same reaction manifold and significantly
broaden its substrate scope by introducing monoclinic sulfur as the electrophilic agent.4 , Use of
mild electrophiles producing less reactive polysulfide intermediates facilitated the stepwise
incorporation of sulfur at each Ca-center. The polysulfide adducts generated via this method
were reduced with sodium borohydride, and the resultant dithiol was oxidized with iodine to
yield epidithiodiketopiperazine 14. While this procedure obviated the need for readily enolizable
1,3-dicarbonyl motifs, strong bases were unfortunately required to deprotonate the unactivated
amides. Issues of diastereoselectivity in thiolation also remained unaddressed.
The final mode of epidithiodiketopiperazine synthesis relied on nucleophilic thiolation of
N-acyliminium ions. Access to alpha-oxidized diketopiperazine structures was central to this
approach and key developments were made in this regard. Schmidt was the first to realize the
potential of this reaction manifold. In his method, initial conversion of proline anhydride (12)
to a diacetate using Pb(OAc) 4 was followed by hydrolysis to yield a pair of hemiaminals. Zinc
chloride-mediated ionization of the alcohols in the presence of hydrogen sulfide then afforded a
dithiol intermediate, and subsequent oxidation provided the target epidithiodiketopiperazine
motif 14. In an alternative approach, Matsunari's 1975 disclosure of epidithiodiketopiperazine
synthesis effectively expanded Trown's method to 3,6-dialkylated diketopiperazines. 4g In that
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report, 3,6-dialkyl diketopiperazines were exhaustively brominated, solvolyzed with methanol,
then reductively dehalogenated to afford Ce-methyl ethers. Application of Schmidt's thiolation
protocol then provided the targets of interest. Deviating from an oxidative approach to Ca-
oxygenated N-acyliminium precursors, Ottenheijm chose to access the same substrates through
the construction of diketopiperazine substrates using a-ketoacid chlorides. 4h As in prior
examples, these alpha-activated species could be converted to the epidisulfide through zinc-
mediated hydrogen sulfide incorporation using Schmidt's protocol. The final contribution came
from Overman in 2007 with the report of a radical-promoted intramolecular C-H abstraction and
copper-mediated Ca-oxidation of the resultant radical. 4 p Scandium-mediated ionization and
thiolation with hydrogen sulfide comprised the endgame sequence. It is noteworthy that all of
the aforementioned methods relied on Lewis acid-catalyzed ionization and incorporation of H2S.
These seminal developments in ETP synthesis notwithstanding, stereocontrolled access to cis-
dithiols continued to remain a major challenge.
Prior Total Syntheses of Epidithiodiketopiperazine Alkaloids
In the 1970s, Kishi published a series of landmark reports describing the total syntheses
of (±)-dehydrogliotoxin,5a (+)-sporidesmin A (31),5b (±)-gliotoxin (39) 5d and (±)-hyalodendrin
(45).5f These syntheses, the first of any epidithiodiketopiperazine-containing natural products,
featured an inside-out strategy, commencing with the construction of an
epidithiodiketopiperazine core structure followed by its elaboration to the target compounds.
Kishi noted in his reports5 f that he had settled upon this strategy cognizant of the harsh
conditions required for sulfur incorporation on diketopiperazines using exisiting methodologies.
By his estimation, sulfur should be incorporated early on, protected, then unraveled in the final
stages. His insightful retrosynthetic analysis and explication of synthetic design clearly
highlighted several key opportunities for future advances in this area of research.
Kishi's synthesis of (±)-3 1 5b began with the thiolation of cyclic dipeptide N-Me-Ala-Gly
anhydride 25 using the aforementioned methodology developed by Trown. Radical bromination
of the alpha centers, elimination, and nucleophilic displacement with potassium thioacetate
provided thioester 26. Hydrolysis of the thioester followed by reaction with anisaldehyde
dithioacetal trimer under Lewis-acidic conditions then provided in 80% yield and 2:1 dr a
masked epidithiodiketopiperazine poised for further elaboration. Indeed, bridgehead lithiation
19
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with n-butyllithium followed by the addition of acid chloride 28 provided indole derivative (±)-
29 in 61% yield. After further manipulation, the acetates of pentacycle (±)-30 were hydrolyzed
and the epidisulfide was revealed by oxidative decomposition of the dithioacetal to afford (±)-
sporidesmin A (31).
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Kishi was able to leverage this synthetic methodology further en route to the synthesis of
5d(±)-gliotoxin (39). In a manner similar to that of his prior work, dithiol 33 was obtained from
diketopiperazine 32 through Trown's methodology then protected as its dithioacetal 34. In this
instance, rather than starting out with bridgehead lithiation, the core structure was initially
derivatized by N-alkylation with Michael acceptor 35 to afford intermediate (±)-36. After
functional group manipulations to generate benzylic chloride 37, bridgehead lithiation and
intramolecular alkylation provided intermediate (±)-38 with a fully intact and elaborated carbon
skeleton in 45% yield. After benzyl ether deprotection, the epidisulfide was unmasked in 65%
yield in the final step using the previously described protocol.
In 1980, Williams and Rastetter5e reported an alternative to Kishi's synthesis of (±)-
hyalodendrin (45) featuring Schmidt's enolate thiolation methodology for ETP synthesis.
Deprotonation of diketopiperazine 40 in the presence of monoclinic sulfur enabled thiolation of
one of the alpha centers; the other was installed through mild thiolation of a 1,3-carbonyl
substructure with a sulfenyl chloride. Global reduction of mixed disulfide 44 followed by
oxidation afforded the target compound in 29% yield.
Retrobiosynthetic Analysis
In the development of our synthetic route to (+)-12,12'-dideoxyverticillin A (1), one of
the overarching goals of the project was defined to be the rapid generation of molecular
complexity in a selective yet generalizable fashion. There are dozens of known members of this
alkaloid family with a collective biological profile that spans antibacterial, 7 anticancer, 1
antiviral,' 9  antiparasitic, antifungal,20  antimalarial, immunosuppressive,
immunomodulatory,3bIsa,21 phytotoxic,22 nematicidal,23 and antiplatelet24 effects. The potential
utility and fascinating structural features of nearly all of these members led us to propose a
unifying strategy for their synthesis. Cognizant of the caveat that biomimetic syntheses are
optimal insofar as the goals of nature are similar to our own, we felt that the most efficient way
to unify the synthesis of each family member would be to learn from and mimic the actual
biosynthetic machinery that produces them.
From structural comparisons of a wide range of cyclotryptophans, cyclotryptamines, and
the more complex epidithiodiketopiperazines, it seemed highly probable that the biosynthetic
machinery is highly tolerant of the wide spectrum of congeners. Incorporation of tryptophan,
21
phenylalanine, glycine, serine, valine, leucine, threonine, and alanine as well as derivatives of
varying oxidation states have all been evidenced within the family. Although we cannot
eliminate the possibility that the enzymes are in fact highly specific and form tightly binding
substrate-enzyme transition state complexes involving the amino acid side chain since not all of
these natural products are produced by a single organism, we did feel comfortable in postulating
the contrary. It followed then that the enzymatic transformations take advantage of the inherent
chemistry of the substrate; substrate control plays a prominent role in reactivity and selectivity.
Such a hypothesis was the key to the evaluation of potential biosynthetic proposals.
Syntheses informed by biogenetic hypotheses are often poised to take advantage of the
blueprint laid out by nature. Such was the case in the development of this synthesis. The
biochemical processes left behind a trail of natural products of gradually increasing complexity,
with each of these simpler natural products potentially serving as stepping stones en route to the
synthesis of the more complex ones. A new method to solve each of the key challenges of the
final target could be developed at each of these markers (Scheme 3).
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Scheme 3. Potential areas for reaction development are identified en route to a final target by plotting a path of
decreasing complexity.
In this research program, (+)-chimonanthine (47), (+)-folicanthine, and (-)-calycanthine 25
were established as our initial targets for the development of completely stereoselective C3-C3'
bond forming strategies. According to biosynthetic hypotheses by Woodward 26 and Robinson
27
in the 1950's, nature rapidly assembles these molecules through oxidative dimerization of
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Scheme 4. Tactical differences between nature's approach and the laboratory approach to the enantioselective
synthesis of dimeric cyclotryptamines.
tryptamines (Scheme 4). Although a radical-radical dimerization approach rapidly generates
molecular complexity, this transformation in particular did not satisfy our needs for complete
absolute and relative stereoselectivity. In fact, nature appears to use this reaction as a
biodiversification step. Decoupling the oxidation and radical dimerization steps allowed us to
handpick a selection of their desirable properties. In contrast to a radical oxidative dimerization,
the preferred synthetic route featured a two electron oxidation step followed by a single electron
reduction to give complete control over the dimerization event (Scheme 4).28
With this technology in hand, the program progressed to more complex fungal
metabolites possessing a diketopiperazine moiety such as (+)-WIN 64821 (46) and (-)-
ditryptophenaline. 29 These structures are highly prone to epimerization and suitable conditions
for their formation were developed.
Using the newly available methods for dimerization and diketopiperazine formation, we
began to address the challenges unique to a dimeric epidithiodiketopiperazine alkaloid such as
(+)-12,12'-dideoxyverticillin A (1). In tackling the biosynthetic origins of the polysulfide bridge
found within the epidithiodiketopiperazine class of alkaloids, we envisioned three fundamentally
different modes of sulfur incorporation arising from the most commonly encountered oxidation
states of the alpha carbons. These would be carbons possessing the +2, +1, and 0 oxidation
states, which correspond to a carbocation (acyliminium ion), carbon-centered radical, and
carbanion (enolate), respectively. Each of these species would react with sulfur-bearing partners
23
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Scheme 5. Possible retrosyntheses for the biogenesis of epidisulfides.
of complementary polarity. These three modes comprised the first retrosynthetic divergence and
are delineated in Scheme 5.
Initially, the direct thiolation of an enolate seemed appealing; possible electrophilic sulfur
sources would include elemental sulfur as well as disulfides of amino acids or other metabolites
like glutathione. Literature precedent for this mode of sulfur incorporation,3 0 however, involved
the generation of metal enolates using strong bases such as sodamide, lithium diisopropylamide,
or even bis-lithiated bases followed by trapping with monoclinic sulfur or sulfur monochloride.
Although we could not preclude this sort of reactivity in the biosynthetic machinery, access to
such high energy intermediates seemed improbable and milder means of sulfur incorporation
seemed far more desirable in our biogenetic hypothesis. We thus focused on sulfur nucleophile
addition to acylimine and acyliminium ion intermediates.
Routes invoking the intermediacy of an acyliminium ion can be further elaborated to
account for their origin from a diketopiperazine precursor. Acyliminium ions can be generated
via protonation of an enamide derived by p-elimination of a carbonyl compound, by direct
elimination of an a-hydroxy amino acid, or by direct p-elimination of an N-hydroxy amino acid
derivative as is represented by 59, 60, and 61, respectively in Scheme 5. These three pathways
were evaluated in turn against the body of work produced by Kirby,3 1 Sammes, 32 and Taylor3 3 on
the biosynthesis of gliotoxin (39), a related monomeric epidithiodiketopiperazine alkaloid.
The option of accessing an acyliminium ion through protonation of an enamide was
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Scheme 6. Kirby's studies on the incorporation of p-deuterated phenylalanine into gliotoxin.
acid derivatives in biological processes. 34  They usually arise from the p-elimination of side
chain hydroxyls or thiols from cysteine, threonine, serine or other post-translationally modified
p-hydroxy amino acids such as P-hydroxytryptophans. Despite such a possibility, Kirby's
studies regarding the incorporation of p-deuterated phenylalanine into gliotoxin,35 in particular,
rendered this route highly improbable. Scheme 6 summarizes the results of his study. Although
conversion of a doubly deuterated phenylalanine 64 to mono-deuterated gliotoxin 63 shows the
product forming competency of the didehydroamino acid intermediate under consideration,
Kirby's observation of dideuterogliotoxin 65 among the reaction products greatly diminished the
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Scheme 7. Ottenheijm's biosynthetic hypothesis
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possibility that the ultimate source of the acyliminium ion is the elimination product of a p-
hydroxy amino acid derivative.
This then left the next two options, which involve direct generation of a C-N 7-bond via
elimination of either an a-hydroxy amino acid or an N-hydroxy amino acid. A hypothesis
invoking the latter of these two processes was championed by Ottenheijm and co-workers.4'
Through a series of experiments on monomeric model systems as well as by observation of
hydroxamic acids in natural products such as mycelianamide and astechrome, Ottenheijm
presented the viability of N-hydroxyamino acids in accessing epidithiodiketopiperazines. He
speculated that N-hydroxy-a-amino acids are biosynthetic precursors to a-functionalized a-
amino acids. The biosynthetic hypothesis that he has laid out for gliotoxin (39) is depicted in
Scheme 7. Despite the overall plausibility of this sequence, the oxidation of the diketopiperazine
seemed to be temporally displaced in relation to the N-methylation and oxidative cyclization
steps.
From a structural perspective, we noticed that nearly all of the dimeric
epidithiodiketopiperazines we had assembled in our catalog of related compounds contained an
N-methyl amide. We were inclined to interpret this as an indication that N-methylation occurs
prior to epidisulfide formation during the biosynthetic pathway. Such a hypothesis, however,
would be inconsistent with an N-hydroxylation pathway because of the saturated valency of the
nitrogen atom.
From a more mechanistic perspective, our preference for a Ca-hydroxylated species over
an N-hydroxylated species as the direct progenitor of the acylimine intermediate is
fundamentally rooted in our prediction that epidithiodiketopiperazine formation is a late stage
process. Given the presence of dimeric diketopiperazines like (+)-WIN 64821 (46) and (-)-
ditryptophenaline, although we lacked biochemical proof of lineage, we conjectured that sulfur
incorporation is a post-dimerization process. Furthermore, as in the case of the N-methyl amide,
if the biosynthetic pathway were to invoke an N-hydroxylated species, the valency of an N-
hydroxy intermediate would require the acylimine precursor to be generated prior to the
oxidative radical dimerization-cyclization sequence. Formation of a kinetically unstable
acylimine and nucleophilic trapping with sulfur at this stage raised several potential problems.
Such a pathway left us unable to adequately rationalize the presumed diastereoselectivity in the
epidisulfide formation. We observed that the sulfur atoms in all dimeric
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epidithiodiketopiperazines with a C2-symmetric core have the same relative stereochemistry with
respect to the C3-C3' stereogenic centers. In the absence of nearby stereogenic centers,
however, we would not expect the level of consistency in the stereochemistry of sulfur
incorporation across the entire subset of such dimeric epidithiodiketopiperazines as we do
observe. Additionally, application of the N-hydroxylation hypothesis, which was originally
proposed in the context of the monomeric gliotoxin (39), to the dimeric
epidithiodiketopiperazines would invoke a radical oxidative dimerization-cyclization sequence in
the presence of redox active and radically sensitive epidisulfides, which while possible would be
suboptimal.
Thus, the a-hydroxylation pathway proceeding via intermediate 60 (Scheme 5) seemed
the most attractive route to us. Such hydroxylations are known to occur in natural products such
as in the biosynthesis of ergotamine, 36 and one could similarly propose that the oxidations of
these diketopiperazines are accomplished by cytochrome P450 monooxygenases. In accord with
our underlying premise of substrate controlled reactivity and selectivity, we conjectured in our
hypothesis that a monooxygenase would potentially be able to exploit the similar chemical
reactivities of each of the four Ca-H bonds inherent in the symmetry of the dimer as well as the
pseudosymmetry of the diketopiperazines in order to effect a perhydroxylation. Such a
hydroxylation would in effect allow us to access an acyliminium intermediate that Kirby also
invokes in his proposal for thiolation as a late stage process.3 '
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Scheme 8. Feeding studies performed with radiolabeled sulfur to determine the origins of the sulfur atoms in
epdithiodiketopiperazines.
Kirby's proposal for thiolation3 1 commenced with the nucleophilic attack of a cysteine
amino acid onto an acylimine. Although the source of the acylimine was not defined, a cysteine
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Enzyme Annotation (sequence homology) Proposed biosynthetic role
0 GliP/SirP Non-ribosomal peptide synthetase Synthesis of the dioxopiperazine
N GliT/SirT Thioredoxin reductase Formation of the disulfide bond
E GliC/SirC Cytochrome P450 monooxygenase Unknown
* Glil/Sirl Amino cyclopropane carboxylate synthase Unknown (Make/break C-S bonds?)
* GliJ/SirJ Dipeptidase Unknown
* GliM/SirM O-Methyl transferase Unknown
N GliN/SirN Methyl transferase Unknown
* GliG/SirG Glutathione S-transferase Unknown (Make/break C-S bonds?)
GliA/SirA ATP-binding cassette transporter Efflux of ETPs from fungi
N GliZ/SirZ Zinc finger transcriptional regulator Regulation of genes in cluster
Figure 2. Howlett's biosynthetic gene cluster annotation and functional analysis.
residue was believed to be the sulfur source based on 35S feeding studies that Towers and Wright
had conducted (Scheme 8).3 And despite the fact that 35S was incorporated using a variety of
sulfur sources such as sulfate, methionine, and cysteine, Kirby noted that 35S labeled cysteine
resulted in the highest level of radiolabel incorporation. His proposal also implicated pyridoxal
in the sulfur transfer.31
At this juncture, we evaluated our hypothesis (Figure 2) against the genomic data
presented by Howlett and co-workers3 as a biogenetic hypothesis must withstand tests of not
only chemical but also biological feasibility. Howlett's studies primarily encompassed the
biosynthetic pathways of sirodesmin PL (74) and gliotoxin (39). Juxtaposition of their
biosynthetic gene clusters allowed the scientists to identify genes encoding proteins that seem to
be conserved between the two clusters and are presumed to be involved in modification of the
core epidithiodiketopiperazine moiety.
Based on conservation between the sirodesmin and gliotoxin clusters as well as gene
knockout and mutation studies, gene products bearing sequence homology to the following
enzymes were hypothesized to be part of the core epidithiodiketopiperazine biosynthetic
pathway: zinc finger transcriptional regulator, 1 -aminocyclopropane-1-carboxylic acid synthase,
dipeptidase, two module non-ribosomal peptide synthetase (NRPS), cytochrome P450
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monooxygenase, 0-methyl transferase, glutathione S-transferase, ATP-binding cassette (ABC)
type transporter, methyl transferase, and thioredoxin reductase.
The zinc finger transcriptional regulator, as the name implies, controls regulation of the
expression of the epidithiodiketopiperazine biosynthetic gene cluster. Immunity is built against
the self-generated toxins through expression of either an ABC transporter in the case of
sirodesmin or a major facilitator superfamily transporter in the case of gliotoxin. The presence
then of an NRPS and dipeptidase validates the claims of a dipeptide condensation followed by
cyclization.3c8 In terms of thiolation chemistry, there was insufficient information to make any
definite claims, but the l-aminocyclopropane-1-carboxylic acid synthase was implicated in the
thiolation sequence due to its known capability of cleaving C-S bonds. Presence of a
thioredoxin reductase was also assumed to be involved in formation of the disulfide bond.
We were further informed by radio-labeled amino acid feeding studies performed by
Kirby during his studies on the biosynthesis of gliotoxin (39). In those studies, he created all
four stereoisomers of cyclo-Trp-Ala and individually fed them to the organism producing the
secondary metabolite and discovered that only the LL-isomer was incorporated efficiently into
the target compound.3 9 In addition, given the stereoablative nature of the acyliminium ion
formation, we expected that the stereochemical information of the amino acid would be
temporarily destroyed and the final stereochemistry would have to be recovered through a
substrate controlled diastereoselective thiolation. Despite the stereochemistry of the final
product coinciding with that of the unnatural amino acids, this observation was consistent with
the most likely scenario in which L-amino acids, the ones abundantly available in nature, are
processed by the biosynthetic machinery and incorporated into the natural product.
Using all of the information we have gathered and the hypotheses we have formulated,
we set out to achieve the synthesis in the laboratory.
Results and Discussion
Total Synthesis of (+)-12,12'-Dideoxyverticillin A
Our retrosynthetic analysis of (+)-1 imitates a plausible biosynthetic sequence of events
linking dimeric epidithiodiketopiperazines to common a-amino acid precursors (Scheme 9). We
envisioned preparation of (+)-1 by mild oxidation of the tetrathiol 75, which could be accessed
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Scheme 9. Retrosynthetic analysis of (+)-12,12'-dideoxyverticillin A (1) based on a biosynthetic hypothesis.
biosynthetic hypothesis for monomeric epidithiodiketopiperazines invoking thiolation via an N-
hydroxylation-dehydration sequence, we speculated that a post-dimerization Ca-hydroxylation
would enable substrate directed hemiaminal thiolation through the intermediacy of an
acyliminium ion. Intermediate 77, which we hypothesized to arise from a dimerization event,
could be assembled from the readily available cyclo-dipeptide 78 using the concise cobalt-
mediated dimerization strategy reported from our laboratories. 25,29 The imposing challenges
associated with quadruple Ca-methine hydroxylation of 77 and the tetrathiolation of intermediate
76 notwithstanding, the need for absolute and relative stereochemical control (Scheme 9) of the
six tetrasubstituted carbons of (+)-1 posed noteworthy strategic concerns. We envisioned the
introduction of the C3 and C3' vicinal quaternary stereocenters as a prelude to stereochemical
control of the four thiolated-carbon stereogenic centers of (+)-1 in a strategy reminiscent of
Seebach's self-reproduction of chirality.4' Such a final stage tetrathiolation followed by
immediate disulfide formation would obviate the need to mask the notoriously sensitive
epidithiodiketopiperazine functional group in the early stages of the synthesis.
The dimeric diketopiperazine (+)-85 was assembled in six steps from commercially
available amino acid derivatives (Scheme 10).42 The sequential treatment of amide (-)-79 with
trifluoroacetic acid followed by cyclization with morpholine readily afforded access to the
desired cis-diketopiperazine (-)-80 in 84% yield (>20 g). Exposure of cyclo-L-tryptophan-L-
alanine (-)-80 to molecular bromine in acetonitrile at 0 'C furnished the desired monomeric
tetracyclic bromide (+)-81 in 76% isolated yield. 4 2 Treatment of tetracyclic bromide (+)-81 with
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Scheme 10. Concise enantioselective total synthesis of (+)-12,12'-dideoxyverticillin A (I). Isolated yields are given
for each step. Conditions: (a) trifluoroacetic acid (TFA), dichloromethane (CH 2Cl2), 23 'C, 4 h; tert-butanol
(tBuOH), morpholine, 23 0C, 48 h. (b) Br 2, acetonitrile (MeCN), 0 'C, 5 min. (c) methyl iodide (Mel), K2CO 3,
acetone, 23 0C, 5 d. (d) tris(triphenylphosphine)cobalt(I) chloride (CoCl(PPh3)3), acetone, 23 'C, 30 min. (e)
bis(pyridine)silver(I) permanganate (Py2 AgMnO4 ), CH2 Cl 2, 23 'C, 2 h. (f) tert-butyl(chloro)dimethylsilane
(TBSCI), (R)-(+)-4-pyrrolidinopyridinyl(pentamethylcyclopentadienyl)-iron (PPY) 5 mol%, triethylamine (Et 3N),
N,N-dimethyl formamide (DMF), 23 'C. (g) 5% Na(Hg), NaH2 PO 4, methanol (MeOH), 23 'C. (h) K2CS 3, TFA,
CH 2Cl2 , 28 min. (i) ethanolamine, 23 'C; K13, pyridine, CH 2CI2 , 23 0C. The thermal ellipsoid representation of
synthetic (+)-1 from X-ray crystallographic analysis is shown with most hydrogens omitted for clarity.
82 in 77% yield. 43 Reductive dimerization of the tertiary benzylic bromide (+)-82 with
tris(triphenylphosphine)cobalt(I) chloride in acetone provided the key dimeric octacyclic
intermediate (+)-83 in 46% yield.44 Preference for cis-fusion on 5,5-ring systems made this an
effective strategy for simultaneously securing the two vicinal C3 and C3' quaternary
stereocenters. This chemistry is amenable to multi-gram scale synthesis of (+)-83 (e.g., 43%
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cC (+)-81, R = H(+)-82, R = Me
dI
yield on 8 g-scale).
Guided by our biosynthetic hypothesis for late stage functionalization of the
diketopiperazines (i.e., 77-->75, Scheme 9), we sought methods for Ce-oxidation of the dimeric
octacycle (+)-83. Initially, we focused on the oxidation of the readily accessible enol tautomers
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or corresponding enolates of (+)-83. Unfortunately, these strategies were plagued by formation
of partially oxidized and diastereomeric products in addition to significant competing
decomposition. Likewise, a variety of soft-enolization and electrophilic amide activation
strategies failed to provide the necessary C-methine oxidation. Although we ultimately
developed conditions for dihydroxylation (or didehydrogenation) of a model monomeric
tetracyclic diketopiperazine 91 (Scheme 11) along with its conversion to the corresponding
monomeric epidithiodiketopiperazine 96,42 none of these methodologies proved effective when
applied to the more challenging dimeric octacyclic bisdiketopiperazine (+)-83, likely due to
additional modes of C3-C3' bond fragmentation and/or unfavorable interactions between the
tetracyclic subunits.
Careful analysis of the bond dissociation energies45 involved in our successful radical
based abstraction of Ca-methines in the model tetracycle 9142 suggested weak Ca-H bonds due to
stabilization of the ensuing Ca-radicals in diketopiperazines. Thus, the use of mild oxidants
typically reserved for hydrogen atom abstraction from formyl groups became a focus of our
efforts in pursuit of an effective strategy for single-step tetrahydroxylation of dimeric octacycle
(+)-83. After extensive experimentation, we discovered that the treatment of the
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Scheme 11. Functionalization of exploratory models and key observation enabling our first-generation synthesis of
(+)-12,12'-dideoxyverticillin A (1).
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Scheme 12. Radical clock-based mechanistic probe for permanganate-based hydroxylation of amino acid residues.
diketopiperazine 91 with tetra-n-butylammonium permanganate (3.0 equiv) 46 in pyridine at 23
0C for 2 h provided the desired tetracyclic diol 94 in 78% yield primarily as one diastereomer.
Application of these conditions to the oxidation of the more challenging dimeric octacycle (+)-83
resulted in 40% yield of the desired tetraol as a complex mixture of hemiaminal diastereomers.
As this tetrahydroxylation was fraught with competing epimerization of Ca-methines and
incomplete oxidation leading to complex product mixtures, 42 we sought to refine this reaction.
Further studies revealed that bis(pyridine)-silver(I) permanganate (Py 2AgMnO 4)4
oxidized dimeric octacycle (+)-83 selectively and efficiently. Under optimal conditions,
treatment of dimer (+)-83 with Py2AgMnO 4 (4.8 equiv) in dichloromethane at 23 *C for 2 h
afforded the desired dimeric octacyclic tetraol (+)-84 in 63% yield as a single diastereomer
(Scheme 10). The high level of diastereoselection42 is consistent with a fast abstraction-rebound
mechanism,48'49 as suggested by hydroxylation of the radical-clock hydantoin 97 (74%) (Scheme
12) and X-ray diffraction analysis of tetraol (+)-84. Oxidation of the corresponding cyclo-D-Trp-
L-Ala derivatives under these conditions resulted only in oxidation at the alanine Ca(Ala)-
methines, leaving the Ca(D-Trp)-methines unchanged.4 2 This observation, which has important
consequences for the choice of natural or unnatural amino acid precursors, is attributed to a non-
optimal conformation of the C-H bond for abstraction and/or the sterically disfavored approach
of the oxidant from the concave face of the 5,5-ring system.
The dimeric octacyclic tetraol (+)-84 proved highly acid- and base-sensitive. Its treatment
with Bronsted acids led to formation of tetraene 99 (Scheme 13),50 whereas its exposure to base
resulted in either decomposition or conversion to hemiaminal diastereomers.4 2 The high
sensitivity of tetraol (+)-84 to base may be attributed to reversible ring opening at the C15-
aminal allowing deleterious side reactions of the alpha-keto amide derivative 100 (Scheme 13).
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Scheme 13. Sensitivity of dimeric octacyclic tetraol (+)-84 to both acidic and basic conditions
With multi-gram access to dimeric octacyclic tetraol (+)-84, we focused on its conversion
to alkaloid (+)-1. Removal of the benzenesulfonyl groups with sodium amalgam in methanol
buffered with dibasic sodium phosphate unveiled an unstable diaminotetrahemiaminal 101
(Scheme 14). Immediate exposure of this labile compound to condensed hydrogen sulfide at -78
*C with a Lewis acid, followed by warming, resulted in formation of the corresponding tetrathiol
102 as a mixture of hemithioaminal diastereomers. Oxidation of the crude mixture of tetrathiols
with potassium triiodide resulted in (+)-12,12'-dideoxyverticillin A (1), albeit in low overall
yields (2-15%, 3-steps) from tetraol (+)-84.
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Scheme 14. First generation synthesis of (+)-12,12'-dideoxyverticillin A (1) from dimeric tetraol (+)-84 and thermal
ellipsoid representation of (+)-84. Conditions: (a) 5% Na(Hg), Na2HPO4, MeOH, 23 'C. (b) H2 S, CH2Cl 2 ,
hafnium(IV) trifluoromethanesulfonate (Hf(OT) 4 ), -78--23 'C, 14 h. (c) K13 , pyridine, CH 2CI2, 23 'C, 2-15% for
3-steps.
The fragility of tetraol (+)-84 and derivatives 101 and 102, the poor mass balance of this
capricious three-step sequence, and our preference to avoid the use of pressurized toxic hydrogen
sulfide led us to seek a superior strategy for the synthesis of the epidithiodiketopiperazine
substructure of this family of alkaloids. After substantial experimentation we realized that a
simple tactical conversion of the tetraol (+)-84 to the diol (+)-85 (Scheme 10) imparted
considerable stability to this structure, consistent with prevention of an undesired
diketopiperazine ring-opening. The use of Fu's PPY-catalyst (5 mol%) 51 was optimal for the
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selective derivatization of both alanine-derived hemiaminals of (+)-84. Treatment of a
methanolic solution of diol (+)-85 containing monobasic sodium phosphate with sodium
amalgam cleanly unveiled the stable diaminodiol (+)-86 in 87% yield as a surrogate for our
hypothetical biosynthetic intermediate 76 (Scheme 9).
At this juncture, we envisioned that coordinating the introduction of the two sulfur atoms
on each diketopiperazine ring would provide greater stereochemical control and structural
stability. Inspired by the Woodward-Prevost cis-dihydroxylation of alkenes with carboxylate
ions,52 and cognizant of the observation from Kishi's seminal synthesis of gliotoxin that
epidithiodiketopiperazines are acutely sensitive toward basic, reductive, oxidative and strongly
acidic conditions, we reasoned that the use of a trithiocarbonate53 would deliver a sulfurated
product poised for mild unveiling of the targeted tetrathiol at an advanced stage. In the event,
treatment of diaminodiol (+)-86 with potassium trithiocarbonate and trifluoroacetic acid in
dichloromethane resulted in rapid formation and isolation of the desired dimeric
bisdithiepanethione (+)-88 in 56% yield,42 4 likely via kinetic trapping of iminium ion 87
followed by intramolecular dithiepanethione formation. In this single operation, four carbon-
oxygen bonds are exchanged for four carbon-sulfur bonds, the stereochemistry at all four tertiary
thiols is secured, and the targeted cis-dithiodiketopiperazine substructure of 75 is attained.
Addition of ethanolamine to a solution of bisdithiepanethione (+)-88 at 23 'C rapidly
afforded the proposed biosynthetic precursor diaminotetrathiol 75,55 which is subject to mild
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oxidation to (+)-1 upon exposure to air. Under optimized conditions, following the formation
of diaminotetrathiol 75, partitioning of the reaction mixture between aqueous hydrochloric acid
and dichloromethane and immediate addition of potassium triiodide to the organic layer provided
(+)-12,12'-dideoxyverticillin A (1, [a]21D = +590 (c 0.30, CHCl 3); lit. [a]21D +624.1 (c 0.3,
Cld3))' in 62% yield as a colorless solid. All spectroscopic data for (+)-1 matched those
reported in the literature.' Furthermore, we unambiguously secured the structure of synthetic
(+)-1 by crystallographic analysis.
This concise strategy for the synthesis of (+)-1 required a carefully choreographed
sequence of events. In this sequence, the inherent chemistry of intermediates was maximally
utilized in generation of chemical complexity and stereochemical control. For example,
unveiling of the aniline nitrogen (NI) of (+)-83 followed by attempted tetrahydroxylation led to
complete decomposition under a variety of conditions. The challenges associated with the high
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sensitivity of (+)-83 toward epimerization at the L-amino acid derived Ca-stereocenters was
compounded by the requirement for oxidation prior to epimerization (vide supra). Furthermore,
thiolation of the oxidized diketopiperazines at an earlier stage led to significant reductive
cleavage or elimination of the sensitive carbon-sulfur bonds during subsequent transformations.
These key insights guided our described strategy, whereby the conversion of diaminodiol (+)-86
to dimeric dithiepanethione (+)-88 enabled tetrathiolation with concomitant inversion of all four
Ca-stereocenters, allowing rapid epidithiodiketopiperazine formation.
Collectively, our observations on the inherent reactivity of these structures hint at a
plausible biosynthetic sequence for alkaloid (+)-1 (Scheme 9). While the viability of the
proposed biosynthetic intermediates is supported through chemical synthesis, the successful
implementation of our synthetic strategy offers a potential roadmap to the function of enzymes
involved in the biosynthesis of epidithiodiketopiperazine alkaloids. For instance, Howlett's
studies of the epidithiodiketopiperazine biosynthetic gene clusters 338 have identified genes
encoding proteins with unassigned function that have sequence homology to cytochrome P450
mono-oxygenases. The mechanistic semblance of our permanganate diketopiperazine
hydroxylation to the well studied C-H abstraction-hydroxylation of substrates by P450
oxygenasess6 prompts consideration of the involvement of these genes in the Ce-oxidation of the
diketopiperazine core.
Modified Biosynthetic Hypothesis
Several hypotheses have been set forth in the literature regarding the biosynthetic origins
of the epidithiodiketopiperazines. 3c,41,31-33,57,58 Our own hypothesis seeks to refine the initial
proposals set forth by Kirby3 1 through the amalgamation of his seminal biosynthetic studies with
the genomic studies conducted by Howlett3 c as well as our own key observations regarding the
chemical reactivities of this unique structural motif. While a full exposition on the development
of the hypothesis has been laid out previously,58 we summarize below our unified hypothesis for
the biosynthesis of various epipolythiodiketopiperazines by divergent sulfidation of a common
diketopiperazine precursor (Scheme Si).
Our proposal commences with a dimeric diketopiperazine intermediate of the type 103,
which will be represented by a single diketopiperazine in Scheme 15. It contains the natural
amino acid stereochemistry at both of the stereocenters shown and would be generated through
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Scheme 15. A plausible unifying hypothesis for the biosynthetic pathway governing the incorporation of sulfur in
epidithiodiketopiperazine alkaloids.
action of the NRPS found in the epidithiodiketopiperazine gene cluster. We then envision a role
for the cytochrome P450 monooxygenase, which has been identified by Howlett, as one that
effects the oxidation of the diketopiperazine precursors to the a-hydroxy-at- amino acids. The
mechanism of our permanganate oxidation closely resembles the mechanism of action of a
cytochrome P450 monooxygenase 56 as both involve radical C-H abstraction followed by
hydroxylation through a metal oxo species. The stereoselectivity and the yield of this complex
chemical transformation speak volumes about the inherent chemistry of the diketopiperazine
structure. Our ability to effect such a task in the laboratory without resort to complex
supramolecular scaffolds lends credence to the hypothesis that the transformations involved in
the epidithiodiketopiperazine biosynthesis benefit from substrate control.
This labile hemiaminal thus generated can be eliminated readily with the use of mild
acids to yield an acyliminium species, which may possibly be trapped by a sulfur nucleophile.
Howlett's finding that an enzyme with sequence homology to a glutathione S-transferase is
encoded in the core epidithiodiketopiperazine biosynthetic gene cluster brings to our awareness
the possibility that glutathione is the active nucleophile. It would certainly be consistent with the
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increased levels of 35S incorporation observed by Kirby in radio-labeled cysteine feeding studies.
The glutathione can then possibly undergo hydrolysis either to the cysteine-glycine dipeptide
adduct, or double hydrolysis to the cysteine adduct. This form of nucleophilic sulfur addition
followed by hydrolysis of the tripeptide to the di- and monopeptide is precedented in the
leukotriene (LT) biosynthetic pathway starting from arachodonic acid. In that pathway, an
epoxide on LTA 4 is opened by glutathione to yield LTC4. Partial hydrolysis and loss of the
glutamate residue yields LTD4. Finally, loss of the glycine of the glutathione dipeptide leads to a
cysteine adduct, LTE 4.59
In epidithiodiketopiperazine biosynthesis, putative dipeptide adduct 107 or the cysteine
adduct 108 are likely candidates for action by the gene product bearing sequence homology to 1-
aminocyclopropane-1-carboxylic acid synthase. Through the aid of a PLP cofactor, one can
imagine elimination of the a-thioether from the cysteine residue to generate the desired tetrathiol
species (Scheme 15). Oxidation of the dithiols would yield epidithiodiketopiperazine 113.
Our hypothesis also posits that the various sulfur homologs of the
epipolythiodiketopiperazines arise from a common advanced diketopiperazine precursor through
the sequential and iterative introduction of sulfur atoms. While we do not disfavor the
hypotheses that the various sulfur homologs of 113 arise as disproportionation products or from
the insertion of sulfur via its various allotropes or via polysulfanes, 60 it is appealing to consider
the hypothesis that the epitrithiodiketopiperazines may be formed through a process similar to
that described above. Initial attack of glutathione onto disulfide 113 culminates with either
autoxidation or a PLP to PAP mediated redox reaction to yield epitrisulfide 116. Analogously,
epitetrasulfides may be obtained by attack of a glutathione at the least sterically hindered sulfur
atom of 116 to generate trisulfide 117 and ultimately epitetrasulfide 119. Alternatively, attack at
the terminal sulfur atoms is also plausible and would give rise to epitetrasulfide 119 through the
intermediacy of a disulfane and mixed disulfide. This hypothesis is characterized by a
systematic and iterative generation of higher order polysulfides.
These proposals, which are simple hypotheses requiring further biochemical
experimentation for verification, reflect the strong interdependency of chemistry and biology in
probing the depths of biosynthetic transformations. While noting that this family turned out to
be a highly privileged family of molecules-one in which enzymatic processes play a relatively
minimal role in guiding reactivity and selectivity-when the fundamental tenets of biomimetic
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syntheses apply, biogenetic hypotheses can prove to be a very powerful tool in the development
of new chemistry as well as for the elucidation of biological processes.
Over the past couple of years, we were delighted to witness the progress that the
scientific community has made in elucidating the biogenetic origins of the intriguing class of
epidithiodiketopiperazine-containing alkaloids. Elucidation of a biosynthetic pathway is an
endeavor that often takes the collaborative efforts of scientists in the fields of bioinformatics,
biochemistry, molecular biology, chemical biology, and also synthetic chemists. Synthetic
chemists have long had a hand in the proposition of biosynthetic hypotheses, most often guided
by their understanding of chemical reactivity, but also by drawing upon information derived
from the other fields allied in these efforts. Kirby,3 1 Taylor,3 3 and Sammes 32 are chemists who
have been pioneers in the area of epidithiodiketopiperazine biosynthesis. Other chemists, such
as Ottenheijm,4 1 Schmidt, 61 and Movassaghi58 have also had a hand in proposing biosynthetic
hypotheses and bringing our unique expertise to the elucidation of possible biosynthetic
pathways.
We were pleased to find that several aspects of our hypothesis have now been validated
experimentally by the Hertweck group in the context of gliotoxin (39) biosynthesis. 62 This
includes the intermediacy of a diol arising from Ce-oxidization of a diketopiperazine by a
62b
cytochrome P450 monooxygenase and its substitution by glutathione as was reported in 2011.
The diol and the glutathione adducts that were observed in Hertweck's report mirror structures
104 and 106, respectively, from our own proposal (Scheme 15).58 The degradation of the
glutathione adduct to the corresponding cysteine adducts has also been verified in 2012.62c This
transformation exactly mirrors that depicted in our hypothesis for the conversion of 106-+111
(Scheme 15). 8 Although the intermediates found in these studies exactly mirror those proposed
in our biosynthetic hypothesis, which was published up to three years in advance, it is
unfortunate that reference to our work has been completely omitted. Regrettably, reference to
the work of other synthetic chemists such as Kirby,3 1 Sammes, 32 Taylor,3 3 and Ottenheijm4 1 are
also absent from their discussions. Overlooking prior reports can have a ripple effect extending
to other members of the scientific community who may inadvertently omit references relevant to
their own reports.63 As we have described above, there is much to be gained from the synergistic
interactions between allied fields in the elucidation of biosynthetic pathways.
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Conclusion
Alkaloid (+)-1 potently inhibits the tyrosine kinase activity of the epidermal growth
factor receptor (median inhibitory concentration = 0.14 nM), exhibits antiangiogenic activity,
and has efficacy against several cancer cell lines. The strategy and methodologies described in
this chapter are expected to yield ready access to related compounds and provide an inroad to
further biological studies. We have attempted to capture the power of biosynthetic
considerations as a guiding principle for synthetic planning and as an inspiration for the
development of new reactions.
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Experimental Section
General Procedures. All reactions were performed in oven-dried or flame-dried round-
bottomed flasks. The flasks were fitted with rubber septa and reactions were conducted under a
positive pressure of argon. Stainless steel syringes or cannulae were used to transfer air- and
moisture-sensitive liquids. Where necessary (so noted), solutions were deoxygenated by
dinitrogen purging for a minimum of 10 min. Flash column chromatography was performed as
described by Still et al. using granular silica gel (60-A pore size, 40-63 p1m, 4-6% H20 content,
Zeochem)'. Analytical thin-layer chromatography was performed using glass plates pre-coated
with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin
layer chromatography plates were visualized by exposure to ultraviolet light and an aqueous
solution of ceric ammonium molybdate (CAM) followed by heating (>1 min) on a hot plate
(-250 C). Organic solutions were concentrated on BUchi R-200 rotary evaporators at -20 torr
(house vacuum) at 25-35 'C.
Materials. Commercial reagents and solvents were used as received with the following
exceptions: dichloromethane, acetonitrile, tetrahydrofuran, methanol, pyridine, and triethylamine
were purchased from J.T. Baker (Cycletainer TM) and were purified by the method of Grubbs et
2
al. under positive argon pressure2
Instrumentation. Proton nuclear magnetic resonance (OH NMR) spectra were recorded with
Varian inverse probe 500 INOVA and Varian 500 INOVA spectrometers, are reported in parts
per million on the 6 scale, and are referenced from the residual protium in the NMR solvent
(CDCl 3: 6 7.24 (CHCl 3), DMSO-d 6: 6 2.50 (DMSO-d 5)). Data is reported as follows: chemical
shift [multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling
constant(s) in Hertz, integration, assignment]. Carbon-13 nuclear magnetic resonance (13 C
NMR) spectra were recorded with a Varian 500 INOVA spectrometer, are reported in parts per
million on the 6 scale, and are referenced from the carbon resonances of the solvent (CDCl 3: 6
77.23, DMSO-d 6 : 6 39.51). Data is reported as follows: chemical shift (assignment). Infrared
data (IR) were obtained with a Perkin-Elmer 2000 FTIR, and are reported as follows: frequency
of absorption (cm-1), intensity of absorption (s = strong, m = medium, w = weak, br = broad).
Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.
2 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518.
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Optical rotations were measured on a Jasco-1010 polarimeter. We are grateful to Dr. Li Li for
obtaining the mass spectrometric data at the Department of Chemistry's Instrumentation Facility,
Massachusetts Institute of Technology. The structure of dimeric octacyclic tetraol (+)-14 and
(+)-12,12'-dideoxyverticillin A (1) were obtained with the assistance of Dr. Peter Mfiller at the
X-ray diffraction facility of the Department of Chemistry, Massachusetts Institute of
Technology.
Positional Numbering System. At least three numbering schemes for dimeric diketopiperazine
alkaloids exist in the literature. 3 In assigning the 'H and 13C NMR data of all intermediates en
route to our total synthesis of (+)-1 we wished to employ a uniform numbering scheme. For ease
of direct comparison, particularly between early intermediates, non-thiolated diketopiperazines,
and advanced compounds, the numbering scheme used by Barrow for (+)-WIN-64821 (using
positional numbers 1-18) was optimal and is used in this supporting document. In key instances
the products are accompanied by the numbering system as shown below for this document.
While Fenical's isolation report refers to (+)-1 as "(+)-11,1 '-dideoxyverticillin A," we use the
alternate name "(+)-12,12'-dideoxyverticillin A."
O H 0 H O H
12 Me~JN NIS NPh Ph N 10 S10
NS~ 1 iZMe 1N N MeMe " . 1 0 /AS N H12 NH SeA ~ N'
e o101 6 3 N N ~ l P h W - N2
7 H 0 8 H 0 8 H 0
(+)-11,11'-Dideoxyverticillin A (1) (+)-WIN-64821 (46) (+)-12,12'-Dideoxyverticillin A (1)
Fenical's isolation report Barrow's numbering for the This document
simpler diketopiperazine
framework
3 (a) Von Hauser, D.; Weber, H. P.; Sigg, H. P. Helv. Chim. Acta 1970, 53, 1061. (b) Barrow, C. J.; Cai, P.; Snyder,
J. K.; Sedlock, D. M.; Sun, H. H.; Cooper, R. J. Org. Chem. 1993, 58, 6016. (c) Springer, J. P.; Buchi, G.; Kobbe,
B.; Demain, A. L.; Clardy, J. Tetrahedron Lett. 1977, 28, 2403.
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Additional Notes.
A) The halocyclization of the diketopiperazine (-)-80.
/ H Br2  Br,, NH Br NH
PhO2SN H*<AMe CN,o N i- l II MNH
o SO2Ph 0 SO2Ph O
(-)-80 (+)-81, 76% (-)-S1,19%
Scheme Si. Diastereoselective synthesis of tetracyclic diketopiperazine bromide (+)-81.
* Under the optimal reaction conditions, the tetracyclic diketopiperazine bromide (+)-81 was
the major product of the halocyclization (76%), and the corresponding (2R,3R)-diastereomer
(-)-S1 was isolated in 19% yield.
* Use of excess bromine was necessary for complete conversion of (-)-80 to tetracyclic
bromide (+)-81. The amount of bromine used did not affect the level of diastereoselection.
* Lower reaction temperatures (-40 *C) resulted in a slightly higher level of diastereoselection
(5:1) albeit with less efficient conversion.
e The use of several other less electrophilic halogenating agents was less effective.
B) Sensitivity and epimerization of tetracyclic and dimeric octacyclic diketopiperazines.
H 0  H 
0
Br. N'Me Br. N MeN' KOEt N
N2
6 N H EtOH, 23 0C N 1HN~
SO2 Ph 
0  61% S02Ph 
0
(+)-82 S2
Scheme S2. Epimerization of tetracyclic diketopiperazine (+)-82.
* Treatment of the base sensitive tetracyclic bromide (+)-82 with potassium ethoxide resulted
in epimerization to the (1 1R)-diastereomer S2 in 61% yield. The trans-diketopiperazine
substructure of S2 is directly assigned by exclusion of known cis-diastereomers (both endo-
and exo-diketopiperazines). The C1I stereochemistry is consistent with the chemical shift of
the D-tryptophan derivatives in this series.
O SO2Ph O SO2Ph % nOe--Me H, N Me H N
0 Cs2CO3, CD30D R ."
MeN , NMe _ _MeN ,,H , N'
Me H :Nor Re~ 11N
O N IH NaOEt, EOH O N 5 R
N H e 'H Me(+)-83 SO2Ph O R = H, S3 Nh OP R =D, S3-d4 S P
Scheme S3. Deuterium incorporation and epimerization studies of dimeric octacyclic diketopiperazine (+)-83.
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* No immediate deuterium incorporation into (+)-83 was observed upon its dissolution in
methanol-d 4 in the absence of a base additive.
* However, dissolution of dimeric octacyclic diketopiperazine (+)-83 in methanol-d 4 with
cesium carbonate (10 equiv) at 23 'C lead to complete deuterium incorporation at all four
C-methines, rapidly giving a complex mixture of diastereomers. Within 6 h, the major
product was the corresponding (1 1R, 11 'R)-diastereomer S3-d 4 as a single symmetrical
diastereomer. The stereochemistry of S3-d 4 was assigned by analogy to the non-deuterated
sample prepared below.
* Treatment of dimeric diketopiperazine (+)-83 with sodium ethoxide (20 equiv) in ethanol at
23 'C resulted in the (I IR,1 l'R)-S3 in 75% yield. The stereochemistry of C1I was assigned
based on observed key nOe data (Fig. S3).
e Octacyclic dimer S3 is less prone to enolization at C 11 as compared to (+)-83. While
treatment of S3 with cesium carbonate in methanol-d4 at 23 'C did not result in deuterium
incorporation at C1I of S3, after reflux for 12 h full deuterium incorporation was observed
giving S3-d 4.
* Taken together these observations highlight the preference for conversion of the L-tryptophan
derived (I lS)-stereochemistry of (+)-83 to the corresponding (1 IR)-stereochemistry, an
observation that played a key role in our ultimate strategy for securing the carbon-sulfur C 11-
and C 11'-stereochemistry (and by relay the C15- and C 1 5'-stereochemistry).
C) Comparison of the base stability of octacyclic tetraol (+)-84 with octacyclic diol (+)-85.
* Treatment of a solution of octacyclic tetraol (+)-84 in chloroform-di with 1,8-
diazabicyclo[5.4.0]undec-7-ene (10 equiv) at 23 'C led to immediate signal broadening (in
situ IH NMR monitoring) and decomposition. In contrast, treatment of the octacyclic diol
(+)-85 under identical conditions led to no observable change or decomposition over 24 h
and resulted in full recovery of (+)-85.
* The low mass balance in the conversion of octacyclic tetraol (+)-84 to alkaloid (+)-1
(Scheme 14) may be due in part to competing reduction of the tautomeric cA-ketoamide 100
(Scheme 13) or the corresponding derivative from the highly sensitive diaminotetraol 101
(Scheme 14).
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D) Oxidation of the (hR.11'KR)-octacyclic diketopiperazine S3 using the optimal reaction
conditions.
O SO2Ph O SO2Ph0H N .- Me HN
Me -N O Py2AgMnO4  HO ,.N N O
N i:HN ". 11,Me- K M Me" ,k ,~ Me
M' N CH 2CI 2,23*C I H - N0 N 152 0 H
,N 'Me 2h Me
N 'H N4'H Me
S3 SO2Ph O 68% SO 2Ph O
Scheme 4. Oxidation of the dimeric octacyclic diketopiperazine S3.
0 Treatment of (11R,11'R)-octacyclic diketopiperazine S3 with Py2AgMnO 4 under the optimal
conditions developed for octacyclic dimer (+)-83 led to isolation of diol S4 as a single
diastereomer in 68% yield. The CII and CI1' methines were not hydroxylated, whereas C 15
and C15' methines were both hydroxylated.
E) Notes on the optimal conditions used for tetrahydroxylation of octacyclic dimer (+)-13.
* The C,-methine of amino acids has an approximate bond dissociation (BDE) energy of 82-
96 kcal/mol that varies as a function of the <p,y angles.4'5
* While several representative amino acid derived cyclic-substrates, including 83, 91, 97, and
S3, were successfully oxidized under these conditions at the desired Ca-methines, the
unsuccessful oxidation of simple N-acetyl-L-proline methyl ester and N-acetyl-L-alanine
methyl ester highlight the sensitivity of this chemistry to subtle variations in BDE's of the
Ca-methines of interest. Geometrical constraints in the successful substrates may in part be
responsible for lower BDE's.
F) Synthesis of epidithiodiketopiperazines.
Me HO 1. Py2AgMnO4  Me O Me 0Me 2. TFA, CH 2CI 2  - Me BF3 OEt2, H2S ' N' Me
59% (2-steps) PhSSPh
N IH o N N S
" h OMe 1. NBS, AIBN, 80 OC N H 23 *C, 28 h N Oh O
S 2 Ph 
0  2. Nal, 2-Me-2-butene S 2 Ph 53% SO2Ph 0
91 88% (2-steps) 93 96, >2:1 dr
Scheme 5. Synthesis of the pentacyclic epidithiodiketopiperazine 96.
4 Rauk, A.; Yu, D.; Taylor, J.; Shustov, G. V.; Block, D. A.; Armstrong, D. A. Biochemistry 1999, 38, 9089.
' Brocks, J. J.; Welle, F. M.; Beckhaus, H.-D.; Ruchardt, C. Tetrahedron Lett. 1997, 38, 7721.
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* We initially prepared diene S5 via a sequence involving free-radical bromination to a
tetrabromide intermediate that was converted to the diene of interest in 88% yield (2-steps).
* While these bromination conditions did not translate to the necessary conversion of dimeric
octacyclic diketopiperazine (+)-83 to the corresponding tetraene 99 (Scheme 13), they did
provide us with insight that led to the development of the optimal conditions.
* Diene S5 was later accessed by permanganate oxidation of tetracyclic diketopiperazine 21 to
the corresponding diol 94 (Scheme 11) followed by acid promoted dehydration, a reaction
pathway later observed in rapid dehydration of tetraol (+)-84 to tetraene 99 (Scheme 13). In
tetracyclic model systems, oxidation of the diketopiperazine was also possible by sequential
treatment with potassium hexamethyldisilazide and Davis oxaziridine to give the
corresponding diols. However, these conditions were highly ineffective in the more
challenging dimeric diketopiperazine series, requiring the development of the stereoselective
tetrahydroxylation strategy described in the text.
" Treatment of diene S5 with hydrogen sulfide in the presence of a Lewis acid and diphenyl
disulfide (an internal oxidant we included for efficient disulfide formation), gave the desired
pentacyclic epidithiodiketopiperazine 96.
* In this model system and the closely related C3-allyl series, the epidithiodiketopiperazines
are formed with at least 2:1 diastereomeric ratio favoring the diastereomer with the desired
C1I and C15 stereochemistry-(l IS,15S)-as supported by circular dichroism (CD) studies.
Even higher levels of C 11 -stereochemical control were observed with other alkyl thiols
nucleophiles.
* Importantly, the level of diastereoselection favoring the desired and natural stereochemistry
is greatly enhanced in the dimeric system with a larger C3 (and C3') substituent.
" It is important to note that simple exposure of the penultimate intermediate 75 to air leads to
direct and rapid formation of (+)-1, suggesting the cis-dithiodiketopiperazine stereochemistry
of 75 as illustrated (Scheme 10). A series of studies for the nucleophilic introduction of the
carbon-sulfur bonds at C I and C15, including those described above for synthesis of 96, all
point to a high preference for nucleophilic thiol addition at C1I favoring the (I IS)-
stereochemistry. While the proposed CI1 and C 15 stereochemistry of (+)-88 could not be
confirmed by nOe studies, the proposed intermolecular nucleophilic addition at C I of 87 are
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consistent with the inferred stereochemistry for (+)-88 based on the above observations, rapid
air oxidation of 75, and the X-ray structure of (+)-1.
G) Use of PPY in silylation of octacyclic tetraol (+)-84.
* Fu's (R)-(+)-4-pyrrolidinopyrindinyl(pentamethylcyclopentadienyl)iron catalyst (PPY) was
the most effective additive for the silylation of (+)-84. The use of 4-dimethylaminopyridine
(DMAP), or 4-pyrrolidinopyridine provided the desired diol (+)-85 in 46% and 52% yield,
respectively.
* Interestingly, the use of (S)-PPY in this transformation provided the desired product in only
36% yield.
" Based on analysis of the crude reaction mixture, the greater efficiency of PPY over DMAP
(55% vs. 46%) in this transformation is thought to be the enhanced selectivity for silylation
of the C15 alcohol over the C1I alcohol. Only one t-butyldimethylsilyl group per
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(-)-79
(-)-(S)-Methyl 2-((S)-2-(tert-butoxvcarbonvlamino)-3-(1-(phenylsulfonyl)-1H-indol-3-
Vl)propan-amidolpropanoate (79): A round-bottomed flask was charged sequentially with N-
sulfonylated tryptophan (-)-S6 6 (8.16 g, 18.4 mmol, 1 equiv, >99% ee, prepared from
commercially available N-Boc tryptophan in one step), N-hydroxybenzotriazole, (3.74 g, 27.6
mmol, 1.50 equiv), L-alanine methyl ester hydrochloride (S7, 3.81 g, 27.3 mmol, 1.48 equiv), 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (5.60 g, 34.2 mmol, 1.85 equiv),
and powdered 4A molecular sieves (4.0 g), and the contents were placed under an atmosphere of
argon. Anhydrous dichloromethane (180 mL) was introduced via cannula and the resulting
mixture was placed in an ice-water bath. After 30 min, triethylamine (11.5 mL, 82.5 mmol, 4.48
equiv) was added via syringe and the mixture was allowed to warm slowly to room temperature.
After 14 h, aqueous potassium hydrogen sulfate solution (1M, 150 mL) was added, and the
mixture was extracted. The organic layer was washed with saturated aqueous sodium
bicarbonate solution (150 mL), was washed with deionized water (150 mL), was dried over
anhydrous sodium sulfate, was filtered, and was concentrated under reduced pressure. The
resulting colorless foam was purified by flash column chromatography on silica gel (eluent: 40%
ethyl acetate in hexanes) to provide dipeptide (-)-79 (9.30 g, 95%) as a colorless foam.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDC 3, 20 *C):
FTIR (thin film) cm-1 :
8 7.95 (d, J= 8.3, 1 H, C8H), 7.84 (d, J= 8.2,
2H, SO2Ph-o-H ), 7.54 (d, J= 7.8, 1H, C5H),
7.51 (t, J= 7.4, 1H, SO2Ph-p-H), 7.43 (s, 1H,
C2H), 7.41 (app-t, J = 7.7, 2H, SO 2Ph-m-H),
7.30 (app-t, J= 7.6, 1H, C7H), 7.22 (app-t, J
= 7.5, 1H, C6 H), 6.39 (d, J = 7.0, 1H,
NamideH), 5.06 (s, 1H, NBocH), 4.50-4.43 (m,
1H, C H), 4.43-4.37 (q, J = 7.1, 1H, C15H),
3.68 (s, 3H, OCH3), 3.22-3.07 (br-d, J 6.3,
2H, C12H), 1.41 (s, 9H, C(CH 3)3 , 1.27 (d, J=
7.1, 3H, CCH3 ).
6 173.0 (C16), 170.7 (C13), 155.5 (Ccarbamate),
138.4 (SO 2Ph-ipso-C), 135.4 (C9), 134.1
(SO 2 Ph-p-C), 130.9 (C4), 129.5 (SO 2Ph-m-C),
127.0 (SO 2 Ph-o-C), 125.3 (C2), 124.8 (C7),
123.6 (C6), 119.9 (C5), 117.9 (C3), 113.9 (C8),
80.7 (OC(CH 3)3), 54.5 (C,1), 52.8 (OCH 3),
48.4 (C15 ), 28.5 (OC(CH 3)3), 28.1 (C 12), 18.6
(C] 7).
3387 (br-s), 2980 (w), 1658 (s), 1366 (m),
1175 (m).




TLC (50% ethyl acetate in hexanes), Rf:
calc'd for C26H 32N 30 7S
found: 530.1977.








1) TFA, CH2CI2, 0 *C
2) t-BuOH, morpholine
48 h, 23 *C
84%
0
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Trifluoroacetic acid (20 mL) was added to a solution of the dipeptide (-)-79 (3.81 g, 7.18
mmol, 1 equiv) in anhydrous dichloromethane (50 mL) at 0 0C. After 4 h, the resulting orange
solution was concentrated, and the resulting orange-brown residue was dissolved in t-butanol
(150 mL) and morpholine (30 mL) at 23 0C. After 4 h, a white precipitate was observed in the
clear yellow reaction solution. After 44 h, the resulting thick white suspension was concentrated
under reduced pressure. The resulting paste was dissolved in NN-dimethylformamide (120 mL)
at 65 *C and slowly poured into deionized water (120 mL) at 23 *C. After 12 h, the resulting
suspension was filtered and was dried for 12 h at 50 *C under reduced pressure to afford the
diketopiperazine (-)-80 (2.4 g, 84%) as a flocculent white solid. (The simple trituration of the
product readily provides access to large quantities of the desired product (>20g) by allowing all
prior steps to be carried out on multi-gram scale without chromatographic purification.)
'H NMR (500 MHz, DMSO-d6, 20 *C):
13 C NMR (125.8 MHz, DMSO-d6 , 20 *C):




TLC (10% methanol in dichloromethane), Rf:
6 8.18 (s, 1H, NioH), 8.06 (s, 1H, NI4H), 7.90
(d, J = 7.4, 2H, SO 2Ph-o-H), 7.85 (d, J= 8.2,
1H, C8H), 7.67 (app-t, J = 6.8, 1H, SO2Ph-p-
H), 7.63 (d, J= 7.9, 1H, C5H), 7.57 (app-t, J=
8.0, 2H, SO2Ph-m-H), 7.54 (s, 1H, C2H), 7.30
(app-t, J= 7.7, 1H, C7H), 7.22 (app-t, J= 7.8,
1H, C6H), 4.23 (app-t, J = 4.3, 1H, CIIH),
3.66 (q, J= 7.0, 1 H, CIsH), 3.20 (dd, J= 14.5,
4.1, 1H, C12H), 3.00 (dd, J = 14.5, 4.7, 1H,
C12H), 0.44 (d, J= 7.0, 3H, CCH 3).
6 167.8 (C 13), 166.5 (C1 6), 137.0 (SO 2Ph-ipso-
C), 134.5 (SO2Ph-p-C), 133.9 (C9), 130.9
(C4 ), 129.9 (SO2Ph-m-C), 126.6 (SO2Ph-o-C),
125.4 (C2), 124.7 (C7), 123.2 (C6), 120.5 (C5),
117.3 (C3), 112.8 (C), 54.3 (C1,), 49.6 (C,5 ),
27.8 (C12), 19.3 (C, 7).
3180 (br, in), 2830 (in), 1662 (s), 1442 (s),
1374 (in).
calc'd for C2oHi 9N3NaO4S [M+Na]*:
420.0994, found: 420.0988.
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(+)-81
Monomeric Tetracyclic Diketopiperazine Bromide (+)-81:
A solution of bromine (2.07 M, 12.0 mL, 24.9 mmol, 4.12 equiv) in acetonitrile was
added over 15 seconds via syringe to a suspension of diketopiperazine (-)-80 (2.40 g, 6.04
mmol, 1 equiv) in acetonitrile (60 mL) at 0 'C. After 5 min, a mixture of saturated aqueous
sodium thiosulfate solution and saturated aqueous sodium bicarbonate solution (1:1, 100 mL)
was added to the resulting orange reaction solution. The mixture was extracted with ethyl
acetate (3 x 200 mL), and the combined organic layers were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure to yield a colorless foamy
residue. The residue along with silica gel (10 g) was dissolved in acetone (100 mL), and after 5
min the volatiles were removed under reduced pressure. The sample of product adsorbed onto
silica gel was purified by flash column chromatography on silica gel (eluent: 10% isopropanol,
40% hexanes, 50% dichloromethane) to provide the desired endo-(2S,3S)-monomeric tetracyclic
diketopiperazine bromide (+)-81 (2.19 g, 76%) as the major product. (The minor exo-(2R,3R)-
diastereomer S1 was also isolated from this reaction (540 mg, 19%)).
'H NMR (500 MHz, CDCl 3, 20 "C):
3 C NMR (125.8 MHz, CDCl3, 20 *C):
FTIR (thin film) cm~1 :
HRMS (ESI) (m/z):
8 7.94 (d, J= 7.6, 2H, SO 2Ph-o-H), 7.56 (d, J
= 8.2, 1H, C8H), 7.50 (t, J= 7.5, 1H, SO2Ph-
p-H), 7.40 (app-t, J = 7.8, 2H, SO 2Ph-m-H),
7.34 (d, J = 7.7, 1H, CsH), 7.29 (t, J = 8.5,
1H, C7H), 7.11 (t, J= 7.5, 1 H, C6H), 6.24 (s,
1H, C2H), 5.39 (s, 1H, NI4H), 4.42 (dd, J=
8.9, 5.9, 1H, CIIH), 4.08 (q, J = 6.9, 1H,
Ci 5H), 3.37 (dd, J = 14.3, 5.9, 1H, Cj 2Ha),
2.98 (dd, J= 14.3, 9.1, 1H, C12Hb), 1.47 (d, J
= 6.9, 3H, CCH 3).
6 168.5 (C16), 168.1 (C13), 138.9 (C9), 138.0
(SO 2Ph-ipso-C), 133.9 (SO2Ph-p-C), 133.5
(C4), 131.1 (C7), 129.1 (SO 2 Ph-m-C), 128.4
(SO 2 Ph-o-C), 125.9 (C6), 125.0 (Cs), 117.0
(C), 87.1 (C2), 61.3 (C3), 58.8 (C,1), 52.3
(C, 5 ), 40.0 (C12), 15.6 (C17).









+120 (c = 1.1, CHCl3).
93 *C (dec).
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(+)-82
Monomeric Tetracyclic N-Methyl Diketopiperazine Bromide (+)-82:
Potassium carbonate (13.8 g, 99.8 mmol, 25.1 equiv) and methyl iodide (32 mL) were
sequentially added to a vigorously stirred solution of tetracyclic amide (+)-81 (1.90 g, 3.98
mmol, 1 equiv) in acetone (48 mL) at 23 *C. The reaction flask was covered in aluminum foil,
and the suspension was stirred for 5 days at 23 'C. The volatiles were removed, and the
resulting white residue was partitioned between ethyl acetate (200 mL) and deionized water (200
mL). The layers were separated, and the aqueous layer was further extracted with ethyl acetate
(200 mL). The combined organic layers were dried over anhydrous sodium sulfate, were
filtered, and were concentrated under reduced pressure to provide crude (+)-82 as a yellow foam.
This residue was purified by flash column chromatography on silica gel (eluent: 5% isopropyl
alcohol, 45% dichloromethane, 50% hexanes) to afford the (1 S)-monomeric tetracyclic N-
methyl diketopiperazine bromide (+)-82 (1.32 g, 77%) as a colorless foam. (In addition to (+)-
82, a minor (11R)-diastereomer was also isolated (11%), highlighting the sensitivity of this
system to epimerization.)
'H NMR (500 MHz, CDCl 3, 20 *C):
13 C NMR (125.8 MHz, CDCl3, 20 *C):
FTIR (thin film) cm-:
HRMS (ESI) (m/z):
6 7.92 (d, J = 7.9, 2H, SO 2Ph-o-H), 7.54 (d, J
= 8.0, 1H, CAH), 7.50 (t, J= 7.5, 1H, SO2Ph-
p-H), 7.39 (app-t, J = 7.7, 2H, SO 2Ph-m-H),
7.33 (d, J = 8.1, 1H, C5 H), 7.27 (t, J = 8.3,
1H, C7H), 7.11 (t, J= 7.5, 1H, C6H), 6.24 (s,
1H, C2 H), 4.35 (app-dd, J = 8.9, 6.5, 1H,
C IH), 4.04 (q, J= 7.0, 1H, C14H), 3.34 (dd, J
= 14.4, 6.6, 1H, C12Ha), 3.04 (dd, J = 14.4,
8.9, 1H, C12Hb), 2.89 (s, 3H, NCH3 ), 1.58 (d,
J= 7.0, 3H, CCH 3).
6 167.7 (C 16), 167.4 (C13), 138.9 (C9), 138.0
(SO 2 Ph-ipso-C), 133.9 (C4), 133.8 (SO2 Ph-p-
C), 130.9 (C7), 129.1 (SO 2 Ph-m-C), 128.4
(SO2Ph-o-C), 126.0 (C6 ), 125.0 (Cs), 117.1
(C), 87.3 (C2 ), 61.1 (C3 ), 58.2 (Ci,), 57.2
(C14), 41.4 (C12), 29.7 (C, 8 ), 14.6 (C17).







[]oD22: +84 (c = 1.0, CHCl3).
TLC (5% isopropanol, 45% hexanes,.50% dichloromethane), Rf: 0.34 (UV, CAM).
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Dimeric Octacyclic Diketopiperazine (+)-83:
Tris(triphenylphosphine)cobalt (I) chloride complex 7'8 (442 mg, 502 pmol, 1.50 equiv)
was added as a solid to a solution of tetracyclic bromide (+)-82 (164.0 mg, 334.4 pLmol, I equiv)
in anhydrous, degassed (N2 stream, 10 min) acetone (3.3 mL) at 0 'C. The reaction mixture was
allowed to warm to 23 *C. After 10 min, the resulting blue-green solution was diluted with
dichloromethane (20 mL) and partitioned with saturated aqueous ammonium chloride (20 mL).
The organic layer was collected, and the aqueous layer was further extracted with
dichloromethane (2 x 10 mL). The combined organic layers were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (eluent: 5% isopropyl alcohol, 45% hexane, 50%
dichloromethane) to yield dimeric octacyclic diketopiperazine (+)-83 (63.0 mg, 46%) as a
colorless solid. On a 1.91-g scale the above procedure provided the desired product (+)-83 in
44% yield (701 mg). Notably, on larger scales (e.g., 8.07-g scale, 82:(1IR)-82=5:1) this
dimerization can provide the desired product (+)-13 with similar efficiency (2.41 g, 43%) even
without the challenging chromatographic separation of the minor diastereomer (1 IR)-82 whose
byproducts are easily separated post-dimerization.
'H NMR (500 MHz, CDC13, 20 *C):
3 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
6 8.07 (d, J = 7.7, 4H, SO2 Ph-o-H), 7.60 (t, J
= 7.3, 2H, SO2Ph-p-H), 7.52 (app-t, J = 7.7,
4H, SO 2Ph-m-H), 7.32 (d, J= 7.6, 2H, C5H),
7.28 (t, J = 7.6, 2H, C7H), 7.19 (t, J = 7.5,
2H, C6H), 7.03 (d, J= 8.0, 2H, C8H), 6.42 (s,
2H, C2H), 4.58 (app-t, J = 8.9, 2H, CH),
3.97 (q, J = 7.0, 2H, CI5H), 2.82 (s, 6H,
NCH3 ), 2.75 (dd, J= 15.0, 9.5, 2H, Ci 2Ha),
2.56 (dd, J= 15.0, 8.6, 2H, C12Hb), 1.35 (d, J
= 7.0, 6H, CCH 3).
6 169.3 (C16), 168.2 (C13), 142.2 (C 9), 141.7
(SO 2 Ph-ipso-C), 135.5 (C4), 133.1 (SO2 Ph-p-
C), 129.6 (C6), 129.1 (SO 2 Ph-m-C), 127.5
(Cs), 127.2 (SO 2Ph-o-C), 125.2 (C 7), 117.4
(C), 81.9 (C2 ), 59.5 (C3), 57.4 (C,,), 57.1
(Cs), 34.1 (C, 8 ), 29.9 (C,2 ), 15.1 (C17).
3064 (br, m), 1681 (s), 1478 (m), 1343 (s),
1163 (s).
calc'd for C 4 2H4 0N 6NaO8 S2  [M+Na]*:
843.2241, found: 843.2260.
Aresta, M.; Rossi, M.; Sacco, A. Inorg. Chim. Acta 1969, 3, 227.
8 Baysdon, S. L.; Liebeskind, L. S. Organometallics 1982, 1, 771.
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[a]D21: +21 (c = 1.0, CHC13).
M.p.: 193-195 'C (dec).
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Dimeric Octacyclic Tetraol (+)-84:
Bis(pyridine)silver(I) permanganate (4.43 g, 11.5 mmol, 4.80 equiv) was added as a
solid to a solution of dimeric octacyclic diketopiperazine (+)-83 (1.97 g, 2.40 mmol, 1 equiv) in
anhydrous dichloromethane (24 mL) at 23 'C. After 2 h, the resulting thick brown suspension
was poured into an aqueous sodium bisulfite solution (1 M, 100 mL), and the resulting mixture
was extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed
with aqueous copper sulfate solution (1M, 1 x 100 mL), were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (eluent: 30% acetone in dichloromethane) to
afford dimeric octacyclic tetraol (+)-84 as a colorless solid (1.33 g, 63%). Crystals suitable for
X-ray diffraction were obtained by vapor diffusion of pentane into a saturated solution of dimeric
octacyclic tetraol (+)-84 in acetone at 23 'C. For a thermal ellipsoid representation of (+)-84 see
page S18. (Signal broadening in the 'H NMR spectrum of (+)-84 is partly attributed to the
influence of hydrogen bonding by the C1 50H. Silylation of this hydroxyl group dramatically
decreases signal broadening in addition to providing a less polar compound evident by its Rf on
silica gel.)
'H NMR (500 MHz, CDCl 3, 20 "C):
3C NMR (125.8 MHz, CDCl 3, 20 "C):
FTIR (thin film) cm-':
HRMS (ESI) (m/z):
8 7.95 (d, J = 7.3, 4H, SO 2 Ph-o-H), 7.59 (t, J
= 7.2, 2H, SO 2 Ph-p-H), 7.51 (app-t, J = 7.6,
4H, SO 2Ph-m-H), 7.31 (br-s, 2H, C6H), 7.23-
7.15 (m, 6H, C5H, C7H, C8H), 6.85 (s, 2H,
C2H), 5.54 (br-s, 2H, OH), 4.07 (br-s, 2H,
OH), 3.06 (d, J= 13.3, 2H, CI2Ha, 2.89 (s, 6H,
NCH 3 ), 2.90-2.83 (br-d, 2H, C,2Hb), 1.32 (s,
6H, CCH3).
6 169.3 (C, 6), 167.1 (C,3 ), 142.1 (SO 2 Ph-ipso-
C), 141.4 (C9), 134.0 (C4), 132.9 (SO2Ph-p-
C), 129.9 (C6), 129.0 (SO 2 Ph-m-C), 126.8
(C5), 126.2 (SO 2 Ph-o-C), 125.0 (C7 ), 116.2
(C8), 86.6 (C,,), 85.4 (Ci5 ), 82.6 (C2 ), 58.9
(C3), 43.8 (CI2), 27.7 (CIs), 23.1 (C17).
3420 (br, m), 1684.3 (s), 1352 (s), 1168 (s),
1096 (m).
calc'd for C 42H4 oN 6NaO, 2 S2
907.2038, found: 907.2029.
[M + Na]*:
[a]D" I : +5.0 (c = 1.0, CHCl3).
9 Firouzabadi, H.; Vessal, B.; Naderi, M. Tetrahedron Lett. 1982, 23, 1847.
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M Fe Me O SO 2 Ph % nOe
Me Me Me 0 H, N
Me Me2tBuSiO''- N 0 1%1
Me TBSCI, PPY Me'N _ HO 1DMF, Et 3N 0 OH ', N'
OH 23 0c, 30 min 3 . N 16 -'OSiBuMe2Vle 55% (+)-85 / N 'H Me
8 SO 2Ph 0 17
Dimeric Octacyclic Diol (+)-85:
To a solution of dimeric octacyclic tetraol (+)-84 (11.8 mg, 13.3 pmol, 1 equiv) and (R)-
(+)-4-pyrrolidinopyrindinyl(pentamethylcyclopentadienyl)iron (PPY, 0.3 mg, 0.7 pimol, 0.05
equiv) in anhydrous NN-dimethylformamide (250 pL) at 23 *C was added triethylamine (11.1
pL, 79.8 pmol, 6.00 equiv) followed by tert-butyldimethylsilyl chloride (10.0 mg, 66.5 p1mol,
5.00 equiv) in one portion. After 30 min, the reaction mixture was diluted with ethyl acetate (20
mL) and partitioned with saturated aqueous ammonium chloride solution (10 mL). The aqueous
layer was further extracted with ethyl acetate (2 x 10 mL) and the combined organic layers were
dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure to provide a colorless solid. This solid was purified by flash column chromatography on
silica gel (eluent: gradient, 10% ethyl acetate in hexanes to 30% ethyl acetate in hexanes) to
afford the dimeric octacyclic diol (+)-85 (8.2 mg, 55%) as a white solid.
'H NMR (500 MHz, CDCl 3, 20 *C):
3 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm~1 :
HRMS (ESI) (m/z):
6 7.87 (d, J = 7.9, 4H, SO2Ph-o-H), 7.62 (br s,
2H, CsH), 7.50 (t, J = 7.2, 2H, SO2Ph-p-H),
7.42 (t, J = 7.9, 4H, SO 2 Ph-m-H), 7.12 (m,
4H, C6H, C7H), 7.07-7.04 (m, 2H, CH), 6.84
(s, 2H, C2H), 4.66 (s, 2H, OH), 3.26 (d, J =
15.1, 2H, C12Ha), 3.14 (d, J = 15.1, 2H,
C12H), 2.87 (s, 6H, NCH3), 1.20 (s, 6H,
CCH3 ), 0.80 (s, 18H, SiC(CH3) 3), 0.11 (s, 6H,
SiCH 3), 0.10 (s, 6H, SiCH 3).
6 168.1 (C 16), 166.7 (C 13), 143.0 (SO 2Ph-ipso-
C), 141.4 (C9), 134.1 (C 4), 132.4 (SO2Ph-p-
C), 129.5 (C7 ), 128.7 (SO 2Ph-m-C), 126.3
(Cs), 126.1 (SO 2Ph-o-C), 124.9 (CO), 115.8
(Cs), 87.0 (C15), 86.2 (C11), 82.5 (C 2), 59.3
(C3), 44.7 (C12), 27.6 (Ci 8), 25.8 (SiC(CH3)3),
25.5 (C 1 7), 18.4 (SiC(CH3)3), -2.8 (SiCH3 ), -
3.4 (SiCH3).
3451 (br), 1722 (s), 1682 (s), 1358 (s), 1169
(s).
calc'd for C54 H6 8N6NaO 2 S2 Si 2 [M+Na]*:
1135.3767, found 1135.3733.
+22 (c = 1.0, CHC 3).
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O SO 2Ph O HMe H N /Me H, N
TBSO'* N' TBSO'Y- N 0~TSNC O5% Na(Hg), NaH 2PO4  TMeN HO 
_________ MeN HO 1
6H ~. NMe OH NWeO , N OTBS MeOH, 23 *C, 1 h O O N OTBS
(+)-85 N H Me 87% (+)-86 OSO2Ph 0 H 0 17
Dimeric Octacyclic Diaminodiol (+)-86:
To a vigorously stirred white suspension of dimeric octacyclic diol (+)-85 (48.8 mg, 43.8
ptmol, 1 equiv) and monobasic sodium phosphate (210 mg, 1.75 mmol, 40.0 equiv) in anhydrous
methanol (1.7 mL) at 23 'C was added freshly prepared sodium amalgam (5%-Na, 370 mg, 803
pmol, 18.3 equiv Na) in one portion. After 51 min, a second portion of sodium amalgam (5%-
Na, 370 mg, 803 pmol, 18.3 equiv Na) was added. After 15 min, the reaction mixture was
diluted with ethyl acetate (20 mL) and partitioned with saturated aqueous sodium bicarbonate
solution (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL) and the
combined organic layers were dried over anhydrous sodium sulfate, were filtered, and were
concentrated under reduced pressure to afford a colorless solid. The solid was purified by flash
column chromatography on silica gel (eluent: 30% ethyl acetate, 70% hexanes) to afford the
dimeric octacyclic diaminodiol (+)-86 (31.8 mg, 87%) as a colorless solid.
H NMR (500 MHz, CDCl 3, 20 *C):
3 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm':
HRMS (ESI) (m/z):
TLC (30% ethyl acetate in hexanes), RfJ
6 7.14 (d, J= 7.6, 2H, C5H), 7.08 (app-t, J =
7.5 Hz, 2H, C7H), 6.75 (app-t, J = 7.4, 2H,
C6H), 6.58 (d, J= 7.7, 2H, C8H), 5.86 (s, 2H,
C2H), 5.53 (s, 2H, NIH), 4.24 (s, 2H, CIIOH),
2.90 (s, 6H, NCH 3), 2.85 (s, 4H, C12H), 1.68
(s, 6H, CCH3) , 0.85 (s, 18H, SiC(CH 3)3),
0.23 (s, 6H, SiCH3), 0.14 (s, 6H, SiCH3).
167.7 (C 13), 166.7 (C16), 148.6 (C 9), 130.9
(C4), 129.3 (C 7), 127.1 (C5 ), 119.2 (C6), 109.9
(C), 87.1 (C15), 86.2 (C11), 82.0 (C2 ), 59.0
(C3), 44.4 (C 12), 28.0 (C18 ), 25.7 (C(CH3 )3),
23.8 (C17), 18.3 (C(CH3 )3), -2.5 (SiCH3), -3.4
(SiCH3)
3367 (br), 2929 (m), 1683 (s), 1387 (m), 1147
(m)
calc'd for C4 2H6oN6NaO8 Si 2  [M+Na]*:
855.3903, found: 855.3955









Dimeric Decacyclic Bisdithiepanethione (+)-88:
To a yellow solution of potassium trithiocarbonate10 (80.5 mg, 432 pimol, 10.0 equiv) in
anhydrous dichloromethane (2.6 mL) and trifluoroacetic acid (1.1 mL) at 23 *C was added a
solution of the dimeric diol (+)-86 (36.0 mg, 43.2 pmol, 1.00 equiv) in dichloromethane (700
ptL). The transfer was completed with an additional portion of dichloromethane (300 pL). An
additional portion of trifluoroacetic acid (100 pL) was added to the reaction mixture via syringe.
After 28 min, the reaction mixture was diluted with dichloromethane (20 mL) and washed with
saturated aqueous sodium bicarbonate (20 mL). The aqueous layer was extracted with
dichloromethane (2 x 20 mL) and the combined organic layers were dried over anhydrous
sodium sulfate, were filtered, and were concentrated under reduced pressure to yield a yellow
powder. This powder was purified by flash column chromatography on silica gel (eluent: 3%
acetone, 97% dichloromethane) to afford dimeric decacyclic bisdithiepanethione (+)-88 (18.3
mg, 56%) as a yellow powder.
'H NMR (500 MHz, CDCI3, 20 *C):
13 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (5% acetone in dichloromethane), Rf:
6 7.33 (d, J= 7.6, 2H, C5H), 7.19 (app-t, J=
7.7 Hz, 2H, C7H), 6.90 (app-t, J = 7.4, 2H,
CH), 6.63 (d, J = 7.9, 2H, CH), 5.48 (s, 2H,
C2H), 5.13 (s, 2H, NIH), 3.50 (d, J = 15.2,
2H, C12 Ha), 3.02 (s, 6H, NCH 3), 2.75 (d, J =
15.2, 2H, C12Hb), 1.91 (s, 6H, CCH 3).
6 215.4 (C19), 164.7 (C13), 161.8 (C16), 149.3
(C9), 131.0 (C7), 126.3 (C4), 126.0 (Cs), 120.6
(C6), 111.0 (Cs), 81.5 (C2 ), 74.9 (CO), 73.0
(C, 5 ), 59.0 (C3 ), 42.6 (C12), 28.5 (Ci8 ), 19.9
(C17).
3364 (m, br), 1683 (s), 1608 (m),
1003 (m).




+280 (c = 1.0, CHCl3).
0.37 (UV, CAM).
'0 Stueber, D.; Patterson, D.; Mayne, C. L.; Orendt, A. M.; Grant, D. M.; Parry, R. W. Inorg. Chem. 2001, 40, 1902.
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To a solution of the dimeric decacyclic bisdithiepanethione (+)-88 (11.8 mg, 15.7 pmol,
1.00 equiv) in acetone (500 pL) at 23 'C was added ethanolamine (500 pL) via syringe. After 15
min, the reaction mixture was diluted with dichloromethane (15 mL) and aqueous hydrochloric
acid solution (1 N, 10 mL). The organic layer was collected, and the aqueous layer was
extracted with dichloromethane (2 x 5 mL). A solution of potassium tri-iodide in pyridine (2.5%
w/v) was added drop wise to the combined organic layers until a persistent yellow color was
observed. The resulting mixture was washed with aqueous hydrochloric acid (1 N, 20 mL) and
the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 10 mL),
and the combined organic layers were dried over anhydrous sodium sulfate, were filtered, and
were concentrated under reduced pressure to provide a brown residue. The residue was purified
by flash column chromatography on silica gel (eluent: gradient, 100% dichloromethane to 10%
acetone in dichloromethane) to afford 12,12'-dideoxyverticillin A (+)-1 (6.5 mg, 62%) as a
colorless solid. Crystals suitable for X-ray diffraction were obtained by vapor diffusion of
pentane into a saturated solution of 12,12'-dideoxyverticillin A (+)-1 in dichloromethane at 4 0C.
For a thermal ellipsoid representation of (+)-1 see page S27.
'H NMR (500 MHz, CDCl3, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm~-:
HRMS (ESI) (m/z):
[aCD 21:
TLC (10% acetone in dichloromethane), Rf:
6 7.38 (d, J= 7.5 Hz, 2H, C5H), 7.20 (dt, J=
7.5, 1.0 Hz, 2H, C7H), 6.86 (dt, J = 7.5, 1.0
Hz, 2H, C6H), 6.70 (d, J = 8.0 Hz, 2H, C8H),
5.28 (s, 2H, NiH), 5.24 (s, 2H, C2H), 3.82 (d,
J = 15.0 Hz, 2H, C12H), 2.95 (s, 6H, CI8H),
2.72 (d, J= 15.0 Hz, 2H, C12H), 1.86 (s, 6H,
C17H).
6 165.8 (C13), 162.7 (C16 ), 149.5 (C 9), 130.5
(C7 ), 127.9 (C4 ), 125.3 (Cs), 120.3 (C6 ), 110.8
(C), 80.8 (C2 ), 73.8 (C,,), 73.4 (C15 ), 60.0
(C3 ), 39.9 (C12), 27.7 (C,8 ), 18.0 (C]7).
3367 (m), 1683 (s), 1608 (m), 1468 (m), 1349
(m), 1319 (m), 1254 (m), 1213 (m), 1066 (m),
753 (m).
calc'd for C3 0H2 9N60 4S4 [M+H]*: 665.1133,
found: 665.1128.




Table S1. Comparison of our data for (+)-12,12'-Dideoxyverticillin A (1) with literature:
Assignment" Fenical's Report'2  This Work
(+)- 12,12'-Dideoxyverticillin A (1) (+)-12,12'-Dideoxyverticillin A (1)
H NMR, 300 MHz, CDC13  'H NMR, 500 MHz, CDC13, 20 "C
Ni 5.30(s) 5.28(s)
C2 5.26 (s) 5.24 (s)
C3
C4
C5 7.41 (d, J= 8.0 Hz) 7.38 (d, J= 7.5 Hz)
C6 6.88 (ddd, J= 8.0, 7.0, 1.0 Hz) 6.86 (app-dt, J= 7.5, 1.0 Hz)
C7 7.21 (ddd, J= 8.0, 7.0, 1.0 Hz) 7.20 (app-dt, J= 7.5, 1.0 Hz)










C18 2.97 (s) 2.95 (s)
" Please see page S2 for the positional numbering system used here.
2 Son, B. W.; Jensen, P. R.; Kauffman, C. A.; Fenical, W. Nat. Prod. Res. 1999, 13, 213.
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Table S2. Comparison of our data for (+)-12,12'-dideoxyverticillin A (1) with literature:
AssignmentI Fenical's Report12  This Work
(+)-12,12'-Dideoxyverticillin A (1) (+)-12,12'-Dideoxyverticillin A (1)





















Table S3. Crystal data and structure refinement for dimeric octacyclic tetraol (+)-84.
Identification code d08036






Unit cell dimensions a= 11.7728(2) A a= 900.
b = 12.0547(2) A b= 90 .











Completeness to theta = 67.57'
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter





0.44 x 0.15 x 0.07 mm 3
2.50 to 67.570.
-14<=h<=13, -14<=k<= 14, -42<=<=42
47652




Full-matrix least-squares on F2
9009/4/689
1.040
RI = 0.0388, wR2 = 0.1031
RI = 0.0409, wR2 = 0.1048
0.020(13)
1.217 and -0.269 e.A-3
13 Dimeric octacyclic tetraol (+)-84 crystallized with three molecules of acetone in the unit cell.
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Table S4. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2 X
103) for dimeric octacyclic tetraol
orthogonalized U tensor.
(+)-84. U(eq) is defined as one third of the trace of the








































































































































































































































































































































































































































































































































































































































































































































C(2 1)-C(1 6)-C(1 7)
C(2 I)-C(1 6)-S(1)
C(1 7)-C(16)-S(1)




C(I 8)-C(I 7)-C( 16)
C(1 7')-C(1 8')-C(1 9')






































































Table S6. Anisotropic displacement parameters (A2 x 103) for dimeric octacyclic tetraol (+)-84.
The anisotropic displacement factor exponent takes the form: -2p 2 [h2 a* 2U" + ... + 2 h k a* b*
u12U1]
















































































































































































































































































































































































































































































































































Table S7. Hydrogen coordinates (x 104 ) and isotropic displacement parameters (A2 x 103) for
dimeric octacyclic tetraol (+)-84.



































































































































































































































































































Table S8. Hydrogen bonds for dimeric octacyclic tetraol (+)-84 [A and 0].
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
O(2)-H(20)...O(IT)#1 0.848(19) 2.09(2) 2.858(3) 150(3)
O(2')-H(20')...O(2)#2 0.877(18) 2.01(2) 2.810(3) 151(3)
O(4)-H(40)...O(IS) 0.811(18) 1.934(19) 2.732(3) 168(3)
O(4')-H(40')...O(1T) 0.856(18) 1.95(2) 2.759(3) 158(3)
Symmetry transformations used to generate equivalent atoms:
#1 x- 1/2 ,-y+I /2,-z #2 x+ I/2,-y+I /2,-z
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Table S9. Crystal data and structure refinement for (+)-12,12'-dideoxyverticillin A (1).
Identification code 08235





Space group P 21
Unit cell dimensions a = 7.7892(7) A a= 90'.
b = 20.8034(18) A b= 100.540(2) .











Completeness to theta = 29.570
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter





0.35 x 0.25 x 0.13 mm 3
1.85 to 29.570.
-1I0<=h<= 10, -28<=k<=28, -15<=l<= 15
46036




Full-matrix least-squares on F2
9986 / 73 / 500
1.047
RI = 0.0326, wR2 = 0.0788
RI = 0.0369, wR2 = 0.0819
-0.03(3)
0.624 and -0.235 e.A-3
14 The crystal that was selected for analysis contained (+)-11,1l'-dideoxyverticillin A (1) in 92% of the unit cells
whereas 8% of the unit cells contained the target along with a single chlorine atom on C6 likely due to attempted
crystal growth in chloroform. This was treated as a disorder, the ratio was refined freely, and the free variable
converged at 0.917(3). The calculated empirical formula thus contains non-integer values for the elements H and
Cl.
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Table S10. Atomic coordinates (x 104)
10') for (+)-12,12'-dideoxyverticillin A
orthogonalized U'j tensor.
and equivalent isotropic displacement parameters (A2 X
(1). U(eq) is defined as one third of the trace of the










































































































































































































































































































































































































































































































































































































Table S12. Anisotropic displacement parameters (A2 x 103) for (+)-12,12'-dideoxyverticillin A
(1). The anisotropic displacement factor exponent takes the form: -2p 2[h2 a* 2 U" ± ... + 2 h k a*
b* U12 ]



































































































































































































































































































































































































Table S13. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) for
(+)-12,12'-dideoxyverticillin A (1).












































































































































































Table S14. Hydrogen bonds for (+)-12,12'-dideoxyverticillin A (1) [A and ].
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
N(3)-H(3)...O(3)#1 0.890(16) 1.981(17) 2.844(2) 163(2)
N(6)-H(6)...O(4) 0.842(16) 2.67(2) 3.090(2) 112.5(19)




General Approach to Epipolythiodiketopiperazine Alkaloids:




(+)-12,12'-dideoxyverticillin A (1), R=H (+)-chaetocin A (3), R=H(+)-verticillin A (2), R=OH (+)-chaetocin A diacetate (4), R=Ac
o H 0 H
S KH N S H, N
RO N HO t S N
Me', 
-,* l\~N'Me Me', ,2' , 'M
O N'OR ONN OH
N H SS NH N8 H 0 8 H O
(+)-chaetocin C (5), R=H (+)-12,12'-dideoxychetracin A (7), R=H(+)-chaetocin C diacetate (6), R=Ac (+)-chetracin A (8), R=OH
Figure 1. Representative dimeric epipolythiodiketopiperazine alkaloids.
Dimeric epipolythiodiketopiperazine alkaloids comprise the core bioactive constituents of
the highly cytotoxic extracts from fungi of the Chaetomium genus."2 Studies have recognized the
central role of the polysulfide bridge in the virulence of this class of metabolites,3cd noting an
increase in potency with a corresponding increase in the degree of sulfuration among related
isolates. 2 While the total synthesis of both monomeric 4'5 and dimeric6'7 epidithiodiketopiperazine
alkaloids have been addressed in previous reports, the late stage selective and efficient access to
higher order polysulfides continues to remain a challenge.! In 2009, we reported the first total
synthesis of a dimeric epidithiodiketopiperazine (+)-12,12'-dideoxyverticillin A (j),6,9 and
recently, Sodeoka reported the total synthesis of (+)-chaetocin A (3).7'1 To date, there are no
reported total syntheses of dimeric epitri- and epitetrathiodiketopiperazines. Herein, we present a
general approach to the dimeric epipolythiodiketopiperazine alkaloids via syntheses of the di-,
tri-, and tetrasulfides (+)-chaetocin A (3), (+)-chaetocin C (5), and (+)-12,12'-dideoxychetracin A
(7), respectively.
Previous Synthesis of (+)-Chaetocin A
After completion of our synthesis of (+)-chaetocin A (1), but prior to its publication in
2010, Sodeoka and co-workers reported the first total synthesis of this dimeric
epidithiodiketopiperazine alkaloid 7 mirroring the chemistry and strategies developed in our
synthesis of 12,12'-dideoxyverticillin A (1).6 Their synthesis, outlined in Scheme 1, commenced
89
0O 0
HO H 5-steps HN'Me Br H-'N'Me
CbzN -CO 2H HN BocN H'N a
Me H~A' N H~H
5-steps from CIH 3N CO2Me 9 0 OTBS Boc 0 OTBS
D-serine
O BocHO Ht N 0
TBSO M NOT HO BSrB
0
NcHO . S Brta s Me Br, 3 CMeH MeCN (: v) , N
E C , - 2 COH i N"M H B11N OTBS N''r
13 O Boo 0 OTBS Bo0 OTBS
NH H 12 11
L~.(+)-chaetocin A (1)
Scheme 1. Sodeoka's total synthesis of (+)-chaetocin A (1). Conditions: (a) NBS, MeCN, -30 'C, 88%. (b) NBS, V-
70, CCI4 , 23 'C. (c) pH 7 phosphate buffer/M~eCN (1: 1 v/v), 23 0C, 47% (2-steps). (d) CoCI(PPh3)3, acetone, 23 'C,
55%. (e) 1-2S, BF3;Et2O, CH 2Cl2, -78--+23 'C; 12, 44%.
with the assembly of diketopiperazine 9 from D-serine and D-tryptophan derivatives followed by
bromocyclization. Radical bromination of the labile Ca-H bonds of the diketopiperazine enabled
solvolysis under aqueous conditions to afford diol 12 as a mixture of four diastereomers.
Unfortunately, separation of the major diastereomer by chiral HPLC was necessary before
further progress could be made in the synthesis. Dimerization of diol 12 using CoCl(PPh 3)3 then
afforded tetraol 13, which also required MPLC separation from reduction byproducts. Finally,
Lewis acid-mediated ionization of the hemiaminals enabled thiolation with hydrogen sulfide
with concomitant deprotection of the tert-butoxycarbonyl and silyl ether groups to complete the
total synthesis of (+)-chaetocin A (1). It is important to note that the halocyclization, cobalt-
mediated dimerization, radical halogenation of diketopiperazines, and thiolation bore close
resemblance to transformations reported in our prior studies. The unaddressed issues of
selectivity are the focal points of our own work.
Results and Discussion
Total Synthesis of Epipolythiodiketopiperazines
Complete stereochemical control in thiolation and precision in the degree of sulfidation
served as the central tenets of our retrosynthetic strategy toward epipolythiodiketopiperazines as
delineated in Scheme 2. We envisioned that all sulfur homologs of epipolythiodiketopiperazines
could be derived selectively and systematically from the corresponding polysulfanes by final
90
Y= -, S, SS
S-thiolation
and C15-activation
U II .stereo- and 0~ H i
R I regioselective R=0 1 CI-sulfuration SHON Me n N SHO
Me'Me MeH ~ ~ N Me H
N ~N'R N'A
0~ N 1  0 H
17 NH 0 16 H 0
Scheme 2. Retrosynthetic analysis for epipolythiodiketopiperazine alkaloids.
stage intramolecular cyclization onto a C1 5-iminium ion such as 15. Recognizing dithiol 16 as a
key intermediate, we strived to access all the necessary polysulfanes by oxidation and subsequent
application of an advanced stage stereo- and regioselective C1 1-sulfuration of a common dimeric
diketopiperazine intermediate 17. Such a solution would enable the controlled synthesis of tetra-
hexa-, and octasulfurated congeners.
Our synthesis of dimeric diketopiperazine (-)-22, a common precursor to target
epipolythiodiketopiperazines 3-7, is illustrated in Scheme 3. Bromocyclization of the
diketopiperazine (-)-18,' la which was synthesized in three steps from commercially available N-
Boc-L-tryptophan and L-serine methyl ester hydrochloride, 2 afforded the endo-tetracyclic
bromide (+)-19 in 59% with high diastereoselectivity. 3 Subsequent efforts to accomplish an N-
methylation using our previously developed conditions (K2CO 3, Mel, acetone)' ]a suffered from
elimination of the P-siloxy group; however, kinetic deprotonation followed by methylation at -
40 'C effectively circumvented the problem and afforded (+)-20 in 86% yield. A single-step
exchange of the silyl ether for an acetate then provided the key dimerization substrate (+)-21 in
85% yield, and CoCl(PPh 3)3 mediated reductive radical dimerization provided the dimeric
diketopiperazine (-)-22 in 49% yield." The dimer was selectively tetrahydroxylated6 using
Py2AgMnO 4 to provide our key intermediate (-)-23 in 55% yield. The high chemo- and
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Scheme 3. Enantioselective total synthesis of versatile intermediate (+)-27. Conditions: (a) Br 2, PhH, 59%. (b)
LHMDS, Mel, DM4PU-THF, -78 -> -40 OC, 86%. (c) HF-py, TI-IF, py; AcCi, 85%. (d) CoCl(PPh3)3, CH2CI 2, 49%.
(e) PY2AgWnO 4, CH2Cl2, 55%. (f) H2S, TFA, MeNO 2; LPrCOCl, CH2Cl 2, 53% (2-steps). (g) hv (350 nm), L-ascorbic
acid, ,4-dimethoxynaphthalene, H20, MeCN, 5 %.
Our initial attempts to introduce two pairs of sulfur atoms in a cis-selective fashion
proved ineffective due to the intransigence of the C15- and C15'-hydroxyls toward acid-
promoted ionization conditions. Both stereoelectronic and inductive factors of the serine side
chain adversely influenced the ionization potential of the hemniaminals, and while solvent and
field effects proved influential, harsher ionization conditions were incompatible with nearly all
of our previously examined cis-thiolation strategies.' 4 Development of milder conditions for the
desired chemoselective and stereocontrolled thiolation chemistry proved imperative.15
The innate reactivity differences between the CI I- and the CI15-hemiaminals permitted a
regio- and stereoselective introduction of sulfur critical to our general route to epidi-, epitri-, and
epitetrathiodiketopiperazines (Scheme 3). Exposure of tetraol (-)-23 to trifluoroacetic acid in
hydrogen sulfide-saturated nitromethane generated the sensitive bisthiohemiaminal 25 in a
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Scheme 4. Total synthesis of (+)-chaetocin A. Conditions: (a) N2H4, THF, 0 *C; NaH, Ph3CSCI, 90%. (b) BF 3 -OEt2 ,
2,6-di-'Bu-4-Me-pyridine, Et3SiH, CH 2Cl 2, 82%. (c) Otera's cat., MeOH, PhMe, 85 *C, 92%.
highly diastereoselective fashion.16 Concentration of the reaction mixture followed by addition
of isobutyryl chloride' 7 afforded the octacyclic bisthioisobutyrate (+)-26 in 53% yield (2-steps).
The isobutyrates served the dual role of preventing detrimental hemiaminal opening under polar
protic conditions and activating the C1 5-hemiaminal function in an anticipated mild ionization.
The unique challenges of C1 1-ionization in the presence of the C2-aminal substructure in
this system compelled the precedence of C 1 -thiolation over Ni -desulfonylation, a sequence
opposite to our previously established methodologies for synthesis of
epidithiodiketopiperazines.6 Nonetheless, we discovered that irradiating a solution of (+)-26
with a black light phosphor coated lamp in the presence of the photosensitizer 1,4-
dimethoxynaphthalene and the terminal reductant L-ascorbic acid cleanly provided the desired
diaminodithioisobutyrate (+)-27 in 51% yield.'" 9 Chemoselective hydrazinolysis of the
thioesters in the presence of the primary acetates provided dithiol (+)-30, which served as a
strategic point of divergence en route to the various polysulfide homologs.
Formation and sulfenylation of dithiol (+)-30, which could be performed in a single step,
afforded the corresponding bis(triphenylmethanedisulfide) (+)-28 in 90% yield (X=S, Scheme
4)20 Subsequent ionization of the isobutyrates and efficient cyclization with concomitant loss of
a triphenylmethyl cation were accomplished (82% yield) to give (+)-chaetocin A diacetate (4), a
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Scheme 5. Total synthesis of (+)-chaetocin C (5). Conditions: (a) N2H4, THF; Ph3CSSCl, NEt3 , 86%. (b) TFAA,
DTBMP, MeCN; BF 3-OEt 2 , 91%. (c) Otera's cat., MeOH, PhMe, 90 *C; N2H4 , 95%. (d) Ac 2 0, CH2C 2 , 70%.
derivative used in the isolation and characterizationI of (+)-3. Synchronized loss of the
triphenylmethyl cation was essential in accessing the rapidly disproportionating polysulfanes, a
central component of our synthetic strategy. Mild methanolysis of the acetates using Otera's
catalyst at 85 *C in toluene afforded the natural product (+)-chaetocin A (3) in 92% yield as a
white solid.' 0 All spectroscopic data for (+)-3 and (+)-4 matched those reported in the literature.'
We proceeded to examine our stereoselective thiolation strategy in the synthesis of more highly
sulfurated and challenging epipolythiodiketopiperazines. Bis(triphenylmethanetrisulfide) (+)-31
was smoothly obtained in 86% yield via the common dithiol (+)-30 when
chloro(triphenylmethane)disulfane (X=SS, Scheme 5) was used as the sulfenylating agent.
Attempts to cyclize (+)-31 to form the corresponding epitrithiodiketopiperazine using the
protocol developed for the bisdisulfide (vide supra) were, however, unsuccessful. The slower
rate of cyclization for formation of a larger ring may have enabled competing decomposition
pathways involving active participation of the NI lone pair. Trifluoroacetylation of the amines
imparted sufficient stability to allow subsequent C15-iminium ion formation, affording
trithiodiketopiperazine (+)-33 in 91% yield. Methanolysis of the acetates followed by in situ
hydrazinolysis of the trifluoroacetamides provided (+)-chaetocin C (5) in 95% yield, offering the
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first total synthesis of a dimeric epitrithiodiketopiperazine alkaloid. (+)-Chaetocin C (5) was
converted to (+)-chaetocin C diacetate (6) for direct comparison with data reported in the
isolation report.2 All spectroscopic data for (+)-6 matched those reported in the literature.2'2'
Interestingly, (+)-chaetocin C (5), which contains two epitrisulfide bridges, exists as a
1:2.4:5.5 mixture of three distinct conformers in chloroform at room temperature with the
intermediate conformer being of heterodimeric constitution.22 The distribution changes by
structure, however, as variable temperature NMR studies carried out on the more stable
derivative (+)-33 demonstrated that its three conformers exist in a 1:1.5:2.4 ratio in toluene-d at
90 C23 with the major conformer lacking a C2 symmetry axis. An activation barrier of ca. 23
kcal/mol was determined for their interconversion in 1,3,5-trimethylbenzene-d 2 . We report
the first complete characterization data for all three conformers of (+)-5 and (+)-6.12
Our general strategy for stereocontrolled synthesis of epipolythiodiketopiperazines
proved effective even for the synthesis of congeners possessing a tetrasulfide bridge, a motif
found in natural products such as (+)-chetracin A (8). The versatile dithiol intermediate (+)-30
was converted to the bis(triphenylmethanetetrasulfide) (-)-34 in 80% yield using
chloro(triphenylmethane)trisulfane (X=SSS, Scheme 6). In contrast to the disulfide series,
cyclization of the resulting tetrasulfide required conditions that were more favorable for the
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reversible disengagement of the neighboring acetate from the acyliminium ion. An adjusted
window of reactivity was also observed for the resulting product during post-cyclization
transformations. For example, while Ni-trifluoroacetylation of (-)-34 followed by ionization
provided the octasulfated homolog of 33, removal of the trifluoroacetamides proved ineffective
under a variety of nucleophilic and basic conditions. After significant experimentation, we
recognized that the epitetrasulfides were marginally tolerant toward acidic reaction conditions.
Thus, conversion of diamine (-)-34 to bisformamide 35 not only enabled successful synthesis of
dimeric epitetrathiodiketopiperazine (+)-36, but also allowed rapid removal of the acetyl and
formyl groups by acid catalyzed methanolysis to provide (+)-12,12'-dideoxychetracin A (7) in
52% yield. Unlike the epitrisulfides, the epitetrasulfide appears as a single conformer in solution
on the NMR timescale at room temperature. The preferred helicity of the staggered sulfur atoms
in the solid state was identified through the X-ray structure solution of (+)-7. 12
Anticancer Activity and Structure-Activity Relationship Studies
As part of our ongoing collaboration with the Hergenrother group, we wished to develop
a comprehensive SAR profile for the ETP alkaloids by thorough evaluation of their anticancer
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Figure 2. Molecules synthesized and evaluated for anticancer activity in this study.
Table 1. Assessment of a selection of the top compounds for cytotoxicity in five human cell lines {U-937
(hystiocytic lymphoma), HeLa (cervical carcinoma), H460 (lung carcinoma), 786-0 (renal carcinoma), and MCF-7
(breast carcinoma)} after a 72-hour exposure. Conditions: 72-hour IC50 values (in nM) as determined by MITS (U-
937) and SRB (HeLa, H460, 786-0, and MCF-7).32 Error is standard deviation of the mean, n > 3; IC50 = half
maximal inhibitory concentration; MTS = 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium; SRB = sulforhodamine B.
activities across multiple cell lines. All biological data presented in this section was acquired by
Ms. Karen C. Morrison from the Hergenrother research group.
Sulfur atoms have long been recognized as essential to the anti-cancer activity of ETP
natural products; however, a more refined understanding of structure-activity relationships has
been lacking. To identify how this and other structural elements within the
hexahydropyrroloindoline and diketopiperazine substructures are critical to the anticancer
activity, multiple derivatives of both monomeric and dimeric ETP alkaloids were synthesized
and evaluated. The general strategy for derivatives was to construct sets of compounds that
varied in the substituents about the hexahydropyrroloindoline carboskeleton and the nature,
extent, and configuration of sulfuration. A selection of compounds produced through these
synthetic efforts are depicted in Figure 2. The implementation of a highly modular and generally
applicable strategy for the synthesis of ETP-containing alkaloids has enabled the compilation of
60 derivatives of this class of natural products. This expansive collection of compounds was
instrumental in the development of a comprehensive SAR profile. Both verticillin- and
chaetocin-related compounds were investigated for antitumor activity and four sites were
targeted for derivatization in this study: N1, C3, C17, and C1 I/C15 (Figure 3).
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All 60 compounds synthesized for this study, a selection of which are depicted in Figure
2, were screened for their ability to induce death in two human cancer cell lines: U-937
(leukemic monocyte lymphoma) and HeLa (cervical cancer). In order to probe further the
potential of ETP alkaloids as anticancer agents, compounds that demonstrated anticancer activity
at I gM or below and were among the most potent from the primary screening (1, 3-7, 33, 37,
38), were tested in culture against a panel of three supplementary human cancer cell lines
representing three additional tumor histologies (H460, lung carcinoma; 786-0, renal carcinoma;
MCF-7, breast carcinoma). As shown in Table 1, the ETPs retain similar patterns of potency
across all of the cell lines although some compounds, such as 37, retain higher levels of activity
than others, such as 33. Generally, U-937 and HeLa are slightly more sensitive to the ETPs than
the other three cell lines with the former non-adherent lymphoma cell line U-937 showing the
highest susceptibility to the ETP class. High levels of potency were generally observed for
compounds tested against this cell line.
High Activity Low activity Low activity No activity
R No sulfur
H, N a-epidisulfide
R N SMe, SBn, SMOM,
NS S SMEM
Me'
O Moderate activity High activity
HN F, BrHNI N 11/Br~ sc~
O n=0>1>2 X=S-O
R2N Me 0N x Me
C N'H 0  17
MeO R O
X=SAc,SSMe
Minimal change in activity
Minimal change in activity Monomers:
H > Me
SO2Ph > H ~ TFA Dimers:
Me - CH2OH > CH20Ac
Figure 3. Summary of epipolythiodiketopiperazine structure-activity relationship.
The polysulfide dimers (+)-12,12'-dideoxyverticillin A (1), (+)-chaetocins A (3) and
C (5), (+)-12,12'-dideoxychetracin A (7), 37, and bisdithiepanethione 38 are the most active
compounds across the complete panel of compounds tested. In the case of the Ni,N1'-
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benzenesulfonylated analog of (+)-12,12'-dideoxyverticillin A (37), the potency is
dramatically increased (2 orders of magnitude more potent than the parent natural product 1
on the five tested cell lines). Our SAR studies show that the number of sulfur atoms in the
bridge for homodimeric ETP derivatives has no significant effect.
Human cancer cell lines were most responsive to variations in functionalization at the C3
and C II/Cl 5 centers while displaying a more modest response to modification at the N 1 and
C17 positions. In particular, it was found that the compounds were highly potent only if the
diketopiperazines were sulfurated at the Cl l/C 15 sites in a manner consistent with a species
capable of being converted to a P-epidisulfide in the biological milieu. Furthermore, the
anticancer potencies of this collection of compounds correlate positively with the steric
environment at the C3 position, rendering the dimeric ETP alkaloids the most potent with
(sub)nanomolar IC5 0's against a range of human cancer cell lines. The muted sensitivity of these
cell lines to variations in NI and C17 substitution make these ideal sites for compound
optimization.
Notwithstanding the considerable attention this class of compounds has gained from
biologists and chemists, the exact modes of action by which they operate have yet to be fully
determined. The large collection of compounds described herein will enable a more thorough
evaluation of the specific biological targets of the ETP-containing alkaloids. Novel synthetic
dimer 37, in particular, has remarkable potency. Importantly, these compounds are efficiently
prepared through concise synthetic routes that afford substantial chemical and structural
diversity. The implementation of this synthetic discovery platform provides a unique
opportunity to study important biological and physiological processes, to validate biological
hypotheses, and to discover very promising small-molecules. Additionally, the ETPs would be
excellent candidates for antibody-drug conjugate therapies,26 a strategy which requires highly
potent compounds and selectively delivers drug to a cellular target.
Cell culture MTS and SRB cytotoxicity assays revealed potent and wide-ranging
anticancer activity for natural and unnatural ETP derivatives in the (sub)nanomolar range
against a broad variety of cancer types and demonstrated a broad structure-activity
relationship: five homodimers exhibited potency in the single digit nanomolar range, while
chaetocins A (3) and C (5) as well as verticillin-related compound 37 displayed
subnanomolar IC50 values. In addition to their activity against cancer cells, the ETPs are not
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active against human erythrocytes. These compounds, which have been shown to induce
caspase-dependent apoptosis, are attractive candidates for further studies investigating mode
of action and exploring translational potential.
Conclusion
We have developed a general approach to the dimeric epipolythiodiketopiperazines, with
the solution yielding the first total synthesis of dimeric epitri- and epitetrathiodiketopiperazines.
The hallmark of our synthesis of (+)-chaetocin A (3), (+)-chaetocin C (5), and (+)-12,12'-
dideoxychetracin A (7) is the high level of stereochemical control and chemoselectivity in
sulfidation of a common dimeric diketopiperazine to access dimeric
epipolythiodiketopiperazines, a strategy consistent with a biogenetic hypothesis for divergent
sulfidation of a common diketopiperazine precursor.'2 We have exploited our understanding of
the reactivity and structure of epipolythiodiketopiperazines to guide the development of the
chemistry. The chemo- and stereoselective nature of this synthesis offers facile access to
compounds with promising biological function. 3
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Experimental Section
General Procedures. All reactions were performed in oven-dried or flame-dried round-bottom
flasks. The flasks were fitted with rubber septa and reactions were conducted under a positive
pressure of argon. Gas-tight syringes with stainless steel needles or cannulae were used to
transfer air- and moisture-sensitive liquids. Where necessary (so noted), solutions were
deoxygenated by sparging with argon for a minimum of 10 min. Flash column chromatography
was performed as described by Still et al. using granular silica gel (60-A pore size, 40-63 tm, 4-
6% H20 content, Zeochem).1 Analytical thin layer chromatography (TLC) was performed using
glass plates pre-coated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent
indicator (254 nm). TLC plates were visualized by exposure to short wave ultraviolet light (254
nm) and an aqueous solution of ceric ammonium molybdate (CAM) followed by heating on a hot
plate (~250 C). Organic solutions were concentrated at 29-30 'C on rotary evaporators capable
of achieving a minimum pressure of~2 torr.
Materials. Commercial reagents and solvents were used as received with the following
exceptions: dichloromethane, acetonitrile, tetrahydrofuran, methanol, pyridine, toluene, and
triethylamine were purchased from J.T. Baker (CycletainerT M ) and were purified by the method
of Grubbs et al. under positive argon pressure.2 1 -Ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride was purchased from Oakwood Products, Inc.; N-
hydroxybenzotriazole was purchased from Aroz Technologies, LLC; methyl iodide was
purchased from Alfa Aesar and neutralized via a gravity column dry-packed with Brockmann I
activated basic aluminum oxide immediately before use; triphenylmethanesulfenyl chloride was
purchased from TCI America, Inc.; and 2,6-di-tert-butyl-4-methylpyridine was purchased from
OChem Inc. All other solvents and chemicals were purchased from Sigma-Aldrich.
Instrumentation. Proton nuclear magnetic resonance ('H NMR) spectra were recorded with
Varian inverse probe 500 INOVA and Varian 500 INOVA spectrometers, are reported in parts
per million on the 6 scale, and are referenced from the residual protium in the NMR solvent
(CDCl 3: 6 7.24 (CHCl 3), CD 2 Cl2 : 6 5.32 (CHDCl 2), DMSO-d 6: 6 2.50 (DMSO-d 5)). Data are
reported as follows: chemical shift [multiplicity (s = singlet, d = doublet, t = triplet, sp = septet,
' Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.
2 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518.
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m = multiplet), coupling constant(s) in Hertz, integration, assignment]. Carbon-13 nuclear
magnetic resonance ( 3 C NMR) spectra were recorded with a Varian 500 INOVA spectrometer,
are reported in parts per million on the 6 scale, and are referenced from the carbon resonances of
the solvent (CDCl 3: 6 77.23, CD2Cl2: 6 54.00, DMSO-d6 : 6 39.51). Data are reported as follows:
chemical shift (assignment). Infrared data (IR) were obtained with a Perkin-Elmer 2000 FTIR,
and are reported as follows: frequency of absorption (cm 1), intensity of absorption (s = strong,
m = medium, w = weak, br = broad). Optical rotations were measured on a Jasco-1010
polarimeter. We are grateful to Dr. Li Li for obtaining the mass spectrometric data at the
Department of Chemistry's Instrumentation Facility, Massachusetts Institute of Technology.
High resolution mass spectra (HRMS) were recorded on a Bruker Daltonics APEXIV 4.7 Tesla
FT-ICR-MS using either an electrospray (ESI) or direct analysis in real time (DART) ionization
source.
Positional Numbering System. At least three numbering schemes for dimeric diketopiperazine
alkaloids exist in the literature. 3 In assigning the 'H and 13C NMR data of all intermediates en
route to our total syntheses of (+)-chaetocin A (3), (+)-chaetocin A diacetate (4), (+)-chaetocin C
(5), (+)-chaetocin C diacetate (6), and (+)-12,12'-dideoxychetracin A (7), we wished to employ a
uniform numbering scheme. For ease of direct comparison, particularly between early
intermediates, non-thiolated diketopiperazines, and advanced compounds, the numbering scheme
used by Barrow for (+)-WIN-64821 (using positional numbers 1-18) was optimal and is used in
this document. In key instances, the products are accompanied by the numbering system as
shown below.
O H 0 H 0 HHIt N H_ HN H
HO SON Ph N Ph HOM NO
MeN 1H H S H, O MeMeN 8N,11 MH 12 N Me"'.i SN
0 1~5N S O H 0~ 3 N P h 01 3 15 OH
6 5 4 13 10 1 7-1
NH NH4 NHH N 0  8 H'-' 8 H 0
(+)-Chaetocin A (3) (+)-WIN-64821 (+)-Chaetocin A (3)
Von Hauser's numbering Barrow's systematic numbering The numbering system used for all monomeric
used in the isolation report for dimeric diketopiperazines and dimeric diketopiperazines in this report
3 (a) Von Hauser, D.; Weber, H. P.; Sigg, H. P. Helv. Chim. Acta 1970, 53, 1061. (b) Barrow, C. J.; Cai, P.; Snyder,
J. K.; Sedlock, D. M.; Sun, H. H.; Cooper, R. J. Org. Chem. 1993, 58, 6016. (c) Springer, J. P.; BUchi, G.; Kobbe,
















A round-bottom flask was charged sequentially with O-silylated L-serine methyl ester
(S2) 4 (18.1 g, 50.6 mmol, 1.30 equiv), N'-sulfonylated N-Boc-L-tryptophan (S1) 5 (17.3 g, 38.9
mmol, 1 equiv, >99% ee), N-hydroxybenzotriazole (7.89 g, 58.4 mmol, 1.50 equiv), and
powdered 4 A molecular sieves (15.0 g). Dichloromethane (400 mL) was then introduced into
the flask and the solution was cooled to 0 *C in an ice-water bath. After 5 min, I -ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrogen chloride (11.2 g, 58.4 mmol, 1.50 equiv) was
added as a solid in one portion to the reaction mixture. Triethylamine (24.4 mL, 175.1 mmol,
4.50 equiv) was subsequently added dropwise via syringe. The ice-water bath was removed and
the reaction mixture was allowed to warm to 23 *C. After 6 h, another portion of I -ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrogen chloride (5.00 g, 26.1 mmol, 0.67 equiv) was
added as a solid. After 12 h, aqueous hydrogen chloride solution (1 N, 700 mL) was added, and
the aqueous layer was extracted with dichloromethane (2 x 250 mL). The combined organic
layers were washed with saturated aqueous sodium bicarbonate solution (700 mL), and the
resulting aqueous layer was extracted with dichloromethane (250 mL). The combined organic
layers were dried over anhydrous sodium sulfate, were filtered over celite, and were concentrated
under reduced pressure. The resulting white foam was purified by flash column chromatography
on silica gel (eluent: 3% acetone in dichloromethane) to provide dipeptide (+)-S3 (30.3 g, 99%)
as a white foam.
'H NMR (500 MHz, CDC 3, 20 *C): 6 7.95 (d, J= 8.3, 1H, C8H), 7.83 (d, J= 8.3,
2H, SO 2Ph-o-H), 7.53 (d, J= 7.7, 4H, SiPh-o-
H), 7.52-7.51 (in, 1H, C5 H), 7.49 (t, J= 7.4,
1H, SO2 Ph-p-H), 7.44-7.37 (m, 1H, C2H),
7.44-7.37 (in, 2H, SiPh-p-H), 7.39-7.36 (in,
4H, SO2Ph-m-H), 7.35 (app-t, J= 7.2, 4H,
SiPh-m-H), 7.28 (app-t, J= 7.28, 1H, C7H),
7.20 (app-t, J= 7.6, 1H, C6 H), 6.61 (br-d, J
7.4, 1H, C14H), 4.96 (br-d, J= 6.8, 1H, C1oH),
4.55 (dt, J= 2.9, 8.0, 1H, CI5H), 4.42 (br-d, J
= 6.3, 1H, Ci H), 4.05 (dd, J= 2.8, 10.4, 1H,
CIyHa), 3.76 (dd, J= 3.2, 10.4, 1H, C17Hb),
3.69 (s, 3H, OCH 3), 3.18 (dd, J= 6.1, 14.8,
1H, C12Ha), 3.05 (dd, J= 5.2, 14.3, 1 H,
C12Hb), 1.40 (s, 9H, OC(CH 3)3 ), 0.97 (s, 9H,
SiC(CH 3)3).
4 Prepared from commercially available L-serine methyl ester hydrogen chloride in one step: Burgey, C. S.;
Williams, T. M.; Deng, Z. J.; Stump, C. A. International Patent 2006, Patent WO 2006/078554 A2.
5 Prepared from commercially available N-Boc-L-tryptophan in one step: Movassaghi, M.; Schmidt, M. A.;
Ashenhurst, J. A. Angew. Chem. Int. Ed. 2008, 47, 1485.
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"C NMR (125.8 MHz, CDC13, 20 C): 6 170.7 (C13 ), 170.3 (C16 ), 155.3 (Ccarbamate),
138.3 (SO 2Ph-ipso-C), 135.6 (SiPh-o-C),
135.6 (SiPh-o-C), 135.3 (C9 ), 133.9 (SO2Ph-
p-C), 132.9 (SiPh-ipso-C), 132.7 (SiPh-ipso-
C), 130.9 (C4), 130.1 (SiPh-p-C), 130.1 (SiPh-
p-C), 129.4 (SO 2Ph-m-C), 128.0 (SiPh-m-C),
127.9 (SiPh-m-C), 126.9 (SO 2 Ph-o-C), 125.0
(C7), 124.7 (C2 ), 123.4 (C6), 119.7 (C), 117.9
(C3), 113.8 (C), 80.4 (OC(CH 3)3), 64.3 (C 17),
54.4 (C11), 54.3 (C15), 52.7 (OCH3), 28.4
(OC(CH 3)3), 28.2 (C 12), 26.8 (SiC(CH 3)3),
19.3 (SiC(CH 3)3).
FTIR (thin film) cm 1: 3424 (br-s), 2932 (w), 1747 (s), 1679 (s), 1513
(s).
HRMS (DART) (m/z): calc'd for C42H5oN30 8SSi [M+H]+: 784.3082,
found: 784.3066.
[a]D 23: +8.4 (c = 0.094, CHC13).
TLC (3% acetone in dichloromethane), Rf. 0.39 (UV, CAM).
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Trifluoroacetic acid (28 mL) was added via syringe to a solution of the dipeptide (+)-S3
(30.3 g, 38.6 mmol, 1 equiv) in dichloromethane (66 mL) at 23 *C. After 1.5 h, the brown
solution was concentrated under reduced pressure to afford a brown residue, which was
dissolved in t-butanol (205 mL) at 30 *C. The reaction mixture was placed in an ice-water bath
and stirred vigorously as morpholine (48 mL) was introduced slowly. The ice-water bath was
then removed, and the reaction mixture was allowed to warm to 23 'C. After 16 h, the orange
solution was concentrated under reduced pressure, and the resulting brown oil was purified by
flash column chromatography on silica gel (eluent: 15% acetone in dichloromethane) to provide
diketopiperazine (-)-18 (24.0 g, 93%) as a fluffy white foam.
IH NMR (500 MHz, CDCl 3, 20 *C):
"C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
6 7.96 (d, J= 8.3, 1H, C8H), 7.81 (d, J= 7.5,
2H, SO2Ph-o-H), 7.61 (app-t, J= 8.0, 4H,
SiPh-m-H), 7.50-7.47 (m, 1H, C5H), 7.48 (s,
1H, C2H), 7.44-7.32 (m, 1H, SO2Ph-p-H),
7.44-7.32 (m, 2H, SiPh-p-H), 7.44-7.32 (m,
4H, SiPh-o-H), 7.44-7.32 (m, 2H, SO 2Ph-m-
H), 7.28 (app-t, 1H, J= 8.0, C7H), 7.18 (app-t,
1H, J= 7.5, C6H), 6.82 (s, IH, N 14H), 6.57 (s,
IH, NIoH), 4.21 (app-d, J= 9.3, 1H, CIIH),
4.07 (app-d, J= 4.4, 1H, CI 5H), 3.92 (dd, J=
4.4, 10.4, 1H, C17Ha), 3.66 (dd, J= 7.7, 10.2,
1H, C17Hb), 3.47 (dd, J= 3.1, 14.8, 1H,
C12Ha), 2.96 (dd, J= 9.7, 14.8, 1H, C12Hb),
1.04 (s, 9H, SiC(CH 3)3).
6 167.3 (C13), 165.6 (C 16), 138.0 (SO 2Ph-ipso-
C), 135.7 (SiPh-m-C), 135.6 (SiPh-m-C),
135.4 (C9), 134.0 (SO2Ph-p-C), 132.7 (SiPh-
ipso-C), 132.6 (SiPh-ipso-C), 130.2 (SiPh-p-
C), 130.2 (C4 ), 129.5 (SO 2 Ph-m-C), 128.1
(SiPh-o-C), 128.1 (SiPh-o-C), 126.9 (SO2Ph-
o-C), 125.4 (C7), 125.3 (C2), 123.7 (C 6),
119.7 (C5 ), 117.1 (C3 ), 113.9 (C8), 65.3 (C 17),
56.7 (CI5), 54.4 (C11), 30.2 (C 12), 27.1
(SiC(CH3)3 ), 19.4 (SiC(CH 3)3).





TLC (15% acetone in dichloromethane), Rf:
calc'd for C36H36N305SSi [M-H]-: 650.2139,
found: 650.2147.
-100 (c = 0.12, CHC 3).
0.13 (UV, CAM).
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Tetracyclic Diketopiperazine Bromide (+)-19:
A solution of bromine (1 M, 231 mL, 231 mmol, 10.0 equiv) in benzene was rapidly
poured into a solution of diketopiperazine (-)-18 (15.4 g, 23.1 mmol, 1 equiv) in benzene (1.50
L) at 23 *C. After 30 min, a saturated aqueous sodium thiosulfate solution (500 mL) was added
to the resulting dark red solution. Once the red color dissipated, the mixture was washed with
saturated aqueous ammonium chloride solution (500 mL). The aqueous layer was extracted with
ethyl acetate (2 x 500 mL), and the combined organic layers were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure. The resulting yellow
foamy residue was purified by flash column chromatography on silica gel (eluent: 5% acetone in
dichloromethane) to provide the diastereomerically pure endo-(2S,3S)-monomeric tetracyclic
diketopiperazine bromide (+)-19 (9.9 g, 59%) as a white foam.
'H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-':
HRMS (DART) (m/z):
6 7.87 (d, J= 7.5, 2H, SO2Ph-o-H), 7.59 (app-
t, J= 6.5, 4H, SiPh-m-H), 7.50 (d, J= 16.2,
1H, CH), 7.48 (t, J= 7.5, 1 H, SO2Ph-p-H),
7.46-7.35 (m, 2H, SiPh-p-H), 7.46-7.35 (m,
4H, SiPh-o-H), 7.46-7.35 (m, 2H, SO 2Ph-m-
H), 7.32 (d, J= 8.5, 1H, C5H), 7.26 (app-t, J
7.5, 1H, C7H), 7.10 (app-t, J= 7.5, 1H, C6H),
6.24 (s, 1H, N14H), 6.22 (s, 1H, C2H), 4.43
(app-t, J= 8.1, 1H, CIH), 4.20 (dd, J= 4.1,
10.9, 1H, C17Ha), 4.09 (dd, J= 4.0, 9.1, 1H
Ci5H), 3.87 (app-t, J= 10.7, 1 H, CI7Hb), 3.29(dd, J= 6.7, 14.5, 1H, C12Ha), 3.02 (dd, J
9.0, 14.4, 1H, C12Hb), 1.02 (s, 9H,
SiC(CH3)3).
6 167.6 (C 3), 165.3 (C,6 ), 138.8 (C9), 137.8
(SO 2Ph-ipso-C), 135.6 (SiPh-m-C), 135.5
(SiPh-m-C), 134.0 (C4), 133.7 (SO 2 Ph-p-C),
132.6 (SiPh-ipso-C), 132.3 (SiPh-ipso-C),
130.9 (C7), 130.2 (SiPh-p-C), 130.2 (SiPh-p-
C), 128.9 (SO 2Ph-m-C), 128.3 (SO 2Ph-o-C),
128.1 (SiPh-o-C), 128.0 (SiPh-o-C), 126.1
(C6), 124.9 (C), 117.2 (C8 ), 87.1 (C2 ), 62.7
(C17), 60.7 (C3 ), 57.9 (C,1), 57.0 (C, 3 ), 40.6
(C,2), 26.9 (SiC(CH3)3), 19.2 (SiC(CH 3)3).
3212 (br, w), 1691 (s), 1369 (m), 1170 (m),
1113 (in).




TLC (5% acetone in dichloromethane), Rf:












Tetracyclic N-Methyl Diketopiperazine Bromide (+)-20:
A round-bottom flask was charged with tetracyclic amide (+)-19 (9.90 g, 13.5 mmol, 1
equiv) and dried azeotropically with benzene (3 x 100 mL) under reduced pressure. The contents
of the flask were returned to atmospheric pressure by backfilling with argon, and anhydrous
tetrahydrofuran (300 mL) was introduced via cannula. Anhydrous 1,3-dimethyl-3,4,5,6-
tetrahydro-2(IH)-pyrimidinone (DMPU, 30 mL, distilled over calcium hydride and stored over
4A molecular sieves) was then added via syringe, and the reaction mixture was cooled to -78 'C.
A solution of lithium bis(trimethylsilyl)amide (2.71 g, 16.2 mmol, 1.20 equiv) in tetrahydrofuran
(100 mL) at -78 'C was then transferred via cannula to the solution containing the tetracyclic
amide (+)-14 over a period of 15 min. The red solution was subsequently warmed to -40 'C.
After 20 min, freshly neutralized methyl iodide (2.10 mL, 33.8 mmol, 2.50 equiv) was added via
syringe. The red color of the solution subsided to yield an orange solution. After 2 h and 15
min, the reaction mixture was quenched by addition of saturated aqueous ammonium chloride
solution (200 mL). The biphasic mixture was immediately diluted with ethyl acetate (1 L). The
organic layer was washed with saturated aqueous ammonium chloride solution (3 x 500 mL),
was dried over anhydrous sodium sulfate, was filtered, and was concentrated under reduced
pressure. The resulting yellow foam was purified by flash column chromatography (eluent:
gradient, 4-+1 0% acetone in dichloromethane) to afford the tetracyclic N-methyl
diketopiperazine bromide (+)-20 (8.7 g, 86%) as a white foam.
'H NMR (500 MHz, CDCl 3, 20 *C):
13 C NMR (125.8 MHz, CDCl 3, 20 *C):
6 7.81 (d, J= 7.5, 2H, SO 2Ph-o-H), 7.50 (app-
t, J= 8.0, 4H, SiPh-m-H), 7.44 (t, J= 7.7, 4H,
SiPh-o-H), 7.39-7.35 (m, 1H, SO2 Ph-p-H),
7.39-7.35 (m, 1H, C8H), 7.34-7.29 (m, 2H,
SiPh-p-H), 7.34-7.29 (m, 2H, SO 2 Ph-m-H),
7.20 (d, J= 7.7, 1H, C5H), 7.05 (app-t, J=
7.5, 1H, C7H), 6.99 (d, J= 7.5, 1H, C6H),
6.30 (s, 1H, C2H), 4.46 (app-t, J= 8.8, 1H,
C IH), 4.23 (dd, J= 1.7, 10.8, 1H, C17Ha),
3.88 (br-s, 1H, C15H), 3.80 (dd, J= 2.6, 11.0,
1H, C17 Hb), 3.22 (dd, J= 7.2, 14.3, 1 H,
C12Ha), 2.84 (dd, J= 9.9, 14.2, 1H, C12Hb),
2.81 (s, 3H, Ci 8H), 0.64 (s, 9H, SiC(CH 3)).
6 165.4 (C13), 163.4 (C16 ), 139.0 (C9), 137.7
(SO 2Ph-ipso-C), 135.8 (C4), 135.6 (SiPh-m-
C), 135.6 (SiPh-m-C), 133.7 (SO 2Ph-p-C),
132.5 (SiPh-ipso-C), 132.1 (SiPh-ipso-C),
130.4 (C7), 130.1 (SiPh-p-C), 130.0 (SiPh-p-
C), 128.9 (SO 2 Ph-m-C), 128.4 (SO 2 Ph-o-C),
128.0 (SiPh-o-C), 128.0 (SiPh-o-C), 126.5
111
FTIR (thin film) cm-1:
HRMS (DART) (m/z):
[a]D23:
TLC (5% acetone in dichloromethane), Rf.
(C), 124.8 (C5), 118.0 (C8), 88.0 (C2), 64.2
(CI5), 61.4 (C17), 60.1 (C 3), 56.3 (C 1), 44.8
(C 12), 30.6 (Ci 8), 26.5 (SiC(CH 3)3), 18.8
(SiC(CH 3)3).
2931 (m), 1693 (s), 1666 (s), 1370 (m), 1113
(s).
calc'd for C 37H3 9BrN30sSSi [M+H]*:
744.1558, found: 744.1579.
+52 (c = 0.11, CHCl 3).
0.15 (UV, CAM).
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Tetracyclic N-Methyl-O-Acetvl Diketopiperazine Bromide (+)-21:
A freshly prepared stock solution of hydrogen fluoride-pyridine (5 mL), pyridine (10
mL), and tetrahydrofuran (35 mL) was poured into a solution of tetracyclic N-methyl
diketopiperazine bromide (+)-20 in tetrahydrofuran (50 mL). After 36 h, acetyl chloride (12.3
mL) was added to the solution via syringe. Another portion of acetyl chloride (4.1 mL) was
added to the solution via syringe after 35 h in order to increase the reaction rate. After 9 h, the
reaction mixture was diluted with ethyl acetate and washed with aqueous hydrogen chloride
solution (IN, 3 x 375 mL). The organic layer was dried over anhydrous sodium sulfate, was
filtered, and was concentrated under reduced pressure. The resulting residue was purified by
flash column chromatography (eluent: 100% ethyl acetate) to afford (+)-21 (2.69 g, 85%) as a
white solid.
'H NMR (500 MHz, CDC13, 20 *C):
13C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (DART) (m/z):
[a]D 23:
TLC (ethyl acetate), Rf
8 7.88 (d, J= 8.2, 2H, SO 2Ph-o-H), 7.54 (d, J
= 8.2, 1H, C8H), 7.50 (t, J= 7.6, 1H, SO 2Ph-
p-H), 7.39 (app-t, J= 7.7, 2H, SO 2Ph-m-H),
7.31 (d, J= 7.7, 1 H, C5H), 7.28 (app-t, J =
8.0, 1H, C7H), 7.12 (app-t, J= 7.6, 1H, C6H),
6.22 (s, 1H, C2H), 4.59 (m, 2H, C17H), 4.45
(app-t, J= 8.4, 1H, CIIH), 4.12 (br-s, 1H,
Ci 5H), 3.15 (dd, J= 7.7, 14.3, 1H, C12 Ha),
2.98 (dd, J= 8.1, 14.3, 1H, C12Hb), 2.92 (s,
3H, Ci8H), 1.62 (s, 3H, CH 3 acetate).
6 170.2 (C=Oacetate), 166.0 (C, 3), 163.1 (C16),
139.1 (SO 2Ph-ipso-C), 137.8 (SO2Ph-p-C),
134.9 (C 7), 134.0 (SO 2Ph-m-C), 130.9
(SO 2Ph-o-C), 129.1 (C6), 128.4 (Cs), 126.3
(C), 125.1 (C 9), 117.2 (C4 ), 87.6 (C2 ), 61.5
(Ci5 ), 61.4 (C17), 60.4 (C3 ), 57.2 (C11), 43.8
(C 12), 30.8 (C, 8 ), 20.4 (CH3 acetate).
1744 (s), 1673 (s), 1366 (m), 1240 (m), 1170
(m).
calc'd for C2 3H2 3BrN30 6 S [M+H]*: 548.0485,
found: 548.0479.




23 *C, 15 min
49%
(+)-21
o SO2PhH H N-
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Octacyclic Diketopiperazine (-)-22:
Tris(triphenylphosphine)cobalt (I) chloride complex6 (6.36 g, 7.22 mmol, 1.50 equiv)
was added as a solid to a solution of tetracyclic bromide (+)-21 (2.64 g, 4.81 mmol, 1 equiv) in
dichloromethane (50 mL, argon sparge, 10 min) at 23 *C. After 15 min, the resulting deep blue-
green solution was loaded onto a silica gel column and purified by flash column chromatography
(eluent: gradient, 15-+20% acetone in dichloromethane) to afford (-)-22 (1.10 g, 49%) as a
white solid.
'H NMR (500 MHz, CD 2 Cl2 , 20 *C):
13 C NMR (125.8 MHz, CD 2 Cl2 , 20 0C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D23 :
TLC (50% acetone in hexanes), Rf:
8 8.10 (d, J= 7.7, 4H, SO2Ph-o-H), 7.67 (t, J
= 7.5, 2H, SO2Ph-p-H), 7.55 (app-t, J= 7.9,
4H, SO 2Ph-m-H), 7.36-7.31 (m, 2H, C5H),
7.36-7.31 (m, 2H, C7H), 7.25 (app-t, J= 7.7,
2H, C6H), 7.02 (d, J= 8.0, 2H, C8H), 6.49 (s,
2H, C2H), 4.68 (app-t, J= 9.1, 2H, Ci8H),
4.50 (dd, J= 2.5, 12.0, 2H, Ci 7Ha), 4.44 (dd, J
= 2.5, 12.1, 2H, C17Hb), 4.06 (br-s, 2H, Ci 5H),
2.87 (s, 6H, Ci8H), 2.79 (dd, J= 9.0, 14.9, 2H,
C12Ha), 2.42 (dd, J= 9.9, 14.8, 2H, C12Hb),
1.60 (s, 6H, CH 3acetate).
6 170.3 (C=Oacetate), 167.3 (C 13), 166.2 (CI6 ),
142.5 (C9 ), 141.8 (SO 2Ph-ipso-C), 136.5 (C4 ),
133.7 (SO2Ph-p-C), 130.1 (C7 ), 128.4
(SO 2Ph-m-C), 128.2 (C5), 127.7 (SO 2 Ph-o-C),
125.7 (C6 ), 117.7 (C), 82.1 (C 2), 61.7(Cis),
61.6 (C, 7 ), 59.2 (C3), 57.2 (C,), 35.4 (C, 2 ),
30.7 (C, 8), 20.7 (CH 3acetate).
1744 (s), 1696 (s), 1343 (s), 1239 (s), 1163
(s).
calc'd for C 46H4 8N 7 01 2S2 [M+NH 4]*:
954.2797, found: 954.2802.
-50 (c = 0.18, CHCl 3).
0.16 (UV, CAM).
6 (a) Aresta, M.; Rossi, M.; Sacco, A. Inorg. Chim. Acta 1969, 3, 227. (b) Baysdon, S. L.; Liebeskind, L. S.
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Bis(pyridine)silver(I) permanganate 7 (3.58 g, 9.31 mmol, 8.00 equiv) was added as a
solid to a solution of octacyclic diketopiperazine (-)-22 (1.09 g, 1.16 mmol, I equiv) in
dichloromethane (30 mL) at 23 *C. After 2.5 h, the dark purple solution was diluted with ethyl
acetate (1 L) and washed sequentially with aqueous sodium bisulfite solution (IN, 250 mL),
saturated aqueous copper sulfate solution (250 mL), and saturated aqueous ammonium chloride
solution (3 x 250 mL). The organic layer was dried over anhydrous sodium sulfate, was filtered,
and was concentrated under reduced pressure. The residue was then diluted in chloroform (250
mL) and washed with water (250 mL). The aqueous layer was extracted with ethyl acetate (2 x
250 mL) and the combined organic layers were dried with anhydrous sodium sulfate, were
filtered, and were concentrated under reduced pressure to afford a white solid containing
octacyclic tetraol (-)-23 (635.6 mg, 55%).8 The crude product was used directly in the next step
due to difficulties in purifying the highly polar tetraol by flash column chromatography on silica
gel. 9 10
'H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, CDCl 3, 20 *C):
6 8.06 (d, J= 7.3, 4H, SO 2Ph-o-H), 7.62 (t, J
= 7.3, 2H, SO2Ph-p-H), 7.51 (app-t, J= 7.6,
4H, SO 2Ph-m-H), 7.29-7.21 (m, 2H, C5H),
7.29-7.21 (m, 2H, C7H), 7.16 (app-t, J= 7.5,
2H, C6H), 7.00 (d, J= 8.3, 2H, CsH), 6.98 (s,
2H, C2H), 5.53 (br-s, 2H, OH), 4.52 (br-s, 2H,
OH), 4.28 (br-s, 2H, Ci 7Ha), 4.21 (d, J= 11.2,
2H, C17Hb), 2.97 (br-s, 4H, C12H), 2.87 (s, 6H,
Ci 8H), 1.49 (s, 6H, CH 3acetate).
6 169.3 (C=Oacetate), 167.9 (C16), 167.0 (C13),
141.4 (C 9), 140.7 (SO 2Ph-ipso-C), 134.8 (C4 ),
133.8 (SO 2Ph-p-C), 130.1 (C7), 129.2
(SO 2Ph-m-C), 128.0 (C5 ), 127.6 (SO 2Ph-o-C),
125.3 (C6), 116.5 (C8), 86.3 (C11), 85.4 (C, 5),
82.7 (C 2), 64.0 (C17), 57.9 (C3), 42.8 (C12 ),
27.4 (C18), 20.5 (CH3 acetate).
7 Firouzabadi, H.; Vessal, B.; Naderi, M. Tetrahedron Lett. 1982, 23, 1847.
8 The yield was calculated by 'H NMR spectroscopy using an internal standard.
9 Analytically pure samples of this highly polar tetraol could be obtained by sequential flash column
chromatography on standard silica gel (eluent: gradient, 30% acetone in dichloromethane to 100% acetone) and
SiliCycle ultra pure silica gel (eluent: 30% acetone in ethyl acetate).
' Signal broadening in the 'H and 13 C NMR spectra of (-)-23 is attributed to the influence of hydrogen bonding by
the C 50H.
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FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D21:
TLC (20% acetic acid in dichloromethane), Rf:
3433 (br, s), 1748 (s), 1690 (s), 1348 (s), 1166
(s).
calc'd for C46H44N6NaO16 S2 [M+Na]*:
1023.2147, found: 1023.2115.
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Octacyclic Dithioisobutyrate (+)-26:
A slow stream of hydrogen sulfide gas was passed through a solution of octacyclic tetraol
(-)-23 (635.6 mg, 634.9 pmol, 1 equiv) in anhydrous nitromethane (100 mL) by discharge of a
balloon equipped with a needle (18 gauge) extending into the reaction mixture, providing a
saturated hydrogen sulfide solution. After 30 min, trifluoroacetic acid (11 mL) was added via
syringe, and the slow introduction of hydrogen sulfide into the mixture was maintained for
another 10 min. The reaction mixture was left under an atmosphere of hydrogen sulfide for an
additional 20 min. The reaction mixture was concentrated under reduced pressure. The residue
was dissolved in dichloromethane (100 mL) and cooled in an ice-water bath to 0 'C. 4-
(Dimethylamino)pyridine (1.80 g, 14.8 mmol, 23.0 equiv) was added to the solution of the
dithiol followed by addition of isobutyryl chloride (1.03 mL, 9.84 mmol, 15.5 equiv). After 45
min, methanol (300 ptL) was added to the solution, and the mixture was allowed to warm to 23
'C. The crude reaction mixture was then loaded onto a silica gel column and purified by flash
column chromatography (eluent: 50% ethyl acetate in hexanes) to afford the octacyclic
dithioisobutyrate (+)-26 (445 mg, 53%) as a white solid.
IH NMR (500 MHz, CDCl 3, 20 "C):
13C NMR (125.8 MHz, CDCl3, 20 "C):
8 8.01 (d, J= 7.8, 4H, SO 2Ph-o-H), 7.57 (t, J
= 7.2, 2H, SO2Ph-p-H), 7.50 (app-t, J= 7.9,
4H, SO 2Ph-m-H), 7.19 (d, J= 7.8, 2H, C5H),
7.18 (d, J= 8.3, 2H, CH), 6.99 (app-t, J=
8.2, 2H, C7H), 6.96 (s, 2H, C2H), 6.75 (app-t,
J= 7.4, 2H, C6H), 4.63 (d, J= 11.9, 2H,
C17 Ha), 4.49 (d, J= 11.9, 2H, CI7 Hb), 3.56 (d,
J= 14.2, 2H, C12 Ha), 3.42 (d, J= 14.2, 2H,
C12Hb), 2.83 (s, 6H, Ci8H), 2.56 (app-sp, J=
7.2, 2H, CHisobutyrate), 2.04 (s, 6H, CH3acetate),
1.98 (app-sp, J = 7.0, 2H, CHthioisobutyrate), I .I I
(d, J= 7.0, 6H, CH3isobutyrate), 1.08 (d, J= 7.0,
6H, CH3isobutyrate), 0.69 (d, J= 7.0, 6H,
CH3thioisobutyrate), 0.65 (d, J = 7.0, 6H,
CH3thioisobutyrate).
8 200.4 (C=Othioisobutyrate), 174.4
(C=Oisobutyrate), 169.8 (C=Oacetate), 164.2 (C13 ),
161.3 (C16), 143.5 (C9), 140.9 (SO 2Ph-ipso-
C), 133.2 (SO 2Ph-p-C), 130.6 (C4), 129.7
(C7), 129.2 (SO 2Ph-m-C), 127.1 (SO 2 Ph-o-C),
124.1 (Cs), 123.8 (C6), 113.3 (C8 ), 85.9 (C1 ),
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FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D24
TLC (50% ethyl acetate in hexanes), Rf:
81.3 (C2 ), 73.8 (C11), 63.7 (C1 7), 60.2 (C3 ),
42.8 (C12), 42.6 (C13), 33.5 (CHthioisobutyrate),
28.7 (CHisobutyrate), 21.2 (C 18 ), 19.1 (CH3 acetate),
18.8 (CH3isobutyrate), 18.6 (CH3isobutyrate).
2972 (w), 1753 (s), 1703 (s), 1379 (m), 1173
(m).
calc'd for C62H68N6NaOi 8 S4 [M+Na]*:
1335.3365, found 1335.3339.











Me O NO) 2Ph M M(+)-26 Me Me
350 nm, ascorbic acid
1,4-dimethoxynaphthalene
H20, MeCN, 23 *C
51%
Octacyclic Diaminodithioisobutyrate (+)-27:
A 50-mL pyrex pear-shaped flask was sequentially charged with octacyclic
dithioisobutyrate (+)-26 (300 mg, 228.6 ptmol, 1 equiv), ascorbic acid (432 mg, 6.86 mmol, 30.0
equiv), and 1,4-dimethoxynaphthalene (2.58 g, 13.72 mmol, 60.0 equiv), and the mixture was
placed under an argon atmosphere. A solution of water in acetonitrile (20% v/v, 48 mL), which
was sparged with argon for 10 min at 23 'C, was transferred to the flask via cannula. A 220 W
low pressure mercury lamp with a black light phosphor coating (350 nm) was then placed 12 cm
away from the flask and turned on. After 3 h, another portion of 1,4-dimethoxynaphthalene
(1.00 g, 5.31 mmol, 23.2 equiv) was added to the reaction mixture. After 1.5 h, another portion
of ascorbic acid (432 mg, 6.86 mmol, 30.0 equiv) was added to the reaction mixture. After 2 h
45 min, another portion of 1,4-dimethoxynaphthalene (1.00 g, 5.31 mmol, 23 equiv) and ascorbic
acid (432 mg, 6.86 mmol, 30.0 equiv) were added to the reaction mixture. After 7 h, the lamp
was turned off, and the reaction mixture was diluted with dichloromethane (300 mL) and washed
with saturated aqueous ammonium chloride solution (200 mL). The aqueous layer was extracted
with dichloromethane (2 x 100 mL). The combined organic layers were dried over anhydrous
sodium sulfate, were filtered, and were concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (eluent: 40% ethyl acetate in hexanes) to
afford the octacyclic diaminodithioisobutyrate (+)-27 (120 mg, 51%) as a white solid.
'H NMR (500 MHz, CDCl 3, 20 *C):
13 C NMR (125.8 MHz, CDCl3, 20 *C):
8 7.30 (d, J= 7.5, 2H, C5H), 7.09 (app-t, J=
7.5, 2H, C7H), 6.73 (app-t, J= 7.1, 2H, C6H),
6.58 (d, J= 7.5, 2H, C8H), 5.88 (s, 2H, C2H),
4.86 (s, 2H, NIH), 4.83 (d, J= 11.5, 2H,
C17Ha), 4.44 (d, J= 11.5, 2H, C17Hb), 3.32
(br-s, 2H, C12Ha), 2.83 (s, 6H, C18H), 2.80 (br-
s, 2H, C12Hb), 2.56 (app-sp, J= 7.1, 2H,
CHisobutyrate), 2.06 (s, 6H, CH3acetate), 2.05 (in,
2H, CHthioisobutyrate), 1 1 9 (d, J = 7.1, 12H,
CH3isobutyrate), 0.83 (d, J = 7.1, 6H,
CH3thioisobutyrate), 0.76 (d, J = 6.9, 6H,
CH3thioisobutyrate).
6 200.9 (C=Othioisobutyrate), 175.4
(C=Oisobutyrate), 169.9 (C=Oacetate), 166.1 (C),
161.3 (C16), 150.7 (C9), 129.7 (C7), 129.3
(C4 ), 126.0 (C5), 119.4 (C6), 110.4 (C8), 86.5
(C15), 81.3 (C2 ), 73.6 (C11), 63.1 (C17), 60.3
(C 3), 43.2 (CHthioisobutyrate), 41.0 (C 12), 34.1
(CHisobutyrate), 28.3 (C18), 21.2 (CH 3acetate), 19.2
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FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (50% ethyl acetate in hexanes), Rf:
(CH3thioisobutyrate), 19.0 (CH3thioisobutyrate), 18.7
(CH3isobutyrate), 18.6 (CH3isobutyrate).
3390 (br, w), 1748 (s), 1692 (s), 1381 (m),
1223 (m).
calc'd for C5oH60N6NaO14S2 [M+Na]*:
1055.3501 found: 1055.3544.
+116 (c = 0.10, CHCl 3).
0.35 (UV, CAM).
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(+)-chaetocin A diacetate (4)
Octacyclic Bis(triphenylmethanedisufide) H+-28 and (+-Chaetocin A Diacetate (4):
Anhydrous hydrazine (5.1 jiL, 163 iimol, 10.0 equiv) was added via syringe to a solution
of diaminodithioisobutyrate (+)-27 (16.8 mg, 16.3 jimol, 1 equiv) in tetrahydrofuran (2.5 mL) at
0 'C. After 10 mmn, hexanes-washed sodium hydride (9.8 mg, 407 pmol, 25.0 equiv) and solid
triphenylmethanesulfenyl chloride (50.6 mg, 163 jimol, 10.0 equiv) were sequentially added to
the reaction mixture under an inert atmosphere. After 1 h, the solution was poured into a
separatory funnel containing saturated aqueous ammonium chloride solution (30 mL) and
dichloromethane (30 mL). The aqueous layer was extracted with dichloromethane (2 x10 mL),
and the combined organic layers were dried over anhydrous sodium sulfate, were filtered, and
were concentrated under reduced pressure. The residue was purified by flash column
chromatography on silica gel (eluent: 35% ethyl acetate in hexanes) to afford dimeric
bis(triphenylmethanedisulfide) (+)-28 (21.0 mg, 90%) as a clear waxy solid."
Dichloromethane (1 mL) was added via syringe to a flask charged with
bis(triphenylmethanedisulfide) (+)-28 (7.4 mg, 5.14 pmol, I equiv) and 2,6-di-tert-butyl-4-
methylpyridine (26.4 mg, 128 pmol, 25.0 equiv) under an argon atmosphere. Triethylsilane (8.2
pL, 51.4 pmol, 10.0 equiv) was then added to the solution at 23 *C via syringe followed by
borontrifluoride-etherate (12.9 pL, 103 p mol, 20.0 equiv). After 25 min, a saturated aqueous
ammonium chloride solution (5 mL) was added to the solution. The reaction mixture was diluted
with dichloromethane (15 mL) and washed with saturated aqueous ammonium chloride solution
(10 mL). The aqueous layer was extracted with dichloromethane (2 x 5 mL), and the combined
organic layers were dried over anhydrous sodium sulfate, were filtered, and were concentrated
" Atropisomerism-induced peak broadening prevented complete NMR spectroscopic characterization of this
product. Resolution of the peaks via variable temperature NMR was not possible due to the thermal instability of
the compound. The following supplementary data were obtained for intermediate (+)-28: FTIR (thin film) cm-':
3396 (br, w), 2923 (w), 1748 (m), 1690 (s), 1376 (m), 1223 (m), 733 (w), 700 (m). HRMS (ESI) (m/z): calc'd for
C8oH76NaN6O12S4 [M+Na]*: 1463.4296, found: 1463.4287. [a]D2 3 : +83 (c = 1.0, CHCl3). TLC (30% ethyl acetate in
hexanes), Rf 0.20 (UV, CAM).
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under reduced pressure. The residue was purified by flash column chromatography on silica gel
(eluent: 50% ethyl acetate in hexanes) to afford (+)-chaetocin A diacetate (4) (3.3 mg, 82%) as a
white solid.
'H NMR (500 MHz, CDCl3, 20 *C):
3 C NMR (125.8 MHz, CDC 3, 20 *C):
FTIR (thin film) cm-1:
6 7.39 (d, J= 7.5, 2H, C5H), 7.22 (app-t, J=
8.2, 2H, C7H), 6.88 (app-t, J= 7.5, 2H, C6H),
6.70 (d, J= 7.9, 2H, C8H), 5.30 (s, 2H, NiH),
5.28 (s, 2H, C2H), 4.87 (d, J= 12.7, 2H,
C17Ha), 4.57 (d, J= 12.7, 2H, C17Hb), 3.78 (d,
J= 15.2, 2H, C12Ha), 3.03 (s, 6H, Ci 8H), 2.69
(d, J= 15.1, 2H, C12Hb), 2.11 (s, 6H,
CH3acetate).
6 169.7 (C=Oacetate), 165.4 (C13), 160.9 (C16),
149.6 (C9 ), 130.6 (C7), 127.6 (C4 ), 125.5 (C5),
120.2 (C6), 110.9 (Cs), 81.0 (C2 ), 74.9 (CI5 ),
74.2 (C,1), 60.1 (C3), 59.8 (C17), 39.8 (C, 2),
28.3 (CIs), 20.8 (CH 3 acetate).
3369 (br, w), 2920 (w), 1753




TLC (40% ethyl acetate in hexanes), Rf:
12 Literature value: (a) [a]D20 = +679 (c 0.99, CHCl3), V
1970, 53, 1061. (b) [a]D2 0 = +674.4 (c 0.078, CHCl3),
Knoshita, T. Chem. Pharm. Bull. 1988, 36, 1942.
calc'd for C 34 H32N 6NaO8 S4 [M+Na]*:
803.1057, found: 803.1037.
+651 (c = 0.10, CHCl3).12
0.08 (UV, CAM).
on Hauser, D.; Weber, H. P.; Sigg, H. P. Helv. Chim. Acta
Saito, T.; Suzuki, Y.; Koyama, K.; Natori, S.; litaka, Y.;
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Otera's catalyst 3 (1.1 mg, 1.80 pmol, 0.50 equiv) was added as a solid to a sealed tube
reaction vessel containing a solution of (+)-chaetocin A diacetate (4) (2.8 mg, 3.59 Imol, I
equiv) in toluene (1.25 mL) and methanol (125 pL) under an inert atmosphere. The resulting
reaction mixture was heated to 85 *C. After 7 h and 20 min, the solution was diluted with
chloroform (10 mL) and loaded onto a silica gel column and purified by flash column
chromatography (eluent: 0.2% ammonium hydroxide, 1.8% methanol, 98% chloroform) to afford
(+)-chaetocin A (3) (2.3 mg, 92%) as a white solid.
'H NMR (500 MHz, DMSO-d 6, 20 "C):
'H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, DMSO-d 6, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
6 7.42 (d, J= 7.4, 2H, CsH), 7.07 (app-t, J=
7.4, 2H, C7H), 7.03 (s, 2H, NIH), 6.68 (app-t,
J= 7.5, 2H, C6H), 6.62 (d, J= 7.8, 2H, C8H),
5.84 (t, J= 5.5, 2H, OH), 5.23 (br-s, 2H,
C2H), 4.20 (dd, J= 5.2, 12.7, 2H, Ci 7Ha), 4.09
(dd, J= 4.9, 12.7, 2H, C17Hb), 3.61 (d, J=
15.2, 2H, C12Ha), 3.00 (s, 6H, Ci8H), 2.89 (br-
d, J= 14.4, 2H, C12Hb).
6 7.40 (d, J= 7.6, 2H, CsH), 7.23 (app-t, J
7.6, 2H, C7H), 6.90 (app-t, J= 7.5, 2H, C6H),
6.72 (d, J= 7.9, 2H, CsH), 5.23 (s, 2H, C2H),
5.23 (s, 2H, NIH), 4.23 (dd, J= 5.1, 12.8, 2H,
C17Ha), 4.16 (dd, J= 9.1, 13.0, 2H, CI7Hb),
3.81 (d, J= 15.1, 2H, C12Ha), 3.26 (app-t, J=
6.7, 2H, OH), 3.06 (s, 6H, Ci 8H), 2.72 (d, J
15.2, 2H, C12Hb).
6 165.5 (C 3 ), 160.7 (C16), 150.0 (C9 ), 129.6
(C7 ), 127.8 (C4 ), 124.8 (Cs), 117.9 (C6), 109.0
(C8), 79.6 (C2 ), 77.0 (C, 5), 73.5 (C,,), 59.4
(C3 ), 58.6 (C17), 39.1 (C12), 27.6 (C, 8 ).
6 165.9 (C13), 163.1 (C, 6 ), 149.3 (C9 ), 130.7
(C7 ), 127.6 (C4), 125.4 (C5), 120.6 (C6), 110.9
(C8), 80.7 (C2), 76.0 (C, 5), 73.5 (C,,), 60.8
(C,7), 60.0 (C3 ), 39.5 (C12), 27.5 (C,8 ).
" Otera, J.; Dan-oh, N.; Nozaki, H. J. Org. Chem. 1991, 56, 5307.
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FTIR (thin film) cm-:
HRMS (ESI) (m/z):
3387 (br, m), 2926 (w), 1678 (s), 1609 (w),
1468 (w), 1352 (m), 1319 (w), 1063 (m), 752
(m).
calc'd for C30H28N6NaO6S4 [M+Na]*:
719.0845, found: 719.0858.
+724 (c = 0.085, DMSO). 14[a]D23:
TLC (0.2% ammonium hydroxide, 1.8% methanol, 98% chloroform), Rf: 0.13 (UV, CAM).
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Anhydrous hydrazine (5.9 ptL, 188 pmol, 3.94 equiv) was added via syringe to a solution
of diaminodithioisobutyrate (+)-27 (49.3 mg, 47.7 pmol, 1 equiv) in tetrahydrofuran (10 mL) at
0 *C. After 23 min, triethylamine (131 iL, 939 pmol, 19.7 equiv) and solid
chloro(triphenylmethyl)disulfane 5 (129 mg, 376 imol, 7.88 equiv) were sequentially added to
the reaction mixture under an inert atmosphere. After 7 min, saturated aqueous ammonium
chloride (10 mL) was added to the reaction mixture. The solution was then poured into a
separatory funnel containing saturated aqueous ammonium chloride (50 mL) and
dichloromethane (60 mL). The aqueous layer was extracted with dichloromethane (2 x 30 mL),
and the combined organic layers were dried over anhydrous sodium sulfate, were filtered, and
were concentrated under reduced pressure. The residue was purified by flash column
chromatography on silica gel (eluent: 35% ethyl acetate in hexanes) to afford dimeric
bis(triphenylmethanetrisulfide) (+)-31 (61.9 mg, 86%) as a white solid.
'H NMR (500 MHz, CDCl3, 20 *C):
13 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
8 7.34-7.19 (m, 2H, C5H), 7.19-7.06 (m,
18H, C(C 6H5 )3), 7.19-7.06 (m, 2H, C7H),
6.99-6.81 (m, 12H, C(C 6H 5)3), 6.41 (br-s, 2H,
CH), 6.28 (br-s, 2H, C6H), 5.78 (br-s, 2H,
C2H), 4.82 (br-s, 2H, NIH), 4.69 (d, J= 11.7,
2H, C 7Ha), 4.35 (d, J= 11.9, 2H, C17 Hb),
2.75 (s, 6H, C18H), 2.72-2.57 (m, 4H, C12H),
2.53 (app-sp, J= 7.1, 2H, CHisobutyrate), 1.77 (s,
6H, CH 3 acetate), 1.20-1.12 (m, 12H,
CH3isobutyrate).
6 175.3 (C=Oisobutyrate), 170.1 (C=Oacetate),
165.6 (C), 161.6 (C,6 ), 150.2 (C9), 143.5
(C(C 6H5)3), 130.7 (C(C 6H5)3), 129.8 (C7),
129.0 (C4), 128.0 (C(C 6H5)3 ), 127.3
(C(C 6H5)3 ),126.8 (Cs), 119.5 (C6), 110.1 (C),
86.8 (C, 5 ), 81.7 (C2 ), 74.7 (C,1), 73.6
(C(C 6H 5)3), 63.7 (C17), 60.5 (C 3), 42.0 (C12),
34.1 (CHisobutyrate), 28.3 (CIs), 21.3 (CH3 acetate),
18.7 (CH3isobutyrate), 18.6 (CH3sobutyrate).
1746 (s), 1691 (s), 1382 (m), 1222 (m), 699
(m).
1s Williams, C. R.; Britten, J. F.; Harpp, D. N. J. Org. Chem. 1994, 59, 806.
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HRMS (ESI) (m/z): calc'd for C8oH76N 6NaO1 2S6 [M+Na]f:
1527.3738, found: 1527.3747.
[a]D23 :
TLC (35% ethyl acetate in hexanes), Rf:
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(+)-N-Trifluoroacetyl Chaetocin C Diacetate (33):
Trifluoroacetic anhydride (79.2 pL, 570 pmol, 20.0 equiv) was added via syringe to a
solution of bis(triphenylmethanetrisulfide) (+)-31 (42.9 mg, 28.5 tmol, I equiv) and 2,6-di-tert-
butyl-4-methylpyridine (234 mg, 1.14 mmol, 40.0 equiv) in acetonitrile (3 mL) at 23 *C. After I
h, boron trifluoride diethyl etherate (71.8 tL, 570 imol, 20.0 equiv) was added to the reaction
mixture via syringe to produce a bright yellow solution. After 30 min, the solution was diluted
with ethyl acetate (75 mL) and washed with aqueous hydrogen chloride (IN, 3 x 50 mL). The
organic layer was dried over anhydrous sodium sulfate, was filtered, and was concentrated under
reduced pressure. The residue was purified by flash column chromatography on silica gel
(eluent: 50% ethyl acetate in hexanes) to afford (+)-N-trifluoroacetyl chaetocin C diacetate (33)
(27.0 mg, 91%) as a white solid. Based on 'H NMR analysis at 90 *C in toluene-d8, the product
exists as a 1:3.39:2.32 mixture of minor symmetric:asymmetric:major symmetric conformers.
'H NMR (500 MHz, toluene-d8 , 90 *C):l 6  Major symmetric conformer: 6 7.93-7.78 (m,
2H, C8H), 7.00-6.79 (m, 2H, C7H), 7.00-6.79
(m, 2H, C5H), 6.76-6.65 (m, 2H, C6H), 6.35
(s, 2H, C2H), 4.52 (d, J= 12.5, 2H, C, 7Ha),
4.05 (d, J= 12.4, 2H, C17Hb), 3.19 (d, J=
14.7, 2H, C12Ha), 2.80 (s, 6H, CI8H), 2.66 (d,
J= 14.8, 2H, C12Hb), 1.52 (s, 6H, CH 3acetate).
Asymmetric conformer: 6 7.93-7.78 (m, I H,
C8H), 7.93-7.78 (m, 1H, CH'), 7.00-6.79 (m,
lH, C7H), 7.00-6.79 (m, 1H, C7H'), 7.00-6.79
(m, 1H, C5 H), 7.00-6.79 (m, I H, C5H'), 6.76-
6.65 (m, I H, C6H), 6.76-6.65 (m, 1H, C6H'),
6.61 (s, 1H, C2H'), 6.38 (s, IH, C2H), 4.63 (d,
J= 12.1, 1H, C17Ha'), 4.52 (d, J= 12.5, 1H,
CI 7Ha), 4.10 (d, J= 12.4, 1H, C17Hb'), 4.05 (d,
J= 12.4, 1H, C17Hb), 3.25 (d, J= 14.8, 1H,
C 12Ha), 3.09 (d, J= 14.8, 1H, C12Ha'), 2.80 (s,
3H, Ci 8H), 2.73 (d, J= 15.0, 1H, C12Hb), 2.61
(s, 3H, CI 8H'), 2.46 (d, J= 14.7, 1 H, C12Hb'),
1.52 (s, 3H, CH3acetate), 1.49 (s, 3H, CH3acetate').
16 Higher temperatures were required to resolve the trifluoroacetamide related atropisomers. Reliable heteronuclear
correlation data were not obtained at this temperature. Assignments are based on integration and homonuclear
correlation data as well as analogies drawn to related systems.
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13C NMR (125.8 MHz, toluene-d8, 90 'C):17
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[C]D23
TLC (50% ethyl acetate in hexanes), Rf:
Minor symmetric conformer: 6 7.93-7.78 (m,
2H, C8H), 7.00-6.79 (m, 2H, C7H), 7.00-6.79
(m, 2H, CsH), 6.76-6.65 (m, 2H, C6H), 6.64
(s, 2H, C2H), 4.63 (d, J= 12.1, 2H, Cl 7 Ha),
4.10 (d, J= 12.4, 2H, C17Hb), 3.13 (d, J=
14.5, 2H, C12Ha), 2.62 (s, 6H, C18H), 2.53 (d,
J= 14.7, 2H, C12Hb), 1.49 (s, 6H, CH 3acetate).
6 168.4, 168.3, 168.0, 166.7, 164.3, 162.8,
143.5, 143.4, 142.5, 142.3, 132.2, 131.2,
131.1, 131.0, 130.6, 130.5, 126.6, 126.5,
126.4, 126.3, 119.4, 118.6, 118.2, 118.1,
115.9, 115.8, 81.7, 80.6, 79.3, 78.9, 75.0, 74.2,
62.8, 61.6, 57.7, 57.6, 57.5, 45.4, 45.1, 43.1,
42.8, 29.2, 27.9.
1710 (s), 1693 (s), 1347 (w), 1221 (m), 1157
(w).
calc'd for C38H30F6N6NaO1 oS6 [M+Na]*:
1059.0144, found: 1059.0137.
+448 (c = 0.065, CHC13).
0.20 (UV, CAM).
" Higher temperatures were required to resolve the trifluoroacetamide related atropisomers. Reliable heteronuclear
correlation data could not be obtained at this temperature. Furthermore, the lack of a single set of dominant signals
arising from the unique monomeric subunits of a single conformer contributed to the difficulties in both a partial or
full assignment of the peaks in the 3C NMR spectra. The chemical shifts of the collective population of conformers
are reported.
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CF3  ClKu BuBu
O O Bu-Sn-O-SnIrOH H
S 1 H, N HO-Sn-O-Sn-Bu S H, NI B, Iu I~ll
AcO SN Ou B HO'N O
Me'N SS N'Me Otera's catalyst N Me' S 5 ' 'Me18
NisO~ N2- 23 WC 0Me1N8JiO
O N .,,,-.IOAc MeOH, PhMe, 90 *C; O N -
N N,17 HOH
N 'H S N2H4, 23 *C & N 'H S
O O 95% 
8 H O
F3C
(+)-33 (+)-chaetocin C (5)
(+)-Chaetocin C (5):
Otera's catalyst 8 (4.9 mg, 8.15 pimol, 0.50 equiv) was added as a solid to a sealed tube
reaction vessel containing a solution of (+)-N-trifluoroacetyl chaetocin C diacetate (33) (16.9 mg,
16.3 imol, 1 equiv) in toluene (2 mL) and methanol (200 ptL) under an inert atmosphere. The
resulting reaction mixture was heated to 90 *C. After 10 h, the solution was allowed to cool to
room temperature, then anhydrous hydrazine (15.4 iL, 489 pmol, 30.0 equiv) was added via
syringe. After 15 min, saturated aqueous ammonium chloride (30 mL) was added to the reaction
mixture and the aqueous layer was extracted with dichloromethane (30 mL). The aqueous layer
was further extracted with dichloromethane (2 x 10 mL). The combined organic layers were
dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The residue was purified by flash column chromatography on silica gel (eluent: 0.2%
ammonium hydroxide, 1.8% methanol, 98% chloroform) to afford (+)-chaetocin C (5) (11.8 mg,
95%) as a white solid. Based on 'H NMR analysis at 20 *C in chloroform-d, the product exists as
a 1:2.35:5.47 mixture of minor symmetric:asymmetric:major symmetric epitrisulfide conformers.
'H NMR (500 MHz, CDCl 3, 20 *C): Major symmetric conformer: 8 7.23 (app-t, J
7.6, 2H, C7H), 7.16 (d, J = 7.6, 2H, C5H),
6.82 (app-t, J= 7.5, 2H, C6H), 6.75 (d, J=
7.9, 2H, C8H), 5.34 (s, 2H, C2H), 5.24 (s, 2H,
NIH), 4.19 (dd, J= 6.4, 12.9, 2H, C17Ha), 3.95
(dd, J= 8.5, 12.7, 2H, C17Hb), 3.33 (d, J=
14.8, 2H, C12Ha), 3.18 (s, 6H, Ci8H), 2.91
(app-t, J= 7.2, 2H, OH), 2.70 (d, J= 14.6,
2H, C12Hb).
Asymmetric conformer: 6 7.25-7.18 (m, I H,
C7H), 7.25-7.18 (m, 1H, C7H'), 7.18-7.07 (m,
1H, C5H), 7.18-7.07 (m, 1H, C5H'), 6.86-6.73
(in, IH, C6H), 6.86-6.73 (m, 1H, C6H'), 6.78
(d, J= 7.5, 1H, C8H), 6.63 (d, J= 7.8, 1H,
CH'), 5.67 (s, IH, C2H'), 5.44 (s, IH, C2H),
5.39 (s, 1H, NiH'), 5.26 (s, 1H, NIH), 4.98 (s,
1H, OH'), 4.53 (dd, J= 5.8, 13.3, 1H, C17Ha'),
4.30-4.15 (m, 1H, C17Ha), 3.99-3.91 (m, IH,
C17Hb), 3.75 (dd, J= 8.5, 12.7, 1H, C17Hb),
3.35 (d, J= 14.7, 1H, C12Ha), 3.27 (d, J
18 Otera, J.; Dan-oh, N.; Nozaki, H. J. Org. Chem. 1991, 56, 5307.
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1C NMR (125.8 MHz, CDC 3, 20 OC):l 9
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D23:
14.6, 1H, C12Ha'), 3.19 (s, 3H, C18H), 3.02 (s,
3H, C18H'), 2.94 (app-t, J= 7.5, 1H, OH),
2.72 (m, 1H, C12Hb'), 2.64 (d, J= 14.8,
C12Hb).
Minor symmetric conformer: 6 7.25-7.18 (m,
2H, C7H), 7.18-7.07 (m, 2H, C5H), 6.86-6.73
(m, 2H, C6H), 6.52 (d, J= 8.3, 2H, C8H), 5.70
(s, 2H, C2H), 5.31 (s, 2H, N1 H), 5.00 (s, 2H,
OH), 4.58-4.48 (m, 2H, C17Ha), 3.80-3.71
(m, 2H, C17Hb), 3.24 (d, J= 14.8, 2H, C12Ha),
3.04 (s, 6H, C18H), 2.76 (d, J= 14.6, 2H,
C12Hb).
Major symmetric conformer: 6 168.9 (C13),
165.7 (C16), 150.9 (C9), 131.2 (C7), 126.5
(C), 126.4 (C4), 119.9 (C6), 111.3 (C), 80.3
(C2), 79.2 (C 11), 75.4 (C15), 62.5 (C 17), 58.2
(C3), 45.5 (C 12), 27.8 (C18).
3397 (br, m), 2921 (w), 1674 (s), 1609 (w),
1469 (w), 1361 (m), 1319 (w), 1064 (m), 752
(m).
calc'd for C3 0H2 9N60 6S6 [M+H]*: 761.0467,
found: 761.0480.
+393 (c = 0.045, CHCl3).
TLC (0.4% ammonium hydroxide, 3.6% methanol, 96% chloroform), Rf: 0.17 (UV, CAM).
'9 Low population of the unique monomeric subunits of the asymmetric and minor symmetric dimers resulted in a
non-ideal signals for assignments. Superior data was accessible for a better behaved and known derivative. See the
characterization data for the following compound, (+)-chaetocin C diacetate (6), for full 'H and 3C NMR










(+)-chaetocin C (5) (+)-chaetocin C diacetate (6)
(+)-Chaetocin C Diacetate (6):
Acetic anhydride (11.9 pL, 129 imol, 10.0 equiv) was added dropwise via syringe to a
solution of (+)-chaetocin C (5) (9.8 mg, 12.9 pimol, 1 equiv) and 4-dimethylaminopyridine (15.7
mg, 129 pmol, 10.0 equiv) in dichloromethane (2.5 mL) at 23 *C. After 45 min, the solution was
loaded onto a silica gel column and purified by flash column chromatography (eluent: 40% ethyl
acetate in hexanes) to afford (+)-chaetocin C diacetate (6) (7.6 mg, 70%) as a white solid. Based
on IH NMR analysis at 20 0C in chloroform-d, the product exists as a 1:5:6.38 mixture of minor
symmetric:asymmetric:major symmetric epitrisulfide conformers.
'H NMR (500 MHz, CDCl 3, 20 *C): Major symmetric conformer: 5 7.20 (app-t, J =
7.7, 2H, C7H), 7.12 (d, J = 7.3, 2H, C5H),
6.78 (app-t, J = 7.5, 2H, C6H), 6.72 (d, J =
7.9, 2H, CH), 5.43 (s, 2H, C2H), 5.26 (s, 2H,
NiH), 4.77 (d, J= 12.5, 2H, Ci 7Ha), 4.30 (d, J
= 12.4, 2H, C17Hb), 3.33 (d, J = 14.8, 2H,
C12Ha), 3.13 (s, 6H, CI 8H), 2.66 (d, J= 14.8,
2H, C12Hb), 2.11 (s, 6H, CH 3acetate).
Asymmetric conformer: 8 7.23-7.15 (in, I H,
C7H), 7.23-7.15 (in, 1H, C7H'), 7.14-7.07 (m,
1H, C5H), 7.14-7.07 (in, 1 H, C5H'), 6.81-6.74
(m, 1H, C6H), 6.81-6.74 (m, 1H, C6H'), 6.74-
6.69 (in, IH, CH), 6.62 (d, J = 7.7, 1H,
C8H'), 5.74 (s, 1H, C2H'), 5.48 (s, 1H, NIH'),
5.48 (s, 1H, C2 H), 5.28 (s, 1H, NIH), 4.89 (d,
J= 12.3, 1H, C17Ha'), 4.78 (d, J= 12.5, 1H,
C17Ha), 4.36 (d, J= 12.2, 1 H, C17Hb'), 4.31 (d,
J= 12.5, 1H, CI7Hb), 3.36 (d, J= 14.7, 1H,
C12Ha), 3.28 (d, J= 14.8, 1H, C12Ha'), 3.14 (s,
3H, C18H), 2.92 (s, 3H, C18H'), 2.71 (d, J =
14.8, IH, C12Hb), 2.61 (d, J = 14.8, lH,
C12Hb'), 2.12 (s, 3H, CH 3 acetate'), 2.11 (s, 3H,
CH3acetate).
Minor symmetric conformer: 8 7.23-7.15 (in,
2H, C7H), 7.14-7.07 (m, 2H, C5 H), 6.81-6.74
(m, 2H, C6H), 6.62 (d, J= 7.7, 2H, CsH), 5.78
(s, 2H, C2H), 5.49 (s, 2H, NIH), 4.90 (d, J =
11.8, 2H, Ci7Ha), 4.36 (d, J = 12.2, 2H,
C17Hb), 3.28 (d, J = 14.8, 2H, C12Ha), 2.93 (s,
131
13C NMR (125.8 MHz, CDCl3, 20 'C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D23:
TLC (40% ethyl acetate in hexanes), Rf:
6H, CI8H), 2.66 (d, J= 14.8, 2H, C12Hb), 2.12
(s, 6H, CH3acetate).
Major symmetric conformer: 6 169.9
(C=Oacetate), 168.6 (C13), 163.7 (C16), 150.9
(C9 ), 131.2 (C7), 126.5 (C), 126.4 (C4), 119.6
(C6), 111.2 (C8), 80.4 (C2), 79.2 (C11), 74.0
(CI), 61.2 (C17), 58.5 (C 3), 45.5 (C 12 ), 28.2
(C18 ), 21.1 (CH3 acetate).
Asymmetric conformer: 6 169.9 (C=Oacetate),
169.9 (C=Oacetate'), 168.7 (C13), 167.3 (C 13'),
163.7 (C 16), 162.7 (C 16'), 150.9 (C9), 149.5
(C9 '), 131.2 (C7), 130.3 (C 7'), 127.1 (C4'),
126.5 (C4), 126.5 (Cs), 126.2 (Cs'), 120.0
(C6 '), 119.6 (C6 ), 11.1 (C), 110.3 (C8'), 82.4
(C2'), 80.4 (C2 ), 79.2 (C11), 79.2 (CI1 '), 74.9
(C15'), 74.0 (CIs), 62.1 (C 17'), 61.2 (C17 ), 58.7
(C 3'), 58.7 (C3), 45.5 (C12 ), 43.1 (C 12'), 29.3
(C18'), 28.2 (C18), 21.1 (CH3 acetate'), 21.1
(CH3acetate).
Minor symmetric conformer: 6 169.9
(C=Oacetate), 167.3 (C13), 162.7 (C16 ), 149.5
(C9), 130.3 (C7), 127.2 (C4), 126.2 (C), 120.1
(C6), 110.3(C 8 ), 82.4 (C2), 79.2 (C11), 74.9
(C15), 62.1 (C17 ), 58.8 (C3 ), 43.1 (C12 ), 29.3
(C18), 21.1 (CH 3acetate).
3382 (br, m), 1750 (m), 1683 (s), 1609 (w),
1470 (w), 1366 (m), 1319 (w), 1223 (m), 1043
(m), 753 (m).
calc'd for C30H29N60 6S6 [M+H]*: 845.0679,
found: 845.0696.
+660 (c = 0.025, CHCl3).20
0.17 (UV, CAM).
20 Literature value: [a]D20 = +658.3 (c 0.012, CHCI3),
Knoshita, T. Chem. Pharm. Bull. 1988, 36, 1942.
Saito, T.; Suzuki, Y.; Koyama, K.; Natori, S.; litaka, Y.;
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(+)-27 Me Me (+)-30 MeMe
Octacyclic Diaminodithiol (+)-30:
Anhydrous hydrazine (2.4 gL, 75.1 pmol, 5.00 equiv) was added via syringe to a solution
of diaminodithioisobutyrate (+)-27 (15.5 mg, 15.0 pmol, 1 equiv) in tetrahydrofuran (5 mL) at 0
"C. After 10 min, aqueous hydrochloric acid (IN, 10 mL) was added to the reaction mixture.
The aqueous layer was extracted with dichloromethane (3 x 20 mL), and the combined organic
layers were dried over anhydrous sodium sulfate, were filtered, and were concentrated under
reduced pressure. The residue was purified by flash column chromatography on silica gel
(eluent: 50% ethyl acetate in hexanes) to afford octacyclic diaminodithiol (+)-30 (12.5 mg, 93%)
as a white solid.
'H NMR (500 MHz, CDCl 3, 20 *C):
3 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm- 1:
HRMS (ESI) (m/z):
[a]D24 :
TLC (50% ethyl acetate in hexanes), Rf:
8 7.45 (d, J= 7.5, 2H, C5H), 7.16 (app-t, J=
7.5, 2H, C7H), 6.85 (app-t, J= 7.5, 2H, C6H),
6.65 (d, J= 7.8, 2H, C8H), 5.83 (s, 2H, C2H),
4.95 (s, 2H, NiH), 4.72 (d, J = 11.3, 2H,
C17Ha), 4.31 (d, J= 11.4, 2H, C17Hb), 3.05(br-d, J= 13.6, 2H, C12 Ha), 2.83 (s, 6H,
Ci8H), 2.71 (s, 2H, SH), 2.61-2.51 (m, 2H,
C12Hb), 2.61-2.51 (m, 2H, CHisobutyrate), 1.98
(s, 6H, CH 3acetate), 1.22-1.14 (m, 12H,
CH3isobutyrate).
6 175.2 (C=Oisobutyrate), 169.9 (C=Oacetate),
168.3 (C13), 161.1 (C16), 150.7 (C9), 129.8
(C7), 129.4 (C4 ), 126.1 (Cs), 119.4 (C6), 110.4
(C8), 86.5 (Cs), 81.5 (C2 ), 68.6 (C,1 ), 62.6
(C17), 60.3 (C3), 47.3 (C12), 34.0 (CHisobutyrate),
28.0 (Cs), 21.2 (CH 3acetate), 18.8
(CH3isobutyrate), 18.6 (CH3isobutyrate).
3384 (br, m), 1748 (s), 1682 (s), 1385 (in),
1225 (m).
calc'd for C4 2H 4 9N 6012 S2 [M+H]*: 893.2844,
found: 893.2841.
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Octacyclic Bis(triphenylmethanetetrasulfide) (-)-34:
Triethylamine (48.8 1 iL, 350 ptmol, 25.0 equiv) and solid
chloro(triphenylmethyl)trisulfane 5 (52.5 mg, 140 pmol, 10.0 equiv) were sequentially added to a
solution of diaminodithiol (+)-30 (12.5 mg, 14.0 imol, 1 equiv) in tetrahydrofuran (3 mL) at 0
*C under an inert atmosphere. After 7 min, the solution was poured into a separatory funnel
containing saturated aqueous ammonium chloride (30 mL) and dichloromethane (30 mL). The
aqueous layer was extracted with dichloromethane (2 x 20 mL), and the combined organic layers
were dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The residue was purified by flash column chromatography on silica gel (eluent: 30%
ethyl acetate in hexanes) to afford dimeric bis(triphenylmethanetetrasulfide) (-)-34 (17.6 mg,
80%) as a white solid.
'H NMR (500 MHz, CDCl 3, 20 *C):
3 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
6 7.35-7.16 (m, 2H, C5H), 7.35-7.16 (m,
30H, C(C 6H5)3), 7.12 (app-t, J= 7.2, 2H,
C7H), 6.79 (app-t, J = 7.1, 2H, C6H), 6.54 (d,
J= 7.7, 2H, C8H), 5.74 (br-s, 2H, C2H), 4.83
(s, 2H, N1H), 4.77 (d, J= 11.5, 2H, C17Ha),
4.22 (d, J= 11.5, 2H, C17Ha), 2.83-2.69 (m,
4H, C12H), 2.76 (s, 6H, Ci8H), 2.50 (app-sp, J
= 7.0, 2H, CHisobutyrate), 1.98 (s, 6H, CH3acetate),
1.16 (d, J = 7.0, 6H, CH3isobutyrate), 1.13 (d, J=
6.9, 6H, CH3isobutyrate).
5 175.2 (C=Oisobutyrate), 170.1 (C=Oacetate),
165.6 (C13), 161.8 (C16), 150.2 (C 9), 143.2
(C(C 6H5)3 ), 130.4 (C(C 6H5 )3), 129.7 (C 7),
128.8 (C4), 128.1 (C(C 6Hs) 3 ), 127.4
(C(C 6H5)3), 125.8 (C5), 119.4 (C6), 110.2
(C8 ), 86.9 (Cs), 82.1 (C2), 74.4 (C 1 ), 73.5
(C(C 6H5)3 ), 62.3 (C17), 59.5 (C 3 ), 40.2 (C12),
34.0 (CHisobutyrate), 28.1 (Cs), 21.5 (CH 3 acetate),
18.8 (CH3isobutyrate), 18.5 (CH3isobutyrate).
1746 (s), 1692 (s), 1384 (m), 1222 (m), 699
(m).
calc'd for C8oH76N6NaOi 2S8 [M+Na]*:
1591.3179, found: 1592.3161.
-485 (c = 0.16, CHC 3).
134
TLC (30% ethyl acetate in hexanes), Rf:
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0. 19 (UV, CAM).
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Ph3C Me Me O (+)-12,12'-dideoxychetracin A (7)(-)-34 (+)-36
(+)-N-Formyl-12,12'-Dideoxvchetracin A Diacetate (36) and (+)-12,12'-Dideoxychetracin A
(7):
Acetic formic anhydride (1 mL) was added via syringe to a flask charged with
bis(triphenylmethanetetrasulfide) (-)-34 (17.6 mg, 11.2 pmol, 1 equiv) at 23 *C and sonicated for
30 s. After 20 min, the solution was concentrated under reduced pressure to yield a white solid.
Anhydrous acetonitrile (5 mL) was then introduced via syringe followed by boron trifluoride
diethyl etherate (84.8 pL, 673 ptmol, 60.0 equiv) at 23 *C. The solution immediately turned a
bright yellow color. After 2 h, the solution was diluted with dichloromethane (30 mL) and
washed with saturated aqueous ammonium chloride (30 mL). The aqueous layer was extracted
with dichloromethane (2 x 20 mL), and the combined organic layers were dried over anhydrous
sodium sulfate, were filtered, and were concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (eluent: 25% ethyl acetate in toluene) to
afford (+)-N-formyl- 12,12'-dideoxychetracin A diacetate (36) (6.5 mg, 60%) as a white solid.
A methanolic solution of hydrochloric acid (0.5 N, 2.5 mL) was added to a sealed tube
charged with (+)-N-formyl-12,12'-dideoxychetracin A diacetate (36) (6.5 mg, 6.73 pmol, 1
equiv). The white suspension was sonicated for 1 min until a clear solution was obtained. The
solution was then heated to 60 *C. After 45 min, the reaction mixture was allowed to cool to 23
*C and was concentrated under reduced pressure to yield a yellow solid. The residue was
purified by flash column chromatography on silica gel (eluent: 4% isopropanol in
dichloromethane) to afford (+)-12,12'-dideoxychetracin A (7) (2.9 mg, 52%) as an off-white
solid. Crystals suitable for X-ray diffraction were obtained by vapor diffusion of pentane into a
saturated solution of (+)-12,12'-dideoxychetracin A (7) in acetone at 23 *C. For a thermal
ellipsoid representation of (+)-7, see page S42.
'H NMR (500 MHz, CDCl 3, 58 *C): 6 7.38 (d, J= 7.6, 2H, C5H), 7.12 (app-t, J
7.9, 2H, C8H), 6.78 (app-t, J= 7.5, 2H, C7H),
6.53 (d, J= 7.9, 2H, C8H), 5.80 (s, 2H, C2H),
4.99 (br-s, 2H, NIH), 4.34 (d, J= 12.3, 2H,
C 7 Ha), 3.96 (d, J= 11.9, 2H, C17Hb), 3.09 (s,
2 Atropisomerism-induced peak broadening prevented complete NMR spectroscopic characterization of compound
(+)-36. Resolution of the peaks via variable temperature NMR was not possible due to the thermal instability of the
compound. The following supplementary data were obtained for intermediate (+)-36: FTIR (thin film) cm': 1755
(m), 1689 (s), 1486 (w), 1463 (w), 1380 (m), 1213 (m), 1044 (w), 753 (m). HRMS (ESI) (m/z): calc'd for
C3 6H 3 2N 6NaOjoSg [M+Na]*: 986.9838, found: 986.9815. [C]D24 : +300 (c = 0.55, CHCI3). TLC (25% ethyl acetate in
benzene), Rf: 0.22 (UV, CAM).
22 All eight crystal structure data of epitetrathiodiketopiperazines deposited at the Cambridge Crystallographic Data
Centre have the same sense of helicity.
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13C NMR (125.8 MHz, CDCl 3, 20 C):
FTIR (thin film) cm'1:
HRMS (ESI) (m/z):
[aX]D24:
TLC (4% isopropanol in dichloromethane), Rf:
6H, C 18H), 2.98 (d, J= 15.4, 2H, C12 Ha), 2.72
(d, J= 15.0, 2H, C12Hb).
6 168.6 (C 13), 166.8 (C 16), 150.2 (C9 ), 130.5
(C7 ), 128.6 (C 4), 125.6 (C5), 120.1 (C6), 110.2
(Cs), 80.9 (C2 ), 79.7 (C 11), 75.6 (C15), 61.9
(C 17), 60.0 (C3), 46.1 (C 12), 29.1 (C18).
3367 (br, s), 2925 (w), 1669 (s), 1609 (m),
1484 (w), 1413 (m), 1383 (m), 1319 (w), 1224
(m), 1097 (m), 1065 (m), 747 (m), 697 (m).
calc'd for C30H28N 6NaO 6S8 [M+Na] :
846.9728, found: 846.9731.




Me-F N - 0 K2CS 3, TFA PhO2S-N 1 18MN \ HQ Me CH2CI2  Me O H N-Me
M OH N Me--N H N 1 6  Me0 ,, N Me 23 *C, 25 min P N'SO2Ph 17
N H OH 38%
SO2Ph 0S4 38
Dimeric bisdithiepanethione 38:
Dimeric tetraol S4 (200 mg, 226 pmol, 1 equiv) was added as a solid to a yellow solution
of potassium trithiocarbonate (632 mg, 3.39 mmol, 15.0 equiv) in anhydrous dichloromethane
(5.1 mL) and trifluoroacetic acid (1.7 mL) at 23 0C. After 25 min, the reaction mixture was
diluted with dichloromethane (60 mL) and washed with saturated aqueous sodium bicarbonate
(125 mL). The aqueous layer was extracted with dichloromethane (2 x 30 mL) and the
combined organic layers were dried over anhydrous sodium sulfate, were filtered, and were
concentrated under reduced pressure to afford a yellow powder. This powder was purified by
flash column chromatography on silica gel (eluent: 5% acetone in dichloromethane) to afford
dimeric bisdithiepanethione 38 (88.8 mg, 38.0%) as an orange-yellow solid.
'H NMR (500 MHz, CDC 3, 20 *C):
13C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D 24:
TLC (5% acetone in dichloromethane), Rf:
6 7.75-7.65 (m, 2H, C8H), 7.75-7.65 (m, 4H,
SO2Ph-o-H), 7.53 (app-t, J = 7.4, 2H, SO2Ph-
p-H), 7.41 (app-t, J = 8.0, 4H, SO 2Ph-m-H),
7.30-7.14 (m, 6H, C6H, C7H, C5H), 6.86 (s,
2H, C2H), 3.26 (d, J= 14.9, 2H, C12Ha), 3.09
(d, J = 14.9, 2H, C12Hb), 3.01 (s, 6H, C18H),
1.68 (s, 6H, C17H).
6 215.1 (C=S), 164.1 (C13 ), 159.7 (C 16), 142.7
(C9), 141.9 (SO 2Ph-ipso-C), 133.1 (SO2Ph-p-
C), 131.3 (C4), 129.2 (SO2 Ph-m-C), 129.2
(C6), 125.5 (SO 2 Ph-o-C), 125.2 (C7), 124.5
(C), 116.1 (C5 ), 81.6 (C2), 73.9 (C11), 73.6
(C15 ), 59.1 (C3), 44.7 (C12), 28.6 (C18), 19.3
(C 17).
1715 (s), 1691 (s), 1479 (m), 1462 (m), 1447
(m), 1359 (s), 1169 (s), 729 (m).
calc'd for C4 4H 3 6N 6NaO8 S8  [M+Na]*:
1055.0252, found 1055.0255.
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Dimeric epidithiodiketopiperazine 37:
Ethanolamine (500 gL) was added via syringe to a solution of dimeric
bisdithiepanethione 38 (11.2 mg, 10.8 pmol, 1 equiv) in acetone (500 gL) at 23 *C. After 15
min, the reaction mixture was diluted with dichloromethane (30 mL) and aqueous hydrochloric
acid solution (1 N, 30 mL). The organic layer was collected, and the aqueous layer was
extracted with dichloromethane (2 x 5 mL). A solution of potassium triiodide in pyridine (2.5%
w/v) was added dropwise to the combined organic layers until a persistent yellow color was
observed. The resulting mixture was washed with aqueous hydrochloric acid (1 N, 30 mL) and
the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 5 mL),
and the combined organic layers were dried over anhydrous sodium sulfate, were filtered, and
were concentrated under reduced pressure. The residue was purified by flash column
chromatography on silica gel (eluent: 5% acetone in dichloromethane) to afford dimeric
epidithiodiketopiperazine 37 (3.9 mg, 38%) as a white solid.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-:
HRMS (ESI) (m/z):
TLC (5% acetone in dichloromethane), Rf:
6 7.85 (dd, J= 1.4, 7.3, 4H, SO 2Ph-o-H), 7.68
(d, J = 7.5, 2H, CH), 7.54 (tt, J = 1.2, 7.5,
2H, SO2Ph-p-H), 7.46 (app-t, J 8.0, 4H,
SO2Ph-m-H), 7.20 (app-dt, J = 1.3, 7.5, 2H,
CH), 7.16 (app-dt, J = 1.2, 7.5, 2H, C7H),
7.04 (dd, J= 1.0, 7.6, 2H, C5H), 6.83 (s, 2H,
C2H), 3.55 (d, J = 15.2, 2H, C12Ha), 2.97 (s,
6H, Ci 8H), 2.95 (d, J= 15.2, 2H, C12Hb), 1.62
(s, 6H, C17H).
6 164.9 (C13), 160.8 (C16), 142.5 (C9), 142.4
(SO 2Ph-ipso-C), 132.6 (SO2Ph-p-C), 130.9
(C4), 130.6 (C), 129.0 (SO 2Ph-m-C), 125.7
(SO 2Ph-o-C), 125.2 (C7 ), 124.7 (C), 116.3
(C5), 81.9 (C2), 73.8 (Ci5 ), 73.4 (CI), 60.5
(C3 ), 41.9 (CI2 ), 27.8 (Ci8 ), 17.9 (C17).
1716 (s), 1688 (s), 1480 (m), 1462 (m), 1447
(w), 1348 (s), 1168 (m).
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C3-Propyl dithiepanethiones 45 and 46:
A solution of the tetracyclic diol S5 (228 mg, 470 pmol, 1 equiv) in dichloromethane (3.5
mL) was added to a yellow solution of potassium trithiocarbonate (438 mg, 2.35 mmol, 5.00
equiv) in anhydrous dichloromethane (7 mL) and trifluoroacetic acid (3 mL) at 23 *C. An
additional portion of trifluoroacetic acid (1.5 mL) was added to the reaction mixture via syringe.
After 25 min, the reaction mixture was diluted with dichloromethane (60 mL) and washed with
saturated aqueous sodium bicarbonate (125 mL). The aqueous layer was extracted with
dichloromethane (2 x 30 mL) and the combined organic layers were dried over anhydrous
sodium sulfate, were filtered, and were concentrated under reduced pressure to yield a yellow
powder. This powder was purified by flash column chromatography on silica gel (eluent: 20%
acetone in dichloromethane) to afford diastereomeric dithiepanethiones 45 (137 mg, 52.0%) and
46 (38.7 mg, 14.7%) as yellow films.
CDCl 3, 20 *C):
13 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
8 7.72 (d, J = 7.5, 2H, SO 2Ph-o-H), 7.52 (t, J
= 7.5, 1H, SO2 Ph-p-H), 7.40 (app-t, J = 7.9,
2H, SO2Ph-m-H), 7.35 (d, J= 7.1, 1H, CH),
7.29 (app-dt, J = 1.7, 8.2, 1H, C7H), 7.19
(app-dt, J = 0.9, 7.7, 1H, C6 H), 7.16 (dd, J=
1.4, 7.6, 1H, C5H), 6.29 (s, 1H, C2H), 3.00 (s,
3H, Ci 8H), 2.98 (d, J= 15.1, 1H, C 12Ha), 2.75
(d, J= 15.1, 1H, C12H), 1.79 (s, 3H, C17H),
1.47-1.31 (in, 2H, CH 2CH 2CH 3), 1.47-1.31
(m, 1 H, CH2CHaHbCH 3 ), 1.19-1.06 (in, 1 H,
CH 2CHaHbCH 3), 0.78 (app-t, J = 7.0, 3H
CH 2CH2CH 3).
6 215.9 (C=S), 164.7 (C13), 160.5 (CI), 141.6
(C9), 140.4 (SO 2Ph-ipso-C), 135.4 (C4), 133.3
(SO2 Ph-p-C), 129.7 (C7), 129.2 (SO 2Ph-m-C),
126.5 (SO 2 Ph-o-C), 125.9 (C6), 123.6 (C5 ),
117.6 (Cs), 83.7 (C2 ), 74.6 (C11), 73.5 (C15),
54.5 (C3), 46.1 (C 12 ), 40.5 (CH2CH 2CH3 ),
28.5 (CIs), 19.7 (C17), 18.0 (CH 2CH2CH3 ),
14.3 (CH 2CH2CH3).
1711 (s), 1686 (s), 1477 (m), 1461 (m), 1447
(m), 1365 (s), 1167 (s), 732 (m).




'H NMR (500 MHz,
TLC (40% ethyl acetate in hexanes), Rf:
a-epimer 46:
'H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, CDCl 3, 20 0C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (40% ethyl acetate in hexanes), Rf:
6 7.79 (dd, J= 1.0, 7.3, 2H, SO 2 Ph-o-H), 7.57
(d, J = 8.0, 1 H, C8H), 7.53 (t, J = 7.5, 1 H,
SO2Ph-p-H), 7.40 (app-t, J= 7.8, 2H, SO2Ph-
m-H), 7.27 (app-dt, J = 1.4, 7.8, 1H, C7H),
7.12 (app-dt, J= 0.9, 7.6, 1 H, C6H), 7.06 (dd,
J= 0.8, 7.5, 1 H, C5H), 6.06 (s, I H, C2H), 3.42
(d, J= 15.7, 1H, CI2 Ha), 2.97 (s, 3H, Ci 8H),
2.44 (d, J = 15.7, 1 H, CI2Hb), 1.95 (s, 3H,
C17H), 1.37-1.26 (m, 1H, CH 2CHaHbCH 3),
1.26-1.14 (m, 1H, CH 2CHaHbCH 3), 0.97-0.83
(m, 2H, CH 2 CH 2 CH 3), 0.69 (app-t, J = 6.8,
3H, CH 2CH 2CH 3).
6 216.8 (C=S), 164.3 (C13), 161.4 (Ci 5 ), 139.3
(C9), 138.9 (SO 2Ph-ipso-C), 138.3 (C4), 133.8
(SO2Ph-p-C), 129.3 (SO 2Ph-m-C), 129.3 (C7),
127.7 (SO 2 Ph-o-C), 126.3 (C6), 124.4 (Cs),
118.3 (C), 84.5 (C2 ), 74.8 (C,,), 74.1 (Ci 5 ),
55.0 (C3 ), 42.4 (C12), 40.0 (CH 2CH 2CH 3),
28.6 (C18), 21.0 (C17), 18.3 (CH 2 CH2CH3 ),
14.2 (CH 2CH 2CH 3).
1712 (s), 1691 (s), 1476 (m), 1461 (m), 1447
(m), 1368 (s), 1333 (s), 1172 (s), 727 (w).
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Ethanolamine (500 pL) was added via syringe to a solution of dithiepanethione 45 (13.3
mg, 23.8 ptmol, 1 equiv) in acetone (500 pL) at 23 0C. After 15 min, the reaction mixture was
diluted with dichloromethane (30 mL) and aqueous hydrochloric acid solution (2 N, 30 mL).
The organic layer was collected, and the aqueous layer was extracted with dichloromethane (2 x
2 mL). A solution of potassium triiodide in pyridine (2.5% w/v) was added dropwise to the
combined organic layers until a persistent yellow color was observed. The resulting mixture was
washed with aqueous hydrochloric acid (2 N, 30 mL) and the layers were separated. The
aqueous layer was extracted with dichloromethane (2 x 5 mL), and the combined organic layers
were dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The residue was purified by flash column chromatography on silica gel (eluent: 1%
acetone in dichloromethane) to afford epidithiodiketopiperazine 43 (8.6 mg, 70%) as a clear film.
'H NMR (500 MHz, CDCl 3, 20 *C):
3 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (1% acetone in dichloromethane), Rf:
8 7.80 (d, J= 7.0, 2H, SO 2Ph-o-H), 7.53 (t, J
= 7.0, 1H, SO2 Ph-p-H), 7.46-7.37 (m, 1H,
C8H), 7.46-7.37 (m, 2H, SO 2 Ph-m-H), 7.29(app-dt, J= 1.1, 7.7, 1H, C7H), 7.16 (app-t, J
= 7.6, 1H, C6H), 7.12 (d, J= 7.6, 1H, CsH),
6.09 (s, 1H, C2H), 3.19 (d, J = 15.2, 1H,
C12Ha), 2.98 (s, 3H, C18H), 2.57 (d, J= 15.2,
1H, C12Hb), 1.87 (s, 3H, C17H), 1.43-1.30 (m,
1 H, CH 2CHaHbCH 3), 1.22-1.04 (m, 1 H,
CH 2CHaHbCH 3), 1.22-1.04 (m, 2H,
CH2CH 2CH3), 0.77-0.68 (m, 3H,
CH2CH 2CH 3).
6 165.9 (C13), 161.6 (C16), 141.1 (C9), 139.8
(SO 2 Ph-ipso-C), 137.6 (C4), 133.4 (SO2Ph-p-
C), 129.3 (C7), 129.2 (SO2Ph-m-C), 127.4
(SO 2 Ph-o-C), 125.9 (C6), 123.6 (C5 ), 118.4
(C), 83.7 (C2), 73.7 (C, ,), 73.5 (C15 ), 55.9
(C3), 41.8 (C12), 40.0 (CH2CH 2CH 3), 27.7
(C, 8 ), 18.3 (CH 2CH2CH 3), 18.0 (C17), 14.3(CH 2CH 2CH3).
1713 (s), 1688 (s), 1478 (m), 1460 (m), 1447
(m), 1341 (s), 1172 (s), 719 (w).














Ethanolamine (500 pL) was added via syringe to a solution of dithiepanethione 46 (13.3
mg, 23.8 gmol, I equiv) in acetone (500 pL) at 23 *C. After 15 min, the reaction mixture was
diluted with dichloromethane (30 mL) and aqueous hydrochloric acid solution (2 N, 30 mL).
The organic layer was collected, and the aqueous layer was extracted with dichloromethane (2 x
5 mL). A solution of potassium triiodide in pyridine (2.5% w/v) was added dropwise to the
combined organic layers until a persistent yellow color was observed. The resulting mixture was
washed with aqueous hydrochloric acid (2 N, 30 mL) and the layers were separated. The
aqueous layer was extracted with dichloromethane (2 x 5 mL), and the combined organic layers
were dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The residue was purified by flash column chromatography on silica gel (eluent: 30%
ethyl acetate in dichloromethane) to afford epidithiodiketopiperazine 44 (9.6 mg, 78%) as a clear
film.
'H NMR (500 MHz, CDCl3, 20 *C):
"C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (30% ethyl acetate in hexanes), Rf:
6 7.83 (dd, J= 0.8, 8.2, 2H, SO 2Ph-o-H), 7.53
(t, J = 7.4, 1 H, SO2 Ph-p-H), 7.51 (d, J = 7.9,
1H, C8H), 7.40 (app-t, J = 8.1, 2H, SO 2Ph-m-
H), 7.28-7.19 (m, 1H, C7H), 7.13-7.05 (m,
1H, C6 H), 7.13-7.05 (m, 1H, CsH), 6.14 (s,
1H, C2H), 3.57 (d, J= 14.9, 1H, Ci 2Ha), 2.89
(s, 3H, Ci8H), 2.37 (d, J= 14.9, 1H, C12Hb),
1.93 (s, 3H, C17H), 1.38-1.14 (m, 2H,
CH2CH 2CH 3), 1.00-0.85 (m, 2H,
CH 2CH2CH3), 0.70 (app-t, J = 7.2, 3H,
CH 2CH2CH 3).
6 165.7 (C13), 162.9 (C16), 139.3 (C 9), 139.1
(SO 2Ph-ipso-C), 137.4 (C4), 133.7 (SO2 Ph-p-
C), 129.3 (SO 2Ph-m-C), 129.3 (C 7), 127.7
(SO 2 Ph-o-C), 126.1 (C6 ), 124.5 (Cs), 118.1
(Cs), 84.3 (C2 ), 74.6 (C,1), 73.9 (C, 5 ), 56.4
(C3), 40.5 (C12), 39.7 (CH2CH 2CH 3), 27.5
(C18 ), 18.7 (C17), 18.1 (CH 2CH2CH 3), 14.2
(CH 2CH2CH3).
1694 (s), 1447 (m), 1366 (s), 1331 (m), 1172
(s), 722 (w).
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Dimeric bis(triphenylmethanetrisulfide) (+)-39:
Anhydrous hydrazine (0.8 ptL, 25 gmol, 5.00 equiv) was added via syringe to a solution
of diaminodithioisobutyrate (+)-26 (6.6 mg, 5.0 tmol, 1 equiv) in tetrahydrofuran (2 mL) at 0 *C.
After 18 min, triethylamine (17.5 pL, 126 pmol, 25.0 equiv) and solid
chloro(triphenylmethyl)disulfane (17.2 mg, 50.3 ptmol, 10.0 equiv) were sequentially added to
the reaction mixture under an inert atmosphere. After 13 min, saturated aqueous ammonium
chloride (3 mL) was added to the reaction mixture. The solution was then poured into a
separatory funnel containing saturated aqueous ammonium chloride (10 mL) and
dichloromethane (15 mL). The aqueous layer was extracted with dichloromethane (2 x 5 mL),
and the combined organic layers were dried over anhydrous sodium sulfate, were filtered, and
were concentrated under reduced pressure. The residue was purified by flash column
chromatography on silica gel (eluent: 35% ethyl acetate in hexanes) to afford dimeric
bis(triphenylmethanetrisulfide) (+)-39 (7.4 mg, 82%) as a slightly off-white solid.
'H NMR (500 MHz, CDCl 3, 20 *C):
"C NMR (125.8 MHz, CDCl 3, 20 *C):
6 8.04 (d, J = 7.5, 4H, SO 2Ph-o-H), 7.64 (t, J
= 7.5, 2H, SO2Ph-p-H), 7.52 (app-t, J = 7.9,
4H, SO 2 Ph-m-H), 7.22-7.12 (m, 2H, CH),
7.22-7.12 (m, 18H, C(C 6H5 )3), 6.99-6.90 (m,
12H, C(C 6H5 )3), 6.80 (s, 2H, C2H), 6.65 (br-s,
2H, C5H), 6.57 (app-t, J= 8.1, 2H, C7H), 6.08
(app-t, J = 7.0, 2H, C6H), 4.43 (d, J = 11.9,
2H, C17Ha), 4.23 (d, J = 11.7, 2H, C,7Hb),
3.31 (d, J = 14.5, 2H, C12Ha), 2.92 (d, J =
14.4, 2H, C12Hb), 2.71 (s, 6H, Ci 8H), 2.54
(app-sp, J= 7.1, 2H, CHisobutyrate), 1.79 (s, 6H,
CH3acetate), 1. 11 (d, J = 7.0, 6H, CH3isobutyrate),
1.08 (d, J = 7.1, 6H, CH3isobutyrate).
6 174.1 (C=Oisobutyrate), 170.1 (C=Oacetate),
164.1 (C), 161.2 (C1 6), 143.3 (C(C 6 H5 )3),
142.8 (C 9), 140.5 (SO 2Ph-ipso-C), 133.4
(SO2 Ph-p-C), 130.7 (C 4), 130.5 (C(C 6 H5 )3),
129.6 (SO2 Ph-m-C), 129.4 (C 7), 128.0
(C(C 6H5 )3 ), 127.3 (C(C 6H5 )3), 127.3 (SO 2Ph-
o-C), 124.0 (C), 123.8 (C6), 112.8 (C), 86.2
(CIs), 80.9 (C2), 75.2 (C), 73.3 (C(C 6H5 )3),
64.7 (CI7), 60.7 (C3 ), 42.8 (C12), 33.6
144
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D24
TLC (35% ethyl acetate in hexanes), Rf:
(CHisobutyrate), 28.7 (C18), 21.4 (CH 3acetate), 18.8
(CH3isobutyrate).
1749 (s), 1708 (s), 1480 (m), 1462 (m), 1447
(m), 1380 (s), 1220 (m), 1173 (s), 729 (m),
699 (m).
calc'd for C92 H88N 70 16S8
1802.4048, found 1802.4073.




Table Si. Comparison of our data for (+)-Chaetocin A (3) with literature:
Assignment23  Hauser et al. Report2 4  This Work
(+)-Chaetocin A (3) (+)-Chaetocin A (3)
'H NMR, 60 MHz, DMSO-d 6  'H NMR, 500 MHz, DMSO-d6 , 20
OC
NI 6.5-7.5 (m) 7.03 (s)
C2 5.30 (s) 5.23 (br-s)
C3
C4
C5 6.5-7.5 (m) 7.42 (d, J= 7.4 Hz)
C6 6.5-7.5 (m) 6.68 (app-t, J= 7.5 Hz)
C7 6.5-7.5 (m) 7.07 (app-t, J= 7.4 Hz)




3.64 (d, J= 15 Hz) 3.61 (d, J= 15.2 Hz)





4.20 (dd, J= 5.2, 12.7 Hz)
C17 4.18 (d, J= 5Hz) 4.09 (dd, J= 4.9, 12.7 Hz)
C18 3.02(s) 3.00 (s)
OH 5.80 (t, J= 5 Hz) 5.84 (app-t, J= 5.5 Hz)
23 Please see page 104 for the positional numbering system used in this report.
24 Von Hauser, D.; Weber, H. P.; Sigg, H. P. Helv. Chim. Acta 1970, 53, 1061.
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Table S2. Comparison of our data for (+)-Chaetocin A (3) with literature:
Assignment23  Sodeoka et al. Report2s This Work
(+)-Chaetocin A (3) (+)-Chaetocin A (3)
H NMR, 500 MHz, CDC13, 24 *C H NMR, 500 MHz, CDC 3, 20 *C
NI 5.25(s) 5.23 (s)
C2 5.25 (s) 5.23 (s)
C3
C4
C5 6.74 (app-d, J= 7.5 Hz) 7.40 (d, J= 7.6 Hz)26
C6 6.92 (dt, J= 0.9, 7.5 Hz) 6.90 (app-t, J= 7.5 Hz)
C7 7.25 (dt, J= 1.4, 7.5 Hz) 7.23 (app-t, J= 7.6 Hz)









C17 4.25 (dd, J= 6.0, 12.8 Hz) 4.23 (dd, J= 5.1, 12.8)4.18 (dd, J= 9.2, 12.8 Hz) 4.16 (dd, J= 9.1, 13.0)
C18 3.08(s) 3.06 (s)
OH 3.29 (dd, J= 6.0, 9.2 Hz) 3.26 (app-t, J= 6.7 Hz)
2s Iwasa, E.; Hamashima, Y.; Fujishiro, S.; Higuchi, E.; Ito, A.; Yoshida, M.; Sodeoka, M. J. Am. Chem. Soc. 2010,
132, 4078.
26 Our assignment of these resonances is supported by key COSY signals ('H,'H) in ppm: (7.40,6.90), (6.90,7.23),
(7.23,6.72), key HSQC signals ('H,13C) in ppm: (7.40,125.4), (7.23,130.7), (6.90,120.6), (6.72,110.9), and key
HMBC signals ('H, 3 C) in ppm: (7.40,60.0), (6.90,127.6), (7.23,149.3).
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Table S3. Comparison of our data for (+)-Chaetocin A (1) with literature:
Assignment 23  Sodeoka et al. Report2 s This Work3 1
(+)-Chaetocin A (3) (+)-Chaetocin A (3)

















Table S4. Comparison of our data for (+)-Chaetocin A diacetate (4) with literature:
Assignment23 Hauser et al. Report2 Saito et al. Report27  This Work
(+)-Chaetocin A diacetate (4) (+)-Chaetocin A diacetate (4) (+)-Chaetocin A diacetate (4)
'H NMR, 60 MHz, CDCl3 'H NMR, 400 MHz, CDC13 'H NMR, 500 MHz, CDCl 3,
20 0C
N I 5.35 (s) 5.33 (s) 5.30 (s)
C2 5.35 (s) 5.33 (s) 5.28 (s)
C3
C4
C5 6.5-7.4 (m) 6.72-7.42 (m) 7.39 (d, J= 7.5 Hz)
C6 6.5-7.4 (m) 6.72-7.42 (m) 6.88 (app-t, J= 7.5 Hz)
C7 6.5-7.4 (m) 6.72-7.42 (m) 7.22 (app-t, J= 8.2 Hz)




C12 3.80 (d, J= 15 Hz) 3.81 (d, J= 15.1 Hz) 3.78 (d, J= 15.2 Hz)2.70 (d, J= 15 Hz) 2.75 (d, J= 15.1 Hz) 2.69 (d, J= 15.1 Hz)
C13 - - -
N14 - - -
C15 - - -
C16 - - -
C7 4.84 (d, J= 12.5 Hz) 4.98 (d, J= 12.7 Hz) 4.87 (d, J= 12.7 Hz)4.60 (d, J= 12.5 Hz) 4.61 (d, J= 12.7 H z) 4.57 (d, J= 12.7 Hz)
C18 2.97 (s) 3.05 (s) 3.03 (s)
CH 3 CO 2 2.02 (s) 2.13 (s) 2.11 (s)
27 Saito, T.; Suzuki, Y.; Koyama, K.; Natori, S.; litaka, Y.; Knoshita, T. Chem. Pharm. Bull. 1988, 36, 1942.
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Table S5. Comparison of our data for (+)-Chaetocin A diacetate (4) with literature:
Assignment 3  Saito et al. Report2 7  This Work3 1
(+)-Chaetocin A diacetate (4) (+)-Chaetocin A diacetate (4)
















CH 3CO 2  20.5 20.8
CH 3CO 2 169.4 169.7
28 In ref. 27, it is acknowledged that the C5-C8 assignments might be interchanged.
29 Our assignment of these resonances is supported by key COSY signals ('H,'H) in ppm: (7.39,6.88), (6.88,7.22),
(7.22,6.70), key HSQC signals ('H, 3 C) in ppm: (7.39,125.5), (7.22,130.6), (6.88,120.2), (6.70,110.9), and key
HMBC signals (H, 13 C) in ppm: (7.22,149.6), (6.88,127.6).
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Table S6. Comparison of our data for (+)-Chaetocin C diacetate (6) with literature:
Assignment ' Saito et al. Report27 '3 0  This Work
(+)-Chaetocin C diacetate (6) (+)-Chaetocin C diacetate (6)
'H NMR, 400 MHz, CDC13  'H NMR, 500 MHz, CDC13, 20 0C
5.26 (s)
NI ca. 5.3 [5.28 (s), 5.48 (s)]
{5.49 (s)}




7.12 (d, J= 7.3)
C5 6.66-7.42 [7.07-7.14 (m), 7.07-7.14 (m)]
{7.07-7.14 (m)}
6.78
C6 6.66-7.42 [6.74-6.81 (m), 6.74-6.81 (m)]
{6.74-6.81 (m)}
7.20 (app-t, J= 7.7)
C7 6.66-7.42 [7.15-7.23 (m), 7.15-7.23 (m)]
{7.15-7.23 (m)}
6.72 (d, J= 7.9)
C8 6.66-7.42 [6.74-6.69 (m), 6.62 (d, J= 7.7)]




2.66 (d, J= 14.8)
2.69 (d, J= 15.0) [2.71 (d, J= 14.8), 2.61 (d, J= 14.8)]
C{2 2.63 (d, J= 15.0)} {2.66 (d, J= 14.8)}3.60 (d, J= 15.0) 3.33 (d, J= 14.8)32
{3.30 (d, J= 15.0)} [3.36 (d, J= 14.7), 3.28 (d, J= 14.8)]
{3.28 (d, J= 14.8)}
C13
30 The chemical shifts of the "minor" conformer are in braces (e.g. {A}).
31 The chemical shifts of the asymmetric conformer are in brackets (e.g. [A, B] where A is the shift for the
monomeric subunit possessing a conformation consistent with the major symmetric conformer and B is the shift for
the subunit possessing a conformation consistent with the minor symmetric conformer); the chemical shifts for the
minor symmetric conformer are in braces (e.g. {A}).
32 Our assignment of this resonance is supported by the key COSY signal ('H,1 H) in ppm: (3.33,2.66), key HSQC







4.3 0 (d, J = 12.4)
4.33 (d, J= 12.5) [4.31 (d, J= 12.5), 4.36 (d, J= 12.2)]
{4.38 (d, J= 12.5)} {4.36 (d, J= 12.2)}
C17 4.80 (d, J= 12.5) 4.77 (d, J= 12.5)
{4.91 (d, J= 12.5)} [4.78 (d, J= 12.5), 4.89 (d, J= 12.3)]
{4.90 (d, J= 11.8)}
3.15 3.13 (s)
C18 {2.941 [3.14 (s), 2.92 (s)]
{2.94} _ _{2.93 (s)}
2.11 (s)
CH 3 CO 2  2.13 [2.11 (s), 2.12 (s)]{2.12 (s)}
Table S7. Comparison of our data for (+)-Chaetocin C diacetate (6) with literature:
Assignment23  Saito et al. Reporte7  This Work-"
(+)-Chaetocin C diacetate (6) (+)-Chaetocin C diacetate (6)
"C NMR, 100 MHz, CDC13  'C NMR, 125 MHz, CDC13, 20 *C
C2 80.2 {82.1} 80.4 [80.4, 82.4] {82.4}
C3 58.4 {59.6} 58.5 [58.7, 58.7] {58.8}
C4 126.2 {126.9} 126.4 [126.5, 127.1] {127.2}
C5 119.428 126.5 [126.5, 126.2] {126.2}3
C6 130.9 {130.1}28 119.6 [119.6, 120.0] {120.1} 3
C7 126.2 {125.9}28 131.2 [131.2, 130.3] {130.3}
C8 110.9 {110.8} 111.2 [111.1, 110.3] {110.3}
C9 150.6 {149.3} 150.9 [150.9, 149.5] {149.5}
C11 73.9 {74.1}34 79.2 [79.2, 79.2] {79.2}35
C12 45.3 {42.9} 45.5 [45.5, 43.1] {43.1}
C13 168.4 {167.1} 168.6 [168.7, 167.3] {167.3}
C15 79.0 {74.7}34 74.0 [74.0, 74.9] {74.9}35
C16 163.5 {162.5} 163.7 [163.7, 162.7] {162.7}
C17 61.0 {61.9} 61.2 [61.2, 62.1] {62.1}
C18 28.0 {29.1} 28.2 [28.2, 29.3] {29.3}
CH3 CO 2  20.8 21.1 [21.1, 21.1] {21.1}
CH 3 CO2 169.6 {169.1} 169.9 [169.9, 169.9] {169.9}
3 Our assignment of these resonances is supported by key COSY signals ('H,'H) in ppm: (7.12,6.78), (6.78,7.20),
(7.20,6.72), key HSQC signals (1H,13 C) in ppm: (7.20,131.2), (7.12,126.5), (6.78,119.6), (6.72,111.2), and key
HMBC signals ('H, 3 C) in ppm: (7.12,58.5), (7.20,150.9), (7.12,150.9).
3 In ref. 27, it is acknowledged that the CI1, C15 assignments for the major conformer might be interchanged. It is
also acknowledged that the C 11, C15 assignments for the minor conformer might be interchanged.
35 Our assignment of these resonances is supported by key HMBC signals (1H, 3 C) in ppm: (3.13,74.0), (4.30,74.0),
(4.77,74.0), (2.66,79.2), (3.33,79.2), (5.43,79.2).
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Activation Energy Calculation for Epitrithiodiketopiperazine Conformer Interconversion.
An approximation for the rate constants of epitrisulfide conformer interconversion in 1,3,5-
trimethylbenzene-d was extracted from changes in the 'H NMR peak separation for select
signals. Data were collected at temperatures that were beyond the coalescence point of the
signals of the asymmetric dimer with the corresponding signals from the major and minor
symmetric dimers while also sufficiently short of the coalescence point for the signals resulting
from the two epitrisulfide conformers. In the intermediate exchange regime, defined by k ~ Avo
where k is the exchange rate constant and Avo is the peak separation of the signals of the
interconverting species at a temperature where negligible exchange is occurring, the exchange
rate constant can be approximated by k = -(Av' 2 - Ae 2 ). AVe is the temperature dependent peak
separation of the corresponding resonances of the interconverting species in the intermediate
exchange regime.36
The activation energy was calculated from the Arrhenius equation: k = Ae-R, where R =
1.98 cal/mol, Ea is the activation energy, A is a constant pre-exponential factor, and T is the
temperature. The expression can also be written as in k = - + c, where C is a constant.
Ci 7Ha signals: Avo = 87.00 Hz


















































In k v. T1 Plot for C 7 H,
6 - R2 - 0.9504
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2.3 2.35 2.4 2.45 2.5
rx 103 (K-1)







2.3 2.35 2.4 2.45 2.5
T-l 1 n3 Iv-1
Ea = 25.6±0.4 kcal/mol I In
Averaging the two values gives Ea = 23.3±2.4 kcal/mol.
36 (a) Gasparro, F. P.; Kolodny, N. H. J. Chem. Ed. 1977, 54, 258. (b) Johnson, E. S., in "Advances in Magnetic
Resonance," (Editor: Waugh, J.S.), Academic Press, New York, 1956, Volume 1, Chapter 2, pp. 64-68. (c)






















Table S8. Crystal data and structure refinement for (+)-12,12'-dideoxychetracin A (7).
Identification code d8_10096






Unit cell dimensions a = 7.78280(10) A a= 900.
b = 19.4165(4) A b= 90 .











Completeness to theta = 69.890
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter













Full-matrix least-squares on F2
7024 / 506 / 516
1.043
RI = 0.0569, wR2 = 0.1527
RI = 0.0612, wR2 = 0.1568
0.03(2)
0.682 and -0.622 e.A-3
3 The X-ray diffraction data for (+)-12,12'-dideoxychetracin A (7) reflected the presence of a well-ordered
monomeric subunit possessing an epitetrathiodiketopiperazine substructure as well as another monomeric subunit
with a disorder in the volume occupied by the polysulfide. The disorder was resolved by modeling in both a C2-
symmetric epitetrathiodiketopiperazine dimer as well as a heterodimeric structure containing both epitri- and
epitetrathiodiketopiperazines. The ratio between the two was refined freely and the free variable converged at
0.771(5) in favor of (+)-7. An alternative solution in which an epitetrathiodiketopiperazine possessing a sulfur
arrangement of the opposite helicity was modeled in as the minor disordered component resulted in an even lower
R2 value (RI = 0.0601); however, the S3-S4 bond in the refined model was deemed too short for a true S-S bond
and the model with the trisulfide was adopted as our solution. Consequently, in our solution for the single crystal
selected for analysis, 77.2% of the unit cells contained (+)-7 while 22.8% contained the mixed dimer possessing
both a tri- and tetrasulfide. The 11.4% trisulfide content indicated by this data is likely overrepresented because of
the possible presence of alternative tetrasulfide conformers in the crystal lattice in addition to possible enrichment
during crystallization. Our NMR data place an upper limit of 6% on the amount of trisulfide that was formed during
the polysulfane cyclization and was carried over into the sample used for crystallization.
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Table S9. Atomic coordinates (x 104 ) and equivalent isotropic
10') for (+)- 12,12'-dideoxychetracin A (7). U(eq) is defined as
orthogonalized U" tensor.
displacement parameters (A2 x
one third of the trace of the













































































































































































































































































































































































































































C(1 6A)-N(1 OA)-C( 1 A)
C(I 6A)-N(I OA)-C(2A)
C( 11 A)-N(I OA)-C(2A)














































N(I OA)-C( 11 A)-C(I 2A)
C(13A)-C(1 IA)-C(12A)




0(1 A)-C(I 3A)-N(I 4A)
0(1 A)-C(I 3A)-C( 11 A)
N(14A)-C(13A)-C(1 IA)
C(1 3A)-N(1 4A)-C(1 5A)
C(1 3A)-N(I 4A)-C(I 8A)
C(5I A)-N(I 4A)-C(1 8A)
N(I 4A)-C(1 5A)-C(I 6A)
N(14A)-C(1 5A)-C(1 7A)










N(I OA)-C(I 6A)-C(1 5A)
0(3A)-C(1 7A)-C(1 5A)









































































C( 11 B)-N(1 OB)-C(2B)
N(IOB)-C(1 1B)-C(31B)





























N(1 4B)-C(I 5B)-C(1 6B)
N(14B)-C(15B)-C(17B)











Table Si1. Anisotropic displacement parameters (A2 x 10') for (+)-12,12'-dideoxychetracin A
(7). The anisotropic displacement factor exponent takes the form: -2p 2[h2 a*2Ul "± ... + 2 h k a*
b* U 12]



























































































































































































































































































































































































































Table S12. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) for
(+)-12,12'-dideoxychetracin A (7).













































































































































































Concise Total Synthesis and Stereochemical Revision of (+)-




Dimeric diketopiperazine alkaloids, which comprise an important class of natural
products, possess an expansive repertoire of biological activities intimately mirroring their
structural diversity.] An important source of diversity of great strategic relevance to their
synthesis is the nature of the dimeric linkage. In recent years, much progress has been made
toward the rapid construction of the C3sp3-C3'sp32,3,4 as well the C3sp3-N 15 bond connectivity.
In this report, we aim to broaden the spectrum of dimerization modes that are predisposed for
rapid disconnection. We describe herein a Friedel-Crafts based method for the regioselective
and directed C3-functionalization of advanced diketopiperazine intermediates employing a range
of ir-nucleophiles. The concision and broad relevance of this approach to the synthesis of C3-
arylated hexahydropyrroloindole alkaloids6 (Figure 1) are highlighted through the first total
syntheses of Fijan actinomycete Streptomyces sp. derived alkaloids (+)-naseseazines A (1) and B
(2),7 an endeavor culminating in their stereochemical revision.
HO0
OH 3 'NH O ' NH P
9. N
H 2N / HOH
NH 7R N NH NH
N H'WI?~nR'-: H 
,, 0H H0H 0 7'N H iii
(+)-naseseazine A (1), R=H, R'=Me (+)-naseseazine A (1), R=H, R'=Me H 0 Ph
(+)-naseseazine B (2), R,R'=(CH 2)3  (+)-naseseazine B (2), R,R'=(CH 2)3  (+)-asperazine (3), R=Ph
reported stereochemistry (ref. 7) revised stereochemistry (this report) (+)-pestalazine A (4), R=i-Pr
Meli H Me H MeN0N N HH
3 NH
H - N - NHH H =N H NMeHN 0 HN/ MeN ~ 9. -'"H
MeN" A MeN' \ --- NH
NMe NMe N' NMe
N H N H N-NMe ''H~~NH: NH~N N
8 H H NH
NHN N N
HH Me H N Me Q N Me
(--)-hodgkinsine (5) (-)-quadrigemine C (6) (+)-caledonine (7) N
Figure 1. Representative C3-arylated hexahydropyrroloindole alkaloids and revised structures of (+)-naseseazines A
(1) and B (2).
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Previous Syntheses of C3-Arylated Hexahydropyrrolindole Alkaloids
Stimulated by the intriguing molecular architecture and potent biological activity of (+)-
asperazine (3), Overman and co-workers made their initial foray into the synthesis of C3-arylated
hexahydropyrroloindoles in 2001 through the synthesis of this unique C3-C8'-linked dimeric
diketopiperazine alkaloid (Scheme 1).6a, The dimeric linkage was forged through Stille cross-
coupling, and the critical quaternary C3-stereogenic center was established through another
pioneering application of Heck cyclizations to complex target synthesis from that group. The
diastereoselective Heck reaction utilized in this first total synthesis of a C3-arylated
hexahydropyrroloindole would form the basis of Overman's future work in the oligomeric
cyclotryptamine alkaloids.




Boc Me Boc Me Boc Me
N 8 1) Pd2(dba)-CH~l 1) 2-iodoaniline, AIMe3,/ NE1) Pd2(dba)3 C1 3  N Boc Me BoMe
Boc (2-furyl) 3P, Cul, NMP, Boc K2CO3, CH2CI2, 94%SEM
- SB2) DMSO, 130 CO 2Me 2) NaH, SEMCI, 79% _/ N
Ou 82% (2-steps) H 10 H  O
MeN C e 0HNBoc No |
Me g O+Me O_ Me 11
H -- Ph Me Me
O N H
He'. N OH, 0 H, O 1) Pd2 (dba)3-CHCl3 ,
H Me NkMe (2-furyl) 3P, DMA,
H ,Boc Me H2 (1000 psi) Boc Me PMP, 66%
NHO Pd/C, DMF N 2) TBAF, 85%
H MeN 95%, 4:1 dr B 
*NH tN Me NM
N , N 0 A N C0 0 e
H 0 Ph 13 12
apserazine (3)
Scheme 1. Overman's diastereoselective Heck cyclization-based synthesis of asperazine (3).
Motivated by the prospect of accessing the higher-order oligomeric cyclotryptamines
featuring up to seven C3-C8' linkages yet lacking opportunities for substrate-controlled
diastereoselective transformations, the Overman group developed a chiral catalyst-controlled
diastereoselective Heck cyclization reaction. The utility of this transformation has been
demonstrated en route to enantiodivergent syntheses of hodgkinsine (5) and hodgkinsine B
(Scheme 2 ),6e' and further application of this chemistry in a double diastereodifferentiating
manner led to elegant syntheses of (-)-quadrigemine C (6) and its rearranged congener (-)-
psycholeine. 6b This Heck-based approach to stereo- and regiocontrolled generation of C3-
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arylated quaternary stereogenic centers served as the only available mode of access to a
synthetically challenging motif ubiquitous among the hexahydropyrroloindole alkaloids.
H H
H H N H N
MeN MeN" 
MeN
Pd(OAc) 2 (5 mol%)
(R)-Tol-BINAP (11 mol%) NMe .,NMe
O., N H PM P, MeCN, 80 C N H e s N HOTf Bn H H-H
N N NMeTs \ ~NMeTs
N 48% N 0 45%
NMeTs 15 (79% ee) 16 (83% ee)
(t)-14 hodgkinsine (5) hodgkinsine B
Scheme 2. Overman's catalyst-controlled diastereoselective Heck cyclization reaction for the enantiodivergent
synthesis of hodgkinsine (5) and hodgkinsine B.
Prior Developments in the Addition of Trifluoroborates to Electrophiles
We sought to offer a complementary means of accessing the C3-aryl bonds at a late stage
using highly-advanced components densely pre-programmed with stereo- and regiochemical
cues for selective bond formation. To do so, we would build upon precedence for the use
trifluoroborate-directed regioselective transformations found in the literature.
Ar
BE3K 17 Me_ O Ar O
or 20 mol% 21*HCI Me or Bn-N Me
HF (1.0 equiv) ' Me
OME, 20 OC N ~e
BF3K 18 D - O H Me
x up to 96% yield X 21
up to 97% ee Me 20
B Me- O 0
MeO /e
MeO 20 mol% 21.DCA MeO
BF3K *O HF (1.0 equiv) 0 MeEtOAc, 23 *C 2322 84%, 93% ee NHTrisyl
N3 tBuLi, THF
Me -78 *C, 86%
Me
MMe e 24 MeBBr3  Me
HO CH 2CI 2, 78-0 *C -- OH
88%, 3.6:1 rr MeO
S Me 25(+)-frondosin B (26) 0 Me
Scheme 3. A. MacMillan's asymmetric organocatalytic styrenyl and Friedel-Crafts alkylation with trifluoroborate
salts. B. Application of the methodology to the total synthesis of (+)-frondosin B (26).
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In 2007, MacMillan developed an enantioselective Friedel-Crafts alkylation reaction
using their eponymous chiral imidazolidinone catalysts in an adaptation of the Petasis reaction
(Scheme 3A).8 They were able to achieve high enantioselectivities along with exclusive
regiochemical preference for nucleophile attack ipso to the trifluoroborate directing group. The
first application of this boron trifluoride-directed chemistry to total synthesis was in their highly
concise organocatalytic three-step total synthesis of (+)-frondosin B (26) in 2010 (Scheme 3B).9
Biogenetic Hypothesis for the Naseseazine Alkaloids
Prior to initiating our synthetic campaign of the naseseazines, we engaged in an analysis
of their biogenesis. Our biosynthetic hypothesis posits that dimerization occurs at an advanced
stage using well-elaborated tryptophan systems, such as cyclodipeptides.' 0 Furthermore, we felt
a plausible dimerization scheme would invoke a cationic mechanism (radical or non-radical) in
contrast to that which is suggested in the isolation report. 7 Two contiguous or non-contiguous
single-electron oxidation events of an indole core accompanied by a Friedel-Crafts addition of
another tryptophan indole could give rise to a number of dimer cognates whose regioisomeric
constitution would be controlled by the structure of an enzyme-binding pocket (Scheme 4).
NH
/N H H




OH H35 cation mediated _. -1
NH27dimerizationrNHM NH
030 0 H1 OH H
H H .~. \/ N H / NHHmrzain 3
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HN~~,I NHN HN H e N H
N -,Me Me
3H 38 H 3
S e. hOH f aan edi d
radicalzaiated\HN 27HH $NH dmraln 3
- +-le H-H H N
O+-aeezn H NH NH
HH H8N H37H
Scem 4. Ou hyohei fo a plusbl bignsso0aeeznsfo dacdc oietds
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Results and Discussion
In pursuit of a maximally convergent synthesis of (+)-naseseazines A (1) and B (2), and
consistent with a plausible hypothesis for their biogenesis,1 1 "2 our retrosynthetic analysis
commenced with the disconnection of the C3-C7'"3 bonds of (+)-1 and (+)-2, affording two
diketopiperazine fragments of comparable complexity (Scheme 5). Tetracyclic bromide 41
could be derived from the bromocyclization of diketopiperazine 43,6 whereas pinacolboronate
40 could be prepared from the corresponding bromodiketopiperazine 42. We envisioned that
ionization of tetracyclic bromide 41 would provide the necessary C3-electrophile,14'15 while
conversion of the pinacolboronate function of diketopiperazine 40 to the corresponding
trifluoroborate16 would offer the necessary C7'-nucleophilic partner for a directed and
regioselective sp 3-sp 2 bond formation (Scheme 5).
C H 
0
NH H,.. O 3




N' ~ F3B N
SN H HY~NH
H 0 39 H 0
(+)-1, R=H, R'=Me I






Me O'B 7 N
Br 7> N R Me O 40 H
42 N Me'Me O
NQH Br- NR
3_ Z111 NH O halocyclization N
N 43 N H R'
H H 0 41
Scheme 5. Retrosynthetic analysis for (+)-naseseazines A (1) and B (2).
In our first generation approach, alanine and proline diketopiperazines (-)-44 and (-)-45,
the requisite tetracyclic bromides en route to the corresponding naseseazine alkaloids, were
synthesized in 89% and 71% yields, respectively, from readily available N"-Boc-N'"-Cbz-L-




N, N Cb , 5
Cbz Cbz
(-)-44, R=H, R'=Me (+)-46, R=H, R'=Me, 67%




N H H  0NR"
0 o
3- N3N
R -fN AR, RSN 1H IH N, HHR" O R" 0
(-)-48, R=H, R'=Me, R"=Cbz (-)-50, R=H, R'=Me, R"=Cbz
c (-)-49, R,R'=(CH2)3, R"=Cbz c7 ()-51, R,R'=(CH2)3, R"=Cbz(+)-iso-naseseazine A (52), 52% (+)-naseseazine A (1), 80%(+)-iso-naseseazine B (53), 61% (+)-naseseazine B (2), 80%
Scheme 6. First-generation syntheses of (+)-1 and (+)-2. Conditions: (a) PyHBr3, TFE, 23 *C. (b) (-)-45, AgSbF6 ,
EtNO 2, 23 'C; for (+)-46, 48:50 = 1:1.4, 53%; for (+)-47, 49:51 = 1:1.4, 47%. (c) H2, Pd/C, AcOH, 23 'C.
tribromide in 2,2,2-trifluoroethanol afforded the respective tetracyclic bromides (+)-46 and (+)-
47 in 67% and 51% yields as single diastereomers (Scheme 6). In possession of all the necessary
components, we sought to validate the feasibility of our planned Friedel-Crafts-based strategy
for C3-arylation at this juncture. Treating a solution of diketopiperazine (-)-45 (1.5 equiv) and
tetracyclic bromide (+)-46 (1 equiv) with silver hexafluoroantimonate in nitroethane under
optimized conditions (vide infra), afforded a mixture of regioisomeric dimers (-)-48 and (-)-50
in 53% combined yield ((-)-48:(-)-50 = 1:1.4). Similarly, the same proline derived
diketopiperazine (-)-45 could be coupled to tetracyclic bromide (+)-47 to give regioisomeric
dimers (-)-59 and (-)-51 in 47% combined yield ((-)-49:(-)-51 = 1:1.4). Hydrogenolytic
removal of the carboxybenzyl groups on compounds 48-51, provided the first access to (+)-iso-
naseseazines A (52) and B (53) as well as our target alkaloids (+)-1 and (+)-2, respectively
(Scheme 6). Notably, selectivity was observed in favor of the regioisomer with the desired C3-
C7' bond connectivity during the coupling reaction." While we were pleased with the utility of
this new mode of heterodimerization, the low level of regioselectivity in this unguided union
prompted further refinement of our new strategy toward a more selective and directed assembly
of complex diketopiperazine fragments.
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We anticipated that the regioselective arylation of tetracyclic bromide (+)-46 could be




Importantly, we wished to increase the ratio of (-)-50 and (-)-51 to (-)-48 and (-)-49,
respectively. In the early stages of our optimization studies, we selected thiophene, with its
innate preference for reaction at the 2-position (Table 1, entry 1, 54:55 = 6.2:1), as our model
system. While 3-cuprate, 3-trimethylstannyl, and 3-zinc chloride thiophene derivatives were
ineffective as directed nucleophiles in the C3-arylation of bromide (+)-46, the use of the
corresponding potassium trifluoroborate derivative proved promising. 18,20 We expected that
using 18-crown-6 as an additive would confer multiple benefits: increased solubility of the
potassium trifluoroborate salt, enhanced nucleophilicity of the arene via ion pairing with the
electrophile, and facilitated trifluoroborate elimination by further dissociation of the potassium-
aryltrifluoroborate ion pair.2 1 Indeed, when silver hexafluoroantimonate was introduced to a
solution of tetracyclic bromide (+)-46, potassium 3-thiophenetrifluoroborate, and 18-crown-6 in
dichloromethane at 23 'C, we obtained the desired C3-arylated product as a mixture of
regioisomers favoring the desired C3-adduct (54:55 = 1:1.3). Sub-ambient temperatures were
then examined to enhance the regioselectivity for C3; however, selectivity did not improve
noticeably at 0 'C in dichloromethane, and conversion to the product was not observed at lower
temperatures. Thus, we turned to higher dielectric-constant media to facilitate the ionization
event.
Nitrile-based solvents such as acetonitrile and benzonitrile enabled ionization; however,
tight solvent-carbocation interactions significantly impeded the nucleophilic reaction, and
hydroxylation2 2 and Ritter reaction adducts23 formed in significant amounts as principal
byproducts. Similarly, use of N,N-dimethylformamide resulted exclusively in hydroxyl and
formate addition products.2 4 Ultimately, we discovered that the use of nitroalkane solvents was
most effective for the desired transformation. The level of regioselection improved for the C3-
thiophenyl adduct at -25 'C in nitromethane (54:55 = 1:2.8). Under optimal conditions,
treatment of (+)-46 with 3-thiophenetrifluoroborate at -45 'C in nitroethane provided the desired
product with an excellent level of regioselection (Table 1, entry 2, 50%, 54:55 = 1:17).
Encouraged by the efficiency and high regioselectivity observed in the trifluoroborate-
directed thiophenylation of bromide (+)-46, we sought to examine the generality of this
chemistry with respect to other 7r-nucleophiles. Table I demonstrates the substrate scope for the
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nucleophilic addition into the C3-position of the tetracyclic bromide (+)-46: allyltri-n-
butylstannane (Table 1, entry 3, 60%), allyltrimethylsilane (Table 1, entry 4, 52%), as well as
(isopropenyloxy)trimethylsilane (Table 1, entry 5, 91%) act as suitable nucleophiles. Notably,
vicinal quaternary stereocenters can also be installed efficiently, as demonstrated by the addition
of methyl trimethysilyl dimethylketene acetal (Table 1, entry 6, 89%). Electron rich arenes, such
as thiophene, (Table 1, entry 1, 76%) and electron neutral arenes, best represented by toluene
(Table 1, entry 7, 50%), are also able to incorporate efficiently. Toluene itself adds with
S0
Br. NH

































CH 2Cl2, 23 4 56
0
CH2CI2, 23 MeAl 
- 57
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EtN0 2, -45C 61
















Table 1. Lewis acid-promoted C3-nucleophilic substitution. a Isolated yields; averages of two experiments; AgSbF6
(2.0 equiv) and nucleophile (2.0 equiv). b Regioisomeric ratios determined by 'H NMR analysis. The major
regioisomer is shown. C 18-crown-6 (2.0 equiv). The minor regioisomer is the para adduct.
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exclusive selectivity for the para-position, a preference that can be reversed using the
trifluoroborate group.
The regioselectivity of aryltrifluoroborate addition, although moderate, is eroded in the
presence of ortho-substituents such as in ortho-tolyltrifluoroborate (Table 1, entry 8, 60:59 =
3.9:1) and 2-methoxyphenyl trifluoroborate (Table 1, entry 9, 61:61' = 2.4:1), likely reflecting a
sterically demanding transition state in the formation of quaternary stereocenters. Unfortunately,
electron deficient arenes, such as potassium 4-acetylphenyl-trifluoroborate, lead to exclusive C3-
fluorination via fluoride transfer from the aryltrifluoroborate. Nucleophiles without a competent
electrofuge, such as styrene, result in polymerization. This problem can be circumvented through
use of a trifluoroborate group, which likely eliminates faster than a proton (Table 1, entry 10,
59%). In general, the efficiency of the reactions appears to correlate well with the relative
nucleophilicity of the compounds. The mildness of the reaction conditions is also of particular
note. The utility of the method in late-stage applications is highlighted by the preservation of
stereochemical integrity at C 11 and C15, epimerizable stereocenters 3'5 consequential for the
further derivatization of advanced intermediates.R
H 0 OMe O OMe
a,b c
Br N NHBoc 
NHBoc
H Br N Br N
63 64 Cbz (+)-65 Cbz
d,e
O N O N
H f H
\ O
R 7. N (-)-67, R = BPin g Br 7' NCbz (-)-68, R = BF3K Cbz (-)-66
(+)-46 h (-)-50, 56% (+)-naseseazine A (1), 80%
(+)-47 (-)-51,50% (+)-naseseazine B (2), 80%
Scheme 7. Concise and directed synthesis of (+)-naseseazines A (1) and B (2). Conditions: (a) CbzCl, Et3N, DMAP,
CH2 C12, 100%. (b) Boc-a-phosphonoglycine trimethylester, DBU, CH2Cl 2, 97%. (c) H2 (80 psi), (SS)-Et-DUPHOS-
Rh-OTf (1.8 mol%), CH 2Cl 2, MeOH, 97%, >99% ee. (d) TFA, CH2C 2 ; EDC-HCI, HOBt, Et3N, Boc-L-Pro. (e)
TFA, CH 2C 2 ; NH 40H, MeOH, 75% (2-steps). (f) 2-aminobiphenyl(XPhos)PdCl (5 mol%), XPhos (15 mol%),
(BPin) 2, K3PO4 , DMSO, 60 'C, 65%. (g) KHF2 (aq.), MeOH, 88%. (h) AgSbF6 , 18-crown-6, EtNO 2, 23 'C. (i) H2,
Pd/C, AcOH, 23 'C.
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Our planned strategy for the directed union of advanced stage diketopiperazine fragments
for the synthesis of (+)-naseseazines A (1) and B (2) required the synthesis of the trifluoroborate
(-)-68 (Scheme 7). Starting from commercially available 6-bromo-3-carboxaldehyde (63),
benzyloxycarbonylation followed by a Homer-Wadsworth-Emmons reaction with Boc-ca-
26phosphonoglycine trimethylester afforded enamide 64 in 97% yield (2-steps). Catalytic
asymmetric hydrogenation of the olefin using (SS)-Et-DUPHOS-Rh-OTf (1.8 mol%) efficiently
provided the bromotryptophan (+)-65 in 97% yield and >99% ee. 2 7 An expeditious two-step
sequence afforded the bromocyclodipeptide (-)-66 in 75% yield from bromotryptophan
derivative (+)-65 without a need for chromatography. Our initial efforts to introduce the pinacol
boronic ester function via palladium-catalyzed cross-coupling with pinacolborane 28 were mired
by undesired carboxybenzyl deprotection as well as the formation of significant amounts of a
C7'-reduction byproduct. After significant experimentation, we recognized that employing
Buchwald's aminobiphenyl(XPhos)PdCl precatalyst (69, 5 mol%),29 XPhos (15 mol%), K3PO4
(3 equiv), and bis(pinacolato)diboron (3 equiv) in DMSO at 60 'C effectively afford the desired
pinacol boronate (-)-67 in 65% yield (Scheme 7). Treatment of the pinacol boronate (-)-67 with
aqueous potassium hydrogen difluoride gave the key potassium trifluoroborate (-)-68 in 88%
yield.16
Treatment of alanine-derived tetracyclic bromide (+)-46 (1 equiv) with tetracyclic
potassium trifluoroborate (-)-68 (1.5 equiv) in the presence of silver hexafluoroantimonate and
18-crown-6 in nitroethane at 23 'C afforded the desired (-)-dicarboxybenzyl naseseazine A (50)
in 56% yield with complete regioselection (Scheme 7). Under identical conditions, exposure of
proline derived tetracyclic bromide (+)-47 (1 equiv) with tetracyclic potassium trifluoroborate (-
)-68 (1.5 equiv) gave (-)-dicarboxybenzyl naseseazine B (51) in 50% yield as a single
regioisomer (Scheme 3). Excitingly, the ability to override the innate nucleophilic tendencies of
the indole substructure through an appropriately positioned directing group has broad
implications toward the synthesis of related congeners of different regioisomeric constitutions
about the C3sp3-Csp 2 dimeric linkage, such as in (+)-asperazine,30 (+)-pestalazine,31 as well as the
entire superfamily of oligomeric cyclotryptamines,' represented by (+)-caledonine (Figure 1).32
Hydrogenolytic removal of the benzyloxycarbonyl groups from (-)-50 and (-)-51 with
palladium on carbon in acetic acid provided (+)-naseseazine A (1) {[a]2 2 D = +123 (c 0.12,
CH 30H); lit. [] 2 3 D = 139 (c 0.10, CH 30H)} 7 and (+)-naseseazine B (2) {[a]22 D = ±10 1 (c 0.23,
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CH 30H); lit. [a]23 D= +95 (c 0.08, CH30H)}, 7 respectively, each in 80% yield (Scheme 7). All
of the spectroscopic data for (+)-1 and (+)-2 matched those reported in the literature.7 The
agreement between the optical rotation sign of our synthetic samples of naseseazine A (+)-1 and
B (+)-2 and those of the natural alkaloids stands in direct contrast to the predicted absolute
stereochemistry of (+)-1 and (+)-2 based on C3 Marfey's analysis3 3 of degradation products.
Given the use of L-amino acid derivatives in our synthesis of (+)-naseseazine A (1) and B (2),
we revise the absolute stereochemistry of these dimeric natural alkaloids (Figure 1).
Further Developments in C3-Arylated Hexahydropyrroloindoles
After disclosure of our synthesis of the naseseazine alkaloids, other groups have made
further contributions to the synthesis of C3-arylated cyclotryptamines and diketopiperazines. In
2012, MacMillan and co-worker employed an elegant enantioselective copper-catalyzed
arylation-cyclization cascade to construct this substructure (Scheme 8). A chiral Cul(box)
catalyst was employed along with aryl iodonium salts to arylate N-alkyl cyclotryptamides in a
highly concise and efficient manner. The proposed mechanism involves oxidative addition of
copper complex 69 into the C-I bond of the diaryl iodonium reagent to afford aryl-Curi species
70. Upon catalyst-controlled a-facial discrimination and coordination to cyclotryptamide 71,
indolinium 72 is obtained. Reductive elimination then affords the desired C3-Csp2 bond and
A 0
NHBn 10 mol% 69 xAr, 0SNaHCO
3  NBn up to 96% yield
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Scheme 8. A. MacMillan's enantionselective copper-catalyzed arylation-cyclization cascade approach to C3-
arylated hexahydropyrroloindole substructures. B. A plausible mechanism for the arylation reaction.
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elimination of triflic acid completes the catalytic cycle. The amide product that is obtained
contains a nice handle for further elaboration. The method is tolerant of a range of
cyclotryptamide derivatives as well as an impressive array of electron-rich, electron-poor, and
even sterically hindered ortho-substituted arenes. Mesityl-aryl iodonium salts pioneered by the
Gaunt group 35 also proved to be highly effective.
CF3  Mess .PF 6  H
0 H Br HN NN Me 40 NH,,, N14a V TES;O HN_-
a b,c F3C N SH
HO NH (-1 Br Me Me
N M 77 79SN z Me Ar-H ' H H Ar-N N-Ar
75 H 76 Ar = 3,5-(t-Bu)2C6H3 (78)
Scheme 9. Reisman's total synthesis of (+)-naseseazine A (1). Conditions: (a) (CuOTf-PhMe (10 mol%), 78 (40
mol%), 77, CH 2CI 2, 23 'C, 59%. (b) NaBH 4, EtOH, 82%. (c) 79, cat. Pd[P(o-tol) 3] 2, Na 2CO 3, DMF, 100 'C; I N
HCI, MeOH, 56%.
Shortly thereafter, the Reisman group published a similar transformation involving the
copper-catalyzed arylation of cyclotryptamines using diaryliodonium reagents to generate
racemic C3-arylated hexahydropyrroloindole substructures. 36  They found that by using a-
diimine ligands with copper(I) catalysts, they could apply this Cu-catalyzed C-C bond forming
reaction manifold to diketopiperazine substrates and achieve a diastereoselective arylation-
cyclization cascade (Scheme 9).3 Application of the arylation protocol to diketopiperazine 75
and mesityl-aryl iodonium salt 77 provided them with C3-arylated tetracycle 76. Deprotection of
the trifluoroacetamide in 82% yield afforded a bromoaniline derivative, which could be further
elaborated through Larock indole synthesis with alkyne 79 to provide (+)-naseseazine A (1) in
56% yield. MacMillan's methodological advancements along with Reisman's synthesis
highlights a new opportunity for C3-Csp2 bond construction. The direct C-C bond forming
reaction that these reports exploit fundamentally differs from our own approach as our late stage




We have developed a general approach to dimeric diketopiperazine alkaloids containing a
C3sp3-Csp 2 linkage, with the solution yielding a concise 9-step total synthesis of (+)-naseseazines
A (1) and B (2). Our mild and highly regioselective Friedel-Crafts based coupling strategy,
featuring the formation of quaternary stereogenic centers, facilitated the late-stage union of
advanced diketopiperazine structures in a convergent manner. Our total syntheses of (+)-1 and
(+)-2 have also enabled the revision of the absolute stereochemistry of these natural products.
This new fragment assembly strategy, ideated from a close adherence to biogenetically relevant
intermediates and transformations, highlights the power of a strategic framework guided by
retrobiosynthetic38 analysis.
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Experimental Section
General Procedures. All reactions were performed in oven-dried or flame-dried round-bottom
flasks. The flasks were fitted with rubber septa and reactions were conducted under a positive
pressure of argon. Gas-tight syringes with stainless steel needles or cannulae were used to
transfer air- and moisture-sensitive liquids. Where necessary (so noted), reactions were
performed in Schlenk tubes fitted with a PTFE stopcock. Flash column chromatography was
performed as described by Still et al. using granular silica gel (60 A pore size, 40-63 pim, 4-6%
H20 content, Zeochem).' Analytical thin layer chromatography (TLC) was performed using
glass plates pre-coated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent
indicator (254 nm). TLC plates were visualized by exposure to short wave ultraviolet light (254
nm) and an aqueous solution of ceric ammonium molybdate (CAM) followed by heating on a hot
plate (~250 C). Organic solutions were concentrated at 29-30 'C on rotary evaporators capable
of achieving a minimum pressure of ~2 torr.
Materials. Commercial reagents and solvents were used as received with the following
exceptions: dichloromethane, acetonitrile, tetrahydrofuran, methanol, pyridine, toluene, and
triethylamine were purchased from J.T. Baker (Cycletainer T) and were purified by the method
of Grubbs et al. under positive argon pressure.2 Nitroethane was distilled over calcium hydride
and stored over 4 A molecular sieves. I-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride was purchased from Oakwood Products, Inc.; N-hydroxybenzotriazole was
purchased from Aroz Technologies, LLC; 6-bromo-3-formylindole was purchased from Frontier
Scientific, Inc.; (+)-1,2-bis((2S,5S)-2,5-diethylphospholano)benzene(1,5-
cyclooctadiene)rhodium(I) trifluoromethanesulfonate was purchased from Strem Chemicals,
Inc.; and (±)-Boc-a-phosphonoglycine trimethyl ester as well as all amino acid derivatives were
purchased from Chem-Impex International, Inc. All other solvents and chemicals were
purchased from Sigma-Aldrich.
Instrumentation. Proton nuclear magnetic resonance (1H NMR) spectra were recorded with
Varian inverse probe INOVA-500 and Varian INOVA-500 spectrometers, are reported in parts
per million on the 6 scale, and are referenced from the residual protium in the NMR solvent
'Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.
2 Pangbom, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518.
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(CDCl 3: 6 7.24 (CHCl 3), DMSO-d6 : 6 2.50 (DMSO-d 5)). Data are reported as follows: chemical
shift [multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constant(s) in
Hertz, integration, assignment]. Carbon-13 nuclear magnetic resonance (1 3 C NMR) spectra were
recorded with a Varian INOVA-500 spectrometer, are reported in parts per million on the 6
scale, and are referenced from the carbon resonances of the solvent (CDCl 3: 6 77.23, DMSO-d6 :
6 39.51). Data are reported as follows: chemical shift (assignment). Fluorine-19 nuclear
magnetic resonance (19F NMR) spectra were recorded with a Varian Mercury 300 spectrometer,
are reported in parts per million on the 6 scale, and are referenced from the fluorine resonance of
neat trichlorofluoromethane (CFC 3: 6 0). Data are reported as follows: chemical shift
(assignment). Infrared data (IR) were obtained with a Perkin-Elmer 2000 FTIR, and are reported
as follows: frequency of absorption (cm-1), intensity of absorption (s = strong, m = medium, w =
weak, br = broad). Optical rotations were measured on a Jasco-1010 polarimeter. UV-Vis
spectrophotometric data were acquired on a Varian Cary 50 Bio UV-Vis spectrophotometer.
Preprativ HPLC was performed on a Waters system with the 1525 Binary HPLC Pump, 2489
UV/Vis Dtctor, 3100 Mass Detector, System Fluidics Organizer, and 2767 Sample Manager
components. We are grateful to Dr. Li Li for obtaining the mass spectrometric data at the
Department of Chemistry's Instrumentation Facility, Massachusetts Institute of Technology.
High resolution mass spectra (HRMS) were recorded on a Bruker Daltonics APEXIV 4.7 Tesla
FT-ICR-MS using either an electrospray (ESI) or direct analysis in real time (DART) ionization
source.
Positional Numbering System. At least three numbering schemes for diketopiperazine alkaloids
exist in the literature. 3 In assigning the 'H and 13C NMR data of all intermediates en route to our
total syntheses of (+)-naseseazines A and B, we wished to employ a uniform numbering scheme.
For ease of direct comparison, particularly between early intermediates and advanced
compounds, the numbering scheme used by Barrow for (+)-WIN-64821 (using positional
numbers 1-19) was optimal and is used in this document. This numbering system is also
3 (a) Von Hauser, D.; Weber, H. P.; Sigg, H. P. Helv. Chim. Acta 1970, 53, 1061. (b) Barrow, C. J.; Cai, P.; Snyder,
J. K.; Sedlock, D. M.; Sun, H. H.; Cooper, R. J. Org. Chem. 1993, 58, 6016. (c) Springer, J. P.; Bichi, G.; Kobbe,
B.; Demain, A. L.; Clardy, J. Tetrahedron Lett. 1977, 28, 2403.
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consistent with that employed in the isolation paper of (+)-naseseazines A and B.4 In key
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Triethylamine (1.98 mL, 14.2 mmol, 1.50 equiv) was added via syringe to a solution of 6-
bromo-3-formylindole (2.13 g, 9.49 mmol, 1 equiv) and 4-dimethylaminopyridine (116 mg, 949
ptmol, 0.100 equiv) in dichloromethane (25 mL) at 23 'C. Benzyl chloroformate (1.74 mL, 12.3
mmol, 1.30 equiv) was added dropwise to the solution via syringe. After 1 h, another portion of
benzyl chloroformate (267 pL, 1.90 mmol, 0.20 equiv) was added via syringe. After 40 min, the
reaction mixture was diluted with dichloromethane (100 mL) and washed with saturated aqueous
sodium bicarbonate solution (100 mL). The aqueous layer was further extracted with
dichloromethane (2 x 25 mL). The combined organic layers were washed with aqueous
hydrogen chloride (1 N, 100 mL) and the resulting aqueous layer was extracted with
dichloromethane (2 x 25 mL). The combined organic layers were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure. Benzyl 6-bromo-3-formyl-
IH-indole-1-carboxylate (S1) (3.40 g, 100%) was obtained as a white solid. Structural
assignments were made using additional information from gCOSY, HSQC, and HMBC
experiments.
'H NMR (500 MHz, CDCl 3, 20 *C): 8 10.01 (s, IH,
(s, 1 H, C2H),
7.50-7.38 (m,
1H, C6H), 5.48
CioH), 8.35 (s, 1H, C8H), 8.17
8.09 (d, J = 8.4, 1H, C5 H),
5H, Phcbz-H), 7.38-7.50 (m,
(s, 2H, PhcbzCH2).
3 C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (DART) (m/z):
TLC (20% ethyl acetate in hexanes), Rf:
6 185.6 (Cio), 149.9 (C=Ocbz), 136.7 (C9),
136.1 (C2), 134.2 (Phcbz-ipso-C), 129.5
(PhCbz-C), 129.2 (Phcbz-C), 129.1 (PhCbz-C),
128.5 (C6), 125.0 (C4), 123.5 (C), 122.0 (C3),
120.3 (C7), 118.5 (C8), 70.3 (PhcbzCH2).
1753 (s), 1679 (s), 1343 (m), 1224 (s), 1092
(m).










DBU, CH2Cl2, 23 *C
97%
Br





1,8-Diazabicycloundec-7-ene (1.70 mL, 11.4 mmol, 1.20 equiv) was added dropwise to a
solution of carboxaldehyde S1 (3.40 g, 9.49 mmol, 1 equiv) and (±)-Boc-a-phosphonoglycine
trimethyl ester (3.39 g, 11.4 mmol, 1.20 equiv) in dichloromethane (32 mL) at 0 "C. The ice-
water bath was then removed and the reaction mixture was allowed to warm to 23 *C. After 4 h,
the reaction mixture was diluted with dichloromethane (100 mL) and washed with aqueous
hydrogen chloride (1 N, 100 mL). The resulting aqueous layer was extracted with
dichloromethane (2 x 25 mL). The combined organic layers were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure. The resulting oil was
purified by flash column chromatography on silica gel (eluent: 20% ethyl acetate in hexanes) to
afford the enamide 64 (4.85 g, 97%) as a beige foam. Structural assignments were made using
additional information from gCOSY, HSQC, and HMBC experiments.
IH NMR (500 MHz, CDCl 3, 20 *C):
3 C NMR (125.8 MHz, CDCl3, 20 *C):
FTIR (thin film) cm-1 :
HRMS (DART) (m/z):
TLC (20% ethyl acetate in hexanes), Rf:
6 8.27 (br-s, I H, C8H), 7.74 (br-s, 1 H, C2H),
7.46-7.33 (m, 1H, C12H), 7.46-7.33 (m, 1H,
C5 H), 7.46-7.33 (m, 5H, Phcbz-H), 7.30 (dd, J
= 1.8, 8.4, 1H, C6H), 6.44 (s, 1H, N1oH), 5.38
(s, 2H, PhcbzCH 2), 3.82 (s, 3H, OCH3 ), 1.35
(s, 9H, C(CH 3)3).
6 165.7 (C 13), 152.7 (C=Ooc), 150.0
(C=Oc0z), 135.4 (C9), 134.5 (Phcbz-ipso-C),
129.0 (Phcbz-C), 128.8 (Phcbz-C), 128.8
(Phcbz-C), 128.3 (C 1), 127.1 (C2), 126.7 (C6),
124.2 (C 4), 121.4 (C 12), 120.2 (C5), 118.9
(C7 ), 118.3 (Cs), 114.8 (C3), 81.0 (C(CH 3)3),
69.5 (PhcbzCH 2), 52.6 (OCH 3), 28.1
(C(CH 3)3).
3324 (br, m), 2979 (m), 1723 (s), 1244 (s),
759 (m).

















N"-Boc- "-Cbz-6-bromotryptophan methyl ester (+)-65:
Dichloromethane (7.5 mL) and methanol (7.5 mL) were sequentially added via syringe to
a Fischer-Porter tube charged with enamide 64 (4.00 g, 7.56 mmol, 1 equiv) and (+)-1,2-
bis((2S,5S)-2,5-diethylphospholano)benzene(1,5-cyclooctadiene)rhodium(I)
trifluoromethanesulfonate (100 mg, 138 pmol, 1.83 mol%). The reaction vessel was charged
with hydrogen gas (80 psi) and then discharged (4 cycles). The vessel was charged a final time
with hydrogen gas (80 psi) then sealed. After 9.5 h, the Fischer-Porter tube was depressurized
and the reaction mixture was concentrated under reduced pressure. The crude reaction mixture
was purified by flash column chromatography on silica gel (eluent: 25% ethyl acetate in
hexanes) to afford bromotryptophan derivative (+)-65 (3.88 g, 96.6 %, >99% ee) 5 as a white
foam. Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 "C):
FTIR (thin film) cm-1:
HRMS (DART) (m/z):
TLC (25% ethyl acetate in hexanes), Rf:
6 8.35 (br-s, IH, C8H), 7.48-7.30 (m, 1H,
C2H), 7.48-7.30 (m, 1H, C5H), 7.48-7.30 (m,
IH, C6H), 7.48-7.30 (m, 5H, Phcbz-H), 5.41
(app-s, 2H, PhcbzCH2), 5.11 (d, J= 7.8, 1H,
N 1oH), 4.60 (app-q, J = 5.8, 1H, C IH), 3.64
(s, 3H, OCH3 ), 3.21 (dd, J = 5.5, 14.8, 1H,
C12Ha), 3.10 (dd, J = 5.5, 14.8, 1H, C12Hb),
1.38 (s, 9H, C(CH 3)3).
6 172.3 (C13), 155.2 (C=OBoc), 150.4
(C=OCbz), 136.2 (C9), 135.0 (Phcbz-ipso-C),
129.6 (C4), 129.0 (Phcbz-C), 129.0 (Phcbz-C),
128.7 (Phcbz-C), 126.4 (C), 124.2 (C2), 120.3
(C), 118.8 (C 7), 118.6 (Cs), 116.2 (C3), 80.3(C(CH 3)3), 69.2 (PhcbzCH2), 53.7 (C11), 52.6
(OCH3 ), 28.4 (C(CH 3)3), 27.9 (C12).
3369 (m), 2978 (m), 1742 (s), 1715 (s), 1247
(s).
calc'd for C2 5H2 7BrN20 6 [M]*: 530.1047,
found: 530.1071.
+32 (c = 0.19, CHCl3).
0.37 (UV, CAM).
' In order to determine the enantiopurity, bromotryptophan derivative (+)-65 was hydrogenated using palladium on
carbon in acetic acid to remove the N-carboxybenzyl and aryl bromide functional groups. The product was then
compared against commercially available enantioenriched N-Boc-L-Trp-OMe and N-Boc-D-Trp-OMe standards.
Chiral HPLC analysis [Chiralpak IC column; 1.0 mL/min; 15% isopropanol in hexanes; tR(N-Boc-L-Trp-OMe) =






1) TFA, CH2CI2, 23 *C;
NEt3, Na-Boc-L-Pro-OH, HOBt
EDC-HCI, CH2CI2, 23 *C
2) TFA, CH2CI2, 23 *C;
NH4OH, MeOH, 23 *C
75% (2-steps)
Bromoindole diketopiperazine (-)-66:
Trifluoroacetic acid (15 mL) was added via syringe to a solution of N"-Boc-N"-Cbz-L-6-
bromotryptophan methyl ester (+)-65 (3.83 g, 7.21 mmol, 1 equiv) in dichloromethane (50 mL)
at 23 *C. After 1 h, the brown solution was concentrated under reduced pressure to afford a
viscous brown residue, which was dissolved in dichloromethane (100 mL) and cooled to 0 'C in
an ice-water bath. Triethylamine (4.52 mL, 32.5 mmol, 4.50 equiv) was added dropwise via
syringe. N-hydroxybenzotriazole (1.46 g, 10.8 mmol, 1.50 equiv) and N"-Boc-L-proline (3.10 g,
14.4 mmol, 2.00 equiv) were sequentially added to the solution. After 2 min, upon dissolution of
the N"-Boc-L-proline, I -ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrogen chloride (2.07
g, 10.8 mmol, 1.50 equiv) was added and the reaction mixture was allowed to warm to 23 *C.
After 1 h, the reaction mixture was diluted with dichloromethane (60 mL) and washed with
aqueous hydrogen chloride solution (1 N, 250 mL). The aqueous layer was extracted with
dichloromethane (2 x 100 mL). The combined organic layers were washed with saturated
aqueous sodium bicarbonate solution (250 mL) and the resulting aqueous layer was extracted
with dichloromethane (2 x 25 mL). The combined organic layers were dried over anhydrous
sodium sulfate, were filtered, and were concentrated under reduced pressure. The resulting off-
white foam was then dissolved in dichloromethane (50 mL) and trifluoroacetic acid (15 mL) was
added dropwise to the solution. After I h, the solution was concentrated under reduced pressure.
The viscous residue was dissolved in methanol (200 mL) and cooled to 0 'C. Ammonium
hydroxide (28-30% ammonia, 10 mL) was added dropwise and the reaction mixture was
allowed to warm to 23 0C. After 22 h, the reaction mixture was cooled to -78 *C and filtered.
The white precipitate was washed with methanol (2 x 50 mL), which had been cooled to 0 'C in
an ice-water bath, and was dried under reduced pressure at 23 'C to afford diketopiperazine (-)-
66 (2.68 g, 74.9%, 2-steps) as a fluffy white solid. Structural assignments were made using
additional information from gCOSY, HSQC, and HMBC experiments.
IH NMR (500 MHz, DMSO-d6, 20 *C):
"C NMR (125.8 MHz, DMSO-d6, 20 *C):
6 8.21 (s, 1H, C8H), 8.13 (s, 1H, NIoH), 7.66
(d, J= 8.4, 1H, C5H), 7.61 (s, 1H, C2H), 7.53
(d, J= 6.8, 2H, Phcbz-o-H), 7.47-7.37 (m, 1 H,
C6H), 7.47-7.37 (m, 3H, Phcbz-H), 5.46 (app-
s, 2H, PhcbzCH 2 ), 4.42 (app-t, J = 5.2, 1 H,
CnIH), 4.11 (app-t, J= 8.5, 1H, CI5H), 3.38-
3.24 (m, 2H, CI9H), 3.17 (dd, J = 5.2, 15.3,
1H, C12Ha), 3.05 (dd, J = 5.2, 15.3, 1 H,
C12Hb), 2.10-2.00 (m, IH, C17Ha), 1.80-1.63
(m, 2H, C18H), 1.61-1.47 (m, 1 H, C17Hb).
8 169.3 (C16), 165.1 (C13), 149.9 (C=Ocbz),
135.3 (C 9), 135.2 (Phcbz-ipso-C), 129.6 (C4),
128.7 (Phcbz-C), 128.6 (Phcbz-C), 128.4
187
(Phcbz-C), 125.6 (C6), 124.9 (C2 ),
117.3 (C7 ), 117.1 (C8), 116.8
(PhcbzCH2), 58.5 (C15), 54.3 (C11),
27.8 (C 17), 24.8 (C 12), 22.0 (Ci8 ).
FTIR (thin film) cm-1:
HRMS (DART) (m/z):
[X]D24:
TLC (30% acetone in dichloromethane), Rf:
3584 (s), 1737 (s), 1668 (s), 1434 (m), 1247
(m), 1084 (w).
calc'd for C24 H2 3BrN30 4 [M+H]*: 496.0866,
found: 496.0870.


















Pinacol boronic ester (-)-67:
A 25-mL round bottom flask was charged with diketopiperazine (-)-66 (500 mg, 1.01
mmol, I equiv), aminobiphenyl(XPhos)palladium chloride precatalyst complex (39.6 mg, 50.4
pmol, 5.00 mol%), XPhos (72.2 mg, 151 gmol, 15.0 mol%), bis(pinacolato)diboron (769 mg,
3.03 mmol, 3.00 equiv), and tribasic potassium phosphate (643 mg, 3.03 mmol, 3.00 equiv). The
flask was then evacuated and charged with argon (3 cycles). Dimethyl sulfoxide (10 mL) was
introduced to the flask via syringe and the initial suspension was warmed to 60 *C. After 2.5 h,
the black solution was cooled to 23 *C, diluted with ethyl acetate (125 mL), and washed with
saturated aqueous sodium bicarbonate solution (250 mL). The resulting aqueous layer was
extracted with ethyl acetate (2 x 125 mL), and the combined organic layers were dried over
anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure. The
crude reaction mixture was then purified by flash column chromatography on silica gel (eluent:
3% acetone in ethyl acetate) to afford pinacol boronic ester (-)-67 (356 mg, 65.0%) as a white
foam. Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
'H NMR (500 MHz, CDCI3, 20 *C):
"C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
6 8.61 (br-s, IH, C8H), 7.65 (d, J 7.8, 1H,
C6H), 7.59 (s, 1H, C2H), 7.51 (d, J 7.9, 1 H,
CsH), 7.42 (d, J = 7.1, 2H, Phcbz-o-H),
7.36-7.26 (m, 3H, Phcbz-H), 6.79 (s, lH,
NioH), 5.35 (app-s, 2H, PhCbzCH2), 4.25 (app-
d, J= 7.2, 1H, CI1H), 3.84 (app-t, J= 7.1, 1H,
C15H), 3.56 (dd, J = 2.7, 15.2, 1H, Ci 2Ha),
3.53-3.37 (m, 2H, Ci9H), 2.90 (dd, J = 9.5,
15.3, 1H, C12Hb), 2.17-2.05 (m, 1 H, C17Ha),
1.88-1.64 (m, 1H, CI7 Hb), 1.88-1.64 (m, 2H,
Ci8H), 1.29 (s, 12H, OC(CH3 ) 2 pinacol).
6 169.8 (C16), 165.0 (C13), 150.3 (C=OCbz),
135.3 (C 9), 135.0 (Phcbz-ipso-C), 132.3 (C4 ),
129.0 (C6), 128.6 (Phcbz-C), 128.6 (Phcbz-C),
128.4 (Phcbz-C), 125.4 (C2), 125.4 (C7), 121.8
(C8 ), 118.2 (C5 ), 116.1 (C3), 83.7
(OC(CH3)2pinacol), 68.7 (PhcbzCH2), 58.9 (C, 5 ),
54.3 (CI1 ), 45.3 (C19 ), 28.0 (C 17), 26.1 (C12 ),
24.8 (OC(CH3)2pinacol), 22.5 (C]8).





TLC (3% acetone in ethyl acetate), Rf:
calc'd for C3 0H3 5 BN 30 6 [M+H]*: 544.2613,
found: 544.2613.
-63 (c = 0.2, CHC13).
0.20 (UV, CAM).
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CbzN 2 HN 15( -17
(-)-68 0 H
Potassium trifluoroborateindole (-)-68:
An aqueous solution of potassium hydrogen fluoride (4.5 M, 4.73 mL, 21.3 mmol, 20.0
equiv) was added dropwise to a solution of pinacol boronic ester (-)-67 (578 mg, 1.06 mmol, 1
equiv) in methanol (15 mL) at 23 *C. After 1.5 h, the turbid solution was concentrated to dryness
under reduced pressure. The white solid residue was suspended in a dichloromethane and
hexanes solution (1:1, 50 mL) and filtered over Celite to remove the pinacol byproduct. After
further washing with a dichloromethane and hexanes solution (1:1, 50 mL), the solids were
extracted with acetone (80 mL) and the filtrate was concentrated under reduced pressure to
afford potassium 6-trifluoroborateindole (-)-68 (489 mg, 87.8%) as a beige solid. Structural
assignments were made using additional information from gCOSY, HSQC, and HMBC
experiments.
1H NMR (500 MHz, acetone-d 6, 20 *C):
13C NMR (125.8 MHz, acetone-d 6, 20 *C)6 :
19F NMR (282.4 MHz, acetone-d 6, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
5 8.40 (s, IH, CH), 7.54 (d, J = 7.3, 2H,
PhCbz-o-H), 7.52 (s, 1H, C2H), 7.45 (d, J =
7.7, 1H, C6H), 7.43-7.39 (in, 3H, Phcbz-H),
7.36 (d, J= 7.5, 1H, C5H), 6.79 (s, 1 H, NIoH),
5.44 (app-s, 2H, PhcbzCH 2), 4.41 (dd, J = 3.6,
8.3, IH, CnIH), 4.10 (app-t, J = 8.1, lH,
CIsH), 3.54-3.43 (m, IH, C12Ha), 3.54-3.43
(in, 1H, Ci 9 Ha), 3.42-3.33 (m, 1H, CigHb),
2.96 (dd, J= 8.3, 15.5, 1 H, CI2Hb), 2.18-2.07
(m, IH, C17Ha), 1.85-1.70 (m, IH, CI7Hb),
1.85-1.70 (m, 2H, C18H).
8 170.1 (C16), 166.1 (C13), 151.3 (CCbz=O),
136.9 (Phcbz-ipso-C), 136.5 (C9), 129.3
(Phcbz-C), 129.0 (Phcbz-C), 129.0 (Phcbz-C),
129.0 (C4), 127.7 (C6), 123.0 (C2 ), 118.5 (C),
117.6 (C3), 117.5 (C), 68.4 (PhcbzCH2), 59.5
(C15), 55.2 (C11 ), 45.6 (C 19), 28.7 (C 17), 26.6
(C 12), 23.0 (C18).
6 -141.0 (C6BF 3K).
3583 (br, s), 1726 (in), 1666 (s), 1422 (in),
1255 (m).
calc'd for C 24H22 BF 3N 30 4 [M-K]f: 484.1661,
found: 484.1643.
6 C7 is not observed in the 3C NMR spectrum. For other examples of unobservable carbon atoms ipso to the




[a]D21. -42 (c = 0.14, acetone).
192
1) TFA, CH2C 2, 23 *C;
0 NEt3, N-Boc-Ala-OH, HOBt 5 0
OMe EDC-HCI, CH2CI2, 23 *C /Me 8 1 1j NH
CbzN NHBoc 2) TEA, CH2CI2, 23 *C; CbzN 2 HN ANH40H, MeOH, 23*C i Me
89% (2-steps) (-44 O
Alanine diketopiperazine (-)-44:
Trifluoroacetic acid (30 mL) was added via syringe to a solution of N"-Boc-NV"-Cbz-L-
tryptophan methyl ester7 (9.0 g, 19.9 mmol, I equiv) in dichloromethane (100 mL) at 23 0C.
After 1 h, the brown solution was concentrated under reduced pressure to afford a viscous brown
residue, which was dissolved in dichloromethane (200 mL) and cooled to 0 *C in an ice-water
bath. Triethylamine (12.5 mL, 89.5 mmol, 4.50 equiv) was added dropwise via syringe. N-
hydroxybenzotriazole (4.03 g, 29.8 mmol, 1.50 equiv) and N"-Boc-L-alanine (7.53 g, 39.8 mmol,
2.00 equiv) were sequentially added to the resulting solution. After 2 min, upon dissolution of
the Na-Boc-L-alanine, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrogen chloride (5.72
g, 29.8 mmol, 1.50 equiv) was added and the reaction mixture was allowed to warm to 23 'C.
After 13.5 h, aqueous hydrogen chloride solution (1 N, 500 mL) was added and the aqueous
layer was extracted with dichloromethane (2 x 100 mL). The combined organic layers were
washed with saturated aqueous sodium bicarbonate solution (500 mL) and the resulting aqueous
layer was extracted with dichloromethane (2 x 100 mL). The combined organic layers were
dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The resulting off-white foam was then dissolved in dichloromethane (100 mL) and
trifluoroacetic acid (30 mL) was added dropwise to the solution. After 2 h, the solution was
concentrated under reduced pressure. The viscous residue was dissolved in methanol (300 mL)
and cooled to 0 'C. Ammonium hydroxide (28-30% ammonia, 10.5 mL) was added dropwise
and the reaction mixture was allowed to warm to 23 *C. After 23 h, the white precipitate was
filtered and washed with methanol (2 x 50 mL), which had been cooled to 0 'C in an ice-water
bath. The white powder was dried under reduced pressure at 23 'C to afford diketopiperazine
(-)-44 (6.7 g, 89%, 2-steps). Structural assignments were made using additional information
from gCOSY, HSQC, and HMBC experiments.
H NMR (500 MHz, DMSO-d6, 20 *C): 8 8.17 (s, IH, N 14H), 8.10 (s, 1H, N1oH), 8.06
(d, J = 8.1, 1H, C8H), 7.67 (d, J = 7.8, 1 H,
C5H), 7.51 (d, J = 6.3, 2H, Phcbz-o-H), 7.51(s, 1H, C2H), 7.43 (app-t, J = 7.0, 2H, Phcbz-
m-H), 7.38 (t, J = 7.1, 1H, Phcbz-p-H), 7.32
(app-t, J= 7.3, 1H, C7H), 7.25 (app-t, J= 7.9,
1H, C6H), 5.47 (app-s, 2H, PhcbzCH 2), 4.22
(app-t, J = 4.3, 1 H, C IH), 3.71 (q, J = 7.0,
1H, C15H), 3.20 (dd, J= 4.4, 14.7, 1H, C12Ha),
3.03 (dd, J= 4.6, 14.6, 1H, C12Hb), 0.66 (d, J
= 7.0, 3H, C17H).
7 Prepared from commercially available iVa-Boc-tryptophan methyl ester in one step: Kiso, Y.; Inai, M.; Kitagawa,
K.; Akita, T. Chem. Lett. 1983, 5, 739.
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"C NMR (125.8 MHz, DMSO-d6 , 20 C):
FTIR (thin film) cm-1:
HRMS (DART) (m/z):
[a]D24:
TLC (5% methanol in dichloromethane), Rf:
6 168.0 (C 16), 166.6 (C 13), 150.1 (C=OCbz),
135.4 (Phcbz-ipso-C), 134.6 (C9 ), 130.6 (C4 ),
128.7 (Phcbz-C), 128.5 (Phcbz-C), 128.2
(Phcbz-C), 124.6 (C 7), 124.3 (C2), 122.8 (C6),
120.0 (C5), 116.2 (C3), 114.4 (C8), 68.3
(PhcbzCH2), 54.4 (C 11), 49.7 (C 1 5), 27.9 (C 12 ),
19.5 (C1 7).
3584 (m), 3050 (br, s), 1739 (m), 1678 (s),
1453 (m), 1244 (m).
calc'd for C2 2 H2 0N 30 4 [M-H]f: 390.1459,
found: 390.1458.













Tetracyclic bromide A (+)-46:
Pyridinium tribromide (4.24 g, 13.3 mmol, 2.00 equiv) was added to a suspension of
diketopiperazine (-)-44 (2.50 g, 6.62 mmol, 1 equiv) in 2,2,2-trifluoroethanol (132 mL) at 23 *C.
After 20 min, once the white solids have fully dissolved, a solution of saturated aqueous sodium
thiosulfate (100 mL) was added. The reaction mixture was diluted with dichloromethane (200
mL) and washed with saturated aqueous sodium thiosulfate (200 mL). The resulting aqueous
solution was further extracted with dichloromethane (2 x 150 mL) and the combined organic
layers were dried over anhydrous sodium sulfate, were filtered, and were concentrated under
reduced pressure. The crude reaction mixture was then purified by flash column
chromatography on silica gel (eluent: 60% ethyl acetate in hexanes) to afford tetracyclic bromide
(+)-46 (2.08 g, 69.2%) as a white foam. Structural assignments were made using additional
information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl3 , 20 *C):
13 C NMR (125.8 MHz, CDC 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D25:
TLC (60% ethyl acetate in hexanes), Rf:
6 7.65 (d, J= 8.1, 1H, C8H), 7.44 (d, J= 7.2,
2H, Phcbz-o-H), 7.40 (d, J = 7.6, IH, CsH),
7.37 (app-t, J = 7.0, 2H, Phcbz-m-H), 7.32 (t, J
= 7.2, 1H, Phcbz-p-H), 7.24 (app-t, J = 7.6,
1H, C7H), 7.06 (app-t, J= 7.5, 1H, C6H), 6.32
(s, 1H, C2H), 6.21 (s, IH, N14H), 5.42 (d, J=
12.2, 1H, PhCbzCHa), 5.32 (d, J = 12.2, 1H,
PhcbzCHb), 4.32 (dd, J= 3.5, 10.1, 1 H, C, H),
3.93 (q, J= 6.7, 1H, Ci 5H), 3.69 (dd, J= 3.5,
14.1, 1H, C12Ha), 3.06 (dd, J= 10.2, 14.2, 1H,
C12Hb), 1.29 (d, J= 6.8, 3H, C17H).
6 168.9 (C13), 167.3 (C16), 152.9 (C=Ocbz),
139.4 (C9), 135.8 (Phcbz-ipso-C),), 132.7 (C4),
130.9 (C7), 128.6 (PhCbz-C), 128.3 (Phcbz-C),
128.2 (Phcbz-C), 124.7 (C6), 124.6 (C5), 116.8
(C8), 84.6 (C2), 68.3 (PhcbzCH 2 ), 60.3 (C3),
58.0 (C,1), 51.4 (C15), 37.6 (C12), 14.8 (C17).
3273 (br-m), 1720 (s), 1692 (s), 1408 (m), 752
(m).
calc'd for C22H2 1BrN 30 4 [M+H]*: 470.0710,
found 470.0692.







AgSbF6  H Cbz
18-crown-6 4'- 0




(-)-N"'Y"'-Dicarboxybenz-y Naseseazine A (50):
Silver(I) hexafluoroantimonate (73.1 mg, 213 gmol, 5.00 equiv) was added as a solid to a
solution of tetracyclic bromide (+)-46 (20.0 mg, 42.5 gmol, 1 equiv), potassium 6-
trifluoroborateindole (-)-68 (33.4 mg, 63.8 pmol, 1.50 equiv), and 18-crown-6 (56.2 mg, 213
imol, 5.00 equiv) in nitroethane (2 mL) at 23 *C. After 1 h, aqueous hydrogen chloride (2 N, 2
mL) was added. After stirring for 5 min, the reaction mixture was diluted with dichloromethane
(60 mL) and washed with aqueous hydrogen chloride (2 N, 60 mL). The resulting aqueous layer
was further extracted with dichloromethane (2 x 30 mL) and the combined organic layers were
dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The crude reaction mixture was purified by flash column chromatography on silica gel
(eluent: 8% methanol in ethyl acetate) to afford (-)-A" ,N'-dicarboxybenzyl naseseazine A (50)
(19.3 mg, 56.2%) as a white solid. Structural assignments were made using additional
information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
6 8.11 (br-s, 1H, C8H), 7.62 (d, J 7.8, 1H,
CH), 7.46 (s, 1H, C2H), 7.40 (d, J= 7.0, 2H,
Phcbz-o-H), 7.37-7.28 (m, 5H, Phcbz-H),
7.37-7.28 (m, IH, C5.H), 7.28-7.20 (m, 3H,
Phcbz-H), 7.15(app-t, J = 7.6, 1H, C7H), 7.05
(d, J = 7.2, 1 H, C5H), 6.93 (app-t, J = 7.4, 1 H,
C6H), 6.90 (d, J= 8.4, 1H, C6.H), 6.41 (s, 1H,
Nio.H), 6.28 (s, 1H, N14H), 6.28 (s, 1H, C2H),
5.38-5.21 (m, 4H, PhcbzCH2), 4.29 (d, J= 9.5,
1H, CnH), 4.18 (br-s, 1H, C,,H), 4.01 (app-t,
J = 7.5, 1H, Ci 5.H), 3.91 (q, J = 6.8, 1H,
Ci5H), 3.64-3.47 (m, 2H, C19.H), 3.64-3.47(m, 1H, CI2.Ha), 3.30 (d, J= 12.9, 1H, C12Ha),
2.85 (dd, J = 10.7, 15.5, 1H, C12.Hb),
2.81-2.70 (m, 1H, C12Hb), 2.33-2.21 (m, 1H,
CI7 .Ha), 2.04-1.91 (m, 1H, C17.Hb), 2.04-1.91(m, 1H, Ci 8 Ha), 1.91-1.78 (m, 1H, Cis.Hb),
1.30 (d, J = 6.7, 3H, C17H).
8 170.0 (C16), 169.6 (CI3 ), 167.7 (C16),
(C13'), 153.2 (Ccbz=O), 150.6 (Ccbz'=O),
(C9), 139.3 (C7 ), 136.3 (Phcbz-ipso-C),
(C4), 135.0 (C9.), 135.0 (Phcbz.-ipso-C),







FTIR (thin film) cm-1:
HRMS (DART) (m/z):
[a]D24:
TLC (7.5% methanol in ethyl acetate), Rf:
(Phcbz-C), 129.0 (Phcbz-C), 128.6 (Phcbz-C),
128.2 (Phcbz-C), 128.2 (Phcbz-C), 125.3 (C),
124.7 (C2.), 124.3 (C6), 121.4 (C6 ), 119.5
(C), 117.0 (C), 116.1 (C3 ), 113.2 (Cs), 83.9
(C2), 69.1 (PhcbzCH 2), 68.1 (PhcbzCH2), 59.3
(C15 ), 58.9 (C3), 58.5 (C11 ), 54.2 (Ci1 ), 51.9
(C15 ), 45.7 (C19,), 35.4 (C 12), 28.4 (C 17 ), 26.4
(C 12,), 22.8 (C1 8,), 15.3 (C 17).
3226 (br, m), 1688 (s), 1399 (m), 1308 (m),
751 (m).
calc'd for C4 6H4 3N60 8 [M+H]*: 807.3137,
found: 807.3116.























Palladium on charcoal (10% w/w, 1.0 mg, 905 nmol, 0.10 equiv) was added to a solution
of (-)-N",N''-dicarboxybenzyl naseseazine A (50) (7.3 mg, 9.05 pmol, 1 equiv) in acetic acid (1
mL) at 23 'C. A stream of hydrogen gas was passed through the solution for 2 min by discharge
of a balloon equipped with a needle extending into the reaction mixture. After stirring the
solution for 9 h under an atmosphere of hydrogen gas, the solution was filtered over Celite. The
solids were further extracted with methanol and the combined filtrates were concentrated under
reduced pressure. The crude reaction mixture was purified by flash column chromatography on
silica gel (eluent: 5% methanol, 45% tetrahydrofuran, 50% dichloromethane) to afford (+)-
naseseazine A (1) (4.1 mg, 80%) as a white solid. Structural assignments were made using
additional information from gCOSY, HSQC, HMBC, and ROESY experiments.
'H NMR (500 MHz, methanol-d 4, 20 "C):
H NMR (500 MHz, DMSO-d6 , 20 *C):
6 7.57 (d, J= 8.4, 1 H, C5H), 7.40 (d, J= 1.3,
1H, C8H), 7.12 (s, IH, C2.H), 7.05 (app-dt, J
= 1.3, 7.9, 1 H, C7H), 7.03 (dd, J = 1.7, 8.4,
1H, C6.H), 6.85 (dd, J = 0.6, 7.4, 1H, CsH),
6.69 (d, J = 8.0, 1H, C8H), 6.68 (app-dt, J =
0.9, 7.4, 1H, C6H), 5.83 (s, 1H, C2H), 4.65
(dd, J= 7.4, 9.2, 1H, C, IH), 4.39 (dt, J= 1.1,
4.7, 1H, Cn.H), 4.16 (dq, J = 1.4, 6.9, 1H,
C15H), 3.98 (ddd, J = 1.7, 6.3, 10.9, 1H,
Cis.H), 3.42 (app-dt, J = 8.3, 11.7, 1H,
C19.Ha), 3.30-3.20 (m, 1H, C19.Hb), 3.30-3.20
(m, 2H, C12 H), 3.30-3.20 (m, 1H, Ci 2Ha),
2.59 (dd, J= 9.9, 13.6, 1H, C12Hb), 1.96 (app-
ddt, J= 2.0, 7.2, 12.5, 1H, Ci 7 Ha), 1.72-1.61
(m, IH, Cis'Ha), 1.47-1.39 (m, 1H, Cis.Hb),
1.38 (d,J= 7.1, 3H, C17H), 0.96-0.85 (m, 1H,
C17.Hb).
6 10.81 (s, 1H, N 1H), 8.20 (s, IH, N14H), 7.71
(s, 1H, N1oH), 7.56 (d, J = 8.4, IH, Cs.H),
7.28 (s, 1H, C8H), 7.19 (d, J= 1.8, IH, C2.H),
7.04-6.95 (m, 1H, C7H), 7.04-6.95 (m, IH,
C6.H), 6.83 (d, J= 7.3, 1H, CsH), 6.75 (d, J=
2.8, lH, NiH), 6.62 (d, J = 8.0, 1H, C8H),
6.58 (app-t, J = 7.4, 1 H, C6H), 5.65 (d, J =
198
2.8, 1 H, C2H), 4.62 (app-t, J = 8.7, 1 H, C I H),
4.28 (app-t, J= 4.9, 1H, CI 1.H), 4.14 (q, J =
6.5, 1H, C15H), 4.06 (app-t, J = 7.8, 1H,
C15H), 3.41-3.29 (m, 1FH, Cg.Ha), 3.30-3.18(m, 1FH, CI9.Hb) 3.30-3.18 (m, 1 H, C12 'Ha),
3.14-3.00 (m, 1H, C 2Ha), 3.14-3.00 (m, 1fH,
C12'Hb), 2.41 (dd, J= 10.0, 13.6, 1FH, C12Hb),
2.03-1.94 (m, 1H, C17'Ha), 1.74-1.56 (m, 2H,
C.,H), 1.47-1.36 (m, 1H, C17.Hb), 1.23 (d, J
6.9, 3H, C17H).
13 C NMR (125.8 MHz, methanol-d 4, 20 'C):
13C NMR (125.8 MHz, DMSO-d6 , 20 'C):
FTIR (thin film) cm-1:
UV (CH 30H) Xmax (log c):
HRMS (DART) (m/z):
[a]D24:
6 172.7 (C13), 170.9 (C16), 170.9 (
(C13Y), 149.3 (C9 ), 138.1 (C9 .), 1
136.1 (C4), 129.6 (C7), 127.8 (
(C2 ), 125.1 (C), 120.6 (C6 ), 1
119.7 (C), 111.2 (C), 110.4 (
(C3 ), 87.3 (C2 ), 61.4 (C3), 60.5
(C1s), 57.4 (C.11 ), 52.4 (C15), 46.1
(C 12), 29.3 (C 17'), 29.3 (C12'), 22.7
(C 17).
















6 170.0 (C13), 169.1 (C16'), 168.6 (C 16), 165.5
(C 13 ), 148.1 (C9 ), 135.9 (C9'), 135.7 (C 7'),
134.4 (C 4), 127.9 (C7), 126.1 (C4 ), 125.0
(C2'), 123.6 (Cs), 119.2 (Cs), 118.0 (C6),
117.8 (C), 109.3 (C), 109.2 (C'), 109.1 (C3'), 85.0 (C2), 59.3 (C3), 58.5 (CIS), 58.4 (C1),
55.2 (CO'), 50.4 (C15), 44.6 (C19.), 38.8 (C12),
27.7 (C17'), 25.7 (C12'), 21.9 (C18,), 14.8 (C17).
3584 (s), 3272 (br, s), 2924 (w), 1667
1453 (w), 1412 (m), 1346 (w), 1307 (w).
229 (4.67), 285 (3.91).
calc'd for C 30H3 1N6 0 4 [M+H]*:
found: 539.2392.
±123 (c = 0.12, CH 30H).8
(s),
539.2401,
TLC (5% methanol, 47.5% tetrahydrofuran, 47.5% dichloromethane), Rf: 0.15 (UV, CAM).
8 Literature value: [a]D 23 = +139 (c 0.10, CH 30H), see
Feussner, K.; Capon, R. J. Org. Lett. 2009, 11, 3862.
Raju, R.; Piggott, A. M.; Conte, M.; Aalbersberg, W. G. L.;
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1) TFA, CH2CI2, 23 *C;
NEt3, N-Boc-Pro-OH, HOBt 5 0
EDC-HCI, CH2CI2, 23 *C H 19
NOMe 2) TFA, CH2CI2, 23C; CbzN 2 HN
CbN H~cNH40H, MeOH, 23 *C R7
71% (2-steps) (-)-45 0
Proline diketopiperazine (-)-45:
Trifluoroacetic acid (30 mL) was added via syringe to a solution of N"-Boc-N0"-Cbz-L-
tryptophan methyl ester7 (7.10 g, 15.7 mmol, 1 equiv) in dichloromethane (100 mL) at 23 'C.
After 1 h, the brown solution was concentrated under reduced pressure to afford a viscous brown
residue, which was dissolved in dichloromethane (160 mL) and cooled to 0 0C in an ice-water
bath. Triethylamine (9.85 mL, 70.7 mmol, 4.50 equiv) was added dropwise via syringe. N-
hydroxybenzotriazole (3.18 g, 23.6 mmol, 1.50 equiv) and N"-Boc-L-proline (6.76 g, 31.4 mmol,
2.00 equiv) were sequentially added to the solution. After 2 min, upon dissolution of the N"-
Boc-L-proline, 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrogen chloride (4.51 g, 23.6
mmol, 1.50 equiv) was added and the reaction mixture was allowed to warm to 23 'C. After 1 h
and 45 min, another portion of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrogen
chloride (1.50 g, 7.85 mmol, 0.500 equiv) was added. After 1.5 h, aqueous hydrogen chloride
solution (1 N, 500 mL) was added and the aqueous layer was extracted with dichloromethane (2
x 50 mL). The combined organic layers were washed with saturated aqueous sodium
bicarbonate solution (500 mL) and the resulting aqueous layer was extracted with
dichloromethane (2 x 50 mL). The combined organic layers were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure. The resulting off-white
foam was then dissolved in dichloromethane (100 mL) and trifluoroacetic acid (30 mL) was
added dropwise to the solution at 23 'C. After 1 h, the solution was concentrated under reduced
pressure. The viscous residue was dissolved in methanol (400 mL) and cooled to 0 'C.
Ammonium hydroxide (28-30% ammonia, 15 mL) was added dropwise and the reaction mixture
was allowed to warm to 23 0C. After 14 h, another portion of ammonium hydroxide (28-30%
ammonia, 10 mL) was added dropwise via syringe. After 23 h, the reaction mixture was cooled
to -78 0C and filtered. The white precipitate was washed with methanol (2 x 50 mL), which had
been cooled to 0 'C in an ice-water bath, and was dried under reduced pressure to afford
diketopiperazine (-)-45 (4.63 g, 70.6%, 2-steps) as a fine white powder. Structural assignments
were made using additional information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, DMSO-d 6, 20 *C): 6 8.11 (s, 1H, NioH), 8.07 (d, J = 8.0, IH,
C8H), 7.67 (d, J= 7.7, 2H, C5H), 7.60 (s, 1H,
C2H), 7.52 (d, J = 7.7, 1H, Phcbz-o-H),
7.46-7.37 (m, 3H, Phcbz-H), 7.33 (app-dt, J =
0.9, 7.7, 1H, C7H), 7.27 (app-dt, J = 0.9, 7.5,
1 H, C6H), 5.46 (s, 2H, PhcbzCH 2), 4.42 (app-t,
J= 5.2, 1H, C IH), 4.12 (app-t, J= 8.2, 1H,
Ci5H), 3.40-3.26 (in, 2H, CI9H), 3.22 (dd, J=
4.2, 15.3, 1 H, C12Ha), 3.05 (dd, J= 5.6, 15.3,
1H, C12Hb), 2.09-1.99 (m, IH, C17Ha),
1.78-1.62 (in, 2H, Ci8H), 1.62-1.48 (in, 1H,
C17Hb).
200
3C NMR (125.8 MHz, DMSO-d, 20 *C):
FTIR (thin film) cm :
HRMS (DART) (m/z):
[a]D24:
TLC (40% acetone in dichloromethane), Rf:
6 169.3 (C16), 165.2 (C 13), 150.1 (Ccbz=O),
135.4 (PhCbz-iPSO-C), 134.6 (C9), 130.4 (C4 ),
128.6 (Phcbz-C), 128.5 (Phcbz-C), 128.3
(PhCbz-C), 124.5 (C7), 124.0 (C2), 122.7 (C6),
119.7 (C), 116.9 (C3), 114.5 (C), 68.2
(PhcbzCH 2), 58.5 (C15), 54.3 (C 11), 44.7 (C 19),
27.8 (C 17), 24.9 (C 12), 22.0 (Ci 8).
3233 (br,
1399 (m),
m), 1732 (s), 1667 (s), 1455 (m),
1249 (m).
calc'd for C 2 4H2 4N 30 4 [M+H]*: 418.1761,
found: 418.1764.














Tetracyclic bromide B (+)-47:
Pyridinium tribromide (461 mg, 1.44 mmol, 1.20 equiv) was added to a suspension of
diketopiperazine (-)-45 (500 mg, 1.20 mmol, 1 equiv) in 2,2,2-trifluoroethanol (10 mL) at 23 *C.
After 1 h, the reaction mixture was poured into a saturated aqueous sodium thiosulfate solution
(60 mL) and extracted with dichloromethane (60 mL). The resulting aqueous layer was further
extracted with dichloromethane (2 x 30 mL) and the combined organic layers were dried over
anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure. The
crude reaction mixture was purified by flash column chromatography on silica gel (eluent: 75%
ethyl acetate in hexanes) to afford tetracyclic bromide (+)-47 (304 mg, 51.1%) as a beige foam.
Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (75% ethyl acetate in hexanes), Rf:
6 7.64 (d, J = 8.2, 1H, CH), 7.48-7.39 (m,
1H, CsH), 7.48-7.39 (m, 2H, Phcbz-o-H), 7.34
(app-t, J = 7.0, 2H, Phcbz-m-H), 7.29 (t, J =
7.3, 1H, Phcbz-p-H), 7.23 (app-t, J= 7.6, 1H,
C7H), 7.07 (app-t, J= 7.3, 1H, C6H), 6.29 (s,
1H, C2H), 5.41 (d, J = 12.2, 1H, PhCbzCHa),
5.30 (d, J= 12.2, 1H, PhcbzCHb), 4.35 (dd, J=
3.4, 14.3, 1H, C12Ha), 4.00 (app-t, J= 7.9, 1H,
CisH), 3.78 (dd, J = 3.4, 14.3, 1H, C12Ha),
3.37-3.27 (m, 1H, Ci9Ha), 3.18-3.07 (m, IH,
C19Hb), 3.03 (dd, J= 10.1, 14.0, 1H, C12Hb),
2.21-2.09 (m, 1H, C17Ha), 2.09-1.96 (m, 1H,
C17Hb), 1.80-1.68 (m, 2H, Ci8H).
8 167.2 (CI3), 164.3 (C, 6 ), 152.8 (CCbz=O),
139.4 (C9), 135.8 (Phcbz-ipso-C), 132.7 (C4 ),
130.8 (C7), 128.6 (PhCbz-C), 128.3 (Phcbz-C),
128.2 (Phcbz-C), 124.9 (C5), 124.7 (C), 116.6
(C), 84.6 (C2), 68.3 (PhcbzCH 2), 60.6 (C3),
60.5 (CIs), 59.2 (Cu,), 45.1 (C19), 37.5 (C12),
27.3 (C17), 23.3 (C, 8).
1722 (s), 1679 (s), 1479 (m), 1410 (m), 751
(m).
calc'd for C 24 H23BrN30 4 [M+H]*: 496.0866,
found: 496.0877.







AgSbF6  H /Cbz
18-crown-6 ' ~ 0
EtNO 2, 23 *C N
50% C N
- 1 NH 17
8 CbZ 0
(+)-47 (-)-51
(-)-N"'n,-Dicarboxybenzyl Naseseazine B (51):
Silver(I) hexafluoroantimonate (69.2 mg, 202 pmol, 5.00 equiv) was added as a solid to a
solution of tetracyclic bromide (+)-47 (20.0 mg, 40.3 pimol, 1 equiv), potassium 6-
trifluoroborateindole (-)-68 (31.6 mg, 60.4 gmol, 1.50 equiv), and 18-crown-6 (53.3 mg, 202
gmol, 5.00 equiv) in nitroethane (2 mL) at 23 *C. After I h, aqueous hydrogen chloride (2 N, 2
mL) was added. After stirring for 5 min, the reaction mixture was diluted with ethyl acetate (60
mL) and washed with brine (3 x 60 mL). The organic layer was dried over anhydrous sodium
sulfate, was filtered, and was concentrated under reduced pressure. The crude reaction mixture
was purified by flash column chromatography on silica gel (eluent: gradient, 5% methanol in
ethyl acetate-+5% methanol in dichloromethane) to afford (-)-N'",N'"'-dicarboxybenzyl
naseseazine B (51) (16.7 mg, 49.8%) as a white solid. Structural assignments were made using
additional information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 "C):
13C NMR (125.8 MHz, CDCl 3, 20 *C):
6 8.14 (br-s, 1H, Cs.H), 7.66 (d, J = 8.0, 1 H,
CH), 7.49 (s, IH, C2.H), 7.46-7.32 (m, 1H,
C5 H), 7.46-7.32 (m, 7H, Phcbz-H), 7.32-7.25
(m, 1H, C5H), 7.32-7.25 (m, 3H, Phcbz-H),
7.18 (app-t, J = 7.5, 1H, C7H), 7.07-6.97 (m,
1H, C6H), 7.07-6.97 (m, IH, C6H), 6.38 (s,
1H, C2H), 5.82 (s, IH, Nio.H), 5.41-5.22 (m,
4H, PhcbzCH2), 4.37 (d, J = 7.1, 1H, CIiH),
4.26 (dd, J = 2.3, 10.2, 1H, CI1H), 4.04 (app-
t, J= 8.0, 1H, C15H), 4.00 (app-t, J= 7.9, 1H,
Cis.H), 3.65-3.47 (m, 2H, C19H), 3.65-3.47
(m, 1H, C12 Ha), 3.65-3.47 (m, 1H, CI2 .Ha),
3.41-3.31 (m, 1H, CigHa), 3.20-3.10 (m, IH,
C19Hb), 2.91-2.78 (m, IH, C12Hb), 2.91-2.78
(m, 1H, C12.Hb), 2.30-2.23 (m, 1H, C17'Ha),
2.23-2.15 (m, 1H, Ci 7Ha), 2.14-2.04 (m, IH,
C17Hb), 2.03-1.90 (m, 1H, C17.Hb), 2.03-1.90
(m, 1H, Cis.Ha), 1.90-1.66 (m, 2H, C18H),
1.90-1.66 (m, 1H, C18Hb).
6 169.5 (C 16 ), 167.9 (C 16), 165.5 (C1 3), 165.1
(C 3'), 153.2 (Ccbz=O), 150.5 (CCbz'=O), 139.8
(C9), 139.5 (C 7), 136.4 (Phcbz-ipso-C), 135.0(Phcbz.-ipso-C), 135.0 (C 4), 135.0 (C9.), 129.1
203
(C7 ), 129.1 (C'), 129.1 (Phcbz-C), 129.0
(Phcbz-C), 129.0 (Phcbz-C), 128.6 (Phcbz-C),
128.3 (Phcbz-C), 128.2 (Phcbz-C), 125.5 (C),
124.9 (C2 '), 124.4 (C6 ), 121.4 (C6 ), 119.5
(Cs,), 116.8 (Cs), 115.8 (C3'), 113.3 (C8 ), 83.6
(C2 ), 69.3 (Phcbz'CH2), 68.2 (PhcbzCH2), 61.1
(C15 ), 59.7 (C11), 59.4 (C15'), 59.2 (C3 ), 54.2
(C 1), 4 5.7 (C 19,), 4 5.2 (C 19), 3 5.4 (C 12), 28.5
(C 17'), 27.6 (C17), 26.6 (C 12'), 23.6 (C18), 22.8
(CIs).
1721 (s), 1679 (s), 1399 (s), 1249 (m), 751
(m).
calc'd for C4 8H4 5N60 8 [M+H]*: 833.3293,
found: 833.3283.
FTIR (thin film) cm 1 :
HRMS (ESI) (m/z):
[a]D25:
TLC (5% methanol in ethyl acetate), Rf:





















Palladium on charcoal (10% w/w, 2.1 mg, 1.98 imol, 0.25 equiv) was added to a solution
of dicarboxybenzyl naseseazine B (-)-51 (6.6 mg, 7.92 ptmol, I equiv) in acetic acid (1 mL) at
23 'C. A stream of hydrogen gas was passed through the solution for 2 min by discharge of a
balloon equipped with a needle extending into the reaction mixture. After stirring the solution
for 3.5 h under an atmosphere of hydrogen gas, the solution was filtered over Celite. The solids
were further extracted with methanol and the combined filtrates were concentrated under reduced
pressure. The crude reaction mixture was purified by flash column chromatography on silica gel
(eluent: 5% methanol, 45% tetrahydrofuran, 50% dichloromethane) to afford (+)-naseseazine B
(2) (3.6 mg, 80%) as a white solid. Structural assignments were made using additional
information from gCOSY, HSQC, HMBC, and ROESY experiments.
1H NMR (500 MHz, methanol-d 4, 20 "C):
'H NMR (500 MHz, DMSO-d 6, 20 *C):
6 7.57 (d, J= 7.4, 1 H, C5 H), 7.41 (d, J= 1.3,
1H, C8H), 7.12 (s, 1H, C2.H), 7.06 (app-dt, J
= 1.2, 7.9, 1H, C7H), 7.01 (dd, J = 1.6, 8.5,
1H, C6H), 6.83 (d, J= 7.2, 1H, C5H), 6.69 (d,
J = 7.7, 1H, CH), 6.68 (app-t, J = 7.3, 1 H,
C6H), 5.84 (s, 1H, C2H), 4.71 (app-t, J= 8.6,
1H, C IH), 4.39 (app-t, J = 4.6, 1H, C IH),
4.29 (app-t, J= 7.7, 1H, C15H), 3.98 (ddd, J =
1.4, 6.3, 10.7, 1H, C15H), 3.52-3.37 (m, 2H,
C19H), 3.52-3.37 (m, 1H, Ci 9Ha), 3.35-3.21
(m, 2H, C 2 .H), 3.35-3.21 (m, 1H, C12 Ha),
3.35-3.21 (m, 1H, CI9.Hb), 2.57 (dd, J= 10.2,
13.7, 1H, C12Hb), 2.30-2.22 (m, 1H, C17Ha),
2.15-2.04 (m, 1H, C17Hb), 2.04-1.87 (m, 2H,
Ci8H), 2.04-1.87 (m, 1H, C17.Ha), 1.73-1.60(m, 1H, Ci 8 Ha), 1.49-1.40 (m, IH, Ci8.Hb),
0.97-0.87 (m, 1H, C17.Hb).
6 10.81 (s, 1H, NrH), 7.71 (s, IH, Nio.H),
7.57 (d, J = 8.4, 1 H, C5H), 7.30 (d, J = 1.3,
1H, Cs.H), 7.19 (d, J = 2.2, IH, C2.H), 7.00
(app-dt, J = 1.3, 7.9, 1H, C7H), 6.99 (d, J =
8.6, 1H, C6.H), 6.82-6.76 (m, IH, C5H), 6.82-
6.76 (m, 1H, NIH), 6.60 (d, J= 7.6, 1 H, CH),
6.58 (app-dt, J= 1.0, 7.5, 1H, C6H), 5.68 (d, J
205
13C NMR (125.8 MHz, methanol-d 4, 20 'C):
13C NMR (125.8 MHz, DMSO-d6 , 20 "C):
= 3.2, 1H, C2H), 4.72 (app-t, J = 8.2, 1H,
CnIH), 4.35 (app-t, J= 7.9, 1H, CisH), 4.29
(app-t, J = 5.1, 1H, CI1 .H), 4.06 (app-t, J =
8.7, 1H, C15.H), 3.41-3.30 (m, 2H, C19H),
3.41-3.30 (m, 1H, C19 ,Ha), 3.29-3.24 (m, IH,
C19,Hb), 3.22 (dd, J = 4.6, 14.6, 1H, C12.Ha),
3.13 (dd, J= 7.4, 13.6, 1H, C12Ha), 3.05 (dd, J
= 5.8, 14.8, 1H, C 12.Hb), 2.36 (dd, J = 10.5,
13.6, 1H, C12Hb), 2.21-2.11 (m, 1H, C17Ha),
2.03-1.91 (m, 1H, C17,Ha), 2.03-1.91 (m, 1H,
C17Hb), 1.91-1.77 (m, 2H, C18H), 1.75-1.56(m, 2H, C18,H), 1.48-1.36 (m, 1H, C17,Hb).
6 170.9 (C 16 ), 170.3 (C 16), 168.6 (C 13), 167.5
(C1Y), 149.3 (C9 ), 138.1 (C9.), 137.2 (C7.),
136.2 (C4), 129.6 (C7 ), 127.8 (C4.), 126.6
(C2.), 125.1 (Cs), 120.6 (C6 ), 120.6 (C.),
119.8 (C6.), 111.3 (C), 110.5 (C8.), 109.8 (C3.), 87.1 (C2), 61.9 (C1 s), 61.9 (C3 ), 61.7 (C1 ),
60.2 (C 15.), 57.3 (C11), 46.4 (C 19), 46.1 (C19.),
39.7 (C 12), 29.3 (C 17.), 29.3 (C 12.), 28.6 (C 17),
24.4 (C18 ), 22.7 (C 18.).
6 169.1 (C 16 ,), 167.9 (C 16 ), 165.9 (C 13), 165.5
(C13.), 148.1 (C9), 135.9 (C9 .), 135.6 (C7.),
134.6 (C4), 127.9 (C7 ), 126.1 (C4.), 125.0
(C2.), 123.4 (Cs), 119.1 (C5 .), 117.9 (C6),
117.8 (C6.), 109.2 (C8), 109.2 (C8.), 109.2
(C3.), 84.8 (C2 ), 59.9 (C15), 59.8 (C3 ), 59.5
(C 1 ), 58.4 (C15.), 55.2 (C 1.), 44.6 (C19), 44.6
(C19 ,), 38.7 (C 12), 27.6 (C 17.), 27.0 (C 17), 25.6
(C 12 '), 22.9 (C18 ), 21.9 (C18 ').
FTIR (thin film) cm-I:
UV (CH 30H) kmax (log s):
HRMS (DART) (m/z):
[a]D24:
3295 (br, s), 2954 (w), 2882




201 (4.95), 203 (4.98), 204 (4.92), 229 (4.67),
285 (3.92).
calc'd for C3 2H 3 3N 60 4 [M+H]*:
found: 565.2546.
+101 (c = 0.23, CH 30H).9
565.2558,
TLC (5% methanol, 45% tetrahydrofuran, 50% dichloromethane), Rf: 0.19 (UV, CAM).
9 Literature value: [a]D2 3 = +95 (c 0.08, CH 30H), Raju, R.; Piggott, A. M.; Conte, M.; Aalbersberg, W. G. L.;
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(-)-V"W"'-Dicarboxybenzyl iso-Naseseazine A (48):
Silver(I) hexafluoroantimonate (73.0 mg, 213 pmol, 5.00 equiv) was added as a solid to a
solution of tetracyclic bromide (+)-46 (20.0 mg, 42.5 pmol, 1 equiv) and proline
diketopiperazine (-)-45 (26.6 mg, 63.8 pmol, 1.50 equiv) in nitroethane (2 mL) at 23 *C. After 2
h, the reaction mixture was diluted with dichloromethane (60 mL) and washed with brine (60
mL). The resulting aqueous layer was extracted with dichloromethane (2 x 30 mL) and the
combined organic layers were dried over anhydrous sodium sulfate, were filtered, and were
concentrated under reduced pressure. The crude reaction mixture was purified by flash column
chromatography on silica gel (eluent: gradient, 5% methanol in ethyl acetate->5% methanol in
dichloromethane) to afford a regioisomeric mixture of (-)-N"V,"'-dicarboxybenzyl naseseazine
A (50) and (-)-N"'AN-dicarboxybenzyl iso-naseseazine A (48) (18.1 mg, 53%, (-)-50:(-)-48,
1.4:1) as a white solid.
Regioisomers (-)-50 and (-)-48 were separated for the purpose of full and independent
characterization by preparative HPLC [Waters X-Bridge preparative HPLC column, C18, 5 pm,
19 x 250 mm; 20.0 mL/min; gradient, 55%-+65% acetonitrile in water, 15 min; tR((-)-50) = 4.6
min, tR((-)- 4 8 ) = 5.7 min]. Structural assignments were made using additional information from
gCOSY, HSQC, and HMBC experiments.
(-)-1V"/,"'-DicarboxybenzyI iso-Naseseazine A (48):
'H NMR (500 MHz, CDCl 3, 20 *C): 8 8.03 (s, I H, C8 H), 7.65 (d, J = 8.2, 1 H,
C8H), 7.49 (s, 1 H, C5.H), 7.43 (d, J = 7.8, 2H,
Phcbz-o-H), 7.41-7.25 (m, 8H, Phcbz-H),
7.41-7.25 (m, 1 H, C2,H), 7.41-7.25 (in, I H,
CsH), 7.18 (app-dt, J = 1.1, 8.0, 1H, C7H),
7.13 (d, J = 8.9, 1H, C7.H), 7.01 (app-dt, J =
0.8, 7.5, 1H, C6H), 6.42 (s, 1H, C2H), 5.85 (s,
1H, NioH), 5.81 (s, 1H, N14H), 5.40 (s, 2H,
Phcbz.CH 2), 5.37 (d, J = 12.4, 1H, PhCbzCHa),
5.31 (d, J= 12.4, 1H, PhcbzCHb), 4.41 (dd, J=
3.5, 9.8, 1H, C IH), 4.23 (dd, J= 2.7, 9.4, 1 H,
C11.H), 4.03-3.95 (m, 1H, C15H), 4.03-3.95
(m, IH, C15 H), 3.59-3.38 (m, IH, C12Ha),
3.59-3.38 (m, 2H, C19,H), 3.59-3.38 (m, IH,
CI2 Ha), 2.94 (dd, J= 10.0, 13.8, 1H, C12Hb),
2.84 (dd, J= 9.9, 15.3, 1H, CI2 Hb), 2.30-2.19
207
(-)-48
"C NMR (125.8 MHz, CDCl 3, 20 0C):
(m, 1H, C1 7,Ha), 1.94-1.77 (m, 2H, C18,H),
1.94-1.77 (m, I H, C17,Hb), 1.33 (d, J = 6.9,
3H, C17H).
6 169.5 (C16 ), 169.5 (C 13), 167.8 (C16), 165.0
(C13'), 153.3 (Ccbz=O), 150.5 (CCbz'=O), 139.7
(C9 ), 137.2 (C6 '), 136.3 (Ccbz'-ipso-C), 135.4
(C4), 135.1 (Ccbz-ipso-C), 134.9 (C9.), 130.2
(C4 ), 129.2 (C7), 129.1 (Phcbz-C), 129.0(Phcbz-C), 128.8 (Phcbz-C), 128.7 (Phcbz-C),
128.3 (Phcbz-C), 128.3 (Phcbz-C), 125.3 (C5'),
125.1 (C5 ), 124.5 (C6), 123.3 (C7'), 117.1
(C8), 116.3 (Cs), 116.0 (C3 ), 115.9 (C2.), 83.6
(C2), 69.3 (Phcbz'CH2), 68.2 (PhcbzCH2), 59.3
(C 15'), 58.6 (C11), 58.5 (C3), 54.2 (C.11), 52.0
(C 15), 45.6 (C19 ), 35.2 (C 12), 28.4 (C 17 ), 26.8
(C 12'), 22.7 (CI'), 15.3 (C17).
FTIR (thin film) cm- 1:
HRMS (ESI) (m/z):
[a]D24:
TLC (8% methanol in ethyl acetate), Rf:
3251 (br, m), 1720 (s),
1310 (m), 751 (m).
calc'd for C46H43N 60 8
found: 807.3115.
-20 (c = 0.26, CHCl3).
0.06 (UV, CAM).
1688 (s), 1401 (m),
[M+H]*: 807.3137,
(-)-N",N"'-Dicarboxybenzyl Naseseazine A (50):
Please see page 196 for the full characterization data for (-)-N",I"'-dicarboxybenzyl
naseseazine A (50).
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CbzN' H2, 10% Pd/C HN'
/ H 0 AcOH, 23 *C (4H O
NH 52% -:NH
Me 52% Me
Cbz 0 8 H 0
(-)-48 (+)-iso-naseseazine A (52)
(+)-iso-Naseseazine A (52):
Palladium on charcoal (10% w/w, 6.0 mg, 5.67 pmol, 0.25 equiv) was added to a solution
of (--)-N',N''-dicarboxybenzyl iso-naseseazine A (48) (18.3 mg, 22.7 pmol, I equiv) in acetic
acid (1 mL) at 23 'C. A stream of hydrogen gas was passed through the solution for 2 min by
discharge of a balloon equipped with a needle extending into the reaction mixture. After stirring
the solution for 20 h under an atmosphere of hydrogen gas, the solution was filtered over Celite.
The solids were further extracted with methanol and the combined filtrates were concentrated
under reduced pressure. The crude reaction mixture was purified by flash column
chromatography on silica gel (eluent: 7.5% methanol, 42.5% tetrahydrofuran, 50%
dichloromethane) to afford (+)-iso-naseseazine A (52) (6.4 mg, 52.4%) as a white solid.
Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
IH NMR (500 MHz, methanol-d 4, 20 "C):
3C NMR (125.8 MHz, methanol-d 4, 20 *C):
6 7.71 (s, 1H, C5 H), 7.32 (d, J = 8.6, 1H,
C8H), 7.10 (s, 1 H, C2.H), 7.06 (app-dt, J =
1.0, 7.7, 1H, C7H), 7.01 (dd, J= 1.7, 8.6, 1 H,
C7.H), 6.90 (d, J = 7.2, 1 H, C5H), 6.72-6.65
(m, IH, CH), 6.72-6.65 (m, 1H, C6H), 5.87
(s, 1H, C2H), 4.97-4.78 (m, 1H, C,,H), 4.38
(app-t, J= 4.1, 1H, C,.H), 4.23 (dq, J= 1.3,
7.0, 1H, CisH), 3.88 (ddd, J = 1.3, 6.1, 11.0,
1H, CisH), 3.44 (dd, J = 4.6, 14.6, 1H,
C12.Ha), 3.34 (dd, J = 7.2, 13.6, 1H, Ci 2Ha),
3.25-3.15 (m, 1H, CI2.Hb), 3.25-3.15 (m, IH,
Cig9 Ha), 3.06 (app-dt, J = 4.1, 10.3, IH,
C19.Hb), 2.52 (dd, J= 10.7, 13.7, 1H, C,2Hb),
1.89-1.80 (m, 1H, CI7.Ha), 1.62-1.48 (in, IH,
Cis.Ha), 1.40 (d, J= 6.9, 3H, CI 7H), 1.22-1.12
(m, 1H, CisHb), 0.59-0.47 (m, 1H, C17.H).
8 173.1 (C13), 171.0 (C16), 170.2 (Ci 6'), 167.3
(C. 3'), 149.3 (C9), 136.8 (C9.), 136.5 (C4),
134.2 (C.), 129.5 (C7), 128.6 (C4'), 126.8
(C2 ), 125.1 (Cs), 123.2 (C7 ), 120.6 (C6 ),
117.5 (Cs), 113.0 (C8'), 111.2 (C8), 109.8
(C3 .), 87.3 (C2 ), 61.5 (C3), 60.8 (Cii), 60.1
(Cis.), 57.9 (C,.), 52.4 (C15), 45.9 (C19.), 40.3
209
(C12), 30.2 (C12.), 29.2 (C 17 ), 22.3 (Cs18), 15.3
(C 17).
3353 (br-s), 2924 (w), 1662 (s), 1466 (w),
1424 (m), 1345 (w), 1308 (m), 750 (m).
FTIR (thin film) cm 1:




+110 (c = 0.18, CH 30H).
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(-)-AV' ", -Dicarboxybenzyl iso-Naseseazine B (49):
Silver(I) hexafluoroantimonate (69.2 mg, 202 jmol, 5.00 equiv) was added as a solid to a
solution of tetracyclic bromide (+)-47 (20.0 mg, 40.3 pmol, 1 equiv) and proline
diketopiperazine (-)-45 (25.2 mg, 60.4 gmol, 1.50 equiv) in nitroethane (2 mL) at 23 "C. After 2
h, the reaction mixture was diluted with dichloromethane (60 mL) and washed with brine (60
mL). The resulting aqueous layer was extracted with dichloromethane (2 x 30 mL) and the
combined organic layers were dried over anhydrous sodium sulfate, were filtered, and were
concentrated under reduced pressure. The crude reaction mixture was purified by flash column
chromatography on silica gel (eluent: gradient, 5% methanol in ethyl acetate->7.5% methanol in
dichloromethane) to afford a regioisomeric mixture of (-)-N",M"'-dicarboxybenzyl naseseazine
B (51) and (-)-N" N'-dicarboxybenzyl iso-naseseazine B (49) (15.7 mg, 46.8%, (-)-51:(-)-49,
1.4:1) as a white solid.
Regioisomers (-)-51 and (-)-49 were separated for the purpose of full and independent
characterization by preparative HPLC [Waters X-Bridge preparative HPLC column, C18, 5 pm,
19 x 250 mm; 20.0 mL/min; gradient, 55%->65% acetonitrile in water, 15 min; tR((-)-51) = 5.5
min, tR((-)- 4 9 ) = 6.6 min]. Structural assignments were made using additional information from
gCOSY, HSQC, and HMBC experiments.
(-)-N".V''-Dicarboxvbenzvy iso-Naseseazine B (49):
'H NMR (500 MHz, CDCl 3, 20 "C): 8 8.04 (br-s, IH, C8 H), 7.65 (d, J = 8.0, 1 H,
CH), 7.48 (s, 1 H, C2.H), 7.43 (dd, J = 1.1,
7.6, 2H, Phcbz-H), 7.41-7.34 (m, 5H, Phcbz-
H), 7.34-7.25 (m, IH, C5 H), 7.34-7.25 (m,
1H, Cs.H), 7.34-7.25 (m, 3H, Phcbz-H),
7.21-7.14 (m, 1H, C7H), 7.21-7.14 (m, IH,
C7.H), 7.04 (app-dt, J = 0.7, 7.5, 1H, C6H),
6.42 (s, 1H, C2H), 5.70 (s, I H, N1o-H), 5.40 (s,
2H, Phcbz.CH 2), 5.36 (d, J = 12.4, 1H,
PhCbzCHa), 5.30 (d, J = 12.3, 1H, PhcbzCHb),
4.44 (dd, J= 3.5, 9.8, 1H, C, H), 4.23 (dd, J=
2.3, 9.6, 1H, C,H), 4.06 (app-t, J = 7.9, 1 H,
C15H), 4.00 (app-t, J = 7.5, 1H, Cis.H), 3.60(dd, J= 3.8, 13.9, 1H, Ci 2Ha), 3.58-3.45 (m,
2H, C19.H), 3.43 (dd, J = 3.0, 15.2, IH,
CI2 .Ha), 3.40-3.32 (m, 1H, C19Ha), 3.20-3.11
211
(-)-49
13C NMR (125.8 MHz, CDC13, 20 'C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[aID24 :
TLC (8% methanol in ethyl acetate), Rf:
(m, lH, C19Hb), 2.91 (dd, J= 10.0, 13.8, 1H,
C12Hb), 2.85 (dd, J= 10.1, 15.3, 1 H, C12.Hb),
2.32-2.16 (m, 1 H, C17,Ha), 2.32-2.16 (m, 1H,
C17Ha), 2.16-2.04 (m, IH, C17Hb), 1.98-1.65
(m, 2H, C18H), 1.98-1.65 (m, 2H, C1sH),
1.98-1.65 (m, 1H, C1 7 ,Hb).
6 169.4 (C 16), 168.0 (C 16), 165.5 (C 13), 164.9
(C1Y), 153.3 (Ccbz=O), 150.5 (Ccbz'=O), 139.7(C9 ), 137.3 (C.), 136.3 (Phcbz-ipso-C), 135.3
(C4), 135.0 (C9.), 134.9 (Phcbz'-ipso-C), 130.1
(C4'), 129.1 (C7), 129.1 (Phcbz-C), 129.0
(Phcbz-C), 128.8 (PhCbz-C), 128.7 (PhCbz-C),
128.2 (Phcbz-C), 128.2 (Phcbz-C), 125.3 (C),
125.2 (C2'), 124.5 (C6), 123.4 (C7 '), 116.8
(Cs), 116.3 (Cs), 115.9 (Cs,), 115.9 (C3'), 83.5
(C2 ), 69.3 (Phcbz'CH2), 68.2 (PhcbzCH2), 61.1
(C15 ), 59.7 (Ci1), 59.3 (C 15 '), 58.7 (C3), 54.2(C.11), 45.6 (C19,), 45.2 (C19), 35.2 (C12), 28.4
(C 17'), 27.6 (C 17), 26.8 (C 12'), 23.6 (C18 ), 22.7
(C 18').
3584 (m), 2954 (m), 1720 (s), 1677 (s), 1400
(s), 1254 (m), 750 (m).
calc'd for C48H45N60 8 [M+H] :
found: 833.3291.
833.3293,
-32 (c = 0.39, CHC13).
0.05 (UV, CAM).
(-)-A",' -Dicarboxybenzyl Naseseazine B (51):
Please see page 203 for the full characterization data for (-)-N',N"'-dicarboxybenzyl
naseseazine B (51).
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Palladium on charcoal (10% w/w, 4.4 mg, 4.11 pmol, 0.25 equiv) was added to a solution
of (-)-N'",N'"'-dicarboxybenzyl iso-naseseazine B (49) (13.7 mg, 16.5 pmol, 1 equiv) in acetic
acid (1 mL) at 23 *C. A stream of hydrogen gas was passed through the solution for 2 min by
discharge of a balloon equipped with a needle extending into the reaction mixture. After stirring
the solution for 18 h under an atmosphere of hydrogen gas, the solution was filtered over Celite.
The solids were further extracted with methanol and the combined filtrates were concentrated
under reduced pressure. The crude reaction mixture was purified by flash column
chromatography on silica gel (eluent: 7.5% methanol, 42.5% tetrahydrofuran, 50%
dichloromethane) to afford (+)-iso-naseseazine B (53) (5.7 mg, 61.4%) as a white solid.
Structural assignments were made using additional information from gCOSY, HSQC, HMBC,
and nOe experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
"C NMR (125.8 MHz, CDCl 3, 20 *C):
6 8.28 (s, IH, N1H), 7.59 (s, 1H, C5 H), 7.33
(d, J = 8.6, 1H, C8.H), 7.14-7.09 (in, IH,
C2.H), 7.14-7.09 (m, 1 H, C7.H), 7.06 (app-dt,
J = 0.9, 7.6, 1H, C7H), 6.84 (d, J = 7.4, 1H,
CH), 6.68 (app-t, J= 7.4, 1 H, C6H), 6.63 (d,
J= 8.0, 1H, C8H), 5.87 (d, J= 3.2, 1H, C2H),
5.76 (s, 1H, Nio.H), 5.29 (d, J = 3.1, IH,
NIH), 4.67 (dd, J= 7.3, 9.5, 1H, C,1H), 4.33
(dd, J= 3.0, 10.7, 1H, CIH), 4.18 (app-t, J=
8.2, 1H, Ci 5H), 4.08 (app-t, J = 7.8, 1H,
C15sH), 3.66 (dd, J = 3.5, 14.9, 1 H, CI2.Ha),
3.63-3.43 (in, 2H, C19H), 3.63-3.43 (in, 2H,
C19H), 3.31 (dd, J = 7.1, 13.9, IH, C12Ha),
2.99 (dd, J= 10.5, 15.0, 1H, C2.Hb), 2.74 (dd,
J= 10.5, 13.8, 1H, C12Hlb), 2.36-2.22 (m, 1 H,
C17.Ha), 2.36-2.22 (in, 1H, C17Ha), 2.22-2.08
(m, 1H, C17Hb), 2.08-1.76 (m, 2H, Ci8H),
2.08-1.76 (m, 2H, C,.H), 2.08-1.76 (in, IH,
C17.Hb).
6 169.5 (C 16'), 168.2 (CI6 ), 166.2
(C13 ), 147.3 (C 9), 135.8 (C9'),
134.3 (C6), 128.7 (C7 ), 127.0










115.9 (C5'), 112.4 (C8 ), 110.3 (C3 ), 109.8 (C8
), 86.2 (C2), 60.8 (CI1 ), 60.7 (C15 ), 60.3 (C 3),
59.4 (C15 ), 55.2 (C1 ), 45.6 (C19/ 19.), 45.4
(C19 /19,), 38.6 (C12 ), 28.5 (C 17 ), 27.8 (C 17),
27.1 (C12 ), 23.5 (C18), 22.7 (C18 ').
3306 (br, s), 2925 (w), 1660 (s), 1428 (m),
1341 (w), 1312 (w), 1215 (w), 750 (m).
calc'd for C32H3 3N60 4 [M+H]*: 565.2558,
found: 565.2544.
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D24: +43 (c = 0.15, CHCl 3).








S O3' ~ 13
NH
C bz 0 H
(-)-55
(-)-54:(-)-55 = 6.3:1
3-(2-Thienvl)tetracycle (-)-54 and 3-(3-Thienvl)tetracycle (-)-55:
A solution of silver(I) hexafluoroantimonate (0.20 M, 425 pL, 85.1 pmol, 2.00 equiv) in
dichloromethane was added via syringe to a solution of tetracyclic bromide (+)-46 (20.0 mg,
42.5 gmol, I equiv) and thiophene (6.7 gL, 85 pmol, 2.0 equiv) in dichloromethane (2 mL) at 23
*C. After 1 h, brine (200 gL) was added to the solution. The crude reaction mixture was purified
by flash column chromatography on silica gel (eluent: 20% acetone in dichloromethane) to
afford a mixture of regioisomeric 3-(thienyl)tetracycles (Run 1: 15.3 mg, 76.0%, (-)-54:(-)-55,
6.2:1; Run 2: 15.6 mg, 77.5%, (-)-54:(-)-55, 6.4:1) as a clear film.
Regioisomers (-)-54 and (-)-55 were separated for the purpose of full and independent
characterization by preparative HPLC [Waters X-Bridge preparative HPLC column, C18, 5 gm,
19 x 250 mm; 20.0 mL/min; 50% acetonitrile in water; tR((-)- 54 ) = 8.4 min, tR((-)- 5 5 ) = 8.7
min]. Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
3-(2-Thienvl)tetracycle (-)-54:
'H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, CDCl3, 20 *C):
FTIR (thin film) cm-':
6 7.68 (d, J= 8.3, 1H, C8H), 7.38 (d, J= 7.9,
2H, Phcbz-o-H), 7.35-7.27 (m, 3H, Phcbz-H),
7.35-7.27 (m, I H, C5H), 7.24 (app-dt, J = 1.3,
7.8, 1H, C7H), 7.17 (dd, J = 1.2, 5.1, 1H,
C5H), 7.06 (app-dt, J = 1.0, 7.6, IH, C6H),
6.84 (dd, J= 3.6, 5.1, 1H, C4 H), 6.63 (dd, J=
1.2, 3.6, 1H, C3H), 6.22 (s, I H, C2H), 5.46 (s,
1H, NI4H), 5.38 (d, J= 12.3, 1H, PhCbzCHa),
5.28 (d, J= 12.3, 1H, PhcbzCHb), 4.40 (dd, J=
3.3, 10.0, 1H, CIH), 3.99 (q, J = 6.9, 1H,
CisH), 3.54 (dd, J = 3.5, 14.0, 1H, Ci 2Ha),
2.93 (dd, J= 10.1, 13.9, 1H, C12Hb), 1.33 (d, J
= 6.9, 3H, C17H).
6 169.3 (C 13), 167.7 (C 16), 153.2 (CCbz=O),
145.3 (C2 ), 139.9 (C9 ), 136.3 (Phcbz-ipso-C),
134.6 (C4), 129.6 (C7), 128.7 (PhCbz-C), 128.3
(Phcbz-C), 128.2 (Phcbz-C), 127.3 (C4.), 125.3
(Cs), 124.9 (Cs), 124.9 (C3 ), 124.4 (C6),
117.1 (C), 83.9 (C2 ), 68.1 (PhcbzCH 2), 58.4(C,1), 56.3 (C3), 51.9 (C 5), 35.5 (C12), 15.3
(C17).





TLC (ethyl acetate), Rf:
calc'd for C 26H2 4N 30 4 S
found: 474.1470.




H NMR (500 MHz, CDCl 3, 20 'C):
13C NMR (125.8 MHz, CDC13, 20 0C):
FTIR (thin film) cm- 1:
HRMS (ESI) (m/z):
[a]D24:
TLC (ethyl acetate), Rf:
6 7.66 (d, J= 8.1, 1 H,C 8H), 7.37 (dd, J= 1.8,
8.3, 2H, Phcbz-o-H), 7.35-7.30 (m, 3H, Phcbz-
H), 7.29 (d, J= 7.3, 1H, C5H), 7.26 (dd, J =
3.0, 5.1, 1H, C4H), 7.21 (app-dt, J= 1.3, 7.8,
1H, C7H), 7.05 (app-dt, J = 1.0, 7.5, 1H,
C6H), 6.90 (dd, J= 1.4, 5.1, 1H, C5,H), 6.80
(dd, J= 1.4, 3.0, 1H, C2H), 6.24 (s, 1 H, C2H),
5.54 (s, 1H, N14H), 5.40 (d, J = 12.4, 1H,
PhCbzCHa), 5.28 (d, J= 12.3, 1H, PhcbzCHb),
4.37 (dd, J= 3.4, 10.1, 1H, C H), 3.99 (q, J=
6.9, 1H, C15H), 3.47 (dd, J 3.4, 13.8, 1H,
C12Ha), 2.84 (dd, J= 10.1, 13.9, 1H, C12Hb),
1.33 (d, J= 6.9, 3H, C17H).
6 169.3 (C 13), 167.7 (C16 ), 153.2 (Ccbz=O),
142.3 (C3 ), 139.9 (C9 ), 136.3 (Phcbz-ipso-C),
134.8 (C4 ), 129.3 (C7 ), 128.7 (Phcbz-C), 128.3
(Phcbz-C), 128.3 (Phcbz-C), 127.5 (CT), 125.5
(CS), 124.8 (Cs), 124.4 (C6), 121.5 (C2 ),
117.1 (C8 ), 83.0 (C2 ), 68.2 (PhcbzCH2), 58.4
(C 1 ), 56.2 (C3), 51.9 (C 15), 34.4 (C 12), 15.3
(C 17).
3268 (br, m), 1709 (s), 1689 (s), 1481 (m),
1409 (m).
calc'd for C2 6H2 4N30 4 S [M+H]*: 474.1482,
found: 474.1465.
-17 (c = 0.21, CHCl3).
0.43 (UV, CAM).
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S BF3K 4* 5,
NHAgSbF 6  ~ '2 13 13Br, H18-crown-  6 
-N NH
SN N H 17Me EtNO2, -78-"5 C 2 2 N 1MeCbz 50% 8 Cbz 0 8 CbH
(+)-46 (-)-54 (-)-55
(-)-54:(-)-55 = 1:17
3-(2-Thienyl)tetracycle (-)-54 and 3-(3-Thienyl)tetracvcle (-)-55:
A Schlenk tube was charged with tetracyclic bromide (+)-46 (20.0 mg, 42.5 pmol, 1
equiv), potassium 3-thiophenetrifluoroborate (16.2 mg, 85.1 gmol, 2.00 equiv), and 18-crown-6
(22.4 mg, 85.1 gmol, 2.00 equiv). Nitroethane (2 mL) was then introduced via syringe. Upon
dissolution of all solid components, the reaction mixture was cooled to -78 *C. A solution of
silver(I) hexafluoroantimonate (0.17 M, 500 gL, 85.1 pmol, 2.00 equiv) in nitroethane at -78 'C
was then introduced to the Schlenk tube via cannula. The vessel was subsequently fitted with a
PTFE screw cap, sealed, and introduced into a cold bath at -45 *C. After 12 h, aqueous
hydrogen chloride (2 N, 4 mL) was added. The reaction mixture was diluted with ethyl acetate
(60 mL) and washed with brine (3 x 60 mL). The organic layer was dried over anhydrous
sodium sulfate, was filtered, and was concentrated under reduced pressure. The residue was
diluted with dichloromethane (30 mL) and washed with brine (30 mL). The resulting aqueous
layer was extracted with dichloromethane (2 x 30 mL). The combined organic layers were dried
over anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure.
The crude reaction mixture was purified by flash column chromatography on silica gel (eluent:
90% ethyl acetate in hexanes) to afford a mixture of regioisomeric 3-(thienyl)tetracycles (Run 1:
10.4 mg, 51.6%, (-)-54:(-)-55, 1:17; Run 2: 9.5 mg, 47%, (-)-54:(-)-55, 1:17) as a clear film.
3-(2-Thienyl)tetracycle (-)-54:
Please see page 215 for the full characterization data for 3-(2-thienyl)tetracycle (-)-54.
3-(3-Thienyl)tetracycle (-)-55:


















A solution of silver(I) hexafluoroantimonate (0.20 M, 425 pL, 85.1 ptmol, 2.00 equiv) in
dichloromethane was added via syringe to a solution of tetracyclic bromide (+)-46 (20.0 mg,
42.5 pimol, 1 equiv) and allyltributylstannane (26.1 pL, 85.1 pmol, 2.00 equiv) in
dichloromethane (2 mL) at 23 *C. After 1 h, brine (200 pL) was added to the solution. The
crude reaction mixture was then purified by flash column chromatography on silica gel (eluent:
20% acetone in dichloromethane) to afford 3-allyl tetracycle (-)-56 (Run 1: 11.1 mg, 60.5%;
Run 2: 10.9 mg, 59.4%) as a clear film. Structural assignments were made using additional
information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm- 1:
HRMS (ESI) (m/z):
[otID 24:
TLC (ethyl acetate), Rf
8 7.61 (d, J = 7.0, lH, CsH), 7.42 (d, J = 8.3,
2H, Phcbz-o-H), 7.37-7.27 (m, 3H, PhCbz-H),
7.21-7.15 (m, IH, C7H), 7.21-7.15 (m, IH,
C5H), 7.01 (app-dt, J = 0.9, 7.5, 1H, C6H),
5.93 (s, 1H, C2H), 5.84 (br-s, 1H, N14H),
5.47-5.40 (m, 1 H, CH 2CH=CH 2), 5.41 (d, J=
12.3, 1H, PhCbzCHa), 5.27 (d, J = 12.3, 1H,
PhCbzCHb), 5.03-4.94 (m, 2H, CH 2CH=CH 2),
4.19 (dd, J= 3.9, 10.1, 1H, C H), 3.93 (q, J=
6.8, 1H, CisH), 3.03 (dd, J = 4.0, 13.8, IH,
C12Ha), 2.44-2.28 (m, 2H, CH 2CH=CH 2),
2.44-2.28 (m, 1H, C12Hb), 1.30 (d, J = 6.8,
3H, C17H).
6 169.5 (C13), 167.6 (C1 6), 153.3 (Ccbz=O),
140.3 (C9), 136.4 (Phcbz-ipso-C), 135.0 (C4),
132.2 (CH 2CH=CH2), 128.9 (C), 128.7
(Phcbz-C), 128.4 (PhCbz-C), 128.3 (Phcbz-C),
124.2 (C), 124.1 (C6), 119.9 (CH 2CH=CH2),
116.8 (Cs), 81.1 (C2), 68.1 (PhcbzCH 2), 58.1
(C,1), 54.7 (C3), 51.9 (C, 5), 42.4
(CH 2CH=CH 2), 32.8 (C12), 15.4 (C17).
3264 (br, m), 1687 (s), 1481 (m), 1410 (m),
1328 (m).
calc'd for C2 5H2 6N30 4 [M+H]*: 432.1918,
found: 432.1906.
-37 (c = 0.26, CHCl 3).
0.34 (UV, CAM).
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N -- Me CH 2CI2 , 23 -C 2 - MeH8 H H1Cbz 0  52% a Cbz (+)-46 (-)-56
3-Allvltetracycle (-)-56:
A solution of silver(I) hexafluoroantimonate (0.20 M, 425 p.L, 85.1 ptmol, 2.00 equiv) in
dichloromethane was added via syringe to a solution of tetracyclic bromide (+)-46 (20.0 mg,
42.5 gmol, 1 equiv) and allyltrimethylsilane (13.5 gL, 85.1 pmol, 2.00 equiv) in dichloromethane
(2 mL) at 23 *C. After I h, brine (200 pL) was added to the solution. The crude reaction
mixture was purified by flash column chromatography on silica gel (eluent: 20% acetone in
dichloromethane) to afford 3-allyl tetracycle (-)-56 (Run 1: 9.5 mg, 52%; Run 2: 9.6 mg, 52%)
as a clear film.















A solution of silver(I) hexafluoroantimonate (0.20 M, 425 pL, 85.1 pmol, 2.00 equiv) in
dichloromethane was added via syringe to a solution of tetracyclic bromide (+)-46 (20.0 mg,
42.5 pmol, 1 equiv) and (isopropenyloxy)trimethylsilane (85% purity, 16.6 pL, 85.1 pmol, 2.00
equiv) in dichloromethane (2 mL) at 23 *C. After I h, brine (200 pL) was added to the solution.
The crude reaction mixture was purified by flash column chromatography on silica gel (eluent:
20% acetone in dichloromethane) to afford 3-acetonyltetracycle (-)-57 (Run 1: 17.3 mg, 90.9%;
Run 2: 17.2 mg, 90.4%) as a clear film. Structural assignments were made using additional
information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCI3, 20 *C):
3 C NMR (125.8 MHz, CDCl 3, 20 "C):
FTIR (thin film) cm- 1:
HRMS (ESI) (m/z):
taDa24t:
TLC (ethyl acetate), Rf:
6 7.60 (app-s, IH, C8H), 7.41 (d, J= 7.1, 2H,
PhCbz-O-H), 7.34 (app-t, J = 6.8, 2H, Phcbz-m-
H), 7.32-7.27 (m, lH, Phcbz-p-H), 7.19 (d, J=
7.5, 1H, C5H), 7.16 (app-t, J= 7.8, 1H, C7H),
6.99 (app-t, J= 7.5, 1H, C6H), 6.29 (br-s, I H,
N14H), 6.12 (s, IH, C2H), 5.39 (d, J = 12.3,
1H, PhCbzCHa), 5.27 (d, J = 12.3, 1H,
PhCbzCHb), 4.42 (dd, J= 5.3, 9.8, 1H, C IH),
3.97 (q, J= 6.7, 1H, CI5H), 2.98 (dd, J= 5.4,
13.5, 1H, C12Ha), 2.90 (d, J = 18.4, 1H,
CH2C(=O)CH3), 2.65 (d, J = 18.4, 1H,
CH 2C(=O)CH 3), 2.52 (dd, J= 10.1, 13.5, 1H,
C12Hb), 2.04 (s, 3H, CH2C(=O)CH 3), 1.31 (d,
J= 6.8, 3H, C17H).
6 206.0 (CH 2C(=O)CH3), 170.0 (C13 ), 167.7
(C16), 153.6 (Ccbz=O), 139.8 (C9 ), 136.2
(Phcbz-ipso-C), 135.9 (C4), 129.0 (C7), 128.7
(Phcbz-C), 128.5 (Phcbz-C), 128.3 (Phcbz-C),
124.4 (C6), 124.3 (Cs), 116.9 (Cs), 80.5 (C2 ),
68.2 (PhcbzCH 2), 58.2 (C,,), 51.9 (CIs), 51.4
(C3), 49.2 (CH 2C(=O)CH3 ), 33.4 (C12), 31.0
(CH2C(=O)CH3), 15.6 (C17).
3271 (br, m), 1712 (s), 1688 (s), 1481(m),
1410 (m).
calc'd for C2 5H2 6N30 5 [M+H]*: 448.1867,
found: 448.1846.














/ N H 0 H176 Cbz
(-)-58
3-(Methyl-a,a-dimethylacetate)tetracycle (-)-58:
A solution of silver(I) hexafluoroantimonate (0.20 M, 425 gL, 85.1 pmol, 2.00 equiv) in
dichloromethane was added via syringe to a solution of tetracyclic bromide (+)-46 (20.0 mg,
42.5 gmol, 1 equiv) and methyl trimethysilyl dimethylketene acetal (17.2 pL, 85.1 pmol, 2.00
equiv) in dichloromethane (2 mL) at 23 *C. After 1 h, brine (200 pL) was added to the solution.
The crude reaction mixture was purified by flash column chromatography on silica gel (eluent:
20% acetone in dichloromethane) to afford 3-(methyl-a,a-dimethylacetate)tetracycle (-)-58 (Run
1: 18.4 mg, 88.2%; Run 2: 18.8 mg, 89.9%) as a clear film. Structural assignments were made
using additional information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
"C NMR (125.8 MHz, CDCl3 , 20 *C):
FTIR (thin film) cm-':
HRMS (ESI) (m/z):
8 7.69 (app-s, I H, C8H), 7.38 (m, 2H, Phcbz-0-
H), 7.32 (app-t, J = 7.5, 2H, Phcbz-m-H),
7.29-7.25 (m, 1H, Phcbz-p-H), 7.20 (app-t, J=
7.2, 1H, C7H), 7.18 (d, J = 7.6, 1H, CH),
7.01 (app-dt, J = 0.9, 7.6, 1H, C6H), 6.45 (s,
1H, C2H), 6.17 (br-s, 1H, Ni 4H), 5.58-5.08
(br-m, 2H, PhcbzCH 2), 4.38-4.27 (br-m, I H,
CIIH), 3.95 (q, J = 6.2, 1H, CisH), 3.63 (s,
3H, OCH 3), 2.91-2.75 (br-m, 1H, C12Ha),
2.71-2.57 (br-m, 1H, C12Hb), 1.32 (d, J= 6.8,
3H, C17H), 1.26 (s, 3H, C(CH 3)2), 0.88 (s, 3H,
C(CH3) 2).
8 176.6 (CO 2CH3 ), 170.1 (C13), 167.7 (C16),
153.1 (CcbzO=), 141.2 (C9), 136.5 (Phcbz-
ipso-C), 133.0 (Cs), 129.3 (C7), 128.6 (PhCbz-
C), 128.2 (Phcbz-C), 128.1 (Phcbz-C), 126.3
(Cs), 123.9 (C6), 117.2 (C 4), 80.3 (C2 ), 68.1
(PhcbzCH 2), 58.7 (C3 ), 58.2 (C,,), 52.4
(OCH3 ), 51.9 (Ci 5), 47.7 (C(CH 3)2), 33.4
(C12), 21.7 (C(CH 3)2), 21.7 (C(CH 3)2), 15.7
(C1 7).
3266 (br, m), 1717 (s), 1688 (s), 1482 (m),
1410 (m).
calc'd for C 27H30N30 6 [M+H]*: 492.2129,
found: 492.2137.
-52 (c = 0.29, CHC13).
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A solution of silver(I) hexafluoroantimonate (0.20 M, 425 ptL, 85.1 Ptmol, 2.00 equiv) in
dichloromethane was added via syringe to a solution of tetracyclic bromide (+)-46 (20.0 mg,
42.5 pmol, 1 equiv) and toluene (9.1 pL, 85 pmol, 2.0 equiv) in dichloromethane (2 mL) at 23
"C. After 1 h, brine (200 gL) was added to the solution. The crude reaction mixture was purified
by flash column chromatography on silica gel (eluent: 20% acetone in dichloromethane) to
afford 3-(4-tolyl)tetracycle (-)-59 (Run 1: 11.1 mg, 54.2%; Run 2: 9.3 mg, 45%) as a clear film.
Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D 24:
TLC (20% acetone in dichloromethane), Rf:
8 7.64 (d, J= 7.9, 1H, C8H), 7.37 (d, J= 7.5,
2H, Phcbz-o-H), 7.35-7.26 (m, 3H, Phcbz-H),
7.35-7.26 (m, 1 H, CsH), 7.18 (app-t, J = 7.9,
1H, C7H), 7.07-7.00 (m, 2H, C3.H), 7.07-7.00
(m, 2H, C2.H), 7.07-7.00 (m, 1H, C6H), 6.34
(s, 1H, C2H), 5.85 (s, 1H, N14H), 5.41 (d, J=
12.4, 1H, PhCbzCHa), 5.28 (d, J = 12.3, IH,
PhcbzCHb), 4.37 (dd, J= 3.4, 10.1, 1H, C, H),
3.98 (q, J= 6.8, 1H, CIsH), 3.49 (dd, J= 3.4,
13.8, 1H, C12Ha), 2.85 (dd, J= 10.3, 13.9, 1H,
CI2Hb), 2.26 (s, 3H, ArCH3), 1.33 (d, J= 6.8,
3H, C17H).
6 169.6 (C13), 167.7 (C16), 153.1 (Ccbz=O),
139.8 (C9), 138.8 (C4.), 137.5 (C,), 136.3
(PhCbz-ipso-C), 135.1 (C4), 129.8 (C2 ), 129.1
(C7), 128.7 (Phcbz-C), 128.2 (PhCbz-C), 128.2(Phcbz-C), 125.7 (C3 ), 125.1 (Cs), 124.3 (C),
117.0 (C), 83.3 (C2), 68.1 (PhcbzCH 2), 58.6
(C,,), 58.3 (C 3), 51.9 (C15), 35.0 (CI 2), 21.1
(ArCH3), 15.3 (C, 7).
3268 (br, m), 1712 (s), 1689 (s), 1409 (m),
1313 (m).
calc'd for C29H28N30 4 [M+H]*: 482.2074,
found: 482.2056.





4a aIM. ,t 1 Me 0
13j \ '2 13NBr,, NH AgSbF6  6~ N H . N
NH e 18-crown-6 He H e
Cbz 0 EtNO 2, -78--45 *C 8 Cbz 0 8 Cbz 0
(+)-46 26% (-)-59 (-)-60
(-)-59:(-)-60 = 1:3.9
3-(4-Tolyl)tetracycle (-)-59 and 3-(2-Toly)tetracycle (-)-60:
A Schlenk tube was charged with tetracyclic bromide (+)-46 (20.0 mg, 42.5 pmol, I
equiv), potassium o-tolyltrifluoroborate (16.8 mg, 85.1 gmol, 2.00 equiv), and 18-crown-6 (22.4
mg, 85.1 pmol, 2.00 equiv). Nitroethane (2 mL) was then introduced via syringe. Upon
dissolution of all solid components, the reaction mixture was cooled to -78 "C. A solution of
silver(I) hexafluoroantimonate (0.17 M, 500 1iL, 85.1 pmol, 2.00 equiv) in nitroethane at -78 0C
was then introduced to the Schlenk tube via cannula. The vessel was subsequently fitted with a
PTFE screw cap, sealed, and introduced into a cold bath at -45 *C. After 12 h, aqueous
hydrogen chloride (2 N, 4 mL) was added. The reaction mixture was diluted with ethyl acetate
(60 mL) and washed with brine (3 x 60 mL). The organic layer was dried over anhydrous
sodium sulfate, was filtered, and was concentrated under reduced pressure. The residue was
diluted with dichloromethane (30 mL) and washed with brine (30 mL). The resulting aqueous
layer was extracted with dichloromethane (2 x 30 mL). The combined organic layers were dried
over anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure.
The crude reaction mixture was purified by flash column chromatography on silica gel (eluent:
90% ethyl acetate in hexanes) to afford a mixture of regioisomeric 3-(tolyl)tetracycles (Run 1:
5.1 mg, 25%, (-)-59:(-)-60, 1:4.2; Run 2: 5.4 mg, 26%, (-)-59:(-)-60, 1:3.7) as a clear film.
Regioisomers (-)-59 and (-)-60 were separated for the purpose of full and independent
characterization by preparative HPLC [Waters X-Bridge preparative HPLC column, C18, 5 pm,
19 x 250 mm; 20.0 mL/min; 50% acetonitrile in water; tR((-)-6 0) = 11.5 min, tR((-)- 5 9 ) = 12.4
min]. Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
3-(4-Tolyl)tetracvcle (-)-59:
Please see page 223 for the full characterization data for 3-(4-tolyl)tetracycle (-)-59.
3-(2-Tolvl)tetracycle (-)-60:
'H NMR (500 MHz, CDCl 3, 20 *C): 6 7.66 (d, J = 8.0, 1H, C8H), 7.34-7.22 (in,
5H, Phcbz-H), 7.34-7.22 (m, 1H, C5H), 7.34-
7.22 (C7H), 7.19 (d, J = 7.4, IH, C6.H), 7.16
(app-dt, J= 1.0, 7.4, 1H, Cs.H), 7.10 (app-dt, J
= 1.0, 7.5, 1H, C6H), 7.01 (app-dt, J = 1.2,
7.5, 1H, C4.H), 6.85 (d, J = 7.8, 1H, C3 H),
6.50 (s, 1 H, C2H), 5.62 (s, I H, N 14H), 5.33 (d,
J= 12.4, 1H, PhCbzCHa), 5.24 (d, J= 12.4, 1H,
PhcbzCHb), 4.50 (dd, J = 5.7, 9.6, 1H, CIIH),
224
"C NMR (125.8 MHz, CDCl 3, 20 0C):
FTIR (thin film) cm- :
HRMS (ESI) (m/z):
[oX]D24:
TLC (ethyl acetate), Rf:
4.02 (q, J= 6.8, 1 H, CI 5H), 3.26 (dd, J= 5.8,
14.4, IH, Cj 2Ha), 3.04 (dd, J= 9.7, 14.3, I H,
C12Hb), 2.40 (s, 3H, ArCH 3), 1.34 (d, J= 6.9,
3H, C 17H).
6 169.6 (C 13), 168.0 (C16), 153.3 (Ccbz=O),
140.1 (C9 ), 137.9 (C2,), 136.3 (Phcbz-ipso-C),
135.8 (C1 ), 135.5 (C 4), 133.2 (C6'), 129.2
(C7), 128.7 (Phcbz-C), 128.2 (C3 .), 128.2 (C5'),
128.2 (Phcbz-C), 128.1 (Phcbz-C), 126.4 (C4.),
125.9 (C), 124.2 (C6), 117.2 (C8), 82.6 (C2),
68.0 (PhcbzCH 2), 59.1 (C3), 59.0 (Cli), 52.1
(C15), 36.0 (C 12), 21.9 (ArCH 3), 15.5 (C 17).
1689 (s), 1481 (m), 1405 (m), 1329 (m), 751
(m).
calc'd for C29H28N 30 4 [M+H]*: 482.2074,
found: 482.2066.























3-(4-Methoxyphenvl)tetracycle (-)-S2 and 3-(2-Methoxyphenyl)tetracycle (-)-61:
A Schlenk tube was charged with tetracyclic bromide (+)-46 (20.0 mg, 42.5 pmol, I
equiv), potassium 2-methoxytrifluoroborate (18.2 mg, 85.1 gmol, 2.00 equiv), and 18-crown-6
(22.4 mg, 85.1 pmol, 2.00 equiv). Nitroethane (2 mL) was then introduced via syringe. Upon
dissolution of all solid components, the reaction mixture was cooled to -78 "C. A solution of
silver(I) hexafluoroantimonate (0.17 M, 500 pL, 85.1 gmol, 2.00 equiv) in nitroethane at -78 'C
was then introduced to the Schlenk tube via cannula. The vessel was subsequently fitted with a
PTFE screw cap, sealed, and introduced into a cold bath at -45 'C. After 12 h, aqueous
hydrogen chloride (2 N, 4 mL) was added. The reaction mixture was diluted with ethyl acetate
(60 mL) and washed with brine (3 x 60 mL). The organic layer was dried over anhydrous
sodium sulfate, was filtered, and was concentrated under reduced pressure. The residue was
diluted with dichloromethane (30 mL) and washed with brine (30 mL). The resulting aqueous
layer was extracted with dichloromethane (2 x 30 mL). The combined organic layers were dried
over anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure.
The crude reaction mixture was purified by flash column chromatography on silica gel (eluent:
90% ethyl acetate in hexanes) to afford a mixture of regioisomeric 3-(methoxyphenyl)tetracycles
(Run 1: 11.9 mg, 56.2%, (-)-S2:(-)-61, 1:2.2; Run 2: 11.1 mg, 52.5%, (-)-S2:(-)-61, 1:2.7) as a
clear film.
Regioisomers (-)-S2 and (-)-61 were separated for the purpose of full and independent
characterization by preparative HPLC [Waters X-Bridge preparative HPLC column, C18, 5 gm,
19 x 250 mm; 20.0 mL/min; gradient, 40%-*60% acetonitrile in water, 20 min; tR(S2) = 12.5
min, tR( 6 1) = 14.6 min]. Structural assignments were made using additional information from
gCOSY, HSQC, and HMBC experiments.
3-(4-Methoxyphenyl)tetracycle (-)-S2:
'H NMR (500 MHz, CDCl 3, 20 *C): 8 7.65 (d, J= 7.9, 1H, CH), 7.37 (dd, J= 1.1,
8.2, 2H, Phcbz-o-H), 7.35-7.26 (m, 3H, Phcbz-
H), 7.35-7.26 (in, IH, C5H), 7.20 (app-dt, J=
1.2, 8.1, 1H, C7H), 7.07-7.02 (m, 1H, C6H),
7.07-7.02 (m, 2H, C3 H), 6.76 (d, J = 8.9, 2H,
C2.H), 6.31 (s, 1H, C2H), 5.42 (s, 1H, N14H),
5.41 (d, J= 12.2, 1H, PhCbzCHa), 5.28 (d, J=
12.3, 1H, PhcbzHb), 4.38 (dd, J = 3.4, 10.1,
IH, CIIH), 4.00 (q, J = 6.8, 1H, Ci 5H), 3.73
(s, 3H, OCH3), 3.50 (dd, J = 3.4, 13.9, IH,
C12Ha), 2.84 (dd, J= 10.2, 13.9, 1H, C12Hb),
1.33 (d, J= 6.8, 3H, C17H).
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(+)-46
3 C NMR (125.8 MHz, CDCl 3, 20 0C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (ethyl acetate), Rf:
6 169.3 (C, 3 ), 167.7 (C16), 159.0 (CI,), 153.2
(Ccbz=O), 139.8 (C9), 136.4 (Phcbz-ipso-C),
135.1 (C 4), 133.7 (C4 ), 129.1 (C7), 128.7
(Phcbz-C), 128.7 (Phcbz-C), 128.3 (Phcbz-C),
127.1 (C3 ), 125.2 (Cs), 124.4 (C6), 117.1
(C), 114.5 (C2.), 83.5 (C2), 68.1 (PhcbzCH 2),
58.7 (C,1), 58.1 (C3), 55.5 (OCH3), 51.9 (C15),
35.0 (C12), 15.4 (C17).
1709 (s), 1688 (s), 1409 (m), 1312 (m), 1254
(m).
calc'd for C2 9H28N 30 5
found: 498.2032.




'H NMR (500 MHz, CDC13, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 0C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
6 7.61 (d, J= 7.5, 1 H, CH), 7.36 (d, J= 7.1,
1 H, CH), 7.32-7.20 (m, I H, C7H), 7.32-7.20
(m, 5H, Phcbz-H), 7.32-7.20 (m, I H, CsH),
7.13 (app-t, J = 7.5, 1 H, C6H), 6.92 (d, J =
8.0, 1 H, C6.H), 6.75 (app-t, J= 7.4, 1 H, C4 H),
6.66 (dd, J= 1.6, 7.8, 1 H, C3.H), 6.45 (s, I H,
C2H), 5.90-5.75 (m, IH, N14H), 5.36 (d, J=
12.5, 1H, PhCbzCHa), 5.19 (d, J = 12.5, 1H,
PhcbzCHb), 4.52 (dd, J= 5.8, 9.9, 1 H, C, H),
4.05 (q, J = 6.8, 1H, CisH), 3.89 (s, 3H,
OCH3), 3.12 (dd, J = 5.8, 13.5, 1 H, C12Ha),
3.01 (dd, J= 10.1, 13.5, 1 H, C2Hb), 1.36 (d, J
= 6.9, 3H, C17H).
6 170.1 (C 3), 167.6 (C,6 ), 156.8 (C,), 153.4
(CCbz=O), 140.5 (C9 ), 136.4 (Phcbz-ipso-C),
135.4 (C4 ), 129.4 (Cs), 129.2 (C3 ), 129.1
(C7), 128.8 (C2'), 128.6 (Phcbz-C), 128.1
(Phcbz-C), 127.9 (Phcbz-C), 126.8 (C5), 124.2
(C6), 120.8 (C4 ), 117.5 (Cs), 111.5 (C6 ), 82.1
(C2 ), 67.9 (PhcbzCH2), 58.7 (C,,), 56.8 (C3),
55.6 (OCH3), 52.0 (CIs), 36.3 (C12 ), 15.9
(C17).
1712 (s), 1688 (s), 1482 (m), 1409 (m), 1326
(m).




TLC (ethyl acetate), Rf.




















A solution of silver(I) hexafluoroantimonate (0.20 M, 425 gL, 85.1 pmol, 2.00 equiv) in
nitroethane was added via syringe to a solution of tetracyclic bromide (+)-46 (20.0 mg, 42.5
pmol, I equiv), potassium trans-styryltrifluoroborate (17.9 mg, 85.1 pmol, 2.00 equiv), and 18-
crown-6 (22.4 mg, 85.1 pmol, 2.00 equiv) in nitroethane (2 mL) at 23 "C. After 1 h, aqueous
hydrogen chloride (2 N, 4 mL) was added. The reaction mixture was diluted with ethyl acetate
(60 mL) and washed with brine (3 x 60 mL). The organic layer was dried over anhydrous
sodium sulfate, was filtered, and was concentrated under reduced pressure. The crude reaction
mixture was purified by flash column chromatography on silica gel (eluent: 20% acetone in
dichloromethane). The fractions containing the desired product were combined and were
concentrated under reduced pressure. The resulting residue was loaded onto a silica gel column
and purified by flash column chromatography (eluent: 90% ethyl acetate in hexanes) to afford 3-
(trans-styryl)tetracycle (-)-62 (Run 1: 12.6 mg, 60.0%; Run 2: 12.0 mg, 57.2%) as a white foam.
Structural assignments were made using additional information from gCOSY, HSQC, and
HMBC experiments.
H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
6 7.68 (d, J= 8.0, 1H, C8H), 7.41 (d, J= 7.1,
2H, Phcbz-o-H), 7.33-7.18 (in, 1H, C7H),
7.33-7.18 (m, 1H, C5H), 7.33-7.18 (m, 8H,
ArH), 7.08 (app-t, J= 7.5, 1H, C6H), 6.25 (d,
J = 16.0, 1H, CH=CHPh), 6.09 (d, J= 14.4,
1H, CH=CHPh), 6.07 (s, IH, C2H), 5.77 (br-s,
IH, N14H), 5.39 (d, J= 12.3, 1H, PhCbzCHa),
5.29 (d, J= 12.3, 1H, PhcbzCHb), 4.31 (dd, J=
3.1, 10.0, IH, C11H), 3.97 (q, J = 6.8, 1H,
Ci5H), 3.28 (dd, J = 3.3, 13.9, 1H, C12Ha),
2.63 (dd, J= 10.2, 13.8, 1H, C12Hb), 1.32 (d, J
= 6.8, 3H, C17H).
6 169.5 (C), 167.7 (CI6), 153.4 (Ccbz=O),
140.4 (C9), 136.3 (Phcbz-ipso-C), 136.1
(Phstyrene-ipSO-C), 133.1 (C 4), 131.7
(CH=CHPh), 129.4 (CH=CHPh), 129.3
(Phcbz-C), 128.8 (Phcbz-C), 128.7 (Phcbz-C),
128.4 (Phcbz-C), 128.3 (Phcbz-C), 128.2
(Phcbz-C), 126.8 (C7), 125.2 (C5), 124.3 (C),
116.9 (C8), 81.9 (C2 ), 68.2 (PhcbzCH2), 58.3
(C11), 57.2 (C 3), 51.9 (C15), 33.3 (C12), 15.3
(C 17).
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FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D24:
TLC (ethyl acetate), Rf:
3262 (br, m), 1712 (s), 1690 (s), 1409 (m),
1315 (m).
calc'd for C30H 2 8N 30 4 [M+H]*: 494.2074,
found: 494.2084.
-23 (c = 0.081, CHCl3).
0.44 (UV, CAM).
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Table Si. Comparison of our data for (+)-Naseseazine A (1) with literature:
Assignment'0  Raju et al. Report4 ' This Work
(+)-Naseseazine A (1) (+)-Naseseazine A (1)
1H NMR, 600 MHz, methanol-d 4  'H NMR, 500 MHz, methanol-d 4, 20 C
NI - -
C2 5.83 (s) 5.83 (s)
C3 - -
C4
C5 6.85 (d, J= 7.4) 6.85 (dd, J= 0.6, 7.4)
C6 6.67 (t, J= 7.5) 6.68 (app-dt, J= 0.9, 7.4)
C7 7.05 (t, J= 7.2) 7.05 (app-dt, J= 1.3, 7.9)
C8 6.69 (d, J= 7.6) 6.69 (d, J= 8.0)
C9
NIO
C 1 4.64 (dd, J= 7.4, 8.4) 4.65 (dd, J= 7.4, 9.2)
C12 3.26 (m) 3.30-3.20 (m)2.59 (dd, J= 10.2, 13.7) 2.59 (dd, J= 9.9, 13.6)
C13 -_-
N14 -_-
C15 4.15 (q, J= 6.9) 4.16 (dq, J= 1.4, 6.9)
C16 -_-
C17 1.38 (d, J = 6.9) 1.38 (d, J= 7. 1)
NI' --
C2' 7.11 (s) 7.12 (s)
C3' --
C4' -_-
C5' 7.57 (d, J= 8.4) 7.57 (d, J= 8.4)
C6' 7.02 (d, J= 8.4) 7.03 (dd, J= 1.7, 8.4)
C7' -_-
C8' 7.40(s) 7.40 (d, J= 1.3)
C9'
N 10'--
Cl l' 4.39 (br-t, J= 4.5) 4.39 (app-dt, J= 1.1, 4.7)
C12' 3.28(m) 3.30-3.20 (m)
C13' -
N14'
C15' 3.97 (dd, J 6.6, 10.8) 3.98 (ddd, J 1.7, 6.3, 10.9)
C16'-
C17 1.97 (m) 1.96 (app-ddt, J= 2.0, 7.2, 12.5)0.93 (m) 0.96-0.85 (m)
C18' 1.66 (m) 1.72-1.61 (m)1.43 (m) 1.47-1.39 (m)
C19, 3.42 (dt, J = 8.1, 11.8) 3.42 (app-dt, J = 8.3, 11.7)3.24 (m) 3.30-3.20 (m)
10 Please see page 182 for the positional numbering system used in this report.
" The reference points for the residual protium and carbon resonances of the NMR solvent were not listed.
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Table S2. Comparison of our data for (+)-Naseseazine A (1) with literature:
Assignmentlo Raju et al. Report'" This Work
(+)-Naseseazine A (1) (+)-Naseseazine A (1)
'H NMR, 600 MHz, DMSO-d 6  'H NMR, 500 MHz, DMSO-d6 , 20 0C
NI 6.72 (d, J= 2.8) 6.75 (d, J= 2.8)
C2 5.65 (d, J= 2.8) 5.65 (d, J= 2.8)
C3
C4
C5 6.82 (d, J= 7.3) 6.83 (d, J= 7.3)
C6 6.57 (dt, J= 0.7, 7.5) 6.58 (app-t, J= 7.4)
C7 7.00 (t, J= 7.2) 7.04-6.95 (m)
C8 6.61 (d, J= 7.8) 6.62 (d, J= 8.0)
C9
NIO
C11 4.60 (dd, J= 8.4, 9.9) 4.62 (app-t, J= 8.7)
C12 3.08 (dd, J= 7.6, 13.6) 3.14-3.00 (m)
C12_2.41 (dd, J= 9.9, 13.6) 2.41 (dd, J 10.0, 13.6)
C13
N14 8.17(s) 8.20 (s)
C15 4.13 (q, J= 6.9) 4.14 (q, J= 6.5)
C16 - _-
C17 1. 21 (d, J = 6.9) 1.23 (d, J = 6.9)
NI' 10.79 (d, J= 1.9) 10.81 (s)
C2' 7.17 (d, J = 2.2) 7.19 (d, J = 1. 8)
C3'
C4' 1
C5' 7.55 (d, J= 8.3) 7.56 (d, J= 8.4)
C6' 6.98 (d, J= 8.2) 7.04-6.95 (m)
C7'
C8' 7.27 (d, J= 1.2) 7.28 (s)
C9' -
N10' 7.68 (s) 7.71 (s)
C11' 4.27 (br-t, J= 5.2) 4.28 (app-t, J= 4.9)
C12' 3.21 (dd, J= 4.8, 15.0) 3.30-3.18 (m)
3.03 (dd, J= 5.8, 14.9) 3.14-3.00 (m)
C13'-
N 14'
C15' 4.06 (dd, J= 7.5, 10.0) 4.06 (app-t, J= 7.8)
C16'-
1.96 (m) 2.03-1.94 (m)
C17' 1.40 (m) 1.47-1.36 (m)
C18' 1.61 (i) 1.74-1.56 (m)
3.34 (m) 3.41-3.29 (m)
C19 3.25 (m) 3.30-3.18 (m)
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Table S3. Comparison of our data for (+)-Naseseazine A (1) with literature:
Assignment'4 Raju et al. Report4 ' This Work Chemical Shift
(+)-Naseseazine A (1) (+)-Naseseazine A (1) Difference A6
"C NMR, 151 MHz "C NMR, 126 MHz 6 (this work) - 6 (Raju et.
methanol-d 4  methanol-d 4, 20 OC al. report)
C2 87.1 87.3 0.2
C3 61.2 61.4 0.2
C4 135.8 136.1 0.3
C5 124.9 125.1 0.2
C6 120.2 120.6 0.4
C7 129.2 129.6 0.4
C8 110.9 111.2 0.3
C9 149.1 149.3 0.2
C11 60.2 60.5 0.3
C12 39.7 39.9 0.2
C13 172.6 172.7 0.1
C15 52.1 52.4 0.3
C16 170.6 170.9 0.3
C17 15.2 15.4 0.2
C2' 126.2 126.6 0.4
C3' 109.5 109.7 0.2
C4' 127.6 127.8 0.2
C5' 120.3 120.5 0.2
C6' 119.5 119.7 0.2
C7' 137.2 137.3 0.1
C8' 110.1 110.4 0.3
C9' 137.9 138.1 0.2
CI ' 57.2 57.4 0.2
C12' 29.0 29.3 0.3
C13' 167.3 167.5 0.2
C15' 60.0 60.2 0.2
C16' 170.6 170.9 0.3
C17' 29.0 29.3 0.3
C18' 22.5 22.7 0.2
C19' 45.8 46.1 0.3
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Table S4. Comparison of our data for (+)-Naseseazine B (2) with literature:
Assignmentl Raju et al. Report4'" This Work
(+)-Naseseazine B (2) (+)-Naseseazine B (2)
1H NMR, 600 MHz, methanol-d 4  1H NMR, 500 MHz, methanol-d 4, 20 C
NI -
C2 5.85 (s) 5.84 (s)
C3 --
C4 -
C5 6.84 (dt, J= 0.9, 7.2) 6.83 (d, J= 7.2)
C6 6.68 (t, J= 7.6) 6.68 (app-t, J= 7.3)
C7 7.06 (dt, J= 1.3, 7.6) 7.06 (app-dt, J 1.2, 7.9)
C8 6.69 (d, J= 7.6) 6.69 (d, J 7.7)
C9 -_-
NIO
C1l 4.75 (dd, J= 8.7, 10.2) 4.71 (app-t, J= 8.6)
C 12 3.27 (m) 3.35-3.21 (m)
2.59 (dd, J 10.2, 13.8) 2.57 (dd, J= 10.2, 13.7)
C13
N14
C15 4.33 (dd, J= 7.1, 9.5) 4.29 (app-t, J= 7.7)
C16 -
2.28 (m) 2.30-2.22 (m)
C17 2.11(m) 2.15-2.04 (m)
2.00 (m) 2.04-1.87 (m)
C18 1.95 (m) 2.04-1.87 (m)
3.49 (m) 3.52-3.37 (m)
C19 3.44(m) 3.52-3.37 (m)
NI -F-
C2' 7.12(s) 7.12 (s)
C3'
C4'
C5' 7.58 (d, J= 8.4) 7.57 (d, J= 7.4)
C6' 7.03 (dd, J= 1.8, 8.4) 7.01 (dd, J= 1.6, 8.5)
C7'
C8' 7.41 (d,j= 1.4) 7.41 (d, J=1.3)
C9'
NI0'-
C li' 4.40 (br-t, J= 4.7) 4.39 (app-t, J= 4.6)
3.32 (m) 3.35-3.21 (m)
C12' 3.28(m) 3.35-3.21 in
C13' --
N 14' -
C15' 3.99 (ddd, J= 1.6, 6.6, 11.4) 3.98 (ddd, J 1.4, 6.3, 10.7)
C16' 1
1.97 (m) 2.04-1.87 (m)
C17' 0.92 (m) 0.97-0.87 (m)
1.67 (m) 1.73-1.60 (m)
C18' 1.44 (m) 1.49-1.40 (m)
3.43 (m) 3.52-3.37 (m)C19' 3.24 (m) 3.35-3.21 (m)
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Table S5. Comparison of our data for (+)-Naseseazine B (2) with literature:
Assignment 0  Raju et al. Report4 "1  This Work
(+)-Naseseazine B (2) (+)-Naseseazine B (2)
H NMR, 600 MHz, DMSO-d6  'H NMR, 500 MHz, DMSO-d, 20 C
NI 6.75 (d, J= 3.2) 6.82-6.76 (m)
C2 5.65 (d, J= 3.2) 5.68 (d, J= 3.2)
C3
C4
C5 6.82 (d, J= 7.3) 6.82-6.76 (m)
C6 6.58 (dt, J= 0.9, 7.4) 6.58 (app-dt, J= 1.0, 7.5)
C7 7.00 (t, J= 7.2) 7.00 (app-dt, J= 1.3, 7.9)
C8 6.61 (d, J= 7.8) 6.60 (d, J= 7.6)
C9
N10 -__ _ __ _ _-__ _
C11 4.71 (dd, J= 7.5, 10.5) 4.72 (app-t, J= 8.2)
C12 3.12 (dd, J= 7.5, 13.6) 3.13 (dd, J 7.4, 13.6)2.36 (dd, J 10.5, 13.6) 2.36 (dd, J 10.5, 13.6)
C13 - _-
N14 -_ -
C15 4.34 (t, J= 8.0) 4.35 (app-t, J= 7.9)
C16 -_-
C17 2.15 (m) 2.21-2.11 (m)1.95 (m) 2.03-1.91 (m)
C18 1.85(m) 1.91-1.77(m)
C19 3.34(m) 3.41-3.30 (m)
NI' 10.80 (d, J= 1.8) 10.81 (s)
C2' 7.18 (d, J= 2.2) 7.19 (d, J= 2.2)
C3'
C4'
C5' 7.56 (d, J= 8.4) 7.57 (d, J = 8.4)
C6' 6.98 (dd, J= 1.5, 8.4) 6.99 (d, J= 8.6)
C7'
C8' 7.29 (d, J= 1.5) 7.30 (d, J= 1.3)
C9' -
NIO' 7.67(s) 7.71 (s)
ClI' 4.27 (br-t, J= 5.1) 4.29 (app-t, J= 5.1)
C12' 3.20 (dd, J= 4.5, 15.0) 3.22 (dd, J= 4.6, 14.6)3.04 (dd, J= 6.0, 15.0) 3.05 (dd, J= 5.8, 14.8)
C13' -_-
N14' 1
C15' 4.06 (dd, J= 7.6, 9.0) 4.06 (app-t, J= 8.7)
C16' --
C17 1.97 (m) 2.03-1.91 (m)1.41 (m) 1.48-1.36(m)
C18' 1.62 1.75-1.56(m)
C19' 3.34 (m) 3.41-3.30 (m)3.24(m) 3.29-3.24(m)
235
Table S6. Comparison of our data for (+)-Naseseazine B (2) with literature:
Assignment'0  Raju et al. Report4'1  This Work Chemical Shift
(+)-Naseseazine B (2) (+)-Naseseazine B (2) Difference A6
"C NMR, 151 MHz 3 C NMR, 126 MHz 6 (this work) - 6 (Raju et.
methanol-d 4  methanol-d 4, 20 C al. report)
C2 86.8 87.1 0.3
C3 61.7 61.9 0.2
C4 136.0 136.2 0.2
C5 124.8 125.1 0.3
C6 120.3 120.6 0.3
C7 129.1 129.6 0.5
C8 111.0 111.3 0.3
C9 149.0 149.3 0.3
C11 61.3 61.7 0.4
C12 39.5 39.7 0.2
C13 168.4 168.6 0.2
C15 61.8 61.9 0.1
C16 170.2 170.3 0.1
C17 28.3 28.6 0.3
C18 24.1 24.4 0.3
C19 45.9 46.4 0.5
C2' 126.1 126.6 0.5
C3' 109.5 109.8 0.3
C4' 127.6 127.8 0.2
C5' 120.3 120.6 0.3
C6' 119.4 119.8 0.4
C7' 136.9 137.2 0.3
C8' 110.3 110.5 0.2
C9' 137.9 138.1 0.2
CI1' 57.0 57.3 0.3
C12' 29.2 29.3 0.1
C13' 167.3 167.5 0.2
C15' 59.9 60.2 0.3
C16' 170.7 170.9 0.2
C17' 29.1 29.3 0.2
C18' 22.4 22.7 0.3
C19' 45.8 46.1 0.3
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Marfey's Analysis of (+)-Naseseazine B (2).
Marfey's analysis was performed on synthetic (+)-naseseazine B (2) using the method
described in the isolation report.4 (+)-Naseseazine B (2) (350 pg, 620 nmol, 1 equiv) was
dissolved in aqueous hydrochloric acid (6 N, 1.40 mL) and heated to 100 'C in a sealed vial.
After 12 h, the reaction mixture was allowed to cool to 23 *C then concentrated under reduced
pressure. A solution of 1-fluoro-2,4-dinitrophenyl-5- L-alanine amide (L-FDAA) in acetone (1%
w/v, 700 ptL) and aqueous sodium bicarbonate (1 M, 140 ptL) were sequentially added to the
residue and the resulting solution was heated to 37 'C. After 1 h, the reaction mixture was
allowed to cool to 23 'C and aqueous hydrochloric acid (1 M, 140 piL) was added. The solution
was then diluted with acetonitrile (5.67 mL) and passed through a syringe filter (Acrodisc GHP,
13 mm diameter, 0.45 ptm pore size). An aliquot of this solution (10 ptL) was diluted in water
(450 pL) and analyzed by HPLC.
A standard solution of L-Ala-NH 2-DNP- L-Pro was prepared from L-proline. A solution
of L-FDAA in acetone (1% w/v, 100 jiL) and aqueous sodium bicarbonate (1 M, 20 piL) were
sequentially added to an aqueous solution of L-proline (50 mM, 50 ptL). The solution was then
heated to 37 'C. After 1 h, the reaction mixture was allowed to cool to 23 'C and aqueous
hydrochloric acid (1 M, 20 ptL) was added. The solution was then diluted with isopropanol (810
ptL) and passed through a syringe filter (Acrodisc GHP, 13 mm diameter, 0.45 ptm pore size).
An aliquot of this solution (1 ptL) was diluted in water (450 ptL) and analyzed by HPLC.
A standard solution of L-Ala-NH 2-DNP-D-Pro was prepared analogously from D-proline.
HPLC conditions: Waters X-Bridge analytical HPLC column, C18, 5 pm, 4.6 x 250 mm;
2.00 mL/min; gradient, 0%->30% acetonitrile in water, 30 min; tR(L-Ala-NH 2-DNP-L-Pro) =
13.1 min, tR(L-Ala-NH 2-DNP-D-Pro) = 16.0 min. HPLC traces were obtained using UV
detection (340 nm) and product identity was further corroborated with HPLC traces of mass
spectrometric data (ESI+). See Figure SI for the HPLC traces of L-FDAA derived (+)-
naseseazine B hydrolysate, the corresponding amino acid standards, and their co-injection. The
HPLC analysis confirms the presence of L-proline residues in the synthetic samples of (+)-
naseseazine B (2) and is consistent with our use of L-proline building blocks en route to the
natural product. Marfey's analysis thus lends further support to our stereochemical reassignment
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Figure 1. Representative Cl 2-hydroxylated epipolythiodiketopiperazines.
Dimeric epipolythiodiketopiperazine alkaloids are a fascinating class of fungal
metabolites notable for their complex molecular architectures and potent biological activities.''2,
The collection of natural products claiming membership in this class of mycotoxins displays a
general structural consensus centered around a tryptophan-derived hexahydropyrroloindoline
substructure, C3-linked dimeric construction, as well as an eponymous
epipolythiodiketopiperazine (ETP) motif (Figure 1). Despite these commonalities, the individual
alkaloids exploit a number of diversifying features to derive their identity. These modifications
include the nature of their C3-dimeric linkage,4,s,6,7,8,9,10 the degree of sulfuration,"" 2 , 3 the
choice of amino acid incorporated at the ancillary position of the cyclo-dipeptide, and the degree
of oxidation of the core structure. In this report, we focus on the specific synthetic challenges
associated with introduction of the C12-hydroxyl group 14 prevalent in this class of alkaloids as
well as on the development of new synthetic methods designed to meet such challenges.
(+)-Bionectins A (1) and C (2)15 were first isolated in 2006 by Zheng et al. from fungi of
the Bionectra byssicola species. When screened for activity against pathogenic microorganisms,
(+)-1 exhibited significant bacteriostatic activity against methicillin-resistant and quinolone-
resistant Staphylococcus aureus gram-positive eubacteria with MICs as low as 10 ptg/mL.
Structurally, these molecules possess a C3-indolylated core structure as well as C12-
hydroxylation, a ubiquitous feature found in over three-quarters of the ETP alkaloids. The
Overman group has recently reported the first total syntheses of alkaloids containing the C12-
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oxidation through an elegant late-stage diastereoselective dihydroxylation of the
hexahydropyrroloindoline core.10 Herein, we describe a complementary approach based on the
elaboration of a p-hydroxytryptophan derivative. We hoped to exploit the generality of our
strategies to epidithiodiketopiperazine alkaloids by using p-hydroxytryptophan in lieu of
tryptophan as our feedstock material. This required an efficient synthesis of this amino acid
derivative as well as the complete evaluation of any potential effects of C12-hydroxylation on
the level of diastereoselection in the halocyclization reaction for the tetracyclic core synthesis;
the viability of a C3-indolylation strategy; the oxidation of the diketopiperazine; and the rate,
regioselectivity, and stereoselectivity of the diketopiperazine sulfidation.
Results and Discussion
Retrosynthetic Analysis
Our retrosynthetic analysis of (+)-bionectins A (1) and C (2) is outlined in Scheme 1. We
envisioned that (+)-2 could be derived from the reductive methylation of (+)-1 in a
biogenetically relevant fashion,16 and based on our prior work with sarcosine-derived systems
such as (+)-gliocladin B, 3a,b we anticipated a highly diastereoselective thiolation event upon
Bronsted acid-mediated ionization of diol 6 in the presence of an alkyl mercaptan. The latent
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Scheme 1. Retrosynthetic analysis for (+)-bionectins A (1) and C (2).
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hydrogen sulphide group would enable intervening transformations with which a dithiol or
disulphide would be incompatible; the alkyl thioether would subsequently be unravelled under
mild conditions. We then envisioned access to the necessary diol via oxidation of a C3-
indolylated carbocyclic core structure 7. At this juncture, based on the severe steric pressures
and inductive deactivation imposed by the C12-hydroxyl group, 1 3b we anticipated difficulties in
the application of our intermolecular Friedel-Crafts chemistry5 with respect to reactivity,
efficiency, and selectivity. Nevertheless, we imagined introduction of a directing group on the
nucleophilic indole 8 to facilitate the desired transformation. In particular, we were excited to
explore the possibility of an intramolecular indolylation using an appropriately appended silyl
tether. The necessary 12-hydroxylated tetracycle 9 was envisioned to be accessed based on our
halocyclization strategy for synthesis of related tetracycles5 ,7b, 13 pending ready access to the
requisite p-hydroxytryptophan. 17
Synthetic Approach
Our synthesis of (+)-bionectins A and C commenced with the development of a concise
and scalable route to erythro-p-hydroxytryptophan (Scheme 2). While several methods have
been reported for the synthesis of the threo diastereomer,18 scarce access to the desired
tryptophan derivative was notable. Indeed, Feldman's asymmetric dihydroxylation approach to
this amino acid derivative19 inspired our initial approach and proved to be effective in enabling
our exploratory studies. However, material throughput demands prompted our development of a
new approach. After evaluating several methods, we found that application of Solladie-
Cavallo's titanium (IV)-mediated anti-aldol reaction20 to indole-3-carboxaldehyde 10 and (-)-
pinanone-derived ethyl iminogylcinate 1121 most efficiently afforded the aldol adducts in 81%
yield on greater than 40 gram scale. Silylation of the alcohol22 enabled the facile
chromatographic separation of the isomeric products on silica gel to afford the desired
diastereomer of the pinanone-derived erythro-p-hydroxytryptophan product in 72% yield.
Subsequent hydrolysis of the Schiff base then afforded greater than 20 grams of p-hydroxy-a-
amino ester 13 in 94% ee along with recovery of the chiral auxiliary. The absolute and relative
stereochemistries of the material were verified through single crystal X-ray diffraction analysis
of its 3,5-dinitrobenzamide derivative 14.
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Scheme 2. Asymmetric synthesis of a p-hydroxytryptophan derivative. Conditions: (a) TiCl(OEt) 3, NEt3 ,
CH 2CI2 , 0 -C, 81% (58% desired diastereomer); (b) TBSOTf, 2,6-lutidine, CH 2Cl 2, 0 'C, 72%; (c) 2 N HCl,
THF, 81%; (d) 3,5-dinitrobenzoyl chloride, NEt 3, CH 2Cl2, 23 'C, 94%; (e) N-Boc-sarcosine, EDC HCl, HOBt,
CH 2CI2 , 23 -C, 98%; (f) TFA, CH 2 Cl 2 , 23 0C; AcOH, morpholine, 'BuOH, 80 'C, 97%; (g) Br 2 , MeCN, 0 'C;
anisole, 94%, 9:1 dr; X-ray structures are displayed as ORTEPs at 50% probability.
With a rapid and scalable route to erythro-p-hydroxytryptophan available, we
proceeded to the synthesis of the desired tetracycle 16. Dipeptide formation with N-Boc-
scarcosine followed by unveiling of the amine and intramolecular cyclization with AcOH and
morpholine in tert-butanol afforded diketopiperazine 15 in 97% yield. Exposure of
diketopiperazine 15 to excess bromine in MeCN at 0 'C and subsequent addition of anisole23
led to a diastereoselective halocyclization with concomitant loss of the silyl ether. Under
these optimized conditions, tetracyclic bromide 16 could be accessed in decagram quantities
in 94% yield (9:1 dr, endo:exo) favoring the desired diastereomer. Importantly, we found
that the Cl2 hydroxyl group favors the formation of the desired endo-cyclization product
independent of the ancillary amino acid substituent at the C15 center.24 This finding has
critical implications relevant to the broad applicability of this methodology to the synthesis
of C12-hydroxylated ETP natural products, a majority of which possess the relative
stereochemical relationships embedded in tetracyclic bromide 16.
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Scheme 3. Considerations in design of a new intramolecular Friedel-Crafts chemistry for C12-hydroxylated
diketopiperazines 18.
Friedel-Crafts indolylation at the C3 position in a manner akin to our gliocladin synthesis;
however, due to the inductive effects of the C12-hydroxyl group (Scheme 3), the C3-bromide
proved recalcitrant toward ionization. Under more forcing conditions, C3-carbocation
derivatives 18 could be formed, but their instability required rapid trapping, a feat hindered
by the additional substitution at C12. Application of our optimal conditions for
intermolecular Friedel-Crafts reaction 5 resulted in regioisomeric and diastereomeric products
(Scheme 3).25
After examining a variety of strategies, the most effective proved to be an
intramolecular delivery of the indole fragment. Silylation of tetracyclic alcohol with
chlorodimethyl(N-Boc-2-indole)silane (20)26 provided the desired silyl-tethered indole
adduct 21 in 74% yield (Scheme 4). Gratifyingly, a silver-mediated intramolecular Friedel-
Crafts reaction proceeded smoothly in nitroethane at 0 'C to afford the C3-(3'-indolyl)-
silacyclic product 22 in 68% yield. The structure of a diethyl silyl variant 23, obtained
during optimization studies, was confirmed through X-ray analysis (Scheme 4). The desired
C3-indolylated tetracycle 24 was accessed in 58% yield by treatment of silacyclic product 22
with aqueous hydrochloric acid.
The key indolylated intermediate 24 was subsequently bis(tert-butoxycarbonyl)
protected in 92% yield using Boc2O and DMAP in anticipation of our C-H hydroxylation
chemistry, which proceeds most effectively in the presence of less electron-rich substructures
(Scheme 4). Surprisingly, rather than providing the expected stereoretentive
dihydroxylation product (Scheme 1), oxidation of the tetracycle with excess
bis(pyridine)silver(l) permanganate in dichloromethane afforded triketopiperazine 25 in 45%
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rebound mechanism. 28  Reaction of a permanganate molecule with the persistent,
stereochemically labile carbon- centered radical on the opposite face of the diketopiperazine
would afford the oxidation product.
Recognizing the C1I and C15 alcohols to be recalcitrant toward ionization by virtue
of their proximity to an inductively withdrawing carbonate and their location on a secondary
carbon, respectively, 13b,5b the hydroxyl groups were activated for ionization by acylation with
pivaloyl chloride and DMAP in dichloromethane to provide dipivaloate 27 in 83% yield. At
this juncture, we sought the nucleophilic addition of hydrogen sulphide surrogates.
Constraining our search to functional groups capable of withstanding conditions for the
photoinduced reductive removal of a benzenesulfonyl group, we initially evaluated the use of
thioacid and alkyl mercaptan nucleophiles. While thioacids resulted in categorically low
levels of diastereoselection for the nucleophilic addition, alkyl mercaptans proved highly
diastereoselective on this substrate in affording their bisthioether adduct. Known thioether
reagents such as 2-cyanoethyl and 2-trimethylsilylethyl mercaptans, however, required
intolerably harsh conditions for their conversion to the necessary thiols.
In developing new hydrogen sulphide surrogates, we sought to exploit the reversible
addition of thiols to enones. Additionally, we envisioned that this p-elimination reaction
manifold would be amenable to facilitation by enamine catalysis. Putting the principles to
practice, we generated 4-mercaptobutan-2-one (29)29 by addition of hydrogen sulphide to
methyl vinyl ketone and 3-mercaptopropiophenone (30) by addition of thioacetic acid to 3-
chloropropiophenone followed by hydrolysis.
Indeed, application of a new method for sulfidation of diketopiperazines proved
critical in our synthesis of (+)-bionectins A and C. Treatment of a solution of dipivaloate 27
and ketomercaptan reagent 29 with trifluoroacetic acid in nitromethane30 at 23 'C yielded a
diastereomeric mixture of bisthioethers 31 in 80% yield and 3:1 dr with concomitant removal
of the tert-butoxycarbonyl groups at the NI' amine and C12 alcohol. The major diastereomer
possessed the desired C1I,C15-stereochemistry and could be isolated in 56% yield upon
photoinduced electron transfer-mediated removal of the benzensulfonyl group. 3  The
bisthioethers were then removed with a mild enamine-mediated transthioetherification
protocol employing pyrrolidine and ethanethiol in THF. Interestingly, the use of a sacrificial
thiol was found optimal in the unveiling of the thiols; exposure to an atmosphere of oxygen
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Scheme 5. Total synthesis of (+)-bionectins A (1) and C (2). Conditions: (a) 4-mercapto-2-butanone, TFA,
MeNO 2, 80%, 3:1 dr; (b) 350 nm, 1,4-dimethoxynaphthalene, L-ascorbic acid, sodium L-ascorbate, H20,
MeCN, 25 'C, 56%; (c) pyrrolidine, EtSH, THF, 23 OC; K13, Py, CH 2Cl 2 , 81%; (d) p-NO 2BzCl, DMAP,
CH 2 Cl 2, 0 -C, 98%; (e) NaBH 4, Mel, Py, MeOH, 0 4C, 97%.
was insufficient in oxidizing the dithiol to a disulphide. It is presumed that the C15 thiol
prefers an equatorial disposition in its ground state and that conformation is not as conducive
to oxidation by molecular oxygen. Mild oxidation with K13 in pyridine then afforded our
target natural product (+)-bionectin A (1) in 81% yield.
Upon complete characterization of (+)-bionectin A (1), we were alarmed to find
discrepancies between our 'H and 13 C NMR spectra3 2 and those offered in the isolation report
of the natural product.' 5 While IJCH, 2 JCH, and 3JCH NMR data had given us reasonable
confidence in our bond connectivities, further information was required to solidify our
stereochemical assignments. To dispel any reservations concerning our structural assignment
of (+)-bionectin A (1), we treated our synthetic sample of (+)-1 with p-nitrobenzoyl chloride
and DMAP in CH 2Cl 2 at 0 *C to afford (+)-bionectin A-p-nitrobenzoate (33) in 98% yield.
Single crystal X-ray diffraction analysis of this C12-p-nitrobenzoate derivative confirmed
without ambiguity the congruence between our structure and that depicted in the isolation
report. Importantly, Overman's recent report also cited similar deviations in their
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characterization data for (+)-1. 10,33 Gratifyingly, our respective spectral data were in perfect
agreement. Given the common variations between spectral data for the synthetic samples
versus the natural sample,3 2 and the possible presence of an NMR inactive impurity in the
original natural sample notwithstanding,3 4 it would be prudent to revisit the original
characterization data for (+)-bionectin A (1)15 or its structural assignment.
Reductive methylation of (+)-bionectin A (1) with sodium borohydride and Mel in
pyridine and methanol afforded (+)-bionectin C (2) in 97% yield.35 All spectroscopic data
for this synthetic product32 matched those reported in the literature for (+)-bionectin C (2)36
and the structurally equivalent compound (+)-gliocladin A.
Conclusion
A concise and efficient synthesis of (+)-bionectins A and C has been described. Our
approach to these natural products featured a new synthesis of erythro-p-hydroxytryptophan
amino acid, an intramolecular Friedel-Crafts reaction of a silyl tethered indole to overcome
the challenges associated with C12-hydroxylation, as well as incorporation of thiol
surrogates and their mild deprotection. The first example of permanganate-mediated
stereoinvertive hydroxylation of the a-stereocenters of diketopiperazines has also been
observed along with the first example of a direct triketopiperazine synthesis from a parent
cyclo-dipeptide. The stereoinvertive oxidation has strong implications for the mechanism of
the hydroxylation reaction. Furthermore, the synthesis and X-ray diffraction analysis of (+)-
bionectin A (1) provides an impetus for reevaluation of the original data 5 or its assignment.
This study forms the basis for a general approach to the synthesis of more complex C12-
hydroxylated epidithiodiketopiperazine alkaloids (Figure 1) to enable exploration of their
chemistry and biological properties. 3
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Experimental Section
General Procedures. All reactions were performed in oven-dried or flame-dried round-bottom
flasks. The flasks were fitted with rubber septa and reactions were conducted under a positive
pressure of argon. Cannulae or gas-tight syringes with stainless steel needles were used to
transfer air- or moisture-sensitive liquids. Where necessary (so noted), solutions were
deoxygenated by sparging with argon for a minimum of 10 min. Flash column chromatography
was performed as described by Still et al. using granular silica gel (60-A pore size, 40-63 ptm, 4-
6% H20 content, Zeochem).' Analytical thin layer chromatography (TLC) was performed using
glass plates pre-coated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent
indicator (254 nm). TLC plates were visualized by exposure to short wave ultraviolet light (254
nm) and an aqueous solution of ceric ammonium molybdate (CAM) followed by heating on a hot
plate (~ 250 'C). Organic solutions were concentrated at 29-30 'C on rotary evaporators capable
of achieving a minimum pressure of -2 torr. The benzenesulfonyl photodeprotection was
accomplished by irradiation in a Rayonet RMR-200 photochemical reactor (Southern New
England Ultraviolet Company, Branford, CT, USA) equipped with 16 lamps (RPR-3500, 24 W,
Xmax= 350 nm, bandwidth ~ 20 nm).
Materials. Commercial reagents and solvents were used as received with the following
exceptions: dichloromethane, acetonitrile, tetrahydrofuran, methanol, pyridine, toluene, and
triethylamine were purchased from J.T. Baker (Cycletainer T M ) and were purified by the method
of Grubbs et al. under positive argon pressure.2 Nitromethane and nitroethane (from Sigma-
Aldrich) were purified by fractional distillation over calcium hydride and were stored over Linde
4A molecular sieves in Schlenk flasks sealed with septa and teflon tape under argon
atmosphere. 3 Titanium (IV) ethoxide (99.99%-Ti) PURATREM and bromine were purchased
from Strem Chemicals, Inc.; N-Boc-L-sarcosine, 1 -ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride, N-hydroxybenzotriazole, tert-butyldimethylsilyl
trifluoromethanesulfonate, trifluoroacetic acid, 4-(dimethylamino)pyridine, silver nitrate were
purchased from Chem-Impex; 1,4-dimethoxynaphthalene and iodomethane were purchased from
Alfa Aesar; di-tert-butyl dicarbonate was purchased from Oakwood Products, Inc.; 2,6-di-tert-
'Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.
2 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518.
3 Armarego, W. L. F.; Chai, C. L. L. Purification of Laboratory Chemicals, 5th ed.; Butterworth-Heinemann: London, 2003.
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butyl-4-methylpyridine (DTBMP) was purchased from OChem Incorporation. All other solvents
and chemicals were purchased from Sigma-Aldrich. 1,4-Dimethoxynaphthalene was purified by
crystallization from absolute ethanol.
Instrumentation. Proton nuclear magnetic resonance ( H NMR) spectra were recorded with a
Bruker AVANCE-600 NMR spectrometer (with a Magnex Scientific superconducting actively-
shielded magnet) or with a Varian inverse probe 500 INOVA spectrometer, are reported in parts
per million on the 6 scale, and are referenced from the residual protium in the NMR solvent
(CDCl 3: 6 7.26 (CHCl3) or DMSO-d: 6 2.50 (DMSO-d)). 4 Data are reported as follows:
chemical shift [multiplicity (br = broad, s = singlet, d = doublet, t = triplet, sp = septet, m -
multiplet), coupling constant(s) in Hertz, integration, assignment]. Carbon-13 nuclear magnetic
resonance ( C NMR) spectra were recorded with a Bruker AVANCE-600 NMR Spectrometer
(with a Magnex Scientific superconducting actively-shielded magnet) or a Bruker AVANCE-400
NMR Spectrometer (with a Magnex Scientific superconducting magnet) or with a Varian 500
INOVA spectrometer, are reported in parts per million on the 6 scale, and are referenced from
the carbon resonances of the solvent (CDCl 3 : 6 77.23 or DMSO-d 6 : 6 39.52). Data are reported
as follows: chemical shift (multiplicity, coupling constant(s) in Hertz, assignment). Infrared data
(IR) were obtained with a Perkin-Elmer 2000 FTIR and are reported as follows: frequency of
absorption (cm 1), intensity of absorption (s = strong, m = medium, w = weak, br = broad).
Optical rotations were measured on a Jasco-1010 polarimeter with a sodium lamp and are
reported as follows: [a]j 0C (c = g/100 mL, solvent). We are grateful to Dr. Li Li and Deborah
Bass for obtaining the mass spectrometric data at the Department of Chemistry's Instrumentation
Facility, Massachusetts Institute of Technology. High resolution mass spectra (HRMS) were
recorded on a Bruker Daltonics APEXIV 4.7 Tesla FT-ICR-MS using an electrospray (ESI)
ionization source.
Positional Numbering System. At least three numbering systems for dimeric diketopiperazine
alkaloids exist in the literature.5 In assigning the 'H and 3 C NMR data of all intermediates en
4 Fulmer, G. R.; Miller, A. J. M.; Sherden, N. H.; Gottlieb, H. E.; Nudelman, A.; Stoltz, B. M.; Bercaw, J. E.; Goldberg, K. I.
Organometallics 2010, 29, 2176.
5 (a) Von Hauser, D.; Weber, H. P.; Sigg, H. P. Helv. Chim. Acta 1970, 53, 1061. (b) Barrow, C. J.; Cai, P.; Snyder, J. K.;
Sedlock, D. M.; Sun, H. H.; Cooper, R. J. Org. Chem. 1993, 58, 6016. (c) Springer, J. P.; Bichi, G.; Kobbe, B.; Demain, A. L.;
Clardy, J. Tetrahedron Lett. 1977, 28, 2403. (d) Zheng, C.-J. ; Kim, C.-J. ; Bae, K. S. ; Kim, Y.-H. ; Kim, W.-G J. Nat. Prod.
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route to our total syntheses of (+)-bionectins A (1) and C (2), we wished to employ a uniform
numbering scheme. For ease of direct comparison, particularly between early intermediates,
non-thiolated diketopiperazines, and advanced compounds, the numbering system used by
Barrow for (+)-WIN-64821 (using positional numbers 1-21) is optimal and used throughout this
report. In key instances, the products are accompanied by the numbering system as shown
below.
(+)-bionectin A (1) (+)-WIN-64821
Kim's isolation report Barrow's numbering for the

















TiC(OEt) 3, NEt 3
CH2CI2, 0 'C, 21 h
81%
6 OH O
8P 3 12 l3OEt






A solution of chlorotitanium (IV) triethoxide6 (22.5 g, 103 mmol, 1.05 equiv) in
dichloromethane (69 mL) was added via cannula to a solution of ethyl 2-((1S,2S,5S)-2-
hydroxypinan-3-imino)glycinate 7 (11, 24.8 g, 97.8 mmol, 1 equiv) in dichloromethane (300 mL)
at 0 *C. A fine powder of 1-(phenylsulfonyl)-1H-indole-3-carbaldehyde 8 (10, 29.3 g, 103 mmol,
1.05 equiv) was then added as a solid to the reaction mixture. Triethylamine (27.3 mL, 196
mmol, 2.00 equiv) was subsequently added dropwise via syringe and the reaction mixture was
stirred at 0 *C. After 21 h, brine (1 L) at 0 'C was added to the reaction mixture and the
resulting bilayer suspension was filtered through Celite. The organic layer was separated, and
the aqueous layer was extracted with dichloromethane (2 x 300 mL). The combined organic
layers were dried over anhydrous sodium sulfate, were filtered, and were concentrated under
reduced pressure. The resulting orange foam was purified by flash column chromatography on
silica gel (eluent: gradient, 30->50% ethyl acetate in hexanes) to provide an inseparable mixture
of diastereomeric aldol products (42.5 g, 80.6%) as a yellow foam.9 Structural assignments were
made using additional information from gCOSY, HSQC, and gHMBC experiments.
IH NMR (600 MHz, CDCl 3, 20 OC): "
"C NMR (150 MHz, CDC13, 20 oC):O
6 7.96 (d, J= 8.3, 1H, C8H), 7.86 (d, J= 8.6,
2H, SO2Ph-o-H), 7.71 (s, 1H, C2H), 7.67 (d, J
= 7.8, 1H, C5H), 7.49 (t, J = 7.6, 1H, SO 2Ph-
p-H), 7.39 (app-t, J = 8.1, 2H, SO 2Ph-m-H),
7.29 (app-t, J= 7.3, 1H, C7H), 7.23 (app-t, J=
7.2, 1H, C6 H), 5.49 (d, J = 6.9, 1H, C12H),
4.46 (d, J= 6.9, 1H, C1IH), 4.11-3.99 (in, 2H,
CO 2CH 2CH3), 3.90 (br-s, I H, C120H), 2.42
(dd, J= 2.0, 17.7, 1 H, C16Ha), 2.19 (dd, J =
2.7, 18.0, 1H, C16Hb), 2.11-2.05 (in, lH,
Ci8Ha), 2.00 (br-s, 1H, C200H), 1.89 (app-t, J
= 5.8, 1H, C19H), 1.87-1.83 (m, 1H, C17H),
1.42 (s, 3H, C2 4H), 1.23 (s, 3H, C2 2 /2 3H), 1.06
(app-t, J = 7.4, 3H, CO 2 CH2 CH 3), 1.02 (d, J=
4.7, IH, Ci8Hb), 0.80 (s, 3H, C22 /2 3H).
6 180.6 (C15), 169.5 (C13), 138.0 (SO 2Ph-ipso-
C), 134.5 (C9), 133.6 (SO2Ph-p-C), 129.9
6 Holoway, H. Chem. Ind. 1962, 3, 214.
7 (a) Oguri, T.; Kaway, N.; Yamada, S. Chem. Pharm. Bull. 1978, 26, 803. (b) Solladie-Cavallo, A.; Simon, M. C. Tetrahedron
Lett. 1989, 30, 6011. (c) Solladia-Cavallo, A.; Simon-Wermeister, M. C.; Schwarz, J. Organometallics 1993, 12, 3743.
8 Wenkert, E.; Moeller, P. D. R.; Piettre,S. R. J. Am. Chem. Soc. 1988, 110, 7188.
9 The aldol products were highly prone to degradation through a retro-aldol pathway; thus, the mixture of diastereomers was
quickly isolated and immediately used in the subsequent reaction.
'0 Only the peaks corresponding to the major diastereomer are tabulated.
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(C4), 129.2 (SO 2Ph-m-C), 126.7 (SO 2Ph-o-C),
124.9 (C7 ), 124.7 (C2 ), 123.1 (C), 122.3 (C3),
120.2 (C), 113.5 (C8), 76.8 (C20), 67.7 (C 12 ),
67.4 (C11), 61.1 (CO 2 CH 2 CH3 ), 50.3 (C 19),
38.5 (C 2 1), 38.2 (C 17), 33.8 (C16), 28.1 (C 24 ),
27.8 (C18), 27.1 (C 2 2/2 3 ), 22.6 (C 2 2/2 3 ), 13.7
(CO 2CH 2CH3).
3422 (br-m), 2926 (s), 1734 (s), 1649 (m),
1557 (w), 1448 (s), 1373 (s), 1273 (m), 1181
(s), 1126 (m), 1089 (m), 1022 (w), 978 (w),
920 (w), 751 (m).
calc'd for C2 9H3 5N2 0 6 S [M+H]*: 539.2210,
found: 539.2198.
FTIR (thin film) cm-I:
HRMS (ESI) (m/z):









PhO 2SN I1N 7
8 ' 23
(+.)-81 H )2 l24Me 19 Me
22
12-Hydroxytryptophan Silyl Ether (+)-S1:
t-Butyldimethylsilyl trifluoromethanesulfonate (21.8 mL, 94.7 mmol, 1.20 equiv) was
added via syringe to a solution of 12-hydroxytryptophan alcohol 12 (42.5 g, 78.9 mmol, I equiv)
and 2,6-lutidine (18.7 mL, 161 mmol, 2.04 equiv) in dichloromethane (900 mL) at 0 *C. After 2
h, saturated aqueous ammonium chloride solution (750 mL) was added to the reaction mixture
and the resulting solution was allowed to warm to 23 *C. After 10 min, the layers were
separated and the aqueous layer was further extracted with dichloromethane (2 x 200 mL). The
combined organic layers were dried over anhydrous sodium sulfate, were filtered, and were
concentrated under reduced pressure. The resulting orange foam was purified by flash column
chromatography on silica gel (eluent: 20% ethyl acetate in hexanes) to provide the 12-
hydroxytryptophan silyl ether (+)-S1 (37.1 g, 72.0%) as a yellow oil. Structural assignments
were made using additional information from gCOSY, HSQC, and gHMBC experiments.
'H NMR (600 MHz, CDCl 3, 20 *C):
3 C NMR (150 MHz, CDCl 3, 20 *C):
6 7.97 (d, J = 8.3, 1 H, CH), 7.84 (d, J = 7.4,
2H, SO 2Ph-o-H), 7.77 (d, J = 7.8, 1H, C5H),
7.52 (s, 1H, C2H), 7.50 (t, J= 7.9, 1H, SO 2Ph-
p-H), 7.39 (app-t, J = 8.2, 2H, SO 2Ph-m-H),
7.30 (app-t, J= 7.3, 1H, C7H), 7.24 (app-t, J=
7.1, 1H, C6 H), 5.53 (d, J = 8.5, 1H, C12H),
4.41 (d, J= 8.6, 1H, CIH), 4.23-4.14 (m, 2H,
CO 2 CH 2 CH3), 2.42 (app-dt, J= 2.5, 18.1, 1H,
C16Ha), 2.00 (dd, J = 2.9, 18.1, 1H, C16Hb),
1.93-1.90 (m, 1H, CisHa), 1.80 (app-t, J= 5.8,
1H, CI9H), 1.75-1.71 (m, IH, C17H), 1.42 (br-
s, IH, C200H), 1.31 (s, 3H, C2 4H), 1.06 (app-
t, J = 7.2, 3H, CO 2 CH 2CH 3), 1.18 (s, 3H,
C22/23H), 0.82 (s, 9H, Si(CH 3)2C(CH 3)3), 0.70
(d, J= 5.2, 1H, C,8Hb), 0.69 (s, 3H, C2 2/2 3H),
0.03 (s, 3H, Si(CH 3)2C(CH 3)3), -0.30 (s, 3H,
Si(CH 3)2C(CH 3)3).
6 180.2 (C s), 170.0 (C13), 138.3 (SO 2Ph-ipso-
C), 135.2 (C9), 133.9 (SO2Ph-p-C), 129.5
(C4), 129.4 (SO 2Ph-m-C), 126.8 (SO 2Ph-o-C),
125.2 (C7), 124.6 (C3), 124.0 (C 2), 123.3 (C6),
121.0 (C), 114.1 (C8 ), 76.4 (C 20 ), 70.7 (C,1),
70.0 (C12), 61.1 (CO 2 CH2 CH 3), 49.8 (C19),
38.4 (C 2 1), 38.1 (C17), 33.4 (C16), 28.3 (C24),
27.8 (C, 8 ), 27.3 (C 2 2 /2 3 ), 25.7
(Si(CH 3)2 C(CH3)3)), 22.8 (C 22/23), 18.1
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FTIR (thin film) cm-1:
(Si(CH 3)2C(CH3)3), 14.4 (CO 2 CH 2CH3 ), -4.6
(Si(CH 3)2C(CH3)3), -5.3 (Si(CH 3)2 C(CH 3)3).
2929 (s), 1735 (s), 1652 (m), 1559 (w), 1494
(w), 1448 (s), 1372 (s), 1259 (m), 1179 (s),
1088 (s), 977 (w), 837 (m), 780 (m), 750 (m),
686 (m).
calc'd for C3 5H4 9N20 6SSi [M+H]*: 653.3075,
found: 653.3063.
HRMS (ESI) (m/z):
TLC (33% ethyl acetate in hexanes), Rf:









PhO 2SN 1 10NH 2(+)-13
12-Hydroxytryptophan Amine (+)-13:
Aqueous hydrogen chloride solution (2 N, 520 mL) was added to a solution of 12-
hydroxytryptophan silyl ether (+)-S1 (37.1 g, 56.8 mmol, 1 equiv) in tetrahydrofuran (520 mL)
at 23 'C. After 1.5 h, the mixture was concentrated to remove the organic solvent. The resulting
mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were dried
over anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure.
The resulting orange foam was purified by flash column chromatography on silica gel (eluent:
gradient, 20-+30-+100% ethyl acetate in hexanes) to provide 12-hydroxytryptophan amine (+)-
13 (23.0 g, 80.5%) as a yellow foam. Structural assignments were made using additional
information from gCOSY, HSQC, and gHMBC experiments.
'H NMR (600 MHz, CDCl 3, 20 *C):
13C NMR (150 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
8 8.00 (d, J= 8.3, 1H, CH), 7.83 (d, J= 7.4,
2H, SO2Ph-o-H), 7.64 (d, J = 7.9, 1H, C5H),
7.52 (t, J= 7.4, 1H, SO2Ph-p-H), 7.49 (s, 1 H,
C2H), 7.41 (app-t, J = 8.2, 2H, SO 2Ph-m-H),
7.32 (app-t, J = 7.4, 1 H, C7H), 7.22 (app-t, J =
7.3, IH, C6H), 5.01 (d, J = 6.5, IH, C12H),
4.10-3.98 (m, 2H, CO 2 CH 2 CH3), 3.78 (d, J=
6.5, 1H, CIIH), 1.13 (app-t, J = 7.1, 31H,
CO 2 CH 2 CH 3), 0.80 (s, 9H, Si(CH 3)2C(CH 3)3),
0.00 (s, 3H, Si(CH 3)2C(CH 3)3), -0.33 (s, 3H,
Si(CH 3)2C(CH 3)3).
8 172.9 (C13 ), 138.1 (SO 2 Ph-ipso-C), 135.2
(C9), 134.0 (SO2Ph-p-C), 129.4 (SO 2Ph-m-C),
129.0 (C4 ), 126.8 (SO 2 Ph-o-C), 125.2 (C7),
124.6 (C2), 123.5 (C6), 122.9 (C3), 121.1 (C5 ),
114.0 (Cs), 72.0 (C, 2 ), 61.1 (CO 2CH2CH3 ),
60.8 (C), 25.7 (Si(CH 3)2C(CH 3)3), 18.2
(Si(CH 3)2C(CH 3)3), 14.1 (CO 2 CH 2CH3), -4.8





(s), 2858 (s), 1735 (s), 1560 (w), 1448
1372 (s), 1258 (in), 1180 (s), 1088 (m),
(w), 976 (w), 838 (s), 751 (s), 686 (m).
calc'd for C 2 5H3 5N 20 5 SSi [M+H]*: 503.2030,
found: 503.2016.
TLC (50% ethyl acetate in hexanes), Rf.
+31 (c = 0.45, CHCl3).
















Triethylamine (83.1 pL, 596 imol, 2.00 equiv) was added to a solution of 12-
hydroxytryptophan amine (+)-13 (100 mg, 198 jimol, 1 equiv) and 3,5-dinitrobenzoyl chloride
(68.7 mg, 298 pimol, 1.50 mmol) in dichloromethane (10 mL) at 23 'C. After 1 h, saturated
aqueous ammonium chloride solution was added (5 mL) to the reaction mixture. After 5 min,
the layers were separated, and the aqueous layer was further extracted with ethyl acetate (2 x 5
mL). The combined organic layers were dried over anhydrous sodium sulfate, were filtered, and
were concentrated under reduced pressure. The resulting orange foam was purified by flash
column chromatography on silica gel (eluent: gradient, 20->40 % ethyl acetate in hexanes) to
provide 12-hydroxytryptophan 3,5-dinitrobenzamide (+)-14 (129 mg, 93.9%) as a yellow solid.
Structural assignments were made using additional information from gCOSY, HSQC, and
gHMBC experiments.
'H NMR (600 MHz, CDCl 3, 20 *C):
13C NMR (150 MHz, CDCl3, 20 *C):
FTIR (thin film) cm-1:
6 9.20 (s, lH, Bz-p-H), 8.95 (s, 2H, Bz-o-H),
8.05 (d, J = 8.1, 1H, CH), 7.98 (d, J = 7.6,
1H, CsH), 7.86 (d, J = 7.7, 2H, SO 2Ph-o-H),
7.54 (t, J = 7.2, 1 H, SO2 Ph-p-H), 7.47 (s, I H,
C2 H), 7.43 (app-t, J = 7.5, 2H, SO 2Ph-m-H),
7.39 (app-t, J= 7.7, 1H, C7H), 7.35 (app-t, J=
7.2, 1H, C6 H), 7.31 (d, J = 6.5, IH, NioH),
5.48 (app-s, 1H, C12H), 5.10 (d, J = 5.0, 1H,
CIlH), 4.16 (m, 1H, COCH 2aCH 3), 4.06 (m,
1H, CO 2 CH2bCH 3), 1.14 (app-t, J = 7.0, 3H,
CO 2 CH 2 CH 3 ), 0.93 (s, 9H, Si(CH 3)2C(CH 3)3),
0.00 (s, 3H, Si(CH 3)2 C(CH3)3 ), -0.15 (s, 3H,
Si(CH 3)2C(CH3)3).
6 168.8 (C13), 162.4 (C=Oz), 148.9 (Bz-m-
C), 138.2 (SO 2Ph-ipso-C), 137.2 (Bz-ipso-C),
135.5 (C9), 134.1 (SO2Ph-p-C), 129.4
(SO2Ph-m-C), 128.6 (C4), 127.3 (Bz-o-C),
126.8 (SO2Ph-o-C), 125.4 (C7 ), 124.2 (C2),
123.9 (C6), 122.7 (C3 ), 121.7 (Bz-p-C), 120.5
(Cs), 114.0 (C), 70.1 (C12 ), 62.3
(CO 2CH 2 CH 3), 59.3 (C 1), 25.7(Si(CH 3)2C(CH3)3), 18.3 (Si(CH 3)2C(CH3)3),
14.2 (CO 2CH 2CH3), -4.6 (Si(CH 3)2C(CH 3)3),
-5.1 (Si(CH 3)2C(CH 3)3).
3394 (br), 2932 (w), 2362 (m), 1736 (in),
1674 (in), 1545 (s), 1448 (in), 1345 (s), 1253
262
(m), 1180 (s), 1119 (m), 1093 (m), 977 (w),
920 (w), 838 (m), 726 (m).
HRMS (ESI) (m/z):
[a]D 24:.[C(2D en
TLC (20% ethyl acetate in hexanes), Rf-
calc'd for C 32 H 4 0N 5 OioSSi
714.2260, found: 714.2251.
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A round-bottom flask was charged sequentially with 12-hydroxytryptophan amine (+)-13
(7.05 g, 14.0 mmol, I equiv), N-Boc-sarcosine (3.45 g, 18.2 mmol, 1.30 equiv), N-
hydroxybenzotriazole (2.84 g, 21.0 mmol, 1.50 equiv), 1 -ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrogen chloride (5.37 g, 28.0 mmol, 2.00 equiv), and powdered 4 A molecular
sieves (4.00 g), and the contents were placed under an atmosphere of argon. Dichloromethane
(100 mL) was introduced via cannula and the resulting solution was cooled to 0 *C.
Triethylamine (5.86 mL, 42.0 mmol, 3.00 equiv) was subsequently added dropwise via syringe
and the reaction mixture was allowed to warm slowly to 23 'C. After 18 h, saturated aqueous
sodium bicarbonate solution (200 mL) was added, and the aqueous layer was extracted with
ethyl acetate (3 x 250 mL). The combined organic layers were dried over anhydrous sodium
sulfate, were filtered, and were concentrated under reduced pressure. The resulting orange foam
was purified by flash column chromatography on silica gel (eluent: 50% ethyl acetate in
hexanes) to provide dipeptide (+)-S2 (9.05 g, 98%) as a yellow foam. Structural assignments
were made using additional information from gCOSY, HSQC, and gHMBC experiments.
'H NMR (500 MHz, DMSO-d6 , 60 *C):
"C NMR (125.8 MHz, DMSO-d6 , 60 *C):
6 7.97 (d, J= 7.7, 1H, NioH), 7.89 (d, J= 8.3,
1H, CH), 7.87 (d, J = 7.7, 2H, SO2Ph-o-H),
7.76 (d, J = 7.7, 1H, CsH), 7.67 (t, J = 7.3,
1H, SO2Ph-p-H), 7.64 (s, 1H, C2H), 7.55
(app-t, J = 7.7, 2H, SO 2Ph-m-H), 7.33 (app-t,
J = 7.7, 1H, C7H), 7.26 (app-t, J = 7.7, 1H,
C6H), 5.16 (d, J= 7.7, 1H, C12H), 4.75 (app-t,
J = 7.8, 1H, CiH), 4.08 (q, J = 7.1, 2H,
CO 2CH 2CH3), 3.85-3.65 (m, 1 H, Ci 5 Ha), 3.44
(d, J= 17.0, 1H, CisHb), 3.14 (s, 3H, C17H),
1.24 (br-s, 9H, CO 2 C(CH 3)3), 1.17 (t, J= 7.1,
3H, CO 2 CH 2CH 3 ), 0.74 (s, 9H,
Si(CH 3)2C(CH 3)3), -0.04 (s, 3H,
Si(CH 3)2C(CH 3)3), -0.39 (s, 3H,
Si(CH 3)2C(CH 3)3).
6 171.0 (C 13), 169.4 (C, 6 ), 156.2
(CO2C(CH 3)3), 138.5 (SO 2 Ph-ipso-C), 136.1(C9), 135.6 (SO2Ph-p-C), 130.9 (SO 2Ph-m-C),
129.6 (C4 ), 127.6 (SO 2 Ph-o-C), 126.1 (C7),
126.1 (C2), 124.5 (C6), 123.6 (C3), 122.1 (Cs),
114.4 (Cs), 80.3 (CO 2C(CH3)3), 70.2 (C12),
61.8 (CO 2CH 2 CH3 ), 58.6 (C,,), 52.1 (C, 5 ),
35.9 (C17), 29.1 (CO 2C(CH 3)3), 26.5
(Si(CH 3)2C(CH3)3), 18.8 (Si(CH 3)2C(CH3)3),
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15.0 (CO 2CH 2CH 3), -4.1 (Si(CH 3)2C(CH 3)3),
-4.4 (Si(CH 3)2C(CH 3)3).
FTIR (thin film) cm-1: 3414 (br-m), 2933 (s), 2859 (m), 1739
1699 (s), 1510 (m), 1450 (m), 1374 (s),
(m), 1179 (s), 1120 (m), 1024 (w), 975
840 (w), 753 (w), 685 (w).
HRMS (ESI) (m/z): calc'd for C33H48N30 8 SSi [M+H]+: 674.2926,
found: 674.2926.
TLC (50% ethyl acetate in hexanes), Rf:








PhO 2SN HN. <N'Me
(+)-S2 0 Boc
1) TFA, CH2CI223 OC, 1 h
2) tBuOH, morpholine
AcOH, 80 *C, 1.5 h
97%
6
TBSO 0/\ ~H Me
8 /3 12 -13 N'17
PhO 2SN1  HNV 1s
(-)-15 O
Diketopiperazine (-)-15:
Trifluoroacetic acid (27 mL) was introduced dropwise to a solution of dipeptide (+)-S2
(14.6 g, 21.7 mmol, 1 equiv) in dichloromethane (140 mL) at 23 *C. After I h, the reaction
mixture was concentrated to dryness under reduced pressure. The crude residue was dissolved in
tert-butanol (210 mL). Acetic acid (32 mL) and morpholine (32 mL) were successively added to
the solution, and the resulting reaction mixture was warmed to 80 0C. After 1.5 h, the reaction
mixture was concentrated under reduced pressure and the solids were removed by vacuum
filtration over a sintered funnel. The solids were extracted with ethyl acetate and the combined
organic filtrates were concentrated under reduced pressure. The resulting orange oil was purified
by flash column chromatography on silica gel (eluent: gradient, 50-+100% ethyl acetate in
hexanes) to provide diketopiperazine (-)-15 (11.1 g, 97.0%) as a yellow foam. Structural
assignments were made using additional information from gCOSY, HSQC, and gHMBC
experiments.
'H NMR (600 MHz, CDCl 3, 20 *C):
13 C NMR (150 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
6 7.97 (d, J= 8.4, 1 H, C8H), 7.89 (d, J= 7.8,
2H, SO2Ph-o-H), 7.55 (s, IH, C2H), 7.54 (t, J
= 7.4, 1H, SO2Ph-p-H), 7.51 (d, J = 7.9, 1H,
C5H), 7.47 (app-t, J= 7.7, 2H, SO 2Ph-m-H),
7.31 (app-t, J = 7.6, 1 H, C7H), 7.22 (app-t, J =
7.8, 1 H, C6H), 6.39 (br-s, 1H, NH), 5.51 (d, J
= 3.4, 1H, C12H), 4.31 (app-s, 1H, CI1H), 3.19
(d, J = 17.6, 1H, C15Ha), 2.32 (s, 3H, Ci 4H),
2.17 (d, J = 17.6, 1H, C15Hb), 0.89 (s, 9H,
Si(CH 3)2C(CH 3)3), 0.06 (s, 3H,
Si(CH 3)2C(CH 3)3), -0.07 (s, 3H,
Si(CH 3)2C(CH3)3).
6 164.9 (C13), 162.6 (C16), 138.0 (SO 2Ph-ipso-
C), 134.7 (C9), 134.1 (SO2Ph-p-C), 129.6
(SO 2 Ph-m-C), 127.9 (C4), 127.1 (SO 2Ph-o-C),
126.0 (C2), 125.4 (C7), 123.6 (C6), 120.6 (C3 ),
120.5 (C), 113.6 (C8), 70.4 (C 12), 61.7 (C1 ),
50.5 (C15 ), 33.3 (C 17), 25.9
(Si(CH 3)2C(CH3)3), 18.3 (Si(CH 3)2C(CH3)3),
-4.7 (Si(CH 3)2C(CH 3)3 ), -5.1
(Si(CH 3)2 C(CH3)3).
3251 (br m), 2932 (m), 1676 (s), 1448 (m),
1371 (m), 1179 (s), 1122 (m), 979 (w), 838
(w), 751 (w), 686 (w).
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HRMS (ESI) (m/z): calc'd for C26H 34N30 5 SSi [M+H]*: 528.1983,
found: 528.1982.
[a]D24:
TLC (50% ethyl acetate in hexanes), Rf:













B so2Ph 3 N(17
8 S0 2Ph 0 (+)-16
Tetracyclic Bromide (+)-16:
A solution of bromine (2 M, 61.0 mL, 122 mmol, 4.00 equiv) in acetonitrile that was pre-
cooled to 0 'C was poured in one portion into a solution of diketopiperazine (-)-15 (16.1 g, 30.5
mmol, I equiv) in acetonitrile (268 mL) at 0 *C. The reaction progress was monitored by TLC
analysis in 2 min interval. After 8 min, upon complete consumption of starting material, anisole
(19.9 mL, 183 mmol, 6.00 equiv) that was pre-cooled to 0 'C was poured in one portion into the
reaction mixture. After 10 min, a mixture of saturated aqueous sodium thiosulfate solution and
saturated aqueous sodium bicarbonate solution (1:1, 500 mL) was added to the red solution. The
reaction mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layers
were dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The resulting residue was purified by flash column chromatography on silica gel
(eluent: gradient, 20->50% acetone in dichloromethane) to afford a mixture of the endo-
tetracyclic bromide (+)-16 and its minor exo-diastereomer (14.2 g, 94.5%, 8.7:1 dr) as a white
foam." Structural assignments were made with additional information using gCOSY, HSQC,
gHMBC, and NOESY experiments.
'H NMR (600 MHz, CDCl 3, 20 *C):
13C NMR (150 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
24:[cL]D
6 7.98 (d, J = 8.0, 2H, SO 2Ph-o-H), 7.54 (d, J
= 8.3, 1H, C8H), 7.52 (t, J= 7.6, 1H, SO2Ph-
p-H), 7.42 (app-t, J = 7.8, 2H, SO 2 Ph-m-H),
7.33 (d, J = 7.6, 1H, C5H), 7.28 (app-t, J =
7.9, 1H, C7H), 7.11 (app-t, J= 7.6, 1H, C6 H),
6.25 (s, IH, C2H), 4.62 (d, J= 5.9, 1H, C12H),
4.23 (d, J= 5.8, 1H, CIH), 4.16 (d, J= 17.6,
1H, Ci 5 Ha), 3.91 (br-s, IH, OH), 3.84 (d, J=
17.5, 1H, CisHb), 2.88 (s, 3H, C17H).
6 165.8 (CI), 164.9 (C16 ), 139.2 (C9), 137.4
(SO 2 Ph-ipso-C), 134.0 (SO2 Ph-p-C), 131.8
(C 4), 131.2 (C7), 129.1 (SO 2 Ph-m-C), 128.4
(SO 2Ph-o-C), 125.9 (C6), 125.3 (C5 ), 116.8
(C8), 85.1 (C2), 74.2 (C12), 68.0 (C3 ), 63.4
(C,1), 54.0 (Ci5 ), 33.5 (C17).
3367 (br s), 2958 (s), 1677 (s), 1458 (m), 1399
(m), 1364 (m), 1170 (m), 1089 (w), 729 (w),
688 (w).
calc'd for C20H19BrN30 5 S [M+H]*: 492.0223,
found: 492.0222.
+56 (c = 0.30, CHCl3).
" The mixture of diastereomers can be separated easily on smaller scales using the same purification conditions reported here.
However, on decagram scales, it was more practical to carry the diastereomeric mixture to next step.
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THF, 23 *C, 14 h
74%
Indole-Tethered Tetracycle 21:
A solution of n-butyllithium (1.57 M, 18.3 mL, 28.7 mmol, 1.61 equiv) in hexanes was
added dropwise to a solution of freshly distilled diisopropylamine (4.02 mL, 28.7 mmol, 1.61
equiv) in tetrahydrofuran (4.28 mL) at -78 *C. After 5 min, the solution was allowed to warm to
0 'C. After 35 min, the solution of lithium diisopropylamide was transferred via cannula to a
solution of N-Boc-indole (6.24 g, 28.7 mmol, 1.61 equiv) and dimethyldichlorosilane (3.25 mL,
26.8 mmol, 1.50 equiv) in tetrahydrofuran (47.3 mL) at 0 'C. After 8 h, the reaction mixture was
transferred via cannula to a solution of tetracyclic bromide (+)-16 (8.78 g, 17.83 mmol, 1 equiv)
and 4-dimethylaminopyridine (4.68 g, 38.28 mmol, 2.15 equiv) in tetrahydrofuran (63.3 mL) at
23 'C. After 14 h, the reaction mixture was diluted with ethyl acetate (300 mL) and washed with
saturated aqueous sodium bicarbonate solution (500 mL). The aqueous layer was further
extracted with ethyl acetate (2 x 200 mL). The combined organic layers were dried over
anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure. The
resulting orange foam was purified by flash column chromatography on silica gel (eluent:
gradient, 33->50% ethyl acetate in hexanes) to provide the indole-tethered tetracycle 21 (10.1 g,
74.3%) as a white foam. Structural assignments were made using additional information from
gCOSY, HSQC, and gHMBC experiments.
'H NMR (600 MHz, CDCl 3, 20 *C):
13 C NMR (150 MHz, CDCl 3, 20 *C):
6 8.03 (d, J= 7.6, 2H, SO2Ph-o-H), 7.96 (d, J
= 8.3, 1H, C8H), 7.63 (d, J = 7.7, IH, C5H),
7.57 (d, J = 8.1, 1H, CH), 7.53 (t, J = 7.4,
1H, SO2Ph-p-H), 7.44 (app-t, J = 7.9, 2H,
SO2Ph-m-H), 7.31 (app-t, J = 7.4, 1 H, C7.H),
7.27 (app-t, J= 7.9, 1H, C7H), 7.26-7.21 (in,
1H, C5H), 7.26-7.21 (m, 1H, C6H), 7.26-7.21
(in, 1 H, CyH), 7.00 (app-t, J = 7.5, 1 H, C6H),
6.33 (s, IH, C2H), 5.13 (d, J= 3.7, 1H, C,2H),
4.30 (d, J= 3.6, 1H, Cn H), 4.11 (d, J= 17.2,
1H, Ci 5Ha), 3.79 (d, J = 17.2, 1H, CISHb),
2.82 (s, 3H, C17H), 1.69 (s, 9H, CO 2C(CH 3) 3),
0.54 (s, 3H, Si(CH 3)2), 0.50 (s, 3H, Si(CH 3)2).
6 165.5 (C13), 165.2 (C16), 151.7
(C=Ocarbamate), 139.1 (C2 ), 138.9 (C9), 137.8
(SO 2Ph-ipso-C), 137.3 (C9), 133.8 (SO2Ph-p-
C), 131.4 (C4 ), 131.3 (C4), 131.0 (C7 ), 129.0
(SO2Ph-m-C), 128.4 (SO2 Ph-o-C), 125.6 (C6),
125.4 (C), 124.9 (C7 ), 122.7 (C6 ), 121.5
(Cs), 121.1 (CY), 116.5 (C8 ), 115.4 (C), 85.5
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(C 2), 84.6 (CO 2C(CH 3)3), 74.6 (C 12),
(C 3), 66.5 (C11), 54.3 (C 15), 33.6 (C 17),
(CO 2C(CH 3)3), 0.5 (Si(C-1 3)2),
(Si(CH 3)2 ).
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (50% ethyl acetate in hexanes), Rf:
2957 (w), 1715 (s), 1466 (w), 1447
(s), 1335 (m), 1251 (m), 1169 (s),
922 (w), 834 (w), 751 (m), 689 (w).
(w), 1373
1072 (w),
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Silacyclic Tetracycle (+)-22:
A round-bottom flask was charged with indole-tethered tetracycle 21 (6.85 g, 8.95 mmol,
I equiv) and 2,6-di-tert-butyl-4-methylpyridine (3.69 g, 17.9 mmol, 2.00 equiv) and
azeotropically dried with benzene (3 x 50 mL) under reduced pressure. The flask was left under
reduced pressure for 12 h to ensure the complete removal of benzene then returned to
atmospheric pressure by backfilling with argon. Anhydrous nitroethane (200 mL, distilled over
CaH2 and stored over 4A molecular sieves) was then introduced via cannula and the resulting
solution was cooled to 0 'C. A solution of silver (I) tetrafluoroborate (8.69 g, 44.8 mmol, 5.00
equiv) in nitroethane (30 mL) at 0 'C was introduced via cannula to the solution containing the
indole-tethered tetracycle 21 over 1 min. The reaction mixture immediately changed color to a
dark red then to brown. After 1 h, brine (150 mL) was added and the resulting biphasic mixture
was vigorously stirred at 23 'C. After 10 min, the reaction mixture was extracted with ethyl
acetate (3 x 150 mL). The combined organic layers were dried over anhydrous sodium sulfate,
were filtered, and were concentrated under reduced pressure. The resulting white residue was
purified by flash column chromatography (eluent: gradient, 40-+100% ethyl acetate in hexanes)
to afford the silacyclic tetracycle (+)-22 (4.20 g, 68.5%) as a white foam. Structural assignments
were made using additional information from gCOSY, HSQC, gHMBC, and NOESY
experiments.
H NMR (500 MHz, CDCl 3, 20 *C):
"C NMR (125.8 MHz, CDCl 3, 20 "C):
6 8.25 (d, J= 8.3, 2H, SO2Ph-o-H), 7.96 (d, J
= 8.2, 1H, C8H), 7.87 (d, J= 8.4, 1H, C8H),
7.74 (t, J = 7.5, 1H, SO2Ph-p-H), 7.59 (app-t,
J= 7.8, 2H, SO 2Ph-m-H), 7.30 (app-t, J= 7.6,
1H, C7H), 7.15 (app-t, J= 7.5, 1H, C7H), 6.91
(app-t, J= 7.5, 1H, C6H), 6.71 (d, J= 7.4, 1H,
C5H), 6.50 (app-t, J 7.4, 1H, C6.H), 6.39 (s,
1H, C2H), 5.51 (d, J= 8.0, 1H, C5.H), 4.91 (d,
J = 9.5, 1H, C12H), 4.32 (d, J = 9.5, 1H,
C IH), 4.02 (d, J= 18.2, 1H, Ci 5 Ha), 3.95 (d,
J= 18.1, 1H, CisHb), 3.05 (s, 3H, C17H), 1.70
(s, 9H, CO 2C(CH3)3), 0.54 (s, 3H, Si(CH 3)2),
0.48 (s, 3H, Si(CH 3)2 ).
6 167.7 (C 13), 166.5 (C 16), 151.6
(C=Ocarbamate), 139.8 (C9 ), 136.8 (C9 .), 136.3
(SO 2 Ph-ipso-C), 136.0 (C2.), 133.8 (SO2Ph-p-
C), 132.0 (C4 ), 129.8 (C7), 129.6 (SO 2Ph-m-
C), 129.5 (C4 ), 128.4 (SO 2Ph-o-C), 125.3
(C7'), 125.1 (C3.), 124.5 (C6 ), 123.5 (C),
122.7 (C6 ), 119.3 (C.), 115.5 (CO'), 115.2
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FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (33% acetone in hexanes), Rf:
(Cs), 85.6 (CO 2C(CH 3)3), 80.5 (C 12), 79.1
(C2 ), 61.4 (C11), 56.6 (C3 ), 54.2 (C15), 33.5
(C 17), 28.3 (C0 2C(CH 3)3), 1.7 (Si(CH 3 )2), 0.6
(Si(CH 3)2).
2927 (s), 1700 (m), 1652 (w), 1558 (m), 1494
(m), 1454 (w), 1373 (m), 1328 (w), 1258 (w),
1159 (w), 1050 (w), 876 (m), 825 (m), 751
(w).
calc'd for C 3 5H3 6N 4NaO7 SSi [M+Na]+:
707.1966, found: 707.1986.
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3-Indolylated Tetracycle (+)-24:
Aqueous hydrogen chloride solution (6 N, 20 mL) was added in one portion to a sealed
tube charged with a solution of silacyclic tetracycle (+)-22 (1.02 g, 1.49 mmol, 1 equiv) in
tetrahydrofuran (20 mL) at 23 *C. The reaction flask was then sealed and heated to 80 'C. After
40 min, the sealed tube was immediately immersed in an ice-water bath and rapidly cooled to 0
'C. The cold solution was slowly poured into a saturated aqueous sodium bicarbonate solution
(250 mL) at 0 'C and extracted with ethyl acetate (200 mL). The aqueous layer was further
extracted with ethyl acetate (2 x 100 mL), and the combined organic layers were dried over
anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure. The
resulting residue was purified by flash column chromatography (eluent: gradient, 25-+50%
acetone in dichloromethane) to afford the 3-indolylated tetracycle (+)-24 (456 mg, 57.9%) as a
white solid. Structural assignments were made using additional information from gCOSY,
HSQC, gHMBC, and NOESY experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
6 7.94 (br-s, 1H, N 1H), 7.75 (d, J= 8.1, 1 H,
CH), 7.44 (dd, J = 1.2, 8.6, 2H, SO 2Ph-o-H),
7.37-7.27 (m, 1H, SO 2Ph-p-H), 7.37-7.27 (in,
IH, C8 H), 7.37-7.27 (m, 1H, C7H), 7.18-7.13
(m, 1H, C5H), 7.18-7.13 (m, 1H, C7.H), 7.09-
7.01 (m, 2H, SO 2Ph-m-C), 7.09-7.01 (m, 1H,
C6H), 6.91-6.84 (m, IH, C5 H), 6.91-6.84 (m,
1H, C6.H), 6.64 (d, J= 2.7, 1H, C2.H), 6.49 (s,
IH, C2H), 4.92 (dd, J = 3.3, 6.0, 1 H, C12H),
4.42 (d, J= 5.7, 1H, C1IH), 4.09 (d, J= 17.1,
1H, Ci 5Ha), 3.84 (d, J = 17.5, 1H, CisHb),
2.88 (s, 3H, C17H), 2.71 (d, J= 3.2, 1H, OH).
8 166.9 (C 13), 165.4 (C16), 139.6 (C9), 137.4
(SO 2 Ph-ipso-C), 136.9 (C9 .), 134.5 (C4), 133.0
(SO2 Ph-p-C), 129.6 (C7), 128.6 (SO 2 Ph-m-C),
127.5 (SO 2 Ph-o-C), 126.2 (C4'), 125.8 (C2),
125.3 (Cs), 125.2 (C6), 122.8 (C7 ), 120.5
(C5 ), 120.5 (C6 .), 117.3 (Cs), 111.7 (C8'),
110.6 (C 3 .), 82.3 (C 2), 77.4 (C 12), 64.6 (C,,),
59.8 (C3 ), 54.3 (C, 5 ), 33.5 (C, 7).
3388 (br-s), 3061 (m), 2923 (m), 1673 (s),
1458 (m), 1427 (in), 1402 (m), 1357 (in),
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1260 (w), 1168 (m), 1109 (m), 735 (m), 687
(w).




TLC (50% acetone in dichloromethane), Rf:
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Bis(tert-butoxycarbonyl) Tetracycle (-)-S3:
Di-tert-butyl dicarbonate (783 ptL, 3.41 mmol, 4.00 equiv) was added via syringe to a
solution of 3-indolylated tetracycle (+)-24 (450 mg, 852 ptmol, 1 equiv) and 4-
dimethylaminopyridine (52.1 mg, 426 pmol, 0.500 equiv) in dichloromethane (10.0 mL) at
23 'C. After 30 min, the crude reaction mixture was purified by flash column chromatography
on silica gel (eluent: 8% acetone in dichloromethane) to afford bis(tert-butoxycarbonyl)
tetracycle (-)-S3 (568 mg, 91.5%) as a white solid. Structural assignments were made using
additional information from gCOSY, HSQC, and HMBC experiments.
H NMR (500 MHz, CDCl 3, 20 'C):
13 C NMR (125.8 MHz, CDC 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[aID24 :
6 7.98 (d, J= 7.3, 1H, C8.H), 7.73 (d, J= 7.6,
1H, C8H), 7.67 (d, J= 8.1, 1H, C5H), 7.58 (d,
J = 7.7, 1H, C5H), 7.33 (app-t, J = 7.9, 1H,
C6H), 7.30 (app-t, J = 7.3, 1H, C7.H), 7.25(app-t, J= 8.0, 1H, C6H), 7.20 (app-t, J= 7.5,
1H, C7H), 7.02 (t, J= 7.4, 1H, SO2Ph-p-H),
6.88 (d, J= 7.3, 2H, SO 2Ph-o-H), 6.64 (app-t,
J= 7.5, 2H, SO2Ph-m-H), 6.58 (s, 1H, C2H),
5.99 (s, 1H, C2.H), 5.92 (d, J= 4.0, 1H, C12H),
4.53 (d, J= 3.9, 1H, C IH), 4.18 (d, J= 17.4,
1H, Ci5Ha), 3.79 (d, J = 17.4, 1H, Ci5Hb),
2.81 (s, 3H, C17H), 1.50 (s, 9H,
C(CH 3)3carbamate), 0.80 (s, 9H, C(CH3)3carbonate).
8 164.8 (C13), 164.5 (C16), 151.4
(C=Ocarbonate), 148.6 (C=Ocarbamate), 139.2 (C 4),
137.8 (SO 2Ph-ipso-C), 135.8 (C9.), 133.8 (C9 ),
132.2 (SO2 Ph-p-C), 130.1 (C6), 128.1 (C4'),
127.7 (SO 2 Ph-o-C), 127.5 (C2'), 126.8 (Cs),
126.5 (SO 2 Ph-o-C), 126.2 (C7), 124.7 (C 7'),
122.9 (C6.), 121.5 (Cs.), 118.8 (C), 115.9
(C3 ), 115.1 (C8 .), 84.0 (C(CH3 )3carbamate), 82.4
(C(CH 3)3carbonate), 82.3 (C2 ), 78.3 (C12), 63.4
(C,,), 59.6 (C3), 54.1 (CIs), 33.6 (C17), 28.0
(C(CH3)3carbamate), 26.6 (C(CH3)3carbonate).
2979 (w), 1740 (s), 1708 (s), 1686 (s), 1453
(m), 1371 (s), 1280 (s), 1258 (s), 1156 (s),
1100 (m), 750 (m).
calc'd for C38H4ON4NaO9S
751.2408, found 751.2405.
-22 (c = 0.31, CHCl3).
[M+Na]*:
276
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Triketopiperazine (--25:
Bis(pyridine)silver permanganate (945 mg, 2.45 mmol, 8.00 equiv) was added as a solid
to a solution of bis(tert-butoxycarbonyl) tetracycle (-)-S3 (224 mg, 307 gmol, 1 equiv) in
dichloromethane (10.0 mL) at 23 'C. After 1 h, the reaction mixture was diluted with
dichloromethane (100 mL) and washed with aqueous sodium bisulfite solution (1 M, 125 mL).
The resulting aqueous layer was extracted with dichloromethane (2 x 50 mL) and the combined
organic layers were dried over anhydrous sodium sulfate, were filtered, and were concentrated
under reduced pressure. The crude reaction mixture was purified by flash column
chromatography on silica gel (eluent: 50% ethyl acetate in hexanes) to afford triketopiperazine (-
)-25 (105 mg, 45.1%) as a white solid. Structural assignments were made using additional
information from gCOSY, HSQC, and HMBC experiments.
IH NMR (500 MHz, CDCl 3, 20 *C):
"C NMR (125.8 MHz, CDCl3, 20 "C):
FTIR (thin film) cm~':
HRMS (ESI) (m/z):
8 7.97 (d, J= 8.2, 1H, C8H), 7.86 (d, J= 8.0,
1H, C8H), 7.59-7.52 (m, 1H, C5H), 7.59-7.52
(m, 1H, C7H), 7.33 (app-t, J= 7.6, 1H, C6H),
7.32-7.26 (m, 1H, C7.H), 7.32-7.26 (m, 1H,
C5 H), 7.22 (app-t, J = 7.1, 1 H, C6.H), 7.10 (d,
J= 7.5, 2H, SO2Ph-o-H), 6.98 (t, J= 7.5, 1H,
SO2Ph-p-H), 6.93 (s, I H, C2H), 6.61 (app-t, J
= 7.9, 2H, SO 2Ph-m-H), 6.53 (s, 1H, C2.H),
5.69 (s, 1H, C12H), 4.45 (s, 1H, CIOH), 3.34
(s, 3H, C17H), 1.61 (s, 9H, C(CH3)3arbamate),
0.78 (s, 9H, C(CH3) 3carbonate).
6 165.5 (C15 ), 157.0 (C, 3), 151.3 (C16), 150.7
(C=Ocarbonate), 149.0 (C=Ocarbamate), 140.9 (C9),
136.3 (C9 ), 136.2 (SO 2Ph-ipso-C), 133.7 (C4),
132.7 (SO2Ph-p-C), 130.5 (C7 ), 128.0
(SO 2Ph-m-C), 127.4 (C2 ), 127.4 (C4'), 127.0
(SO 2Ph-o-C), 126.5 (C6), 125.3 (C), 124.9
(Cs.), 123.3 (C6 ), 121.8 (C7 ), 120.0 (C),
115.7 (C3 .), 115.2 (C8 '), 90.5 (C,,), 85.3 (C12),
84.4 (C(CH3)3carbamate), 83.5 (C(CH3)3carbonate),
82.2 (C2 ), 57.8 (C3), 28.3 (C(CH3)3arbamate),
28.1 (C17), 26.8 (C(CH3 ) 3 carbonate).
3386 (br-s), 2981 (w), 1738 (s), 1703 (s), 1453
(m), 1371 (s), 1274 (m), 1252 (m), 1156 (m),
751 (m).
calc'd for C3 8H3 9N40,,S [M+H]*: 759.2331,
found 759.2302.
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TLC (40% ethyl acetate in hexanes), Rf:




OBoc 0 NaBH 4
N'Me MeOH, -20 *C
N -ZO 75%
SO2Ph 0 (-)-25
Boc81 N1i OBoc 0
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1 1 "OH
8 SO2Ph 0 (-)-26
Tetracyclic Diol (-)-26:
Sodium borohydride (17.3 mg, 457 pmol, 2.00 equiv) was added as a solid to a solution
of triketopiperazine (-)-25 (174 mg, 229 ptmol, I equiv) in methanol at -20 'C. After 20 min,
saturated aqueous sodium bicarbonate solution (5 mL) was added to the reaction mixture. The
solution was diluted with dichloromethane (60 mL) and washed with saturated aqueous sodium
bicarbonate solution (60 mL). The mixture was extracted with dichloromethane (2 x 60 mL),
and the combined organic layers were dried over anhydrous sodium sulfate, were filtered, and
were concentrated under reduced pressure. The crude reaction mixture was purified by flash
column chromatography on silica gel (eluent: 20% acetone in dichloromethane) to afford
tetracyclic diol (-)-26 (130 mg, 74.9%) as a white solid. Structural assignments were made
using additional information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
3C NMR (125.8 MHz, CDCl3, 20 *C):
FTIR (thin film) cm-:
6 7.97 (d, J= 7.6, 1H, C8H), 7.75 (d, J= 8.1,
I H, CsH), 7.52 (d, J = 7.1, 1 H, C5H), 7.45 (d,
J = 7.9, 1H, Cs-H), 7.36 (app-t, J = 7.8, 1H,
C7H), 7.31 (app-t, J = 7.3, 1H, C7'H), 7.26(app-t, J= 7.6, 1 H, C6.H), 7.23 (app-t, J= 7.5,
1H, C6H), 7.01 (d, J= 7.4, 2H, SO2Ph-o-H),
6.97 (t, J= 7.5, 1H, SO2Ph-p-H), 6.94 (s, 1H,
C2H), 6.58 (app-t, J = 8.1, 2H, SO 2Ph-m-H),
6.43 (s, 1H, C2.H), 5.66 (s, 1H, C12H), 5.39 (d,
J = 3.0, 1H, C15H), 4.92 (d, J = 2.8, 1H,
C1sOH), 4.38 (br-s, IH, C110H), 2.99 (s, 3H,
C17H), 1.59 (s, 9H, C(CH3) 3carbamate), 0.80 (s,
9H, C(CH3)3carbonate).
6 165.4 (C 16), 163.7 (C 13), 151.2
(C=Ocarbonate), 149.0 (C=Ocarbamate), 140.7 (C9),
136.8 (SO 2Ph-ipso-C), 136.3 (C 9.), 134.0 (C4),
132.4 (SO2 Ph-p-C), 129.8 (C7), 127.8
(SO 2Ph-m-C), 127.7 (C4'), 127.3 (C 2.), 126.8
(SO 2Ph-o-C), 126.2 (C6), 125.4 (C), 124.8
(C7 ), 123.1 (C6 ), 122.3 (Cs), 119.7 (C),
116.0 (C3 ), 115.1 (C.), 90.5 (C11), 84.9 (C 12),
84.2 (C(CH 3)3carbamate), 83.0 (C(CH3)3carbonate),
81.4 (C2 ), 77.1 (C15 ), 57.3 (C3 ), 29.6 (C 17),
28.3 (C(CH 3)3carbamate), 26.9 (C(CH 3)3carbonate).
3417 (br-s), 2980 (w), 1738 (s), 1687 (s), 1454




TLC (20% acetone in dichloromethane), Rf:
calc'd for C3 8H4 1N 40 1 1S [M+H]*: 761.2487,
found 761.2481.
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Tetracyclic Dipivaloate (+)-27:
Pivaloyl chloride (75.8 pL, 616 pmol, 4.00 equiv) was added via syringe to a solution of
tetracyclic diol (-)-26 (117 mg, 154 prmol, I equiv) and 4-dimethylaminopyridine (94.1 mg, 771
pmol, 5.00 equiv) in dichloromethane (4 mL) at 23 *C. After 1 h 45 min, methanol (50 pL) was
added to the reaction mixture, and the crude solution was purified by flash column
chromatography on silica gel (eluent: 1% acetone in dichloromethane) to afford tetracyclic
dipivaloate (+)-27 (119 mg, 83.0%) as a white solid. Structural assignments were made using
additional information from gCOSY, HSQC, and HMBC experiments.
H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, CDCI3, 20 *C):
6 7.96 (d. J= 7.9, 1H, C8 H), 7.81 (d, J= 8.1,
1H, C8H), 7.60 (dd, J= 0.7, 7.5, 1H, C5H),
7.45 (br-s, 1H, C5H), 7.39 (app-dt, J = 1.2,
7.7, 1H, C7H), 7.32-7.25 (m, 1H, C6H), 7.32-
7.25 (m, 1H, C7H), 7.20-7.13 (m, 2H, SO2Ph-
o-H), 7.20-7.13 (m, 1H, C6.H), 6.99 (t, J =
7.5, SO2Ph-p-H), 6.91 (s, 1H, C2H), 6.63
(app-t, J = 7.9, 2H, SO 2Ph-m-H), 6.52 (br-s,
IH, C15H), 6.44 (s, IH, C2.H), 5.70 (s, 1H,
C12H), 2.91 (s, 3H, C17H), 1.59 (s, 9H,
C(CH3)3carbamate), 1.40 (s, 9H, C(CH3)3pivaloate),
0.79 (s, 9H, C(CH3)3carbonate), 0.68 (s, 9H,
C(CH3)3pivaloate).
6 177.3 (C=Opivaloate), 176.3 (C=Opivaoate),
161.3 (C 16), 160.8 (C 13), 151.0 (C=Ocarbonate),
149.0 (C=Ocarbamate), 141.5 (C9 ), 136.6
(SO 2Ph-ipso-C), 136.3 (C9.), 133.1 (C4), 132.6
(SO 2Ph-p-C), 130.0 (C 7), 127.9 (SO 2Ph-m-C),
127.5 (C4 ), 127.3 (C2 '), 127.0 (SO 2Ph-o-C),
126.0 (C6), 125.7 (C5 ), 124.7 (C7 .), 123.0
(C6 ), 122.3 (CO.), 119.4 (Cs), 116.6 (CY),
115.0 (Cs.), 92.2 (C11 ), 85.2 (C 12), 84.2
(C(CH3)3carbamate), 83.2 (C 2 ), 82.8
(C(CH3)3carbonate), 78.3 (Cis), 57.9 (C3), 39.3
(C(CH 3) 3pivaoate), 38.7 (C(CH 3) 3pivaioate), 30.7
(C17 ), 28.3 (C(CH3)3carbamate), 27.2
(C(CH3) 3pivaoate), 26.8 (C(CH 3)3carbonate), 26.3
(C(CH3)3pivaoate).
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FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D24:
TLC (1% acetone in dichloromethane), Rf:
2978 (m), 1742 (s), 1699 (m), 1454 (m), 1371
(s), 1276 (m), 1252 (m), 1155 (m), 1123 (s),
750 (m).
calc'd for C 4 8H 56N 4NaO1 3S [M+Na]*:
951.3457, found 951.3451.
+5.3 (c = 0.095, CHCl3).
0.27 (UV, CAM).
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Tetracyclic Bisthioether (+)-37:
Trifluoroacetic acid (3 mL) was added via syringe to a solution of tetracyclic dipivaloate
(+)-27 (109 mg, 117 pmol, 1 equiv) and 3-mercapto-2-butanone12 (366 mg, 3.51 mmol, 30.0
equiv) in nitromethane (3 mL) at 23 'C. After 45 min, the reaction mixture was diluted with
dichloromethane (60 mL) and washed with saturated aqueous sodium bicarbonate solution (100
mL). The aqueous layer was extracted with dichloromethane (2 x 30 mL), and the combined
organic layers were dried over anhydrous sodium sulfate, were filtered, and were concentrated
under reduced pressure. The crude reaction mixture was purified by flash column
chromatography on silica gel (eluent: 20% acetone in dichloromethane) to afford a
diastereomeric mixture of bisthioethers (68.8 mg, 80.2%, 3:1 dr, major:minor) as a beige solid.
A 25-mL Pyrex pear-shaped flask was sequentially charged with the diastereomeric
mixture of bisthioethers (68.8 mg, 93.9 ptmol, 1 equiv), L-ascorbic acid (165 mg, 939 gmol, 10.0
equiv), sodium L-ascorbate (186 mg, 939 pmol, 10.0 equiv), and 1,4-dimethoxynaphthalene
(1.06 g, 5.63 mmol, 60.0 equiv), and the mixture was placed under an argon atmosphere.
Acetonitrile (8 mL) and water (2 mL) were then sequentially introduced via syringe and the
resulting solution was sparged with argon for 5 min at 23 'C. The system was stirred vigorously
and irradiated in a Rayonet photoreactor equipped with 16 radially distributed (r-12.7 cm) 25 W
black light phosphor lamps (mx=350 nm) at 25 'C. After 1.5 h, the lamps were turned off and
the reaction mixture was diluted with dichloromethane (60 mL). The resulting solution was
washed with saturated aqueous sodium bicarbonate solution (60 mL). The aqueous layer was
extracted with dichloromethane (2 x 10 mL), and the combined organic layers were dried over
anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure. The
crude reaction mixture was purified by flash column chromatography on silica gel (eluent:
gradient, 20->25% acetone in dichloromethane) to afford tetracyclic bisthioether (+)-32 (31.0
mg, 55.7%) as a single diastereomer and as a clear film. Structural assignments were made using
additional information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C): 6 8.00 (s, 1H, N1 H), 7.85 (d, J = 7.4, 1H,
C5,H), 7.37 (d, J= 7.3, 1 H, C5H), 7.31 (d, J=
7.5, 1H, C8H), 7.17 (app-t, J= 7.2, 1H, C7,H),
7.14 (app-t, J = 7.2, 1H, C6,H), 7.09 (d, J =
2.5, 1 H, C2,H), 7.05 (app-t, J= 7.5, 1H, C7H),
6.69 (app-t, J = 7.3, 1H, C6H), 6.62 (d, J =
7.7, 1H, CH), 6.29 (s, 1H, C2H), 5.30 (d, J=
1.8, 1H, C12H), 5.07 (s, 1H, N1H), 4.76 (s, 1H,
C1sH), 3.34 (d, J = 2.0, 1H, C120H), 3.10-
3.02 (m, 2H, C2 2H), 3.08 (s, 3H, C17H), 2.98-
2.86 (m, 2H, C2 3H), 2.86-2.77 (m, 1H,
12 Ross, N. C.; Levine, R. J. Org. Chem. 1964, 29, 2346.
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Ci 8Ha), 2.75-2.67 (m, IH, CIsHb), 2.47-2.32
(m, 2H, C19H), 2.20 (s, 3H, C25H), 2.04 (s,
3H, C21H).
3 C NMR (125.8 MHz, CDCl 3, 20 0C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D 24:
TLC (25% acetone in dichloromethane), Rf:
6 206.9 (C 2 4), 206.3 (C2 0), 165.4
(C13 ), 147.5 (C9 ), 137.1 (C9.),
128.8 (C7), 125.8 (C4 ), 123.7
(C2'), 122.4 (C7'), 121.2 (C),
119.3 (C), 114.9 (C3 ), 111.8 (
(C), 81.6 (C2 ), 81.5 (C 12), 73.5
(C15 ), 59.3 (C3), 44.1 (C 23), 42.6


















3371 (br-s), 2930 (w), 1711 (m), 1661 (s),
1423 (m), 1397 (m), 1364 (w), 1238 (w), 743
(m).
calc'd for C 3oH 32N4NaOSS 2  [M+Na]*:
615.1706, found 615.1693.
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(+)-32 0 Me (+)-bionectin A (1)
(+)-Bionectin A (1):
Pyrrolidine (20 pL, 242 pmol, 27.6 equiv) was added via syringe to a solution of
tetracyclic bisthioether (+)-32 (5.2 mg, 8.77 pmol, 1 equiv) and ethanethiol (20 pL, 270 pmol,
30.8 equiv) in tetrahydrofuran (1 mL) at 23 'C. After 2 h, the reaction mixture was diluted with
dichloromethane (10 mL) and washed with aqueous hydrochloric acid (IN, 10 mL). The
aqueous layer was extracted with dichloromethane (2 x 5 mL), and the combined organic layers
were dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced
pressure. The crude reaction mixture was purified by flash column chromatography on silica gel
(eluent: 10% acetone in dichloromethane) to afford (+)-bionectin A (1) (3.2 mg, 81%) as a beige
solid. Structural assignments were made using additional information from gCOSY, HSQC,
HMBC, and NOESY experiments.
H NMR (500 MHz, CDCl 3, 20 "C):
3C NMR (125.8 MHz, CDCl 3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D24:
TLC (10% acetone in dichloromethane), Rf:
6 8.11 (br-s, 1H, N 1.H), 7.91 (d, J= 7.8, 1H,
C5 H), 7.44 (d, J= 7.5, 1H, C5H), 7.32 (d, J=
8.1, 1H, C8 H), 7.18 (app-t, J= 6.9, 1H, C7H),
7.16-7.11 (m, 1H, C6.H), 7.16-7.11 (m, 1H,
C7H), 7.06 (d, J= 2.6, 1 H, C2H), 6.83 (app-t,
J= 7.5, 1H, C6H), 6.69 (d, J= 7.8, 1H, C8H),
6.30 (s, 1H, C2H), 5.36 (br-s, 1 H, NIH),13 5.32
(s, 1H, C12H), 5.19 (s, IH, C120H), 5.17 (s,
IH, C15H), 3.11 (s, 3H, C17H).
6 166.2 (C13 ), 161.9 (C 16), 147.3 (C 9), 137.1
(C9.), 130.9 (C4), 129.6 (C7), 126.3 (C4.),
124.7 (C), 123.5 (C2.), 122.6 (C 7 ), 121.6
(C), 120.1 (C6 ), 120.1 (C6 ), 113.4 (C3 ),
111.7 (C), 110.9 (C), 82.5 (C2), 81.0 (C 12),
77.0 (C1I), 67.7 (C15), 61.6 (C3 ), 32.0 (C17).
3402 (br-s), 2922 (w), 1677 (s), 1482 (w),
1458 (w), 1377 (in), 1237 (m), 1093 (w), 747
(m).
calc'd for C2 2 Hi 9N40 3S2 [M+H]*: 451.0893,
found 451.0891.
+284 (c = 0.11, CHCl3).
0.25 (UV, CAM).
13 The N I H proton was too broad for observation at high concentrations.
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6' N 17
N 97% 6 3 Me
H 0 a H 0
(+)-bionectin A (1) (+)-bionectin C (2)
(+)-Bionectin C (2):
Sodium borohydride (2.2 mg, 57.7 tmol, 10.0 equiv) was added as a solid to a solution of
(+)-bionectin A (1) (2.6 mg, 5.77 pimol, I equiv) and methyl iodide (35.9 gL, 577 pmol, 100
equiv) in pyridine (100 gL) and methanol (200 pL) at 0 'C. After 1 h, the reaction mixture was
diluted with ethyl acetate (10 mL) and washed with saturated aqueous ammonium chloride
solution (10 mL). The aqueous layer was extracted with ethyl acetate (2 x 10 mL), and the
combined organic layers were dried over anhydrous sodium sulfate, were filtered, and were
concentrated under reduced pressure. The crude reaction mixture was purified by flash column
chromatography on silica gel (eluent: gradient, 10->15% acetone in dichloromethane) to afford
(+)-bionectin C (2) (2.7 mg, 97%) as a white solid. Structural assignments were made using
additional information from gCOSY, HSQC, HMBC, and NOESY experiments.
'H NMR (500 MHz, CDCl3, 20 *C):
13 C NMR (125.8 MHz, CDCl3, 20 *C):
FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
TLC (10% acetone in dichloromethane), Rf:
8 8.00 (br-s, 1H, NiH), 7.85 (d, J= 7.9, 1H,
Cs'H), 7.41 (d, J= 7.5, 1 H, C5H), 7.31 (d, J=
7.6, 1H, C8'H), 7.17 (app-dt, J= 1.0, 7.1, 1H,
C7'H), 7.13 (app-dt, J = 1.0, 7.1, 1H, C6'H),
7.10 (d, J = 2.7, 1H, C2'H), 7.08 (app-dt, J=
1.1, 7.6, 1H, C7H), 6.71 (ap-dt, J = 0.7, 7.5,
1H, C6H), 6.63 (d, J 7.8, 1H, C8H), 6.34 (s,
1H, C2H), 5.30 (d, J= 2.1, 1H, C12H), 5.09 (s,
1H, NiH), 4.59 (s, 1H, CisH), 3.24 (d, J= 2.2,
1H, C12OH), 3.10 (s, 3H, C17H), 2.45 (s, 3H,
C15SCH3), 2.06 (s, 3H, Ci1SCH3).
6 165.0 (C16), 164.8 (C13), 147.6 (C9),
(C9'), 131.9 (C4), 129.0 (C7), 126.0
123.4 (Cs), 123.1 (C2'), 122.6 (C7'),
(Cs'), 120.1 (C6'), 119.3 (C), 115.1
111.8 (C8'), 110.1 (C8), 81.8 (C2), 80.5
73.4 (Cii), 67.8 (Cis), 59.1 (C3), 32.4







3399 (br-s), 2921 (w), 1661 (s), 1608 (w),
1483 (w), 1458 (w), 1424 (m), 1397 (m), 1238
(m), 1087 (w), 741 (m).
calc'd for C24H25N403S2 [M+H]*: 481.1363,
found 481.1355.
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(+)-bionectin A (1) (+)-33
Bionectin A p-Nitrobenzoate (33):
p-Nitrobenzoyl chloride (1.6 mg, 8.67 pmol, 1.50 equiv) was added to a solution of (+)-
bionectin A (1) (2.6 mg, 5.78 pmol, I equiv) and 4-dimethylaminopyridine (3.5 mg, 28.9 pmol,
5.00 equiv) in dichloromethane (1 mL) at 0 *C. After 1 h, another portion of p-nitrobenzoyl
chloride (1.5 mg, 8.08 pmol, 1.40 equiv) was added to the reaction. After 1 h 10 min, another
portion of p-nitrobenzoyl chloride (2.2 mg, 11.9 ptmol, 2.05 equiv) was added to the reaction.
After 1 h 20 min, another portion of 4-dimethylaminopyridine (0.7 mg, 5.73 pmol, 0.99 equiv)
was added to the reaction. After I h 10 min, p-nitrobenzoyl chloride (5.0 mg, 26.9 pmol, 4.66
equiv) was added to the reaction. After 38 min, methanol (50 gL) was added to the reaction.
The crude reaction mixture was purified by flash column chromatography on silica gel (eluent:
2% acetone in dichloromethane) to afford (+)-bionectin A p-nitrobenzoate (33) (3.4 mg, 98%) as
a yellow solid. Crystals suitable for X-ray diffraction were obtained by slow evaporation of a
saturated solution of (+)-33 in chloroform at 23 *C. Structural assignments were made using
additional information from gCOSY, HSQC, and HMBC experiments.
'H NMR (500 MHz, CDCl 3, 20 *C):
13C NMR (125.8 MHz, CDCl 3, 20 *C):
6 8.05 (br-s, 1H, N 1 H), 8.04 (d, J = 8.8, 2H,
p-NO2Bz-m-H), 7.75 (d, J = 8.2, 1H, C5.H),
7.72 (d, J = 8.9, 2H, p-NO2Bz-o-H), 7.66 (d, J
= 7.4, CsH), 7.21 (app-t, J = 7.7, 1H, C7H),
7.19 (d, J= 8.1, 1H, C8H), 7.04 (d, J= 2.7,
1H, C2.H), 7.00 (app-t, J = 7.9, 1H, C7.H),
6.95 (app-t, J= 7.6, 1H, C6H), 6.91 (app-t, J=
7.3, 1H, C6.H), 6.73 (d, J = 7.8, 1H, CH),
6.65 (s, 1H, C12H), 6.55 (s, 1H, C2H), 5.40
(br-s, 1H, NIH), 5.26 (s, 1H, CisH), 3.03 (s,
3H, C17H).
8 163.7 (C=OBz), 163.1 (C 13), 161.7 (C 16),
150.4 (p-NO2Bz-p-C), 147.7 (C9), 137.1 (C9.),
134.9 (p-NO2Bz-ipso-C), 130.9 (p-NO2Bz-m-
C), 130.1 (C7 ), 129.5 (C4), 125.7 (C4'), 125.0
(Cs), 124.7 (C2 '), 123.3 (p-NO 2Bz-o-C), 122.7
(C7.), 121.1 (C5.), 120.2 (C6), 120.1 (C6'),
111.8 (Cs.), 111.8 (C3'), 110.9 (C8 ), 81.3 (C2),
80.6 (C12), 75.8 (C11), 68.7 (CIs), 60.9 (C3),
32.3 (C 17).
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FTIR (thin film) cm-1:
HRMS (ESI) (m/z):
[a]D 2:
TLC (2% acetone in dichloromethane), RfJ
3406 (br-s), 1738 (w), 1691 (s), 1608 (w),
1526 (m), 1346 (w), 1263 (m), 1099 (m), 749
(m), 715 (w).
calc'd for C29 H2 1N 5NaO6 S2  [M+Na]*:
622.0825, found 622.0820.
+17 (c = 0.12, CHC 3).
0.28 (UV, CAM).
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17 (+)-Bionectin A (1) (+)-Bionectin A (1) AS14 (+)-Bionectin A (1) AS 14
Assignment 'H NMR, 500 MHz, 'H NMR, 500 MHz, (ppm) 'H NMR, 500 MHz, (ppm)
CDC 3, 20 *C CDCl3  CDC13
Ni 5.36 (br-s) 5.63 (s) -0.27 5.40 (br-s) -0.04
C2 6.30 (s) 6.54 (s) -0.24 6.33 (s) -0.03
C3 - -
C4 - -
C5 7.44 (d, J= 7.5) 7.32 (dd, J = 7.5, 1.0) +0.12 7.46 (d, J 7.5) -0.02
C6 6.83 (app-t, J= 7.5) 6.75 (td, J= 7.5, 1.0) +0.08 6.85 (t, J= 7.5) -0.02
C7 7.16-7.11 (m) 7.07 (td, J= 7.5, 1.0) +0.07 7.19-7.13 (m) -0.03




C12 5.32 (s) 5.28 (s) +0.04 5.35 (s) -0.03
C12OH 5.19(s) - 5.22 (s) -0.03
C13 -
N14 - --
C15 5.17 (s) 5.19 (s) -0.02 5.20 (s) -0.03
C16 - - -
C17 3.11 (s) 3.02 (s) +0.09 3.14 (s) -0.03
N1' 8.11 (br-s) 8.08 (br-s) +0.03 8.06 (br-s) +0.05
C2' 7.06 (d, J= 2.6) 7.11 (d, J 2.4 Hz) -0.05 7.09 (d, J= 2.5) -0.03
C3' -
C4' - -
C5' 7.91 (d, J= 7.8) 7.93 (dd, J 7.8, 1.0) -0.02 7.94 (d, J= 7.8) -0.03
C6' 7.16-7.11 (m) 7.15 (td, J 7.8, 1.0) -0.02 7.19-7.13 (m) -0.03
CT 7.18 (app-t, J= 6.9) 7.20 (td, J 7.8, 1.0) -0.02 7.21 (t, J= 7.1) -0.03
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17 (+)-Bionectin A (1) (+)-Bionectin A (1) A814 (+)-Bionectin A (1) A814
Assignment '3 C NMR, 125 MHz, "C NMR, 125 NHiz, (ppm) 3C NMR, 125 Mz, (ppm)
CDCl3 20 0C CDC13  CDC13
NI - - - - -
C2 82.5 83.1 -0.6 82.3 +0.2
C3 61.6 59.1 +2.5 61.4 +0.2
C4 130.9 131.5 -0.6 130.7 +0.2
C5 124.7 125.3 -0.6 124.5 +0.2
C6 120.1 120.3 -0.2 119.8 +0.3
C7 129.6 129.3 +0.3 129.2 +0.4
C8 110.9 110.5 +0.4 110.7 +0.2
C9 147.3 147.0 +0.3 147.1 +0.2
N1O - -
C1l 77.0 79.1 -2.1 76.7 +0.3
C12 81.0 80.1 +0.9 80.8 +0.2
C13 166.2 167.0 -0.8 165.9 +0.3
N14 - - - -
C15 67.7 70.6 -2.9 67.5 +0.2
C16 161.9 163.1 -1.2 161.7 +0.2
C17 32.0 33.1 -1.1 31.8 +0.2
NI' - - - - -
C2' 123.5 123.3 +0.2 123.3 +0.2
C3' 113.4 113.6 -0.2 113.2 +0.2
C4' 126.3 126.1 +0.2 126.1 +0.2
C5' 121.6 121.4 +0.2 121.4 +0.2
C6' 120.1 120.1 0 119.9 +0.2
C7' 122.6 122.4 +0.2 122.4 +0.2
C8' 111.7 111.7 0 111.5 +0.2
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17 (+)-Bionectin C (2) (+)-Bionectin C (2) AS (+)-Gliocladin A (2) AS1
4  (+)-Bionectin C (2) A614
Assignment 'H NMR, 500 MHz, 'H NMR, 500 MHz, (ppm) 'H NMR, 500 MHz, (ppm) 'H NMR, 500 MHz, (ppm)
CDC13, 20 -C CDC13  CDC13  CDC13
NI 5.09 (s) 5.12 (s) -0.03 5.12 (br-s) -0.03 5.12 (br-s) -0.03
C2 6.34 (s) 6.35 (s) -0.01 6.35 (s) -0.01 6.36 (s) -0.02
C3 -
C4
C5 7.41 (d, J 7.5) 7.42 (dd, J= 7.5, 1.0) -0.01 7.32 (br-d, J= 7.8) +0.09 7.43 (d, J= 7.6) -0.02
C6 6.71 (app-dt, J 0.7, 7.5) 6.73 (td, J= 7.5, 1.0) -0.02 6.73 (td, J= 7.8, 0.9) -0.02 6.74 (t, J= 7.4) -0.03
C7 7.08 (app-dt, J 1.1, 7.6) 7.09 (td, J= 7.5, 1.0) -0.01 7.09 (td, J= 7.8, 1.1) -0.01 7.09 (t, J= 7.8) -0.01
C8 6.63 (d, J 7.8) 6.65 (dd, J= 7.5, 1.0) -0.02 6.65 (br-d, J 7.8) -0.02 6.65 (d, J= 7.7) -0.02
C9 - - -
N1O -
C1l - - -
C12 5.30 (d, J= 2.1) 5.32 (s) -0.02 5.32 (br-d, J= 3.9) -0.02 5.32 (br-d, J= 2.0) -0.02
C 2 0H 3.24 (d, J= 2.2) - 3.28 (d, J= 3.9) -0.04 3.28 (br-d, J= 2.0) -0.04
C13 - -
N14 - - - -
C15 4.59 (s) 4.60 (s) -0.01 4.60 (s) -0.01 4.61 (s) -0.02
C16 - - - - - -
C17 3.10 (s) 3.11 (s) -0.01 3.11 (s) -0.01 3.12 (s) -0.02
Ni' 8.00 (br-s) 8.06 (br-s) -0.06 8.04 (br-s) -0.04 8.05 (br-s) -0.05
C2' 7.10 (d, J= 2.7) 7.11 (d, J= 2.5) -0.01 7.11 (d, J= 2.5) -0.01 7.11 (d, J= 2.4) -0.01
C3' - - -
C4' - -
C5' 7.85 (d, J= 7.9) 7.87 (dd, J 7.8, 1.0) -0.02 7.87 (br-d, J= 7.8) -0.02 7.87 (d, J= 7.8) -0.02
C6' 7.13 (dt, J= 1.0, 7.1) 7.15 (td, J 7.8, 1.0) -0.02 7.15 (td, J= 7.8, 1.4) -0.02 7.15 (t, J= 7.5) -0.02
C7' 7.17 (dt, J= 1.0, 7.1) 7.19 (td, J 7.8, 1.0) -0.02 7.19 (td, J= 7.8, 1.4) -0.02 7.20 (t, J= 7.5) -0.03
C8' 7.31 (d, J= 7.6) 7.32 (dd, J 7.8, 1.0) -0.01 7.32 (br-d, J= 7.8) -0.01 7.32 (d, J= 7.6) -0.01
C9' - - -
CIISCH3  2.06 (s) 2.08 (s) -0.02 2.08 (s) -0.02 2.09 (s) -0.03
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(+)-Bionectin C (2) (+)-Bionectin C (2) AS14  (+)-Gliocladin A (2) A614  (+)-Bionectin C (2) A614
Assignment '3 C NMR, 125 MHz, '3C NMR, 125 MHz, (ppm) 3 C NMR, 125 MHz, (ppm) '3 C NMR, 125 MHz, (ppm)
CDC13 20 *C CDC13  CDC13  CDC13
NI - - - - - -
C2 81.8 81.8 0 81.55 +0.25 81.5 +0.3
C3 59.1 59.1 0 58.94 +0.16 58.9 +0.3
C4 131.9 131.9 0 131.65 +0.25 131.6 +0.3
C5 123.4 123.5 -0.1 123.21 +0.19 123.2 +0.2
C6 119.3 119.3 0 119.10 +0.20 119.1 +0.2
C7 129.0 129.0 0 128.74 +0.26 128.7 +0.3
C8 110.1 110.1 0 109.89 +0.21 109.9 +0.2
C9 147.6 147.6 0 147.42 +0.18 147.4 +0.2
NIO - - - - - - -
Cl1 73.4 73.3 +0.1 73.15 +0.25 73.1 +0.3
C12 80.5 80.6 -0.1 80.26 +0.24 80.2 +0.3
C13 164.8 164.9 -0.1 164.6 +0.2 164.6 +0.2
N14 - - -
C15 67.8 60.8 +7.0 67.59 +0.21 67.6 +0.2
C16 165.0 165.0 0 164.78 +0.22 164.8 +0.2
C17 32.4 32.2 +0.2 32.13 +0.27 32.1 +0.3
NI' - - - - - - -
C2' 123.1 123.3 -0.2 122.91 +0.19 122.9 +0.2
C3' 115.1 115.0 +0.1 114.89 +0.21 114.9 +0.2
C4' 126.0 125.9 +0.1 125.78 +0.22 125.8 +0.2
C5' 121.3 121.3 0 121.08 +0.22 121.1 +0.2
C6' 120.1 120.2 -0.1 119.90 +0.20 119.9 +0.2
C7' 122.6 122.6 0 122.34 +0.26 122.3 +0.3
C8' 111.8 111.8 0 111.53 +0.27 111.5 +0.3
C9' 137.1 137.1 0 136.91 +0.19 136.9 +0.2
CIISCH3  15.7 15.7 0 15.42 +0.28 15.4 +0.3































Completeness to theta = 28.70'
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F 2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole
x8_12215














a= 100.0 100(l0 O.
b= 92.2140(10) .




0.25 x 0.25 x 0.17 mm 3
1.37 to 28.70'.
-1 8<=h<= 18, -21 <=k<=21, -23<=1<=23
106332




Full-matrix least-squares on F 2
36113 / 2892 / 2057
1.030
RI = 0.0751, wR2 = 0.2013
R I = 0.0940, wR2 = 0.2202
0.03(6)
1.234 and -0.691 e.A- 3
Table S6. Atomic coordinates (x 104 ) and equivalent isotropic displacement parameters (A2 x
103) for 12-hydroxytryptophan 3,5-dinitrobenzamide (+)-14. U(eq) is defined as one third of the
trace of the orthogonalized U'- tensor.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































C(18D) 4002(7) 8161(6) 7365(6) 57(2)
C(19D) 3054(7) 8242(6) 7324(6) 62(2)
C(20D) 2826(7) 8642(7) 6728(6) 57(2)
C(21D) 3535(6) 8968(6) 6201(5) 50(2)
N(22D) 1793(6) 8731(6) 6634(5) 66(2)
O(23D) 1197(6) 8487(7) 7109(6) 86(3)
O(24D) 1573(8) 9014(8) 6057(5) 78(3)
N(25D) 4229(10) 7705(8) 7972(9) 73(3)
O(26D) 3637(8) 7524(5) 8461(5) 81(2)
O(27D) 5072(8) 7570(7) 7986(7) 93(3)
N(IOH) 5081(10) 10058(10) 5194(8) 40(2)
C(I5H) 5167(10) 9432(11) 5618(10) 42(2)
O(46H) 5861(10) 9114(11) 5575(9) 50(2)
C(16H) 4280(9) 9089(9) 6086(8) 56(3)
C(17H) 4413(11) 8576(9) 6618(9) 64(3)
C(18H) 3611(12) 8269(8) 7084(8) 69(3)
C(19H) 2707(12) 8436(10) 7005(10) 74(3)
C(20H) 2602(10) 8917(9) 6463(9) 72(3)
C(21 H) 3377(10) 9257(9) 5987(9) 61(3)
N(22H) 1640(12) 9151(12) 6387(10) 86(4)
O(23H) 913(12) 8738(9) 6708(12) 124(6)
O(24H) 1588(9) 9631(12) 5930(10) 127(6)
N(25H) 3776(12) 7801(10) 7704(9) 90(4)
O(26H) 3062(13) 7493(6) 8081(7) 95(4)
O(27H) 4614(12) 7695(13) 7788(11) 109(5)
O(28D) 6664(2) 11721(2) 4376(2) 51(1)
C(29D) 6715(4) 12617(3) 4250(3) 59(1)
C(30D) 6538(6) 12572(5) 3409(4) 85(2)
C(31D) 3327(12) 8399(10) 3588(11) 81(2)
C(32D) 4261(17) 8900(20) 2076(9) 91(3)
Si(1D) 3822(5) 9388(5) 3172(6) 106(2)
C(33D) 2939(8) 9938(10) 2903(8) 97(2)
C(34D) 3485(16) 10533(12) 2323(10) 114(3)
C(35D) 2004(11) 9174(16) 2396(12) 138(5)
C(36D) 2763(14) 10376(14) 3751(11) 119(4)
C(31H) 3624(9) 8146(8) 3607(8) 81(2)
C(32H) 4003(12) 8951(14) 1970(6) 91(3)
Si(1 H) 3902(3) 9101(3) 3120(3) 76(1)
C(33H) 2801(6) 9492(8) 3422(6) 97(2)
C(34H) 2983(13) 10432(10) 3234(9) 114(3)
C(35H) 1805(9) 8803(13) 2928(9) 138(5)
C(36H) 2648(10) 9574(12) 4303(7) 119(4)
C(37D) 7612(3) 9213(3) 1125(2) 45(1)
C(38D) 6600(4) 8918(3) 811(2) 49(1)
C(39D) 6207(5) 8094(3) 300(3) 59(1)







































































































































































































































































































































































































































































































































































































































































N(1 OA)-C(1 5A)-C(1 6A)
C(1 7A)-C(1 6A)-C(21 A)
C(1 7A)-C(1 6A)-C(1 5A)
C(21A)-C(16A)-C(15A)
C(1 8A)-C(1 7A)-C(1 6A)




C(2 1 A)-C(20A)-C(1 9A)
C(21A)-C(20A)-N(22A)
C(1 9A)-C(20A)-N(22A)





























































































0(1 3B)-Si(1 B)-C(3 I B)
C(32B)-Si(1 B)-C(31 B)

























N(I OB)-C( 11 B)-C(1 4B)


























































C(2 1 B)-C(1 6B)-C(I 7B)
C(21 B)-C(1 6B)-C(1 5B)
C(1 7B)-C(I 6B)-C( 15B)
C(1 8B)-C(I 7B)-C(1 6B)




































































































N(I OC)-C( 11 C)-C(1 4C)
N(I OC)-C( 11 C)-C(I 2C)













C(21 C)-C(1 6C)-C(1 7C)
C(21 C)-C(1 6C)-C(1 5C)
C(1 7C)-C(1 6C)-C(1 5C)
C(I 8C)-C(I 7C)-C(I 6C)























































































































































































































































0(45 D)-C(1 4D)-C( 11 D)




N(1 OD)-C(1 5D)-C(1 6D)
C(21 D)-C(1 6D)-C(I 7D)
C(21D)-C(16D)-C(15D)
C(17D)-C(16D)-C(15D)
C(I 6D)-C(1 7D)-C(I 8D)


















C(21 H)-C(1 6H)-C(1 7H)
C(21 H)-C(1 6H)-C(1 5H)
C(17H)-C(16H)-C(15H)
C(16H)-C(17H)-C(1 8H)































































0(1 3D)-Si(1 D)-C(3 1 D)
0(1 3D)-Si(1 D)-C(33D)
C(3 I D)-Si(1 D)-C(33D)
0(13D)-Si(1D)-C(32D)




















































Table S8. Anisotropic displacement parameters (A2 x 103) for 12-hydroxytryptophan 3,5-
dinitrobenzamide (+)-14. The anisotropic displacement factor exponent takes the form: -2p 2 [h2
a*21" + .+ 2 h k a* b* U12]















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S9. Hydrogen coordinates (x 104 ) and isotropic
12-hydroxytryptophan 3,5-dinitrobenzamide (+)-14.
displacement parameters (A 2 x 103) for





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Completeness to theta = 29.80'
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole
x8_11120






a = 9.7839(4) A
b = 16.5231(8) A

















Full-matrix least-squares on F2
11230 / 146 / 536
1.100
RI = 0.0485, wR2 = 0.1186
RI = 0.0544, wR2 = 0.1218
-0.04(6)
0.359 and -0.658 e.A- 3
Table S11. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2 X
103) for silacyclic tetracycle 23. U(eq) is defined as one third of the trace of the orthogonalized
ULi tensor.






















































































































































































































































































































































































































































































































































N(I 4)-C(I 5)-C( 16)
0(1)-C(I 6)-N( 10)
0(1)-C(16)-C(15)
































C(1 0')-0(7')-C(1 I B)






















































C(I 2B)-C( I B)-O(7')
C(12B)-C(1 1B)-C(14B)



























C(1 8A)-C(1 7A)-Si( 1)
Cl(2)-C(1 S)-Cl(1)
Cl(4)-C(2S)-Cl(3)
Table S13. Anisotropic displacement parameters (A2 x 103) for silacyclic tetracycle 23. The
anisotropic displacement factor exponent takes the form: -2p 2[h2 a*2U"I + ... + 2 h k a* b* U12]






























































































































































































































































































































































































































































Table S14. Hydrogen coordinates (x 104 ) and isotropic displacement parameters (A 2 x 103) for
silacyclic tetracycle 23.
x y z U(eq)
























































































































































































































































































































Completeness to theta = 30.510
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole
Table S16. Atomic coordinates
103) for tetracyclic triacetate 28.
UJ tensor.
x8_12224






a = 12.8803(7) A
b = 10.3954(6) A











0.45 x 0.36 x 0.16 mm 3







Full-matrix least-squares on F2
13500 / 1 / 588
1.047
RI = 0.0301, wR2= 0.0833
RI = 0.0311, wR2 = 0.0843
-0.01(3)
0.382 and -0.214 e.A-3
and equivalent isotropic displacement parameters (A2 X
is defined as one third of the trace of the orthogonalized



























































































































































































































































































































































































































































































































































N(1 4)-C(I 5)-C( 16)
0(2)-C(1 6)-N(1 0)
0(2)-C(1 6)-C(1 5)























































































































Table S18. Anisotropic displacement parameters (A2 x 103) for tetracyclic triacetate 28. The
anisotropic displacement factor exponent takes the form: -2p 2[h2 a* 2U" + ... + 2 h k a* b*U12













































































































































































































































































































































































































































































Table S19. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) for
tetracyclic triacetate 28.
x y z U(eq)




































































































































































































































Completeness to theta = 31.00'
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole
x8_13026






a = 11.6928(7) A
b = 11.2669(6) A









0.18 x 0.16 x 0.11 mm 3
0.99 to 3 1.000.






Full-matrix least-squares on F2
17143 / 3313 / 1207
1.231
RI = 0.0465, wR2 = 0.1452
RI = 0.0512, wR2 = 0.1496
0.01(4)
1.032 and -0.389 e.A-3
Table S21. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2 X
103) for (+)-bionectin A p-nitrobenzoate (33). U(eq) is defined as one third of the trace of the
orthogonalized U'- tensor.



























C(4) -5854(2) -5962(2) -6204(2) 14(1)
C(5) -5090(2) -6889(2) -6058(1) 17(1)
C(6) -3949(3) -6632(4) -5796(2) 24(1)
C(7) -3614(3) -5457(4) -5705(2) 27(1)
C(8) -4379(3) -4521(3) -5843(2) 22(1)
C(9) -5502(3) -4794(3) -6093(2) 15(1)
C(12) -7848(2) -6788(3) -6096(2) 14(1)
N(10) -7996(3) -4815(3) -5727(2) 12(1)
C(11) -8111(3) -6024(3) -5507(1) 13(l)
C(13) -9257(3) -6228(3) -5232(1) 18(1)
N(14) -9562(3) -5283(4) -4886(2) 15(1)
C(15) -8714(5) -4370(5) -4730(2) 13(1)
C(16) -8260(4) -3904(2) -5343(2) 12(l)
C(17) -10554(4) -5319(5) -4513(3) 21(1)
0(18) -9784(3) -7165(3) -5299(1) 32(1)
0(19) -8088(3) -2855(2) -5451(2) 16(1)
0(20) -8952(4) -7004(5) -6463(2) 15(1)
C(21) -9094(3) -8091(3) -6747(2) 14(1)
0(22) -8342(2) -8830(3) -6733(2) 26(1)
C(23) -10279(3) -8256(4) -7079(2) 16(1)
C(24) -11206(2) -7584(3) -6917(2) 18(1)
C(25) -12301(2) -7758(3) -7248(2) 22(1)
C(26) -12424(2) -8591(4) -7746(2) 19(1)
C(27) -11518(4) -9299(5) -7903(3) 25(1)
C(28) -10444(3) -9122(5) -7561(3) 24(1)
N(29) -13566(3) -8745(3) -8119(1) 24(1)
0(30) -13768(3) -9602(3) -8490(2) 38(1)
0(31) -14317(2) -8010(3) -8042(1) 32(1)
N(l') -6849(5) -6933(7) -8191(3) 21(1)
C(2') -6434(4) -6775(4) -7548(3) 16(1)
C(3') -7252(4) -6247(4) -7220(2) 15(1)
C(4') -8256(6) -6070(10) -7692(3) 18(l)
C(5') -9370(3) -5610(3) -7671(2) 20(1)
C(6') -10136(2) -5594(3) -8236(1) 24(1)
C(7') -9811(2) -6027(3) -8829(1) 27(1)
C(8') -8729(3) -6504(3) -8865(2) 25(1)
C(9') -7962(3) -6527(4) -8290(2) 19(1)
S(IB) -7687(7) -5010(9) -4185(4) 63(3)
S(2B) -7234(11) -6609(8) -4864(4) 73(3)
N(IB) -6351(12) -4281(11) -6211(8) 16(1)
C(2B) -7450(14) -4843(16) -6389(17) 13(3)
C(3B) -7257(12) -6186(13) -6454(8) 11(1)
C(4B) -5986(11) -6219(12) -6184(8) 15(1)
C(5B) -5281(11) -7175(12) -6052(7) 17(1)
C(6B) -4145(14) -6972(17) -5772(10) 31(4)
C(7B) -3726(13) -5868(16) -5635(9) 31(3)
339
C(8B) -4407(13) -4866(15) -5746(10) 29(3)
C(9B) -5537(11) -5139(13) -6037(10) 22(3)
C(12B) -8105(13) -6850(18) -6161(9) 14(1)
N(1OB) -8109(18) -4973(13) -5811(8) 12(1)
C(l IB) -8256(15) -6208(14) -5624(9) 29(2)
C(13B) -9423(13) -6285(15) -5374(7) 18(1)
N(14B) -9670(20) -5400(20) -4982(13) 27(4)
C(15B) -8840(30) -4480(20) -4814(11) 19(3)
C(16B) -8180(20) -4112(13) -5393(11) 12(1)
C(1 7B) -10630(30) -5560(30) -4595(17) 35(6)
O(18B) -10016(14) -7163(14) -5467(7) 32(1)
0(19B) -7975(18) -3058(12) -5482(10) 16(1)
0(20B) -9120(20) -7100(30) -6562(13) 26(3)
C(21B) -9401(17) -8181(18) -6851(11) 25(3)
0(22B) -8637(11) -8919(16) -6715(9) 26(1)
C(23B) -10454(16) -8200(18) -7216(10) 26(3)
C(24B) -11315(13) -7380(15) -7121(8) 37(4)
C(25B) -12378(11) -7567(12) -7453(6) 22(1)
C(26B) -12632(16) -8492(16) -7889(9) 29(3)
C(27B) -11754(18) -9280(30) -7981(16) 34(4)
C(28B) -10703(17) -9170(20) -7626(14) 33(4)
N(29B) -13725(14) -8544(15) -8259(8) 24(1)
0(30B) -13559(14) -9377(16) -8618(8) 38(1)
0(31B) -14440(11) -7850(14) -8248(6) 32(1)
N(I'B) -6850(20) -6960(30) -8185(13) 21(1)
C(2'B) -6510(20) -6960(20) -7524(13) 16(1)
C(3'B) -7330(20) -6400(20) -7211(11) 15(1)
C(4'B) -8220(30) -6020(50) -7708(11) 18(1)
C(5'B) -9257(17) -5390(20) -7708(9) 20(1)
C(6'B) -9938(12) -5248(13) -8280(6) 24(1)
C(7'B) -9629(11) -5625(14) -8877(6) 27(1)
C(8'B) -8586(13) -6195(15) -8903(8) 25(1)
C(9'B) -7859(18) -6340(20) -8318(9) 19(1)
S(1A) -6988(1) -373(1) -679(1) 31(1)
S(2A) -7280(1) -1843(1) -106(1) 27(1)
N(1A) -8768(2) 321(3) 1061(2) 27(1)
C(2A) -7620(2) -29(2) 1318(1) 16(1)
C(3A) -7733(2) -1349(2) 1538(1) 15(1)
C(4A) -8913(2) -1675(3) 1206(1) 20(1)
C(5A) -9432(2) -2773(3) 1148(1) 27(1)
C(6A) -10570(2) -2843(3) 845(1) 37(1)
C(7A) -11138(2) -1822(4) 611(1) 37(1)
C(8A) -10604(2) -728(3) 651(1) 33(1)
C(9A) -9469(2) -659(3) 949(1) 23(1)
C(12A) -6768(2) -2065(2) 1238(2) 15(1)
N(IOA) -6781(3) -116(3) 832(1) 19(1)
340
C(11A) -6456(2) -1292(2) 674(1) 16(1)
C(13A) -5202(2) -1350(2) 515(1) 20(1)
N(14A) -4952(2) -442(2) 127(1) 22(1)
C(I5A) -5856(3) 368(2) -94(l) 22(1)
C(16A) -6506(3) 797(3) 457(1) 23(1)
C(17A) -3861(3) -397(3) -152(2) 34(1)
O(18A) -4542(2) -2153(2) 688(1) 25(1)
O(19A) -6760(4) 1831(3) 548(2) 32(1)
O(20A) -5773(2) -2170(2) 1718(1) 16(1)
C(21A) -5350(2) -3278(2) 1814(1) 21(l)
O(22A) -5821(2) -4158(2) 1580(1) 38(l)
C(23A) -4233(2) -3297(3) 2250(2) 20(1)
C(24A) -3640(2) -2259(2) 2431(2) 36(1)
C(25A) -2595(2) -2327(3) 2830(2) 40(1)
C(26A) -2186(3) -3425(2) 3023(1) 22(1)
C(27A) -2757(3) -4460(3) 2850(2) 38(1)
C(28A) -3795(3) -4396(3) 2444(2) 36(1)
N(29A) -1066(2) -3514(2) 3437(1) 29(1)
O(30A) -502(2) -2608(3) 3531(2) 50(1)
O(31A) -764(2) -4484(3) 3666(2) 43(1)
N(l'A) -8160(2) -1823(2) 3273(1) 15(1)
C(2'A) -8479(2) -1962(3) 2618(1) 16(1)
C(3'A) -7693(3) -1428(4) 2277(1) 15(1)
C(4'A) -6827(3) -915(4) 2749(2) 15(l)
C(5'A) -5834(2) -215(2) 2715(1) 17(1)
C(6'A) -5213(2) 153(2) 3288(1) 21(1)
C(7'A) -5535(2) -175(3) 3897(2) 20(1)
C(8'A) -6513(3) -838(3) 3949(1) 19(l)
C(9'A) -7154(2) -1190(2) 3367(1) 14(1)
S(1C) -7375(6) -225(6) -752(3) 31(1)
S(2C) -7752(7) -1701(8) -132(3) 40(2)
N(IC) -8583(14) 714(15) 1122(11) 27(3)
C(2C) -7444(15) 222(17) 1325(13) 16(1)
C(3C) -7756(15) -1063(16) 1510(10) 15(1)
C(4C) -8970(13) -1253(14) 1164(7) 24(3)
C(5C) -9583(13) -2270(16) 1068(8) 27(1)
C(6C) -10708(16) -2240(20) 731(9) 37(1)
C(7C) -11068(15) -1130(20) 538(9) 37(1)
C(8C) -10491(13) -70(20) 621(9) 42(4)
C(9C) -9370(13) -175(16) 948(9) 31(4)
C(12C) -6970(20) -1870(30) 1257(14) 15(1)
N(1OC) -6900(30) -40(19) 757(14) 19(1)
C(1IC) -6772(14) -1232(16) 529(11) 22(2)
C(13C) -5539(14) -1400(13) 367(9) 20(1)
N(14C) -5269(14) -422(15) 12(9) 22(l)





































































































































































































































































































































































































































































































































































































0(1 8)-C(l 3)-C(1 1)
N(14)-C(13)-C(1 1)
C(1 3)-N(I 4)-C(1 5)
C(13)-N(14)-C(1 7)
C(1 5)-N(14)-C(1 7)
N(I 4)-C(I 5)-C( 16)
N(14)-C(1 5)-S(1)
C(1 6)-C(1 5)-S(1)
0(1 9)-C(1 6)-N( 10)
0(1 9)-C(1 6)-C(1 5)








































































































C(1 6B)-N(1 OB)-C( 11 B)
C(1 6B)-N(I OB)-C(2B)
C( 11 B)-N(1 OB)-C(2B)

































































N(1 4B)-C(1 5B)-S(1 B)
C(16B)-C(15B)-S(1B)
0(1 9B)-C(1 6B)-N(I OB)
0(1 9B)-C(1 6B)-C( 15 B)
















































































































C(1 3A)-C( 11 A)-S(2A)
0(1 8A)-C(1 3A)-N(I 4A)
0(1 8A)-C(1 3A)-C( 11 A)
N(14A)-C(13A)-C(1 IA)
C(13A)-N(14A)-C(15A)
C(1 3A)-N(I 4A)-C(1 7A)
C(I 5A)-N(1 4A)-C(I 7A)
N(I 4A)-C(1 5A)-C(1 6A)
N(1 4A)-C(1 5A)-S(1 A)
C(1 6A)-C(I 5A)-S(1 A)
0(1 9A)-C(1 6A)-N(1 OA)
0(1 9A)-C(1 6A)-C(1 5A)
N(1 OA)-C(1 6A)-C(1 5A)




















































































































































0(20C)-C(I 2C)-C( 11 C)
C(3C)-C(I 2C)-C( 11 C)
C(1 6C)-N(1 OC)-C(2C)
C(1 6C)-N(1 OC)-C( 11 C)
C(2C)-N(1 OC)-C( 11 C)
N(1OC)-C(1 IC)-C(13C)
N(1 OC)-C(1 1 C)-C(1 2C)
C(13C)-C(1 IC)-C(12C)
N(1 OC)-C( 11 C)-S(2C)
C(I 3C)-C( 11 C)-S(2C)








N(1 4C)-C(I 5C)-S(I C)
C(1 6C)-C(1 5C)-S(1 C)
0(1 9C)-C(I 6C)-N(1 OC)

































































































Table S23. Anisotropic displacement parameters (A2 x 103) for (+)-bionectin A p-nitrobenzoate
(33). The anisotropic displacement factor exponent takes the form: -2p 2[h2 a* 2 U" + ... + 2 h k
a* b*U ]




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S24. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) for
(+)-bionectin A p-nitrobenzoate (33).
x y z U(eq)
352
H(1) -6344 -3251 -6370 19
H(2) -8034 -4360 -6698 16
H(5) -5331 -7687 -6134 21
H(6) -3416 -7255 -5683 29
H(7) -2837 -5286 -5543 32
H(8) -4141 -3721 -5770 26
H(12) -7439 -7541 -5956 17
H(15) -9064 -3703 -4502 16
H(17A) -11077 -5956 -4682 31
H(17B) -10961 -4557 -4556 31
H(17C) -10289 -5467 -4053 31
H(24) -11091 -7007 -6580 22
H(25) -12944 -7320 -7135 26
H(27) -11635 -9885 -8235 30
H(28) -9813 -9597 -7656 29
H(2N) -6510(30) -7290(30) -8508(17) 25
H(2') -5686 -6999 -7358 19
H(5') -9594 -5313 -7274 24
H(6') -10890 -5287 -8223 28
H(7') -10346 -5992 -9211 32
H(8') -8515 -6803 -9263 30
H(IB) -6222 -3512 -6214 19
H(2B) -7907 -4480 -6778 16
H(5B) -5552 -7958 -6147 21
H(6B) -3652 -7634 -5674 37
H(7B) -2944 -5779 -5458 38
H(8B) -4147 -4084 -5640 35
H(12B) -7747 -7624 -6011 17
H(I5B) -9224 -3774 -4647 23
H(17D) -10690 -6395 -4479 52
H(17E) -11347 -5300 -4849 52
H[(17F) -10493 -5078 -4197 52
H(24B) -11167 -6720 -6838 44
H(25B) -12979 -7033 -7382 26
H(27B) -11887 -9899 -8294 41
H(28B) -10134 -9765 -7659 40
H(l'B) -6477 -7314 -8478 25
H(2'B) -5821 -7297 -7317 19
H(5'B) -9476 -5074 -7314 24
H(6'B) -10663 -4870 -8273 28
H(7'B) -10131 -5492 -9265 32
H(8'B) -8370 -6480 -9304 30
H(IA) -8991 1059 986 32
H(2A) -7316 485 1694 19
H(5A) -9030 -3466 1308 33
H(6A) -10950 -3589 800 44
353
H(7A) -11915 -1876 418 45
H(8A) -10998 -39 481 39
H(12A) -7054 -2862 1080 18
H(15A) -5530 1063 -311 27
H(17J) -3322 121 115 52
H(17K) -3993 -83 -597 52
H(17L) -3537 -1197 -161 52
H(24A) -3943 -1510 2285 44
H(25A) -2177 -1630 2964 48
H(27A) -2452 -5204 3002 46
H(28A) -4197 -5100 2303 43
H(2NA) -8550(20) -2130(30) 3580(14) 18
H(2'A) -9148 -2369 2430 19
H(5'A) -5599 -2 2305 21
H(6'A) -4553 638 3271 25
H(7'A) -5070 65 4282 24
H(8'A) -6739 -1047 4361 23
H(1C) -8746 1477 1113 32
H(2C) -6963 676 1672 19
H(5C) -9259 -3003 1227 33
H(6C) -11170 -2927 647 44
H(7C) -11824 -1090 314 45
H(8C) -10818 669 472 51
H(12C) -7381 -2641 1162 18
H(15C) -5843 1054 -457 37
H(17G) -4070 -1348 -408 54
H(17H) -3682 -18 -220 54
H(171) -4599 -261 -843 54
H(24C) -3800 -1806 1909 44
H(25C) -2023 -1950 2490 50
H(27C) -2984 -5114 3143 46
H(28C) -4789 -4772 2657 28
H(l'C) -8549 -2255 3430 18
H(2'C) -9077 -2296 2273 19
H(5'C) -5374 -310 2313 21
H(6'C) -4442 429 3286 25
H(7'C) -4859 -483 4274 33
H(8'C) -6756 -1172 4304 23
354
Appendix A.
Spectra for Chapter I
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tn C13 dres 1.0
at 1.736 homo n
np 131010 temp 20.0
sw 37735.8 PROCESSING
fb not used lb 2.00
bs 4 wtfile
ss 1 proc ft
tpwr 53 fn 131072
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tn C13 homo n
at 1.736 PROCESSING
np 131010 lb 0.30
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fb not used proc ft
bs 8 fn 131072
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SAMPLE DEC. & VT
dfrq 125.672





sfrq 499.746 dmf 10000
tn H1 dseq
at 3.001 dres 1.0
np 63050 homo n
sw 10504.2 DEC2
fb not used dfrq2 0
bs 1 dn2
tpwr 56 dpwr2 1
pw 8.5 dof2 0
dl 2.000 dm2 n
tof 1519.5 dmm2 c
nt 11111 dmf2 200
ct 32 dseq2
alock n dres2 1.0
gain not used homo2 n
FLAGS DEC3
il n dfrq3 0
in n dn3
dp y dpwr3 1
hs nn dof3 0
DISPLAY dm3 n
sp -249.9 dmm3 c
wp 6496.6 dmf3 200
vs 27 dseq3
sc 0 dres3 1.0
wc 250 homo3 n
hzmm 25.99 PROCESSING
'. is 33.57 wtfile
rfl 4865.9 proc ft
rfp 3618.1 fn 262144
th 7 math f
ins 100.000
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at 1.736 dmf 10
np 131010 dseq
sw 37735.8 dres
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fb not used wtfile
bs 8 proc
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Spectra for Chapter III
464
SAMPLE DEC. & VT
dfrq 125.672







sfrq 499.746 dres 1.0
tn H1 homo n
at 3.001 PROCESSING
np 63050 wtfile
sw 10504.2 proc ft
fb not used fn 262144












































fb not used wtfile
bs 8 proc
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fb not used wtfile
bs 8 proc
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Sorted By : Signal
Multiplier : 1.0000
Dilution 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 A, Sig=254,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min) [min] [mAU*s] [mAU] %
---- I------- ------------ I----------I---------- --------
1 10.555 MM 0.3529 2692.25024 127.15382 48.1593
2 13.532 MM 0.5497 2898.05127 87.87537 51.8407
Totals : 5590.30151 215.02919
Results obtained with enhanced integrator!
Summed Peaks Report
Signal 1: DAD1 A, Sig=254,16 Ref=360,100
Final Summed Peaks Report
Signal 1: DAD1 A, Sig=254,16 Ref=360,100 474
14 16 min
Br -... 0 H2 , Pd/C ----. 0
/ AcOH, 23 *C OMe
CbzN NHBoc HN NHBoc
(+)-65____________________________ 
______








0 - ...- 
8 10 12 14 16 min
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 A, Sig=254,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min] [min] [mAU*s] [mAU] %
-I--------I ---- I--------I-----------I----------I--------
1 10.541 MM 0.3542 2863.94800 134.75856 100.0000
Totals : 2863.94800 134.75856
Results obtained with enhanced integrator!
Summed Peaks Report
Signal 1: DAD1 A, Sig=254,16 Ref=360,100
Final Summed Peaks Report
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tn C13 dres 1.0
at 1.736 homo n
np 131010 PROCESSING
sw 37735.8 lb 1.00
fb not used wtfile
bs 8 proc ft
ss 1 fn 131072
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dfrq 125.672 OCDCl3 dn C13 Hdpwr 30 B
dof 0 BrNdm nnn
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SAMPLE DEC. & VT
dfrq 125.673





sfrq 499.748 dmf 10000
tn H1 dseq
at 3.001 dres 1.0
np 63050 homo n
sw 10504.2 DEC2
fb not used dfrq2 0
bs I dn2
tpwr 56 dpwr2 1
pw 8.6 dof2 0
dl 2.000 dm2 n
tof 1519.5 dmm2 c
nt 11111 dmf2 200
ct 22 dseq2
alock n dres2 1.0
gain not used homo2 n
FLAGS DEC3
il n dfrq3 0
in n dn3
dp y dpwr3 1
hs nn dof3 0
DISPLAY dm3 n
sp -249.9 dmm3 c
wp 6496.6 dmf3 200
vs 25 dseq3
sc 0 dres3 1.0
wc 250 homo3 n
hzmm 25.99 PROCESSING
is 33.57 wtfile
rfl 1233.8 proc ft
rfp 0 fn 262144
th 7 math f
ins 100.000
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tn C13 dres 1.0
at 1.736 homo n
np 131010 PROCESSING
sw 37735.8 lb 0.30
fb not used wtfile
bs 8 proc ft
ss 1 fn 131072
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fb not used wtfile
bs 8 proc
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bs 8 proc
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4000.0 3000 2000 1500 1000 500 400.0
cm-I
SAMPLE DEC. & VT
dfrq 125.672





sfrq 499.746 dmf 10000
tn HI dseq
at 3.001 dres 1.0
np 63050 homo n
sw 10504.2 DEC2
fb not used dfrq2 0
bs 1 dn2
tpwr 56 dpwr2 1
pw 8.6 dof2 0
dl 2.000 dm2 n
tof 1519.5 dmm2 c
nt 11111 dmf2 200
ct 10 dseq2
alock n dres2 1.0
gain not used homo2 n
FLAGS DEC3
il n dfrq3 0
in n dn3
dp y dpwr3 1
hs nn dof3 0
DISPLAY dm3 n
sp -249.9 dmm3 c
wp 6496.6 dmf3 200
vs 17 dseq3
Sc 0 dres3 1.0
wc 250 homo3 n
hzmm 25.99 PROCESSING
is 33.57 wtfile
rfl 4865.1 proc ft
rfp 3618.1 fn 262144
th 7 math f
ins 100.000
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SAMPLE DEC. & VT
dfrq 125.672





sfrq 499.746 dmf 10000
tn H1 dseq
at 3.001 dres 1.0
np 63050 homo n
sw 10504.2 DEC2
fb not used dfrq2 0
bs 1 dn2
tpwr 56 dpwr2 1
pw 8.5 dof2 0
dl 2.000 dm2 n
tof 1519.5 dmm2 c
nt 11111 dmf2 200
ct 7 dseq2
alock n dres2 1.0
gain not used homo2 n
FLAGS DEC3
il n dfrq3 0
in n dn3
dp y dpwr3 1
hs nn dof3 0
DISPLAY dm3 n
sp -249.9 dmm3 c
wp 6496.6 dmf3 200
vs 18 dseq3
sc 0 dres3 1.0
wc 250 homo3 n
bzmm 25.99 PROCESSING
is 33.57 wtfile
rfl 4862.9 proc ft
rfp 3618.1 tn 262144
th 7 math f
ins 100.000
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Appendix D.
Spectra for Chapter IV
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fb not used wtfile
bs 8 proc
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fb not used wtfile
bs 8 proc
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fb not used wtfile
bs 8 proc
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fb not used wtfile
bs 8 proc
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bs 8 proc
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fb not used wtfile
bs 8 proc
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Movassaghi Research Group, Massachusetts Institute of Technology Cambridge, MA
Department of Chemistry, Advisor: Professor Mohammad Movassaghi
Graduate Research Assistant, Organic Chemistry
" Total synthesis of (+)-bionectins A and C.
* Total synthesis of (+)-naseseazines A and B.
* Total synthesis of (+)-chaetocins A and C and (+)-12,12'-dideoxychetracin A.
* Total synthesis of (+)-12,12'-dideoxyverticillin A.
Evans Research Group, Harvard University Cambridge, MA
Department of Chemistry and Chemical Biology, Advisor: Professor David A. Evans
Undergraduate Research Assistant, Organic Chemistry
* Total synthesis of (+)-symbioimine.
* Studies toward the total synthesis of serratinine.
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2004 Jeruzalmi Research Group, Harvard University Cambridge, MA
Department of Molecular and Cell Biology, Advisor: David Jeruzalmi
Undergraduate Research Assistant, Structural Biology
* Studies toward understanding the role of proteins involved in the assembly of the p-
clamp that is responsible for DNA polymerase processivity.
2003, 2004 NASA Jet Propulsion Laboratory Pasadena, CA
Technical Assistant to the Manager ofAdvanced Concepts/Technology Innovations
* Independently completed the Intelligent Modular Systems project involving
programming firmware for microprocessors used for motor control, modifying and
implementing JPEG decompression, programming a motion tracking system, and
writing code to test the concept of automatic reconfiguration of a generic module
(microcontroller) upon fault detection.
" Worked as part of a team on an API for a bridge between the IEEE 1394 (Firewire)
and IEEE 1553 busses.
PUBLICATIONS
* Boyer, N.; Morrison, K. C.; Kim, J.; Hergenrother, P. J.; Movassaghi, M. Chem. Sci. 2013, 4, 1646-
1657. "Synthesis and Anticancer Activity of Epipolythiodiketopiperazine Alkaloids."
* Lathrop, S. P.; Kim, J.; Movassaghi, M. Chimia 2012, 66, 389-393. "Radical Mediated
Dimerization and Oxidation Reactions for the Synthesis of Complex Alkaloids."
* Kim, J.; Movassaghi, M. J. Am. Chem. Soc. 2011, 133, 14940-14943. "Concise Total Synthesis and
Stereochemical Revision of (+)-Naseseazines A and B: Regioselective Arylative Dimerization of
Diketopiperazine Alkaloids."
" Kim, J.; Movassaghi, M. J. Am. Chem. Soc. 2010, 132, 14376-14378. "General Approach to
Epipolythiodiketopiperazine Alkaloids: Total Synthesis of (+)-Chaetocins A and C and (+)-12,12'-
Dideoxychetracin A."
e Kim, J.; Movassaghi, M. Chem. Soc. Rev. 2009, 38, 3035-3050. "Biogenetically Inspired Syntheses
ofAlkaloid Natural Products."
e Kim, J.; Ashenhurst, J. A.; Movassaghi, M. Science 2009, 324, 238-241. "Total Synthesis of(+)-
11, II'-Dideoxyverticillin A."
" Kim, J.; Thomson, R. J. Angew. Chem. Int. Ed. 2007, 46, 3106-3107. "Enantioselective Total
Synthesis of the Osteoclastogenesis Inhibitor (+)-Symbioimine."
BOOK CHAPTER
* Kim, J.; Movassaghi, M. (+)-11,1 l'-Dideoxyverticillin A. In Total Synthesis ofNatural Products; Li,
J. J.; Corey, E. J., Eds.; Springer-Verlag: Berlin Heidelberg, 2013; pp 211-233.
PRESENTATIONS
e Total Synthesis ofDimeric Diketopiperazine Alkaloids. Kim, J. Poster Presentation. Center for C-H
Functionalization Symposium, Emory University. October 13, 2012.
e Total Synthesis ofDimeric Diketopiperazine Alkaloids. Kim, J. Poster Presentation. Reaxys PhD
Prize Poster Session, Fall 2012 ACS National Meeting, Philadelphia, PA. August 20, 2012.
* Total Synthesis ofDimeric Epipolythiodiketopiperazine Alkaloids. Kim, J. Research Presentation.
2012 Roche Award Symposium: Excellence in Chemistry, Hoffman-La Roche, Nutley, NJ. May 22,
2012.
614
e General Approach to Epipolythiodiketopiperazine Alkaloids: Total Synthesis of (+)-Chaetocins A
and C and (+)-12,12'-Dideoxychetracin A. Poster Presentation. Gordon Research Conference:
Natural Products, Bryant University. July 24-29, 2011.
e Total Synthesis ofEpipolythiodiketopiperazine Alkaloids. Research Presentation. Graduate Research
Symposium, MIT. May 31, 2011.
TEACHING EXPERIENCE
Spring 2013 Teaching assistant for a graduate-level synthetic organic chemistry course (Professor M.
Movassaghi).
Spring 2008 Teaching assistant for an undergraduate-level organic chemistry course (Professors S. L.
Buchwald and M. Movassaghi).
Fall 2007 Teaching assistant for an undergraduate-level organic chemistry course (Professors T. F.
Jamison and R. L. Danheiser).
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